References

Abbott, C. R., Monteiro, M., Small, C. J., Sajedi, A., Smith, K. L., Parkinson, J. R. C., Ghatei, M. A., & Bloom, S. R. (2005). The Inhibitory Effects Of Peripheral Administration Of Peptide Yy3-36 And Glucagon-Like Peptide-1 On Food Intake Are Attenuated By Ablation Of The Vagal-Brainstem-Hypothalamic Pathway. *Brain Research, 1044*(1), 127-131.

Abbott, C. R., Rossi, M., Kim, M.-S., Alahmed, S. H., Taylor, G. M., Ghatei, M. A., Smith, D. M., & Bloom, S. R. (2000). Investigation Of The Melanocyte Stimulating Hormones On Food Intake; Lack Of Evidence To Support A Role For The Melanocortin-3-Receptor. *Brain Research, 869*(1-2), 203-210.

Abel, E. L. (1975). Cannabis - Effects On Hunger And Thirst. *Behavioral Biology, 15*(3), 255-281.

Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., Simonneau, G., & Begaud, B. (1996). Appetite-Suppressant Drugs And The Risk Of Primary Pulmonary Hypertension. *New England Journal Of Medicine, 335*(9), 609-616.

Abpi. (2013). Guidelines For Professionals Working In The Pharmaceutical Industry. Retrieved 6th September 2013, 2013, From Http://Www.Abpi.Org.Uk/Our-Work/Library/Guidelines/Pages/Default.Aspx

Aceto, M. D., Scates, S. M., Lowe, J. A., & Martin, B. R. (1996). Dependence On Delta(9)-Tetrahydrocannabinol: Studies On Precipitated And Abrupt Withdrawal. *Journal Of Pharmacology And Experimental Therapeutics, 278*(3), 1290-1295.

Adair, L. S. (2008). Child And Adolescent Obesity: Epidemiology And Developmental Perspectives. *Physiology & Behavior, 94*(1), 8-16.

Adams, S. H., Lei, C., Jodka, C. M., Nikoulina, S. E., Hoyt, J. A., Gedulin, B., Mack, C. M., & Kendall, E. S. (2006). Pyy[3-36] Administration Decreases The Respiratory Quotient And Reduces Adiposity In Diet-Induced Obese Mice. *J. Nutr., 136*(1), 195-201.

Adan, R. A. H. (2013). Mechanisms Underlying Current And Future Anti-Obesity Drugs. *Trends In Neurosciences, 36*(2), 133-140.

Addy, C., Wright, H., Van Laere, K., Gantz, I., Erondu, N., Musser, B. J., Lu, K., Yuan, J., Sanabria-Bohórquez, S. M., Stoch, A., Stevens, C., Fong, T. M., De Lepeleire, I., Cilissen, C., Cote, J., Rosko, K., Gendrano Iii, I. N., Nguyen, A. M., Gumbiner, B., Rothenberg, P., De Hoon, J., Bormans, G., Depré, M., Eng, W.-S., Ravussin, E., Klein, S., Blundell, J., Herman, G. A., Burns, H. D., Hargreaves, R. J., Wagner, J., Gottesdiener, K., Amatruda, J. M., & Heymsfield, S. B. (2008). The Acyclic Cb1r Inverse Agonist Taranabant Mediates Weight Loss By Increasing Energy Expenditure And Decreasing Caloric Intake. *Cell Metabolism, 7*(1), 68.

Adrian, T. E., Allen, J. M., Bloom, S. R., Ghatei, M. A., Rossor, M. N., Roberts, G. W., Crow, T. J., Tatemoto, K., & Polak, J. M. (1983). Neuropeptide-Y Distribution In Human-Brain. *Nature, 306*(5943), 584-586.

Adrian, T. E., Bloom, S. R., Bryant, M. G., Polak, J. M., Heitz, P., & Barnes, A. J. (1976). Distribution And Release Of Human Pancreatic Polypeptide. *Gut, 17*(12), 940-944.

Adrian, T. E., Ferri, G. L., Bacaresehamilton, A. J., Fuessl, H. S., Polak, J. M., & Bloom, S. R. (1985). Human Distribution And Release Of A Putative New Gut Hormone, Peptide-Yy *Gastroenterology, 89*(5), 1070-1077.

Ahima, R. S., & Flier, J. S. (2000a). Adipose Tissue As An Endocrine Organ. *Trends In Endocrinology And Metabolism, 11*(8), 327-332.

Ahima, R. S., & Flier, J. S. (2000b). Leptin. *Annual Reviews Of Physiology, 62*, 413 - 437.

Ahima, R. S., Saper, C. B., Flier, J. S., & Elmquist, J. K. (2000). Leptin Regulation Of Neuroendocrine Systems. *Frontiers In Neuroendocrinology, 21*(3), 263-307.

Ahren, B., Landin-Olsson, M., Jansson, P. A., Svensson, M., Holmes, D., & Schweizer, A. (2004). Inhibition Of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, And Reduces Glucagon Levels In Type 2 Diabetes. *Journal Of Clinical Endocrinology & Metabolism, 89*(5), 2078-2084.

Aja, S., Sahandy, S., Ladenheim, E. E., Schwartz, G. J., & Moran, T. H. (2001). Intracerebroventricular Cart Peptide Reduces Food Intake And Alters Motor Behavior At A Hindbrain Site. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 281*(6), R1862-R1867.

Allen, Y. S., Adrian, T. E., Allen, J. M., Tatemoto, K., Crow, T. J., Bloom, S. R., & Polak, J. M. (1983). Neuropeptide-Y Distribution In The Rat-Brain. *Science, 221*(4613), 877-879.

Alon, T., & Friedman, J. M. (2006). Late-Onset Leanness In Mice With Targeted Ablation Of Melanin Concentrating Hormone Neurons. *Journal Of Neuroscience, 26*(2), 389-397.

Alonso, M., Serrano, A., Vida, M., Crespillo, A., Hernandez-Folgado, L., Jagerovic, N., Goya, P., Reyes-Cabello, C., Perez-Valero, V., Decara, J., Macias-Gonzalez, M., Javier Bermudez-Silva, F., Suarez, J., Rodriguez De Fonseca, F., & Javier Pavon, F. (2012). Anti-Obesity Efficacy Of Lh-21, A Cannabinoid Cb1 Receptor Antagonist With Poor Brain Penetration, In Diet-Induced Obese Rats. *British Journal Of Pharmacology, 165*(7), 2274-2291.

Amori, R. E., Lau, J., & Pittas, A. G. (2007). Efficacy And Safety Of Incretin Therapy In Type 2 Diabetes - Systematic Review And Meta-Analysis. *Jama-Journal Of The American Medical Association, 298*(2), 194-206.

Amri. (2011). Amri Announces Successful Completion Of Phase I Clinical Study Of Obesity Compound. Retrieved 16th August, 2013

Anand, B. K., & Brobeck, J. R. (1951). Hypothalamic Control Of Food Intake In Rats And Cats. *Yale Journal Of Biology And Medicine, 24*(2), 123-140.

Anderson, J. W., Greenway, F. L., Fujioka, K., Gadde, K. M., Mckenney, J., & O'neil, P. M. (2002). Bupropion Sr Enhances Weight Loss: A 48-Week Double-Blind, Placebo-Controlled Trial. *Obesity Research, 10*(7), 633-641.

Andrews, C. N., Bharucha, A. E., Camilleri, M., Low, P. A., Seide, B. M., Burton, D. D., Nickander, K. K., Baxter, K. L., & Zinsmeister, A. R. (2007). Effects Of Glucagon-Like Peptide-1 And Sympathetic Stimulation On Gastric Accommodation In Humans. *Neurogastroenterology And Motility, 19*(9), 716-723.

Anini, Y. X., Fu-Cheng, Jean Claude Cuber, Alain, Kervan, Jacques Chariot, Claude Roze. (1999). Comparison Of The Postprandial Release Of Peptide Yy And Prglucagon-Derived Peptides In The Rat. *European Journal Of Physiology, 438*, 299-306.

Anlauf, M., Weihe, E., Hartschuh, W., Hamscher, G., & Feurle, G. E. (2000). Localization Of Xenin-Immunoreactive Cells In The Duodenal Mucosa Of Humans And Various Mammals. *Journal Of Histochemistry & Cytochemistry, 48*(12), 1617-1626.

Antin, J., Gibbs, J., Holt, J., Young, R. C., & Smith, G. P. (1975). Cholecystokinin Elicits The Complete Behavioural Sequence Of Satiety In Rats. *Journal Of Comparative And Physiological Psychology, 89*(7), 784 - 790.

Anzman, S. L., Rollins, B. Y., & Birch, L. L. (2010). Parental Influence On Children's Early Eating Environments And Obesity Risk: Implications For Prevention. *International Journal Of Obesity, 34*(7), 1116-1124.

Apfelbaum, M., & Mandenoff, A. (1981). Naltrexone Suppresses Hyperphagia Induced In The Rat By A Highly Palatable Diet. *Pharmacology Biochemistry And Behavior, 15*(1), 89-91.

Aponte, G., Leung, P., Gross, D., & Yamada, T. (1984). Effects Of Somatostatin On Food-Intake In Rats *Life Sciences, 35*(7), 741-746.

Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & Group, C.-I. S. (2013). A Randomized, Phase 3 Trial Of Naltrexone Sr/Bupropion Sr On Weight And Obesity-Related Risk Factors (Cor-Ii). *Obesity (Silver Spring, Md.), 21*(5), 935-943.

Appel, L. J., Clark, J. M., Yeh, H.-C., Wang, N.-Y., Coughlin, J. W., Daumit, G., Miller, E. R., Iii, Dalcin, A., Jerome, G. J., Geller, S., Noronha, G., Pozefsky, T., Charleston, J., Reynolds, J. B., Durkin, N., Rubin, R. R., Louis, T. A., & Brancati, F. L. (2011). Comparative Effectiveness Of Weight-Loss Interventions In Clinical Practice. *New England Journal Of Medicine, 365*(21), 1959-1968.

Arena. (2010). Fda Issues Complete Response Letter For Lorcaserin New Drug Application. Retrieved 16th August, 2013, From Http://Invest.Arenapharm.Com/Releasedetail.Cfm?Releaseid=521977

Arevalo, C., De Miguel, R., & Hernandez-Tristan, R. (2001). Cannabinoid Effects On Anxiety-Related Behaviours And Hypothalamic Neurotransmitters. *Pharmacology Biochemistry And Behavior, 70*(1), 123-131.

Arias, H. R. (2009). Is The Inhibition Of Nicotinic Acetylcholine Receptors By Bupropion Involved In Its Clinical Actions? *International Journal Of Biochemistry & Cell Biology, 41*(11), 2098-2108.

Ariyasu, H., Takaya, K., Tagami, T., Ogawa, Y., Hosoda, K., Akamizu, T., Suda, M., Koh, T., Natsui, K., Toyooka, S., Shirakami, G., Usui, T., Shimatsu, A., Doi, K., Hosoda, H., Kojima, M., Kangawa, K., & Nakao, K. (2001). Stomach Is A Major Source Of Circulating Ghrelin, And Feeding State Determines Plasma Ghrelin-Like Immunoreactivity Levels In Humans. *J Clin Endocrinol Metab, 86*(10), 4753-4758.

Arjune, D., & Bodnar, R. J. (1990). Decreases In Spontaneous And Glucoprivic Feeding Following Selective Mu And Kappa Opioid Antagonists In Rats. *Society For Neuroscience Abstracts, 16*(1), 775-775.

Arjune, D., Bowen, W. D., & Bodnar, R. J. (1991). Ingestive Behavioural Following Central D-Ala2,Leu5,Cys6 -Enkephalin (Dalce), A Short-Acting Agonist And Long-Acting Antagonist At The Delta Opioid Receptor *Pharmacology Biochemistry And Behavior, 39*(2), 429-436.

Arletti, R., Benelli, A., & Bertolini, A. (1989). Influence Of Oxytocin On Feeding-Behaviour In The Rat *Peptides, 10*(1), 89-93.

Arnone, M., Maruani, J., Chaperon, F., Thiebot, M. H., Poncelet, M., Soubrie, P., & Lefur, G. (1997). Selective Inhibition Of Sucrose And Ethanol Intake By Sr 141716, An Antagonist Of Central Cannabinoid (Cb1) Receptors. *Psychopharmacology, 132*(1), 104-106.

Aronne, L. J., Halseth, A. E., Burns, C. M., Miller, S., & Shen, L. Z. (2010). Enhanced Weight Loss Following Coadministration Of Pramlintide With Sibutramine Or Phentermine In A Multicenter Trial. *Obesity, 18*(9), 1739-1746.

Aronne, L. J., Tonstad, S., Moreno, M., Gantz, I., Erondu, N., Suryawanshi, S., Molony, C., Sieberts, S., Nayee, J., Meehan, A. G., Shapiro, D., Heymsfield, S. B., Kaufman, K. D., & Amatruda, J. M. (2010). A Clinical Trial Assessing The Safety And Efficacy Of Taranabant, A Cb1r Inverse Agonist, In Obese And Overweight Patients: A High-Dose Study. *International Journal Of Obesity, 34*(5), 919-935.

Arora, S., & Anubhuti. (2006). Role Of Neuropeptides In Appetite Regulation And Obesity - A Review. *Neuropeptides, 40*(6), 375-401.

Arsenijevic, D., Gallmann, E., Moses, W., Lutz, T., Erlanson-Albertsson, C., & Langhans, W. (2005). Enterostatin Decreases Postprandial Pancreatic Ucp2 Mrna Levels And Increases Plasma Insulin And Amylin. *American Journal Of Physiology-Endocrinology And Metabolism, 289*(1), E40-E45.

Arterburn, D. E., Crane, P. K., & Veenstra, D. L. (2004). The Efficacy And Safety Of Sibutramine For Weight Loss - A Systematic Review. *Archives Of Internal Medicine, 164*(9), 994-1003.

Arvaniti, K., Huang, O. L., & Richard, D. (2001). Effects Of Leptin And Corticosterone On The Expression Of Corticotropin-Releasing Hormone, Agouti-Related Protein, And Proopiomelanocortin In The Brain Of Ob/Ob Mouse. *Neuroendocrinology, 73*(4), 227-236.

Asakawa, A., Inui, A., Yuzuriha, H., Ueno, N., Katsuura, G., Fujimiya, M., Fujino, M. A., Niijima, A., Meguid, M. M., & Kasuga, M. (2003). Characterization Of The Effects Of Pancreatic Polypeptide In The Regulation Of Energy Balance. *Gastroenterology, 124*(5), 1325-1336.

Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., Richelson, E., & Sulser, F. (1995). Bupropion - A Review Of Its Mechanism Of Antidepressant Activity. *Journal Of Clinical Psychiatry, 56*(9), 395-401.

Ashkzari, M., Modiri, A. R., & Svartengren, J. (2003). Tolerance Does Not Develop After Chronic Infusion Of Mcpp On Food Intake And Body Weight Gain In Rats. *International Journal Of Obesity, 27*(Supplement 1), S58.

Ashton, J. C., Darlington, C. L., & Smith, P. F. (2006). Co-Distribution Of The Cannabinoid Cb1 Receptor And The 5-Ht Transporter In The Rat Amygdale. *European Journal Of Pharmacology, 537*(1-3), 70-71.

Asnicar, M. A., Smith, D. P., Yang, D. D., Heiman, M. L., Fox, N., Chen, Y.-F., Hsiung, H. M., & Koster, A. (2001). Absence Of Cocaine- And Amphetamine-Regulated Transcript Results In Obesity In Mice Fed A High Caloric Diet. *Endocrinology, 142*(10), 4394-4400.

Astrup, A., Buemann, B., Flint, A., & Raben, A. (2002). Low-Fat Diets And Energy Balance: How Does The Evidence Stand In 2002? *Proceedings Of The Nutrition Society, 61*(2), 299-309.

Astrup, A., Grunwald, G. K., Melanson, E. L., Saris, W. H. M., & Hill, J. O. (2000). The Role Of Low-Fat Diets In Body Weight Control: A Meta-Analysis Of Ad Libitum Dietary Intervention Studies. *International Journal Of Obesity, 24*(12), 1545-1552.

Astrup, A., Madsbad, S., Breum, L., Jensen, T. J., Kroustrup, J. P., & Larsen, T. M. (2008). Effect Of Tesofensine On Bodyweight Loss, Body Composition, And Quality Of Life In Obese Patients: A Randomised, Double-Blind, Placebo-Controlled Trial. *Lancet, 372*(9653), 1906-1913.

Astrup, A., Madsbad, S., Breum, L., Kroustrup, J. P., Jensen, T. J., & Larsen, T. M. (2008). The Effect Of Tesofensine On Weight Loss, Appetite, Physical Activity And Qol In Obese Subjects. Results From A 24-Week Randomised, Double-Blind Placebo-Controlled Trial. *Diabetes, 57*, A739-A739.

Astrup, A., Meier, D. H., Mikkelsen, B. O., Villumsen, J. S., & Larsen, T. M. (2008). Weight Loss Produced By Tesofensine In Patients With Parkinson's Or Alzheimer's Disease. *Obesity, 16*(6), 1363-1369.

Astrup, A., Rossner, S., Van Goal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., Lean, M. E. J., & Grp, N. N. S. (2009). Effects Of Liraglutide In The Treatment Of Obesity: A Randomised, Double-Blind, Placebo-Controlled Study. *Lancet, 374*(9701), 1606-1616.

Atkinson, R. L., Berke, L. K., Drake, C. R., Bibbs, M. L., Williams, F. L., & Kaiser, D. L. (1985). Effects Of Long-Term Therapy With Naltrexone On Body Weight In Obesity. *Clinical Pharmacology & Therapeutics, 38*(4), 419-422.

Aventis, S. (2007). Rimonabant USA: Update. Retrieved 16th August, 2013, From Http://En.Sanofi.Com/Images/14384_070326_Pdf_Acomplia.Pdf

Aziz, A., & Anderson, G. H. (2002). Exendin-4, A Glp-1 Receptor Agonist, Modulates The Effect Of Macronutrients On Food Intake By Rats. *Journal Of Nutrition, 132*(5), 990-995.

Aziz, A., & Anderson, G. H. (2003). Exendin-4, A Glp-1 Receptor Agonist, Interacts With Proteins And Their Products Of Digestion To Suppress Food Intake In Rats. *Journal Of Nutrition, 133*(7), 2326-2330.

Badaue-Passos, D., Ventura, R. R., Silva, L. F. S., Olivares, E. L., & Reis, L. C. (2003). Effect Of Brain Serotoninergic Stimulation On Sodium Appetite Of Euthyroid And Hypothyroid Rats. *Experimental Physiology, 88*(2), 251-260.

Badman, M. K., & Flier, J. S. (2005). The Gut And Energy Balance: Visceral Allies In The Obesity Wars. *Science, 307*(5717), 1909-1914.

Bagdade, J. D., Bierman, E. L., & Porte, D. (1967). Significance Of Basal Insulin Levels In Evaluation Of Insulin Response To Glucose In Diabetic And Nondiabetic Subjects. *Journal Of Clinical Investigation, 46*(10), 1549-&.

Bagdy, G., Calogero, A. E., Szemeredi, K., Gomez, M. T., Murphy, D. L., Chrousos, G. P., & Gold, P. W. (1990). Beta-Endophin Responses To Different Serotonin Agonists - Involvement Of Corticotropin-Releasing Hormone, Vasopressin And Direct Pituitary Action. *Brain Research, 537*(1-2), 227-232.

Bagdy, G., Kalogeras, K. T., & Szemeredi, K. (1992). Effects Of 5-Ht(1c) And 5-Ht(2) Receptor Stimulation On Excessive Grooming, Penile Erection And Plasma Oxytocin Concentrations. *European Journal Of Pharmacology, 229*(1), 9-14.

Bagdy, G., & Makara, G. B. (1995). Paraventricular Nucleus Controls 5-Ht2c Receptor-Mediated Corticosterone And Prolactin But Not Oxytocin And Penile Erection Responses. *European Journal Of Pharmacology, 275*(3), 301-305.

Baggio, L. L., & Drucker, D. J. (2007). Biology Of Incretins: Glp-1 And Gip. *Gastroenterology, 132*(6), 2131-2157.

Baggio, L. L., Huang, Q., Cao, X., & Drucker, D. J. (2008). An Albumin-Exendin-4 Conjugate Engages Central And Peripheral Circuits Regulating Murine Energy And Glucose Homeostasis. *Gastroenterology, 134*(4), 1137-1147.

Baggio, L. L., Huang, Q. L., Brown, T. J., & Drucker, D. J. (2004a). Oxyntomodulin And Glucagon-Like Peptide-1 Differentially Regulate Murine Food Intake And Energy Expenditure. *Gastroenterology, 127*(2), 546-558.

Baggio, L. L., Huang, Q. L., Brown, T. J., & Drucker, D. J. (2004b). A Recombinant Human Glucagon-Like Peptide (Glp)-1-Albumin Protein (Albugon) Mimics Peptidergic Activation Of Glp-1 Receptor-Dependent Pathways Coupled With Satiety, Gastrointestinal Motility, And Glucose Homeostasis. *Diabetes, 53*(9), 2492-2500.

Baird, J.-P., Choe, A., Loveland, J. L., Beck, J., Mahoney, C. E., Lord, J. S., & Grigg, L. A. (2009). Orexin-A Hyperphagia: Hindbrain Participation In Consummatory Feeding Responses. *Endocrinology, 150*(3), 1202-1216.

Baldissera, F. G. A., Holst, J. J., Knuhtsen, S., Hilsted, L., & Nielsen, O. V. (1988). Oxyntomodulin (Glicentin-(33-69)) - Pharmacokinetics, Binding To Liver-Cell Membranes, Effects Of Isolated Perfused Pig Pancreas, And Secretion From Isolated Perfused Lower Small-Intestine Of Pigs. *Regulatory Peptides, 21*(1-2), 151-166.

Ballantyne, J. C., Loach, A. B., & Carr, D. B. (1988). Itching After Epidural And Spinal Opiates. *Pain, 33*(2), 149-160.

Ballinger, A., Mcloughlin, L., Medbak, S., & Clark, M. (1995). Cholecystokinin Is A Satiety Hormone In Humans At Physiological Postprandial Plasma-Concentrations. *Clinical Science, 89*(4), 375-381.

Balsiger, B. M., Murr, M. M., Poggio, J. L., & Sarr, M. G. (2000). Bariatric Surgery - Surgery For Weight Control In Patients With Morbid Obesity. *Medical Clinics Of North America, 84*(2), 477-+.

Balthasar, N., Dalgaard, L. T., Lee, C. E., Yu, J., Funahashi, H., Williams, T., Ferreira, M., Tang, V., Mcgovern, R. A., & Kenny, C. D. (2005). Divergence Of Melanocortin Pathways In The Control Of Food Intake And Energy Expenditure. *Cell, 123*(3), 493-505.

Bannon, A. W., Seda, J., Carmouche, M., Francis, J. M., Norman, M. H., Karbon, B., & Mccaleb, M. L. (2000). Behavioral Characterization Of Neuropeptide Y Knockout Mice. *Brain Research, 868*(1), 79-87.

Banting, F. G., & Best, C. H. (1922). The Internal Secretion Of The Pancreas. *Journal Of Laboratory And Clinical Medicine, 7*, 251-266.

Baraboi, E.-D., Smith, P., Ferguson, A. V., & Richard, D. (2010). Lesions Of Area Postrema And Subfornical Organ Alter Exendin-4-Induced Brain Activation Without Preventing The Hypophagic Effect Of The Glp-1 Receptor Agonist. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 298*(4), R1098-R1110.

Barbano, M. F., & Cador, M. (2006). Differential Regulation Of The Consummatory, Motivational And Anticipatory Aspects Of Feeding Behavior By Dopaminergic And Opioidergic Drugs. *Neuropsychopharmacology, 31*(7), 1371-1381.

Barkeling, B., Elfhag, K., Rooth, P., & Rossner, S. (2003). Short-Term Effects Of Sibutramine (Reductil (Tm)) On Appetite And Eating Behaviour And The Long-Term Therapeutic Outcome. *International Journal Of Obesity, 27*(6), 693-700.

Barnes, J. C., Costall, B., Domeney, A. M., & Naylor, R. J. (1986). Lithium And Bupropion Antagonize The Phasic Changes In Locomotor-Activity Caused By Dopamine Infused Into The Rat Nucleus-Accumbens. *Psychopharmacology, 89*(3), 311-316.

Barnes, N. M., & Sharp, T. (1999). A Review Of Central 5-Ht Receptors And Their Function. *Neuropharmacology, 38*(8), 1083-1152.

Barragan-Mejia, M. G., Castilla-Serna, L., Calderon-Guzman, D., Hernandez-Islas, J. L., Labra-Ruiz, N. A., Rodriguez-Perez, R. A., & Santamaria-Del Angel, D. (2002). Effect Of Nutritional Status And Ozone Exposure On Rat Brain Serotonin. *Archives Of Medical Research, 33*(1), 15-19.

Barrera, J. G., D'alessio, D. A., Drucker, D. J., Woods, S. C., & Seeley, R. J. (2009). Differences In The Central Anorectic Effects Of Glucagon-Like Peptide-1 And Exendin-4 In Rats. *Diabetes, 58*(12), 2820-2827.

Barrera, J. G., Sandoval, D. A., D'alessio, D. A., & Seeley, R. J. (2011). Glp-1 And Energy Balance: An Integrated Model Of Short-Term And Long-Term Control. *Nature Reviews Endocrinology, 7*(9), 507-516.

Barrickman, L. L., Perry, P. J., Allen, A. J., Kuperman, S., Arndt, S. V., Herrmann, K. J., & Schumacher, E. (1995). Bupropion Versus Methylphenidate In The Treatment Of Attention-Deficit Hyperactivty Disorder. *Journal Of The American Academy Of Child And Adolescent Psychiatry, 34*(5), 649-657.

Barsh, G. S., Farooqi, I. S., & O'rahilly, S. (2000). Genetics Of Body-Weight Regulation. *Nature, 404*(6778), 644-651.

Barton, C., York, D. A., & Bray, G. A. (1996). Opioid Receptor Subtype Control Of Galanin-Induced Feeding. *Peptides, 17*(2), 237-240.

Baskin, D. G., Figlewicz, D. P., Woods, S. C., Porte, D., & Dorsa, D. M. (1987). Insulin In The Brain. *Annual Review Of Physiology, 49*, 335-347.

Baskin, D. G., Kim, F., Gelling, R. W., Russell, B. J., Schwartz, M. W., Morton, G. J., Simhan, H. N., Moralejo, D. H., & Blevins, J. E. (2010). A New Oxytocin-Saporin Cytotoxin For Lesioning Oxytocin-Receptive Neurons In The Rat Hindbrain. *Endocrinology, 151*(9), 4207-4213.

Bass, C. E., Griffin, G., Grier, M., Mahadevan, A., Razdan, R. K., & Martin, B. R. (2002). Sr-141716a-Induced Stimulation Of Locomotor Activity - A Structure-Activity Relationship Study. *Pharmacology Biochemistry And Behavior, 74*(1), 31-40.

Bataille, D., Tatemoto, K., Coudray, A. M., Rosselin, G., & Mutt, V. (1981). Bioactive Enteroglucagon (Oxyntomodulin) - Evidence For A C-Terminally Extended Glucagon Molecule. *Comptes Rendus De L Academie Des Sciences Serie Iii-Sciences De La Vie-Life Sciences, 293*(6), 323-328.

Batterham, R., L,, Le Roux, C. W., Cohen, M. A., Park, A., J., Ellis, S., M,, Patterson, M., Frost, G. S., Ghatei, M. A., & Bloom, S., R. (2003). Pancreatic Polypeptide Reduces Appetite And Food Intake In Humans. *Journal Of Endocrinology And Metabolism, 88*(8), 3989-3992.

Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G., Ghatei, M. A., & S.R., B. (2003). Inhibition Of Food Itnake In Obese Subjects By Peptide Yy3-36. *New England Journal Of Medicine, 349*(10), 941 - 948.

Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., Cone, R. D., & Bloom, S. R. (2002). Gut Hormone Pyy(3-36) Physiologically Inhibits Food Intake. *Nature, 418*(6898), 650-654.

Batterham, R. L., Heffron, H., Kapoor, S., Chivers, J. E., Chandarana, K., Herzog, H., Le Roux, C. W., Thomas, E. L., Bell, J. D., & Withers, D. J. (2006). Critical Role For Peptide Yy In Protein-Mediated Satiation And Body-Weight Regulation. *Cell Metabolism, 4*(3), 223-233.

Battey, J., & Wada, E. (1991). 2 Distinct Receptor Subtypes For Mammalian Bombesin-Like Peptides *Trends In Neurosciences, 14*(12), 524-528.

Bayliss, W. M., & Starling, E. H. (1902). The Mechanism Of Pancreatic Secretion. *Journal Of Physiology-London, 28*(5), 325-353.

Bays, H. E. (2004). Current And Investigational Antiobesity Agents And Obesity Therapeutic Treatment Targets. *Obesity Research, 12*(8), 1197-1211.

Bear, M., F., Connors, B. W., And Paradiso, M. (2006). *Neuroscience: Exploring The Brain (3rd Ed)*.

Becskei, C., Grabler, V., Edwards, G. L., Riediger, T., & Lutz, T. A. (2007). Lesion Of The Lateral Parabrachial Nucleus Attenuates The Anorectic Effect Of Peripheral Amylin And Cck. *Brain Research, 1162*, 76-84.

Beczkowska, I. W., Bowen, W. D., & Bodnar, R. J. (1992). Central Opioid Receptor Subtype Antagonists Differentially Alter Sucrose And Deprivation-Induced Water-Intake In Rats. *Brain Research, 589*(2), 291-301.

Beczkowska Iw, B. R. (1991). Naloxone And Serotonin Receptor Subtype Antagonisrs: Interactive Effects Upon Deprivation-Induced Intake. *Pharmacology, Biocehmistry And Behavior, 38*, 605-610.

Beczkowska, I. W., Koch, J. E., & Bodnar, R. J. (1992). Naltrexone, Serotonin Receptor Subtyper Antagonists, And Glucoprivic Intake. 1. 2-Deoxy-D-Glucose. *Pharmacology Biochemistry And Behavior, 42*(4), 661-670.

Beczkowska, I. W., Koch, J. E., Elizabeth Bostock, M., Leibowitz, S. F., & Bodnar, R. J. (1993). Central Opioid Receptor Subtype Antagonists Differentially Reduce Intake Of Saccharin And Maltose Dextrin Solutions In Rats. *Brain Research, 618*(2), 261-270.

Beglinger, C., Degen, L., Matzinger, D., D'amato, M., & Drewe, J. (2001). Loxiglumide, A Cck-A Receptor Antagonist, Stimulates Calorie Intake And Hunger Feelings In Humans. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 280*(4), R1149-R1154.

Behan, D. P., Grigoriadis, D. E., Lovenberg, T., Chalmers, D., Heinrichs, S., Liaw, C., & Desouza, E. B. (1996). Neurobiology Of Corticotropin Releasing Factor (Crf) Receptors And Crf-Binding Protein: Implications For The Treatment Of Cns Disorders. *Molecular Psychiatry, 1*(4), 265-277.

Bello, N. T., Kemm, M. H., Ofeldt, E. M., & Moran, T. H. (2010). Dose Combinations Of Exendin-4 And Salmon Calcitonin Produce Additive And Synergistic Reductions In Food Intake In Nonhuman Primates. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 299*(3), R945-R952.

Bengtsson, M. W., Makela, K., Sjoblom, M., Uotila, S., Akerman, K. E. O., Herzig, K.-H., & Flemstrom, G. (2007). Food-Induced Expression Of Orexin Receptors In Rat Duodenal Mucosa Regulates The Bicarbonate Secretory

Response To Orexin-A. *American Journal Of Physiology-Gastrointestinal And Liver Physiology, 293*(2), G501-G509.

Benoit, S. C., Clegg, D. J., Seeley, R. J., & Woods, S. C. (2004). Insulin And Leptin As Adiposity Signals. *Recent Progress In Hormone Research, Vol 59, 59*, 267-285.

Benoit, S. C., Tracy, A. L., Air, E. L., Kinzig, K., Seeley, R. J., & Davidson, T. L. (2001). The Role Of The Hypothalamic Melanocortin System In Behavioral Appetitive Processes. *Pharmacology Biochemistry And Behavior, 69*(3-4), 603-609.

Bensaid, M., Gary-Bobo, M., Esclangon, A., Maffrand, J. P., Le Fur, G., Oury-Donat, F., & Soubrie, P. (2003). The Cannabinoid Cb1 Receptor Antagonist Sr141716 Increases Acrp30 Mrna Expression In Adipose Tissue Of Obese Fa/Fa Rats And In Cultured Adipocyte Cells. *Molecular Pharmacology, 63*(4), 908-914.

Bentley, J. C., Bourson, A., Boess, F. G., Fone, K. C. F., Marsden, C. A., Petit, N., & Sleight, A. J. (1999). Investigation Of Stretching Behaviour Induced By The Selective 5-Ht6 Receptor Antagonist, Ro 04-6790, In Rats. *British Journal Of Pharmacology, 126*(7), 1537-1542.

Berendsen, H. H. G., & Broekkamp, C. L. E. (1991). A Peripheral 5-Ht1d-Like Receptor Involved In Serotonergic Induced Hindlimb Scratching In Rats. *European Journal Of Pharmacology, 194*(2–3), 201-208.

Berger, K., Sivars, U., Winzell, M. S., Johansson, P., Hellman, U., Rippe, C., & Erlanson-Albertsson, C. (2002). Mitochondrial Atp Synthase - A Possible Target Protein In The Regulation Of Energy Metabolism In Vitro And In Vivo. *Nutritional Neuroscience, 5*(3), 201-210.

Bergman, J., Madras, B. K., Johnson, S. E., & Spealman, R. D. (1989). Effects If Cocaine And Related Drugs In Nonhuman-Primates .3. Self-Administration By Squirrel-Monkeys. *Journal Of Pharmacology And Experimental Therapeutics, 251*(1), 150-155.

Berkowitz, B. A., Ngai, S. H., & Finck, A. D. (1976). Nitrous-Oxide Analgesia - Resemblance To Opiate Action. *Science, 194*(4268), 967-968.

Bermudez-Silva, F. J., Suarez, J., Baixeras, E., Cobo, N., Bautista, D., Cuesta-Munoz, A. L., Fuentes, E., Juan-Pico, P., Castro, M. J., Milman, G., Mechoulam, R., Nadal, A., & De Fonseca, F. R. (2008). Presence Of Functional Cannabinoid Receptors In Human Endocrine Pancreas. *Diabetologia, 51*(3), 476-487.

Bermudez-Silva, F. J., Viveros, M. P., Mcpartland, J. M., & Rodriguez De Fonseca, F. (2010). The Endocannabinoid System, Eating Behavior And Energy Homeostasis: The End Or A New Beginning? *Pharmacology Biochemistry And Behavior, 95*(4), 375-382.

Bernardis, L. L., & Bellinger, L. L. (1996). The Lateral Hypothalamic Area Revisited: Ingestive Behavior. *Neuroscience & Biobehavioral Reviews, 20*(2), 189-287.

Bernstein, J. E., Swift, R. M., Soltani, K., & Lorincz, A. L. (1982). Anti-Pruritic Effect Of An Opiate Antagonist, Naloxone Hydrochloride. *Journal Of Investigative Dermatology, 78*(1), 82-83.

Berntson, G. G., Zipf, W. B., Odorisio, T. M., Hoffman, J. A., & Chance, R. E. (1993). Pancreatic-Polypeptide Infusions Reduce Food-Intake In Prader-Willi Syndrome. *Peptides, 14*(3), 497-503.

Berridge, K. (2009). 'Liking' And 'Wanting' Food Rewards: Brain Substrates And Roles In Eating Disorders. *Physiology And Behavior, 97*, 537-550.

Berridge, K. C. (1996). Food Reward: Brain Substrates Of Wanting And Liking. *Neuroscience & Biobehavioral Reviews, 20*(1), 1-25.

Berridge, K. C. (2000). Measuring Hedonic Impact In Animals And Infants: Microstructure Of Affective Taste Reactivity Patterns. *Neuroscience & Biobehavioral Reviews, 24*(2), 173-198.

Berridge, K. C., Ho, C.-Y., Richard, J. M., & Difeliceantonio, A. G. (2010). The Tempted Brain Eats: Pleasure And Desire Circuits In Obesity And Eating Disorders. *Brain Research, 1350*(0), 43-64.

Berthoud, H.-R., Muenzberg, H., Richards, B. K., & Morrison, C. D. (2012). Neural And Metabolic Regulation Of Macronutrient Intake And Selection. *Proceedings Of The Nutrition Society, 71*(3), 390-400.

Bertino, M., Beauchamp, G. K., & Engelman, K. (1991). Naltrexone, An Opioid Blocker, Alters Taste Perception And Nutrient Intake In Humans. *American Journal Of Physiology, 261*(1), R59-R63.

Beyond, W. L. A. (2012). Health Benefits Of Weight Loss Surgery. Retrieved 6th September 2013, 2013, From Http://Weightlossandbeyond.Ca/About-Us/F-A-Q/Health-Facts

Bhasin, S., Wallace, W., Lawrence, J. B., & Lesch, M. (1981). Sudden-Death Associated With Thyoid-Hormone Abuse. *American Journal Of Medicine, 71*(5), 887-890.

Bhatnagar, S., Nowak, N., Babich, L., & Bok, L. (2004). Deletion Of The 5-Ht3 Receptor Differentially Affects Behavior Of Males And Females In The Porsolt Forced Swim And Defensive Withdrawal Tests. *Behavioural Brain Research, 153*(2), 527-535.

Bhavsar, S., Lachappell, R., Watkins, J., & Young, A. (1998). Comparison Of Glucose Lowering Effects Of Exendin-4 And Glp-1 In Diabetic Db/Db Mice. *Diabetes, 47*, A192-A192.

Bhavsar, S., Watkins, J., & Young, A. (1998a). Synergy Between Amylin And Cholecystokinin For Inhibition Of Food Intake In Mice. *Physiology & Behavior, 64*(4), 557-561.

Bhavsar, S. P., Watkins, J. J., & Young, A. A. (1998b). Central And Peripheral Administration Of Exendin-4 Reduces Food Intake In Rats. *Diabetologia, 41*, A214-A214.

Bickerdike, M. J. (2003). 5-Ht(2c) Receptor Agonists As Potential Drugs For The Treatment Of Obesity. *Current Topics In Medicinal Chemistry, 3*(8), 885-897.

Bigliardi, P. L., Stammer, H., Jost, G., Rufli, T., Büchner, S., & Bigliardi-Qi, M. (2007). Treatment Of Pruritus With Topically Applied Opiate Receptor Antagonist. *Journal Of The American Academy Of Dermatology, 56*(6), 979-988.

Bignon, E., Alonso, R., Arnone, M., Boigegrain, R., Brodin, R., Gueudet, C., Heaulme, M., Keane, P., Landi, M., Molimard, J. C., Olliero, D., Poncelet, M ., Seban, E., Simiand, J., Soubrie, P., Pascal, M., Maffrand, J. P., & Le Fur, G. (1999). Sr146131: A New Potent, Orally Active, And Selective Nonpeptide Cholecystokinin Subtype 1 Receptor Agonist. Ii: In Vivo Pharmacological Characterization. *Journal Of Pharmacology And Experimental Therapeutics, 289*(2), 752-761.

Billes, S. K., & Cowley, M. A. (2007). Inhibition Of Dopamine And Norepinephrine Reuptake Produces Additive Effects On Energy Balance In Lean And Obese Mice. *Neuropsychopharmacology, 32*(4), 822-834.

Bindra, D., & Blond, J. (1958). A Time-Sample Method For Measuring General Activity And Its Components. *Canadian Journal Of Psychology, 12*(2), 74-76.

Bishop, M. J., & Nilsson, B. M. (2003). New 5-Ht2c Receptor Agonists. *Expert Opinion On Therapeutic Patents, 13*(11), 1691-1705.

Bisogno, T., Burston, J. J., Rai, R., Allara, M., Saha, B., Mahadevan, A., Razdan, R. K., Wiley, J. L., & Di Marzo, V. (2009). Synthesis And Pharmacological Activity Of A Potent Inhibitor Of The Biosynthesis Of The Endocannabinoid 2-Arachidonoylglycerol. *Chemmedchem, 4*(6), 946-950.

Bittencourt, J. C., Presse, F., Arias, C., Peto, C., Vaughan, J., Nahon, J. L., Vale, W., & Sawchenko, P. E. (1992). The Malanin-Concentrating Hormone

System Of The Rat-Brain - An Immunization And Hybridization Histochemical Characterization. *Journal Of Comparative Neurology, 319*(2), 218-245.

Bjorbaek, C., Elmquist, J. K., Frantz, J. D., Shoelson, S. E., & Flier, J. S. (1998). Identification Of Socs-3 As A Potential Mediator Of Central Leptin Resistance. *Molecular Cell, 1*(4), 619-625.

Blevins, J. E., Eakin, T. J., Murphy, J. A., Schwartz, M. W., & Baskin, D. G. (2003). Oxytocin Innervation Of Caudal Brainstem Nuclei Activated By Cholecystokinin. *Brain Research, 993*(1-2), 30-41.

Blevins, J. E., Schwartz, M. W., & Baskin, D. G. (2004). Evidence That Paraventricular Nucleus Oxytocin Neurons Link Hypothalamic Leptin Action To Caudal Brain Stem Nuclei Controlling Meal Size. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 287*(1), R87-R96.

Blomqvist, A. G., & Herzog, H. (1997). Y-Receptor Subtypes - How Many More? *Trends In Neurosciences, 20*(7), 294-298.

Blouet, C., Jo, Y.-H., Li, X., & Schwartz, G. J. (2009). Mediobasal Hypothalamic Leucine Sensing Regulates Food Intake Through Activation Of A Hypothalamus-Brainstem Circuit. *Journal Of Neuroscience, 29*(26), 8302-8311.

Blum, I. D., Patterson, Z., Khazall, R., Lamont, E. W., Sleeman, M. W., Horvath, T. L., & Abizaid, A. (2009). Reduced Anticipatory Locomotor Responses To Scheduled Meals In Ghrelin Receptor Deficient Mice. *Neuroscience, 164*(2), 351-359.

Blundell, J. E. (1977). Is There A Role For Serotonin (5-Hydroxytryptamine) In Feeding? *International Journal Of Obesity, 1*(1), 15-42.

Blundell, J. E., & Halford, J. C. G. (1998). Serotonin And Appetite Regulation - Implications For The Pharmacological Treatment Of Obesity. *CNS Drugs, 9*(6), 473-495.

Blundell, J. E., & Hill, A. J. (1990). *Effect Of D Fenfluramine On Appetite In Lean And Obese Human Subjects And On Changes Associated With Pms Pre-Menstural Syndrome*.

Blundell, J. E., & Latham, C. J. (1978). Effect Of Pharmacological Agents On Microstructure And Macro-Structure Of Feeding-Behaviour -Implications For Analysis Of Anorectic Drug Action. *International Journal Of Obesity, 2*(3), 362-362.

Blundell, J. E., & Latham, C. J. (1980). Characterization Of Adjustments To The Structure Of Feeding-Behavior Following Pharmacological Treatment - Effects Of Amphetamine And Fenfluramine And The Antagonism Produced By Pimozide And Methergoline. *Pharmacology Biochemistry And Behavior, 12*(5), 717-722.

Blundell, J. E., Latham, C. J., Moniz, E., Mcarthur, R. A., & Rogers, P. J. (1979). Structural Analysis Of The Actions Of Amphetamine And Fenfluramine On Food Intake And Feeding Behaviour In Animals And In Man. *Current Medical Research And Opinion, 6*(Suppl 1), 34-54.

Blundell Je, L. C. (1979). Serotonergic Influences On Food Intake: Effect Of 5-Hydroxytryptophan On Parameters Of Feeding Behaviour In Deprived And Free-Feeding Rats. *Pharmacology, Biocehmistry And Behavior, 11*, 431-437.

Blundell, J. E., & Mcarthur, R. A. (1981). Behavioural Flux And Feeding: Continuous Monitoring Of Food Intake And Food Selection, And The Video-Recording Of Appetitive And Satiety Sequences For The Analysis Of Drug Action. *Anorectic Agents: Mechanisms Of Action And Tolerance, Edited By Garattini S, Samanin R*(Raven Press: New York), 19-43.

Blundell, J. E., Rogers, P. J., & Hill, A. J. (1985). Behavioural Structure And Mechanisms Of Anorexia: Calibration Of Natural And Abnormal Inhibition Of Eating. *Brain Research Bulletin, 15*, 371 - 376.

Bms. (2011). Bms-830216 Information Sheet. Retrieved 16th August, 2013

Bodnar, R. J. (2004). Endogenous Opioids And Feeding Behavior: A 30-Year Historical Perspective. *Peptides, 25*(4), 697-725.

Bodnar, R. J. (2012). Endogenous Opiates And Behavior: 2011. *Peptides, 38*(2), 463-522.

Boeles, S., Williams, C., Campling, G. M., Goodall, E. M., & Cowen, P. J. (1997). Sumatriptan Decreases Food Intake And Increases Plasma Growth Hormone In Healthy Women. *Psychopharmacology, 129*(2), 179-182.

Boess, F. G., & Martin, I. L. (1994). Molecular-Biology Of 5-Ht Receptors. *Neuropharmacology, 33*(3-4), 275-317.

Boggiano, M. M., Chandler, P. C., Oswald, K. D., Rodgers, R. J., Blundell, J. E., Ishii, Y., Beattie, A. H., Holch, P., Allison, D. B., Schindler, M., Arndt, K., Rudolf, K., Mark, M., Schoelch, C., Joost, H. G., Klaus, S., Thone-Reineke, C., Benoit, S. C., Seeley, R. J., Beck-Sickinger, A. G., Koglin, N., Raun, K., Madsen, K., Wulff, B. S., Stidsen, C. E., Birringer, M., Kreuzer, O. J., Deng, X. Y., Whitcomb, D. C., Halem, H., Taylor, J., Dong, J., Datta, R., Culler, M., Ortmann, S., Castaneda, T. R., & Tschop, M. (2005). Pyy3-36 As An Anti-Obesity Drug Target. *Obesity Reviews, 6*(4), 307-322.

Bojanowska, E., & Nowak, A. (2007). Interactions Between Leptin And Exendin-4, A Glucagon-Like Peptide-1 Agonist, In The Regulation Of Food Intake In The Rat. *Journal Of Physiology And Pharmacology, 58*(2), 349-360.

Bojanowska, E., & Radziszewska, E. (2011). Combined Stimulation Of Glucagon-Like Peptide-1 Receptor And Inhibition Of Cannabinoid Cb1 Receptor Act Synergistically To Reduce Food Intake And Body Weight In The Rat. *Journal Of Physiology And Pharmacology, 62*(4), 395-402.

Bolles, R. (1960). Grooming Behaviour In The Rat. *Journal Of Comparative And Physiological Psychology, 53*, 306-310.

Bondarev, M. L., Bondareva, T. S., Young, R., & Glennon, R. A. (2003). Behavioral And Biochemical Investigations Of Bupropion Metabolites. *European Journal Of Pharmacology, 474*(1), 85-93.

Bonhaus, D. W., Weinhardt, K. K., Taylor, M., Desouza, A., Mcneeley, P. M., Szczepanski, K., Fontana, D. J., Trinh, J., Rocha, C. L., Dawson, M. W., Flippin, L. A., & Eglen, R. M. (1997). Rs-102221: A Novel High Affinity And Selective, 5-Ht2c Receptor Antagonist. *Neuropharmacology, 36*(4-5), 621-629.

Bonnefond, C., Palacios, J. M., Probst, A., & Mengod, G. (1990). Distribution Of Galanin Messenger-Rna Containing Cells And Galanin Receptor-Binding Sites In Human And Rat Hypothalamus. *European Journal Of Neuroscience, 2*(7), 629-637.

Boozer, C. N., Leibel, R. L., Love, R. J., Cha, M. C., & Aronne, L. J. (2001). Synergy Of Sibutramine And Low-Dose Leptin In Treatment Of Diet-Induced Obesity In Rats. *Metabolism-Clinical And Experimental, 50*(8), 889-893.

Borgland, S. L., Chang, S.-J., Bowers, M. S., Thompson, J. L., Vittoz, N., Floresco, S. B., Chou, J., Chen, B. T., & Bonci, A. (2009). Orexin A/Hypocretin-1 Selectively Promotes Motivation For Positive Reinforcers. *Journal Of Neuroscience, 29*, 11215-11225.

Borgland, S. L., Taha, S. A., Sarti, F., Fields, H. L., & Bonci, A. (2006). Orexin A In The Vta Is Critical For The Induction Of Synaptic Plasticity And Behavioral Sensitization To Cocaine. *Neuron, 49*(4), 589-601.

Borowsky, B., Durkin, M. M., Ogozalek, K., Marzabadi, M. R., Deleon, J., Heurich, R., Lichtblau, H., Shaposhnik, Z., Daniewska, I., Blackburn, T., Branchek, T. A., Gerald, C., Vaysse, P. J., & Forray, C. (2002). Antidepressant, Anxiolytic

And Anorectic Effects Of A Melanin-Concentrating Hormone-1 Receptor Antagonist. *Nature Medicine, 8*(8), 825 - 830.

Bose, M., Olivan, B., Teixeira, J., Pi-Sunyer, F. X., & Laferrere, B. (2009). Do Incretins Play A Role In The Remission Of Type 2 Diabetes After Gastric Bypass Surgery: What Are The Evidence? *Obesity Surgery, 19*(2), 217-229.

Boston, B. A., Blaydon, K. M., Varnerin, J., & Cone, R. D. (1997). Independent And Additive Effects Of Central Pomc And Leptin Pathways On Murine Obesity. *Science, 278*(5345), 1641 - 1644.

Bouali, S. M., Wimalawansa, S. J., & Jolicoeur, F. B. (1995). In-Vivo Central Actions Of Rat Amylin. *Regulatory Peptides, 56*(2-3), 167-174.

Bourin, M., Colombel, M. C., Redrobe, J. P., Nizard, J., Hascoet, M., & Baker, G. B. (1998). Evaluation Of Efficacies Of Different Classes Of Antidepressants In The Forced Swimming Test In Mice At Different Ages. *Progress In Neuro-Psychopharmacology & Biological Psychiatry, 22*(2), 343-351.

Boustany-Kari, C. M., Jackson, V. M., Gibbons, C. P., & Swick, A. G. (2011). Leptin Potentiates The Anti-Obesity Effects Of Rimonabant. *European Journal Of Pharmacology, 658*(2-3), 270-276.

Bouwknecht, J. A., Van Der Gugten, J., Hijzen, T. H., Maes, R. A. A., Hen, R., & Olivier, B. (2001). Male And Female 5-Ht1b Receptor Knockout Mice Have Higher Body Weights Than Wildtypes. *Physiology & Behavior, 74*(4-5), 507-516.

Boyle, C. N., Rossier, M. M., & Lutz, T. A. (2011). Influence Of High-Fat Feeding, Diet-Induced Obesity, And Hyperamylinemia On The Sensitivity To Acute Amylin. *Physiology & Behavior, 104*(1), 20-28.

Bradbury, M. J., Mcburnie, M. I., Denton, D. A., Lee, K. F., & Vale, W. W. (2000). Modulation Of Urocortin-Induced Hypophagia And Weight Loss By Corticotropin-Releasing Factor Receptor 1 Deficiency In Mice. *Endocrinology, 141*(8), 2715-2724.

Braida, D., Pozzi, M., Cavallini, R., & Sala, M. (2001). Conditioned Place Preference Induced By The Cannabinoid Agonist Cp 55,940: Interaction With The Opioid System. *Neuroscience, 104*(4), 923-926.

Brands, B., Thornhill, J. A., Hirst, M., & Gowdey, C. W. (1979). Supression Of Food-Intake And Body-Weight Gain By Naloxone In Rats. *Life Sciences, 24*(19), 1773-1778.

Bray, G. A. (1996). Static Theories In A Dynamic World: A Glucodynamic Theory Of Food Intake. *Obesity Research, 4*(5), 489-492.

Bray, G. A. (2000). Afferent Signals Regulating Food Intake. *Proceedings Of The Nutrition Society, 59*, 373-384.

Bray, G. A., & Greenway, F. L. (2007). Pharmacological Treatment Of The Overweight Patient. *Pharmacological Reviews, 59*, 151-184.

Bray, G. A., & Popkin, B. M. (1998). Dietary Fat Intake Does Affect Obesity! *American Journal Of Clinical Nutrition, 68*(6), 1157-1173.

Breisch, S. T., Zemlan, F. P., & Hoebel, B. G. (1976). Hyperphagia And Obesity Following Serotonin Depletion By Intraventricular Para-Chlorophenylalanine. *Science, 192*(4237), 382-385.

Brennan, I. M., Feltrin, K. L., Horowitz, M., Smout, A., Meyer, J. H., Wishart, J., & Feinle-Bisset, C. (2005). Evaluation Of Interactions Between Cck And Glp-1 In Their Effects On Appetite, Energy Intake, And Antropyloroduodenal Motility In Healthy Men. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 288*(6), R1477-R1485.

Brennan, I. M., Otto, B., Feltrin, K. L., Meyer, J. H., Horowitz, M., & Feinle-Bisset, C. (2007). Intravenous Cck-8, But Not Glp-1, Suppresses Ghrelin And Stimulates Pyy Release In Healthy Men. *Peptides, 28*(3), 607.

Breum, L., Rasmussen, M. H., Hilsted, J., & Fernstrom, J. D. (2003). Twenty-Four-Hour Plasma Tryptophan Concentrations And Ratios Are Below Normal In

Obese Subjects And Are Not Normalized By Substantial Weight Reduction. *American Journal Of Clinical Nutrition, 77*(5), 1112-1118.

Brewerton, T. D., Lydiard, R. B., Laraia, M. T., Shook, J. E., & Ballenger, J. C. (1992). Csf Beta-Endorphin And Dynorphin In Bulimia-Nervosa. *American Journal Of Psychiatry, 149*(8), 1086-1090.

Britton, D. R., Koob, G. F., Rivier, J., & Vale, W. (1982). Intraventricular Corticotropin-Releasing Factor Enhances Behavioural-Effects Of Novelty. *Life Sciences, 31*(4), 363-367.

Brobeck, J. R. (1946). Physiology Of Heat And Cold. *Annual Review Of Physiology, 8*, 65-88.

Broberger, C. (2005). Brain Regulation Of Food Intake And Appetite: Molecules And Networks. *Journal Of Internal Medicine, 258*(4), 301-327.

Broberger, C., & Hokfelt, T. (2001). Hypothalamic And Vagal Neuropeptide Circuitries Regulating Food Intake. *Physiology & Behavior, 74*(4-5), 669-682.

Broberger, C., Johansen, J., Johansson, C., Schalling, M., & Hokfelt, T. (1998). The Neuropeptide Y/Agouti Gene-Related Protein (Agrp) Brain Circuitry In Normal, Anorectic, And Monosodium Glutamate-Treated Mice. *PNAS, 95*(25), 15043-15048.

Brody, A. L., Mandelkern, M. A., Lee, G., Smith, E., Sadeghi, M., Saxena, S., Jarvik, M. E., & London, E. D. (2004). Attenuation Of Cue-Induced Cigarette Craving And Anterior Cingulate Cortex Activation In Bupropion-Treated Smokers: A Preliminary Study. *Psychiatry Research-Neuroimaging, 130*(3), 269-281.

Broekkamp, C. L., Phillips, A. G., & Cools, A. R. (1979). Facilitation Of Self-Stimulation Behaviour Following Intra-Cerebral Micro-Injections Of Opioids Into The Ventral Tegmental Area. *Pharmacology Biochemistry And Behavior, 11*(3), 289-295.

Brooks, C. M., Lockwood, R. A., & Wiggins, M. L. (1946). A Study Of The Effect Of Hypothalamic Lesions On The Eating Habits Of The Albino Rat. *American Journal Of Physiology, 147*(4), 735-741.

Broom, D., Jutkiewicz, E., Folk, J., Traynor, J., Rice, K., & Woods, J. (2002). Convulsant Activity Of A Non-Peptidic Δ-Opioid Receptor Agonist Is Not Required For Its Antidepressant-Like Effects In Sprague-Dawley Rats. *Psychopharmacology, 164*(1), 42-48.

Brown, C. M., & Coscina, D. V. (1995). Ineffectiveness Of Hypothalamic Serotonin To Block Neuropeptide Y-Induced Feeding. *Pharmacology Biochemistry And Behavior, 51*(4), 641-646.

Brown, D. R., & Holtzman, S. G. (1979). Suppression Of Deprivation-Induced Food And Water-Intake In Rats And Mice By Naloxone. *Pharmacology Biochemistry And Behavior, 11*(5), 567-573.

Brown, J. E., Kassouny, M., & Cross, J. K. (1977). Kinetic Studies Of Food-Intake And Sucrose Solution Preference By Rats Treated With Low-Doses Of Delta-9-Tetrahydrocannabinol. *Behavioral Biology, 20*(1), 104-110.

Brown, L. M., Clegg, D. J., Benoit, S. C., & Woods, S. C. (2006). Intraventricular Insulin And Leptin Reduce Food Intake And Body Weight In C57bl/6j Mice. *Physiology & Behavior, 89*(5), 687-691.

Brown, T., Avenell, A., Edmunds, L. D., Moore, H., Whittaker, V., Avery, L., Summerbell, C., & Team, P. (2009). Systematic Review Of Long-Term Lifestyle Interventions To Prevent Weight Gain And Morbidity In Adults. *Obesity Reviews, 10*(6), 627-638.

Brugman, S., Clegg, D. J., Woods, S. C., & Seeley, R. J. (2002). Combined Blockade Of Both M- And K-Opioid Receptors Prevents The Acute Orexigenic Action Of Agouti-Related Protein. *Endocrinology, 143*(11), 4265-4270.

Bruijnzeel, A. W., & Markou, A. (2003). Characterization Of The Effects Of Bupropion On The Reinforcing Properties Of Nicotine And Food In Rats. *Synapse, 50*(1), 20-28.

Bryant, S. G., Guernsey, B. G., & Ingrim, N. B. (1983). Review Of Bupropion. *Clinical Pharmacy, 2*(6), 525-537.

Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K., & Schoelles, K. (2004). Bariatric Surgery: A Systematic Review And Meta-Analysis. *Jama-Journal Of The American Medical Association, 292*(14), 1724-1737.

Bucinskaite, V., Tolessa, T., Pedersen, J., Rydqvist, B., Zerihun, L., Holst, J. J., & Hellstrom, P. M. (2009). Receptor-Mediated Activation Of Gastric Vagal Afferents By Glucagon-Like Peptide-1 In The Rat. *Neurogastroenterology And Motility, 21*(9).

Buczek, Y., Tomkins, D. M., Higgins, G. A., & Sellers, E. M. (1994). Dissociation Of Serotonergic Regulation Of Anxiety And Ethanol Self-Administration - A Study With Mcpp. *Behavioural Pharmacology, 5*(4-5), 470-484.

Bultman, S. J., Michaud, E. J., & Woychik, R. P. (1992). Molecular Characterization Of The Mouse Agouti Locus. *Cell, 71*(7), 1195-1204.

Bungo, T., Shimojo, M., Masuda, Y., Saito, N., Sugahara, K., Hasegawa, S., & Furuse, M. (1999). Effect Of Naloxone On The Anorexic Action By Glucagon-Like Peptide-1 (7-36) In The Neonatal Chick. *Japanese Poultry Science, 36*(2), 109-115.

Burkhauser, R. V., & Cawley, J. (2008). Beyond Bmi: The Value Of More Accurate Measures Of Fatness And Obesity In Social Science Research. *Journal Of Health Economics, 27*(2), 519-529.

Burton-Freeman, B., & Schneeman, B. O. (2002). Plasma Cholecystokinin Is Associated With Subjective Measures Of Satiety In Women. *American Journal Of Clinical Nutrition, 76*(3), 659-667.

Buse, J., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & Exenatide-113 Clinical Study, G. (2004). Effects Of Exenatide (Exendin-4) On Glycemic Control Over 30 Weeks In Sulfonylurea-Treated Patients With Type 2 Diabetes. *Diabetes Care, 27*(11), 2628-2635.

Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., Blonde, L., & Grp, L.-S. (2009). Liraglutide Once A Day Versus Exenatide Twice A Day For Type 2 Diabetes: A 26-Week Randomised, Parallel-Group, Multinational, Open-Label Trial (Lead-6). *Lancet, 374*(9683), 39-47.

Butler, A., & Cone, R. (2002). The Melanocortin Receptors: Lessons From Knockout Models. *Neuropeptides, 36*(2-3), 77.

Cai, X. J., Widdowson, P. S., Harrold, J., Wilson, S., Buckingham, R. E., Arch, J. R. S., Tadayyon, M., Clapham, J. C., Wilding, J., & Williams, G. (1999). Hypothalamic Orexin Expression - Modulation By Blood Glucose And Feeding. *Diabetes, 48*(11), 2132-2137.

Caldirola, P. M., & Svartengren, J. (2005). Selective Serotonin 5-Ht6 Receptor Antagonist(S) For The Treatment Of Obesity. *Neuropsychopharmacology, 30*, S54-S54.

Caminos, J. E., Bravo, S. B., Garcia-Rendueles, M. E. R., Gonzalez, C. R., Garces, M. F., Cepeda, L. A., Lage, R., Suarez, M. A., Lopez, M., & Dieguez, C. (2008). Expression Of Neuropeptide W In Rat Stomach Mucosa: Regulation By Nutritional Status, Glucocorticoids And Thyroid Hormones. *Regulatory Peptides, 146*(1-3), 106-111.

Campfield, L. A., Smith, F. J., Guisez, Y., Devos, R., & Burn, P. (1995). Recombinant Mouse Ob Protein - Evidence For A Peripheral Signal Linking Adiposity And Central Neural Networks. *Science, 269*(5223), 546-549.

Cangiano, C., Ceci, F., Cascino, A., Delben, M., Laviano, A., Muscaritoli, M., Antonucci, F., & Rossifanelli, F. (1992). Eating Behavior And Adherence To

Dietary Prescriptions In Obese Adult Subjects Treated With 5-Hydroxytryptophan. *American Journal Of Clinical Nutrition, 56*(5), 863-867.

Cani, P. D., Montoya, M. L., Neyrinck, A. M., Delzenne, N. M., & Lambert, D. M. (2004). Potential Modulation Of Plasma Ghrelin And Glucagon-Like Peptide-1 By Anorexigenic Cannabinoid Compounds, Sr141716a (Rimonabant) And Oleoylethanolamide. *British Journal Of Nutrition, 92*(5), 757-761.

Cannon, W. B., & Washburn, A. L. (1912). An Explanation Of Hunger. *American Journal Of Physiology, 29*(5), 441-454.

Carai, M. A. M., Colombo, G., & Gessa, G. L. (2005). Rimonabant: The First Therapeutically Relevant Cannabinoid Antagonist. *Life Sciences, 77*(19), 2339-2350.

Carey, M. P., Ross, J. A., & Enns, M. P. (1981). Naloxone Suppresses Feeding And Drinking But Not Wheel Running In Rats. *Pharmacology Biochemistry And Behavior, 14*(4), 569-571.

Carli, M., & Samanin, R. (1992). Serotonin2 Receptor Agonists And Serotonergic Anorectic Drugs Affect Rats Performance Differently In A 5-Choice Serial Reaction-Time-Task. *Psychopharmacology, 106*(2), 228-234.

Carr, K. D., Bak, T. H., Simon, E. J., & Portoghese, P. S. (1989). Effects Of The Selective Kappa Opioid Antagonist, Nor-Binaltorphimine, On Electrically-Elicited Feeding In The Rat. *Life Sciences, 45*(19), 1787-1792.

Carr, K. D., & Simon, E. J. (1983). The Role Of Opioids In Feeding And Reward Elicited By Lateral Hypothalamic Electrical-Stimulation. *Life Sciences, 33*, 563-566.

Carr, R. D., Larsen, M. O., Jelic, K., Lindgren, O., Vikman, J., Holst, J. J., Deacon, C. F., & Ahren, B. (2010). Secretion And Dipeptidyl Peptidase-4-Mediated Metabolism Of Incretin Hormones After A Mixed Meal Or Glucose Ingestion In Obese Compared To Lean, Nondiabetic Men. *Journal Of Clinical Endocrinology & Metabolism, 95*(2), 872-878.

Carrasco, M. C., Vicens, P., Vidal, J., & Redolat, R. (2004). Effects Of Acute Administration Of Bupropion On Behavior In The Elevated Plus-Maze Test By Nmri Mice. *Progress In Neuro-Psychopharmacology & Biological Psychiatry, 28*(7), 1135-1141.

Carraway, R., & Leeman, S. E. (1973). Isolation Of A New Hypotensive Peptide, Neurotensin, From Bovine Hypothalami. *Journal Of Biological Chemistry, 248*(19), 6854-6861.

Carter, R., Mouralidarane, A., Ray, S., Soeda, J., & Oben, J. (2012). Recent Advancements In Drug Treatment Of Obesity. *Clinical Medicine, 12*(5), 456-460.

Castro, L., Maldonado, I., Campos, I., Varjao, B., Angelo, A. L., Athanazio, R. A., Barbetta, M. C., Ramos, A. C., Fregoneze, J. B., & Silva, E. D. E. (2002). Central Administration Of Mcpp, A Serotonin 5-Ht2b/2c Agonist, Decreases Water Intake In Rats. *Pharmacology Biochemistry And Behavior, 72*(4), 891-898.

Catenacci, V. A., & Wyatt, H. R. (2007). The Role Of Physical Activity In Producing And Maintaining Weight Loss. *Nature Clinical Practice Endocrinology & Metabolism, 3*(7), 518-529.

Chalmers, D. T., Lovenberg, T. W., Grigoriadis, D. E., Behan, D. P., & Desouza, E. B. (1996). Corticotrophin-Releasing Factor Receptors: From Molecular Biology To Drug Design. *Trends In Pharmacological Sciences, 17*(4), 166-172.

Chambers, A. P., Koopmans, H. S., Pittman, Q. J., & Sharkey, K. A. (2006). Am 251 Produces Sustained Reductions In Food Intake And Body Weight That Are Resistant To Tolerance And Conditioned Taste Aversion. *British Journal Of Pharmacology, 147*(1), 109-116.

Chambers, A. P., Sharkey, K. A., & Koopmans, H. S. (2004). Cannabinoid (Cb)(1) Receptor Antagonist, Am 251, Causes A Sustained Reduction Of Daily Food Intake In The Rat. *Physiology & Behavior, 82*(5), 863-869.

Chamorro, S., Della-Zuana, O., Fauchere, J. L., Feletou, M., Galizzi, J. P., & Levens, N. (2002). Appetite Suppression Based On Selective Inhibition Of Npy Receptors. *International Journal Of Obesity, 26*(3), 281-298.

Chan, S. W., Lin, G., Yew, D. T. W., Yeung, C. K., & Rudd, J. A. (2013). Separation Of Emetic And Anorexic Responses Of Exendin-4, A Glp-1 Receptor Agonist In Suncus Murinus (House Musk Shrew). *Neuropharmacology, 70*, 141-147.

Chance, W. T., Balasubramaniam, A., Zhang, F. S., Wimalawansa, S. J., & Fischer, J. E. (1991). Anorexia Following The Intrahypothalamic Administration Of Amylin. *Brain Research, 539*(2), 352-354.

Chapelot, D., Marmonier, C., Thomas, F., & Hanotin, C. (2000). Modalities Of The Food Intake-Reducing Effect Of Sibutramine In Humans. *Physiology & Behavior, 68*(3), 299-308.

Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Lush, C. W., Chen, K., Lacerte, C., Burns, C., Mckay, R., Weyer, C., & Horowitz, M. (2007). Low-Dose Pramlintide Reduced Food Intake And Meal Duration In Healthy, Normal-Weight Subjects. *Obesity, 15*(5), 1179-1186.

Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., & Horowitz, M. (2005). Effect Of Pramlintide On Satiety And Food Intake In Obese Subjects And Subjects With Type 2 Diabetes. *Diabetologia, 48*(5), 838-848.

Chavez-Tapia, N. C., Tellez-Avila, F. I., Bedogni, G., Croce, L. S., Masutti, F., & Tiribelli, C. (2009). Systematic Review And Meta-Analysis On The Adverse Events Of Rimonabant Treatment: Considerations For Its Potential Use In Hepatology. *Bmc Gastroenterology, 9*.

Chelikani, P. K., Haver, A. C., & Reidelberger, R. D. (2005). Intravenous Infusion Of Glucagon-Like Peptide-1 Potently Inhibits Food Intake, Sham Feeding, And Gastric Emptying In Rats. *Am J Physiol Regul Integr Comp Physiol, 288*(6), R1695-1706.

Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., Richardson, J. A., Williams, S. C., Xiong, Y., & Kisanuki Et, A. (1999). Narcolepsy In Orexin Knockout Mice: Molecular Genetics Of Sleep Regulation. *Cell, 98*(4), 437-451.

Chemelli, R. M., Willie, J. T., Xiong, Y., & Yanagisawa, M. (2001). Metabolic Characterization Of Orexin Knockout Mice. *SLEEP, Suppl, 24*.

Chen, A. S., Marsh, D. J., Trumbauer, M. E., Frazier, E. G., Guan, X. M., Yu, H., Rosenblum, C. I., Vongs, A., Feng, Y., Cao, L. H., Metzger, J. M., Strack, A. M., Camacho, R. E., Mellin, T. N., Nunes, C. N., Min, W., Fisher, J., Gopal-Truter, S., Macintyre, D. E., Chen, H. Y., & Van Der Ploeg, L. H. T. (2000). Inactivation Of The Mouse Melanocortin-3 Receptor Results In Increased Fat Mass And Reduced Lean Body Mass. *Nature Genetics, 26*(1), 97-102.

Chen, H. Y., Trumbauer, M. E., Chen, A. S., Weingarth, D. T., Adams, J. R., Frazier, E. G., Shen, Z., Marsh, D. J., Feighner, S. D., Guan, X.-M., Ye, Z., Nargund, R. P., Smith, R. G., Van Der Ploeg, L. H. T., Howard, A. D., Macneil, D. J., & Qian, S. (2004). Orexigenic Action Of Peripheral Ghrelin Is Mediated By Neuropeptide Y (Npy) And Agouti-Related Protein (Agrp). *Endocrinology*, En.2003-1596.

Chen, P., Williams, S. M., Grove, K. L., & Smith, M. S. (2004). Melanocortin 4 Receptor-Mediated Hyperphagia And Activation Of Neuropeptide Y Expression In The Dorsomedial Hypothalamus During Lactation. *J. Neurosci., 24*(22), 5091-5100.

Chen, R. Z., Frassetto, A., Lao, J. Z., Huang, R.-R. C., Xiao, J. C., Clements, M. J., Walsh, T. F., Hale, J. J., Wang, J., Tong, X., & Fong, T. M. (2008).

Pharmacological Evaluation Of Lh-21, A Newly Discovered Molecule That Binds To Cannabinoid Cb1 Receptor. *European Journal Of Pharmacology, 584*(2-3), 338.

Chen, R. Z., Huang, R. R. C., Shen, C. P., Macneil, D. J., & Fong, T. M. (2004). Synergistic Effects Of Cannabinoid Inverse Agonist Am251 And Opioid Antagonist Nalmefene On Food Intake In Mice. *Brain Research, 999*(2), 227-230.

Chen, W., Tang, H., Liu, H., Long, L., Gong, Z., Zheng, J., Chi, M., Xie, Y., Zheng, Z., Li, S., & Wang, L. (2010). Novel Selective Antagonist Of The Cannabinoid Cb1 Receptor, Mj15, With Prominent Anti-Obesity Effect In Rodent Models. *European Journal Of Pharmacology, 637*(1-3), 178-185.

Choi, S., Blake, V., Cole, S., & Fernstrom, J. D. (2006). Effects Of Chronic Fenfluramine Administration On Hypothalamic Neuropeptide Mrna Expression. *Brain Research, 1087*, 83-86.

Chouinard, G. (1983). Bupropion And Amitriptyline In The Treatment Of Depressed-Patients. *Journal Of Clinical Psychiatry, 44*(5), 121-129.

Christensen, M., & Knop, F. (2010). Once-Weekly Glp-1 Agonists: How Do They Differ From Exenatide And Liraglutide? *Current Diabetes Reports, 10*(2), 124-132.

Christensen, R., Kristensen, P. K., Bartels, E. M., Blidda, H., & Astrup, A. (2007). Efficacy And Safety Of The Weight-Loss Drug Rimonabant: A Meta-Analysis Of Randomised Trials. *Lancet, 370*(9600), 1706-1713.

Christie, M. J. (2006). Opioid And Cannabinoid Receptors: Friends With Benefits Or Just Close Friends? *British Journal Of Pharmacology, 148*(4), 385-386.

Chronaiou, A., Tsoli, M., Kehagias, I., Leotsinidis, M., Kalfarentzos, F., & Alexandrides, T. K. (2012). Lower Ghrelin Levels And Exaggerated Postprandial Peptide-Yy, Glucagon-Like Peptide-1, And Insulin Responses, After Gastric Fundus Resection, In Patients Undergoing Roux-En-Y Gastric Bypass: A Randomized Clinical Trial. *Obesity Surgery, 22*(11), 1761-1770.

Chugh, P. K., & Sharma, S. (2012). Recent Advances In The Pathophysiology And Pharmacological Treatment Of Obesity. *Journal Of Clinical Pharmacy And Therapeutics, 37*(5), 525-535.

Churchill, L., Roques, B. P., & Kalivas, P. W. (1995). Dopamine Depletion Augments Endogenous Opioid-Induced Locomotion In The Nucleus Accumbens Using Bothμ1 Andδ Opioid Receptors. *Psychopharmacology, 120*(3), 347-355.

Churruca, I., Casis, L., Portillo, M. P., Macarulla, M. T., Zarate, J., Pascual, J., & Echevarria, E. (2004). Fluoxetine Alters Mu Opioid Receptor Expression In Obese Zucker Rat Hypothalamus. *Neuroscience Research Communications, 35*(1), 1-7.

Cies, J. J., & Giamalis, J. N. (2007). Treatment Of Cholestatic Pruritus In Children. *American Journal Of Health-System Pharmacy, 64*(11), 1157-1162.

Citizen, P. (2011). Petition To Ban Orlistat (Alli, Xenical). Retrieved 16th August, 2013

Clapper, J. R., Athanacio, J., Wittmer, C., Griffin, P. S., D'souza, L., Parkes, D. G., & Roth, J. D. (2013). Effects Of Amylin And Bupropion/Naltrexone On Food Intake And Body Weight Are Interactive In Rodent Models. *European Journal Of Pharmacology, 698*(1-3), 292-298.

Clark, J. T., Kalra, P. S., Crowley, W. R., & Kalra, S. P. (1984). Neuropeptide-Y And Human Pancreatic-Polypeptide Stimulate Feeding-Behavior In Rats. *Endocrinology, 115*(1), 427-429.

Cleary, J., Weldon, D. T., O'hare, E., Billington, C., & Levine, A. S. (1996). Naloxone Effects On Sucrose-Motivated Behavior. *Psychopharmacology, 126*(2), 110-114.

Clementi, G., Valerio, C., Emmi, I., Prato, A., & Drago, F. (1996). Behavioral Effects Of Amylin Injected Intracerebroventricularly In The Rat. *Peptides, 17*(4), 589-591.

Clifton, P. G. (2000). Meal Patterning In Rodents: Psychopharmacological And Neuroanatomical Studies. *Neuroscience And Biobehavioral Reviews, 24*(2), 213-222.

Clifton, P. G., Barnfield, A. M., & Curzon, G. (1993). Effects Of Food-Deprivation And Mcpp Treatment On The Microstructure Of Ingestive Behavior Of Male And Female Rats. *Journal Of Psychopharmacology, 7*(3), 257-264.

Clifton, P. G., Barnfield, A. M. C., & Philcox, L. (1989). A Behavioural Profile Of Fluoxetine-Induced Anorexia. *Psychopharmacology, 97*, 89-95.

Clifton, P. G., Kennett, G. A., Somerville, E. M., & Thornton-Jones, Z. D. (2005). The Selective 5-Ht Receptor Agonist Ver-23779/Ro-4590334 Enhances Satiety And C-Fos Activation In The Mouse. *Abstract At European Behavioural Pharmacology Society Conference Barcelona 2005*.

Clifton, P. G., Lee, M. D., & Dourish, C. T. (2000). Similarities In The Action Of Ro 60-0175, A 5-Ht2c Receptor Agonist, And D-Fenfluramine On Feeding Patterns In The Rat. *Psychopharmacology, 152*(3), 256-267.

Clifton, P. G., Lee, M. D., Somerville, E. M., Kennett, G. A., & Dourish, C. T. (2003). 5-Ht1b Receptor Knockout Mice Show A Compensatory Reduction In 5-Ht2c Receptor Function. *European Journal Of Neuroscience, 17*(1), 185-190.

Clifton, P. G., Rusk, I. N., & Cooper, S. J. (1991). Effects Of Dopamine-D1 And Dopamine-D2 Antagonists On The Free Feeding And Drinking Patterns Of Rats. *Behavioral Neuroscience, 105*(2), 272-281.

Cline, M. A., Nandar, W., & Rogers, J. O. (2007). Xenin Reduces Feed Intake By Activating The Ventromedial Hypothalamus And Influences Gastrointestinal Transit Rate In Chicks. *Behavioural Brain Research, 179*(1), 28-32.

Clinicaltrials.Gov. (2013). Safety Study Of The Inhibition Of Agouti-Related Protein (Agrp) For The Management Of Obesity And Weight Loss. Retrieved 6th September 2013, 2013, From Http://Clinicaltrials.Gov/Ct2/Show/NCT00779519

Cluny, N. L., Chambers, A. P., Vemuri, V. K., Wood, J. T., Eller, L. K., Freni, C., Reimer, R. A., Makriyannis, A., & Sharkey, K. A. (2011). The Neutral Cannabinoid Cb1 Receptor Antagonist Am4113 Regulates Body Weight Through Changes In Energy Intake In The Rat. *Pharmacology Biochemistry And Behavior, 97*(3), 537-543.

Cluny, N. L., Vemuri, V. K., Chambers, A. P., Limebeer, C. L., Bedard, H., Wood, J. T., Lutz, B., Zimmer, A., Parker, L. A., Makriyannis, A., & Sharkey, K. A. (2010). A Novel Peripherally Restricted Cannabinoid Receptor Antagonist, Am6545, Reduces Food Intake And Body Weight, But Does Not Cause Malaise, In Rodents. *British Journal Of Pharmacology, 161*(3), 629-642.

Coda, B. A., Hill, H. F., Schaffer, R. L., Luger, T. J., Jacobson, R. C., & Chapman, C. R. (1993). Enhancement Of Morphine Analgesia By Fenfluramine In Subjects Receiving Tailored Opioid Infusions. *Pain, 52*(1), 85-91.

Cohen, M. A., Ellis, S. M., Le Roux, C. W., Batterham, R. L., Park, A., Patterson, M., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003). Oxyntomodulin Suppresses Appetite And Reduces Food Intake In Humans

10.1210/Jc.2003-030421. *J Clin Endocrinol Metab, 88*(10), 4696-4701.

Cohen, M. R., Cohen, R. M., Pickar, D., & Murphy, D. L. (1985). Naloxone Reduces Food Intake In Humans. *Psychosomatic Medicine, 47*(2), 132-138.

Coll, A. P., & Tung, Y. C. L. (2009). Pro-Opiomelanocortin (Pomc)-Drived Peptides And The Regulation Of Energy Homeostasis. *Molecular And Cellular Endocrinology, 300*, 147-151.

Colombo, G., Agabio, R., Diaz, G., Lobina, C., Reali, R., & Gessa, G. L. (1998). Appetite Suppression And Weight Loss After The Cannabinoid Antagonist Sr141716. *Life Sciences, 63*(8), PL113-PL117.

Colombo, G., Orru, A., Lai, P., Cabras, C., Maccioni, P., Rubio, M., Gessa, G. L., & Carai, M. A. M. (2007). The Cannabinoid Cb(1) Receptor Antagonist, Rimonabant, As A Promising Pharmacotherapy For Alcohol Dependence: Preclinical Evidence. *Molecular Neurobiology, 36*(1), 102-112.

Colombo, G., Serra, S., Vacca, G., Carai, M. A. M., & Gessa, G. L. (2005). Endocannabinoid System And Alcohol Addiction: Pharmacological Studies. *Pharmacology Biochemistry And Behavior, 81*(2), 369-380.

Colon-Gonzalez, F., Kim, G. W., Lin, J. E., Valentino, M. A., & Waldman, S. A. (2013). Obesity Pharmacotherapy: What Is Next? *Molecular Aspects Of Medicine, 34*(1), 71-83.

Commons, T. H. O. (2004). Health - Third Report. Retrieved May 2013, From Http://Www.Publications.Parliament.Uk/Pa/Cm200304/Cmselect/Cmhealth/23/2302.Htm

Compan, V., Dusticier, N., Nieoullon, A., & Daszuta, A. (1996). Opposite Changes In Striatal Neuropeptide Y Immunoreactivity After Partial And Complete Serotonergic Depletion In The Rat. *Synapse, 24*(1), 87-96.

Compan, V., Zhou, M. M., Grailhe, R., Gazzara, R. A., Martin, R., Gingrich, J., Dumuis, A., Brunner, D., Bockaert, J., & Hen, R. (2004). Attenuated Response To Stress And Novelty And Hypersensitivity To Seizures In 5-Ht4 Receptor Knock-Out Mice. *Journal Of Neuroscience, 24*(2), 412-419.

Compton, D. R., Aceto, M. D., Lowe, J., & Martin, B. R. (1996). In Vivo Characterization Of A Specific Cannabinoid Receptor Antagonist (Sr141716a): Inhibition Of Delta(9)-Tetrahydrocannabinol-Induced Responses And Apparent Agonist Activity. *Journal Of Pharmacology And Experimental Therapeutics, 277*(2), 586-594.

Cone, R. (2005). Anatomy And Regulation Of The Central Melanocortin System. *Nature Neuroscience, 8*(5), 571-578.

Cone, R. D. (1999). The Central Melanocortin System And Energy Homeostasis. *Trends In Endocrinology And Metabolism, 10*(6), 211-216.

Cone, R. D., Cowley, M. A., Butler, A., Fan, W., Marks, D. L., & Low, M. J. (2001). The Arcuate Nucleus As A Conduit For Diverse Signals Relevant To Energy Homeostasis. *International Journal Of Obesity, 25*(Suppl. 5), 563 - 567.

Conners, C. K., Casat, C. D., Gualtieri, C. T., Weller, E., Reader, M., Reiss, A., Weller, R. A., Khayrallah, M., & Ascher, J. (1996). Bupropion Hydrochloride In Attention Deficit Disorder With Hyperactivity. *Journal Of The American Academy Of Child And Adolescent Psychiatry, 35*(10), 1314-1321.

Connoley, I. P., Heal, D. J., & Stock, M. J. (1995). A Study In Rats Of The Effects Of Sibutramine On Food-Intake And Thermogenesis. *British Journal Of Pharmacology, 114*, P388-P388.

Connolly, H. M., Crary, J. L., Mcgoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997). Valvular Heart Disease Associated With Fenfluramine-Phentermine. *New England Journal Of Medicine, 337*(9), 581-588.

Cook, S. A., Lowe, J. A., & Martin, B. R. (1998). Cb1 Receptor Antagonist Precipitates Withdrawal In Mice Exposed To Delta(9)-Tetrahydrocannabinol. *Journal Of Pharmacology And Experimental Therapeutics, 285*(3), 1150-1156.

Cooke, J. H., Patterson, M., Patel, S. R., Smith, K. L., Ghatei, M. A., Bloom, S. R., & Murphy, K. G. (2009). Peripheral And Central Administration Of Xenin And Neurotensin Suppress Food Intake In Rodents. *Obesity, 17*(6), 1135-1143.

Cooper, B. R., Hester, T. J., & Maxwell, R. A. (1980). Behavioral And Biochemical Effects Of The Anti-Depressant Bupropion (Wellbutrin) - Evidence For

Selective Blockade Of Dopamine Uptake Invivo. *Journal Of Pharmacology And Experimental Therapeutics, 215*(1), 127-134.

Cooper, B. R., Wang, C. M., Cox, R. F., Norton, R., Shea, V., & Ferris, R. M. (1994). Evidence That The Acute Behavioral And Electrophysiological Effects Of Bupropion (Wellbutrin(R)) Are Mediated By A Noradrenergic Mechanism. *Neuropsychopharmacology, 11*(2), 133-141.

Cooper, S. J. (1980). Naloxone - Effects On Food And Water-Consumption In The Non-Deprived And Deprived Rat. *Psychopharmacology, 71*(1), 1-6.

Cooper, S. J. (2004). Endocannabinoids And Food Consumption: Comparisons With Benzodiazepine And Opioid Palatability-Dependent Appetite. *European Journal Of Pharmacology, 500*(1-3), 37-49.

Cooper, S. J., & Barber, D. J. (1994). Evidence For Serotonergic Involvement In Saccharin Preference In A 2-Choice Test In Rehydrating Rats. *Pharmacology Biochemistry And Behavior, 47*(3), 541-546.

Cooper, S. J., Jackson, A., & Kirkham, T. C. (1985). Endorphins And Food Intake: Kappa Opioid Receptor Agonists And Hyperphagia. *Pharmacology Biochemistry And Behavior, 23*(5), 889-901.

Cooper, S. J., & Kirkham, T. C. (1993). Opioid Mechanisms In The Control Of Food Consumption And Taste Preferences. In A. Herz, H. Akil & E. Simon (Eds.), *Opioids Ii* (Vol. 104 / 2, Pp. 239-262): Springer Berlin Heidelberg.

Cooper, S. J., & Turkish, S. (1989). Effects Of Naltrexone On Food Preference And Concurrent Behavioral-Responses In Food-Deprived Rats. *Pharmacology Biochemistry And Behavior, 33*(1), 17-20.

Cooper, S. J., & Vanderhoek, G. A. (1993). Cocaine - A Microstructural Analysis Of Its Effects On Feeding And Associated Behavior In The Rat. *Brain Research, 608*(1), 45-51.

Cooper, S. J. A. K., T. C. (1993). *Handbook Of Experimental Pharmacology Volume; Opioid Mechanisms In The Control Of Food Consumption And Taste Preferences* (Vol. 104 (2)).

Corp, E. S., Mcquade, J., Krasnicki, S., & Conze, D. B. (2001). Feeding After Fourth Ventricular Administration Of Neuropeptide Y Receptor Agonists In Rats. *Peptides, 22*(3), 493-499.

Corwin, R. L., Gibbs, J., & Smith, G. P. (1991). Increased Food-Intake After Type-A But Not Type-B Cholecystokinin Receptor Blockade. *Physiology & Behavior, 50*(1), 255-258.

Cota, D., Marsicano, G., Lutz, B., Vicennati, V., Stalla, G. K., Pasquali, R., & Pagotto, U. (2003). Endogenous Cannabinoid System As A Modulator Of Food Intake. *International Journal Of Obesity, Volume 27*(Number 3), 289-301.

Cota, D., Marsicano, G., Tschop, M., Grubler, Y., Flachskamm, C., Schubert, M., Auer, D., Yassouridis, A., Thone-Reineke, C., Ortmann, S., Tomassoni, F., Cervino, C., Nisoli, E., Linthorst, A. C. E., Pasquali, R., Lutz, B., Stalla, G. K., & Pagotto, U. (2003). The Endogenous Cannabinoid System Affects Energy Balance Via Central Orexigenic Drive And Peripheral Lipogenesis. *J. Clin. Invest., 112*(3), 423-431.

Cota, D., Tschop, M. H., Horvath, T. L., & Levine, A. S. (2006). Cannabinoids, Opioids And Eating Behavior: The Molecular Face Of Hedonism? *Brain Research Reviews, 51*(1), 85.

Cota, D. G., S. Pasquali, R. Pagotto, U.. (2003). Antagonising The Cannabinoid Receptor Type 1: A Dual Way To Fight Obesity. *Journal Of Endocrinology And Investigation, 26*, 1041-1044.

Cousins, M. J., & Mather, L. E. (1984). Intrathecal And Epidural Administration Of Opioids. *Anesthesiology, 61*(3), 276-310.

Coutts, A. A., & Izzo, A. A. (2004). The Gastrointestinal Pharmacology Of Cannabinoids: An Update. *Current Opinion In Pharmacology, 4*(6), 572-579.

Cowen, P. J., Clifford, E. M., Walsh, A. E. S., Williams, C., & Fairburn, C. G. (1996). Moderate Dieting Causes 5-Ht2c Receptor Supersensitivity. *Psychological Medicine, 26*(6), 1155-1159.

Cowen, P. J., Sargent, P. A., Williams, C., Goodall, E. M., & Orlikov, A. B. (1995). Hypophagic, Endocrine And Subjective Responses To M-Chlorophenylpiperazine In Healthy-Men And Women. *Human Psychopharmacology-Clinical And Experimental, 10*(5), 385-391.

Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdan, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001). Leptin Activates Anorexigenic Pomc Neurons Through A Neural Network In The Arcuate Nucleus. *Nature, 411*, 480 - 483.

Craddock, D. (1976). Anorectic Drugs - Use In General-Practice. *Drugs, 11*(5), 378-393.

Creutzfeldt, W. (1979). Incretin Concept Today. *Diabetologia, 16*(2), 75-85.

Croft, H., Houser, T., Leadbetter, R., Jamerson, B., & Metz, A. (2000). Effects Of Bupropion Sr On Weight In The Long-Term Treatment Of Depression. *Obesity Research, 8*, 10S-10S.

Croft, H., Houser, T. L., Jamerson, B. A., Leadbetter, R., Bolden-Watson, C., Donahue, R., & Metz, A. (2002). Effect On Body Weight Of Bupropion Sustained-Release In Patients With Major Depression Treated For 52 Weeks. *Clinical Therapeutics, 24*(4), 662-672.

Crone, C. C., & Gabriel, G. M. (2004). Treatment Of Anxiety And Depression In Transplant Patients - Pharmacokinetic Considerations. *Clinical Pharmacokinetics, 43*(6), 361-394.

Cullen, M. J., Ling, N., Foster, A. C., & Pelleymounter, M. A. (2001). Urocortin, Corticotropin Releasing Factor-2 Receptors And Energy Balance. *Endocrinology, 142*(3), 992-999.

Cummings, D. E., & Overduin, J. (2007). Gastrointestinal Regulation Of Food Intake. *Journal Of Clinical Investigation, 117*(1), 13-23.

Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., & Weigle, D. S. (2001). A Preprandial Rise In Plasma Ghrelin Levels Suggests A Role In Meal Initiation In Humans. *Diabetes, 50*(8), 1714-1719.

Cummings, D. E., & Schwarts, M. W. (2000). Melanocortins And Body Weight: A Tale Of Two Receptors. *Nature Genetics, 26*, 8 - 9.

Curioni, C., & Andre, C. (2006). Rimonabant For Overweight Or Obesity. *Cochrane Database Of Systematic Reviews*(4).

Currie, P. J. (2003). Integration Of Hypothalamic Feeding And Metabolic Signals: Focus On Neuropeptide Y. *Appetite, 41*(3), 335-337.

Currie, P. J., & Coscina, D. V. (1996). Regional Hypothalamic Differences In Neuropeptide Y-Induced Feeding And Energy Substrate Utilization. *Brain Research, 737*(1-2), 238-242.

Curzon, G., Gibson, E. L., & Oluyomi, A. O. (1997). Appetite Suppression By Commonly Used Drugs Depends On 5-Ht Receptors But Not On 5-Ht Availability. *Trends In Pharmacological Sciences, 18*(1), 21-25.

Dahlstrom, A., & Fuxe, K. (1964). Localization Of Monoamines In Lower Brain Stem. *Experientia, 20*(7), 398-&.

Dakin, C. L., Gunn, I., Small, C. J., Edwards, C. M. B., Hay, D. L., Smith, D. M., Ghatei, M. A., & Bloom, S. R. (2001). Oxyntomodulin Inhibits Food Intake In The Rat. *Endocrinology, 142*(10), 4244-4250.

Dakin, C. L., Small, C. J., Batterham, R. L., Neary, N. M., Cohen, M. A., Patterson, M., Ghatei, M. A., & Bloom, S. R. (2004). Peripheral Oxyntomodulin Reduces Food Intake And Body Weight Gain In Rats

10.1210/En.2003-1338. *Endocrinology, 145*(6), 2687-2695.

Dakin, C. L., Small, C. J., Park, A. J., Seth, A., Ghatei, M. A., & Bloom, S. R. (2002). Repeated Icv Administration Of Oxyntomodulin Causes A Greater

Reduction In Body Weight Gain Than In Pair-Fed Rats. *American Journal Of Physiology-Endocrinology And Metabolism, 283*(6), E1173-E1177.

Dalton, G. L., Lee, M. D., Kennett, G. A., Dourish, C. T., & Clifton, P. G. (2006). Serotonin 1b And 2c Receptor Interactions In The Modulation Of Feeding Behaviour In The Mouse. *Psychopharmacology, 185*(1), 45-57.

Damaj, M. I., Slemmer, J. E., Carroll, F. I., & Martin, B. R. (1999). Pharmacological Characterization Of Nicotine's Interaction With Cocaine And Cocaine Analogs. *Journal Of Pharmacology And Experimental Therapeutics, 289*(3), 1229-1236.

Daniels, A. J., Grizzle, M. K., Wiard, R. P., Matthews, J. E., & Heyer, D. (2002). Food Intake Inhibition And Reduction In Body Weight Gain In Lean And Obese Rodents Treated With Gw438014a, A Potent And Selective Npy-Y5 Receptor Antagonist. *Regulatory Peptides, 106*(1-3), 47-54.

Dansinger, M. L., Gleason, J. A., Griffith, J. L., Selker, H. P., & Schaefer, E. J. (2005). Comparison Of The Atkins, Ornish, Weight Watchers, And Zone Diets For Weight Loss And Heart Disease Risk Reduction. *Jama-Journal Of The American Medical Association, 293*(1), 43-53.

Darga, L. L., Carrollmichals, L., Botsford, S. J., & Lucas, C. P. (1991). Fluoxetines Effect On Weight-Loss In Obese Subjects. *American Journal Of Clinical Nutrition, 54*(2), 321-325.

Date, Y., Mondal, M. S., Kageyama, H., Ghamari-Langroudi, M., Takenoya, F., Yamaguchi, H., Shimomura, Y., Mori, M., Murakami, N., Shioda, S., Cone, R. D., & Nakazato, M. (2010). Neuropeptide W: An Anorectic Peptide Regulated By Leptin And Metabolic State. *Endocrinology, 151*(5), 2200-2210.

Date, Y., Murakami, N., Toshinai, K., Matsukura, S., Niijima, A., Matsuo, H., Kangawa, K., & Nakazato, M. (2002). The Role Of The Gastric Afferent Vagal Nerve In Ghrelin-Induced Feeding And Growth Hormone Secretion In Rats. *Gastroenterology, 123*(4), 1120 -1128.

Daubenmier, J., Kristeller, J., Hecht, F. M., Maninger, N., Kuwata, M., Jhaveri, K., Lustig, R. H., Kemeny, M., Karan, L., & Epel, E. (2011). Mindfulness Intervention For Stress Eating To Reduce Cortisol And Abdominal Fat Among Overweight And Obese Women: An Exploratory Randomized Controlled Study. *Journal Of Obesity, 2011*, 651936-651936.

Davies, D. J., Baxter, J. M., & Baxter, J. N. (2007). Nutritional Deficiencies After Bariatric Surgery. *Obesity Surgery, 17*(9), 1150-1158.

Day, C., & Bailey, C. J. (1998). Effect Of The Antiobesity Agent Sibutramine In Obese-Diabetic Ob/Ob Mice. *International Journal Of Obesity, 22*(7), 619-623.

Day, J. E. A. (2009). A New Glucagon And Glp-1 Co-Agonist Eliminates Obesity In Rodents. *Nature Chemical Biology, Advance Online Doi,1038/Nchembio.209*.

Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., Holland, J., Hembree, J., Abplanalp, W., Grant, E., Ruehl, J., Wilson, H., Kirchner, H., Lockie, S. H., Hofmann, S., Woods, S. C., Nogueiras, R., Pfluger, P. T., Perez-Tilve, D., Dimarchi, R., & Tschoep, M. H. (2009). A New Glucagon And Glp-1 Co-Agonist Eliminates Obesity In Rodents. *Nature Chemical Biology, 5*(10), 749-757.

De Gobbi, J. I. F., Martinez, G., Barbosa, S. P., Beltz, T. G., De Luca, L. A., Jr., Thunhorst, R. L., Johnson, A. K., & Menani, J. V. (2007). 5-Ht2 And 5-Ht3 Receptors In The Lateral Parabrachial Nucleus Mediate Opposite Effects On Sodium Intake. *Neuroscience, 146*(4), 1453-1461.

De Lecea, L., Kilduff, T. S., Peyron, C., Gao, X.-B., Foye, P. E., Danielson, P. E., Fukuhara, C., Battenberg, E. L. F., Gautvik, V. T., Bartlett, F. S., Ii, Frankel, W. N., Van Den Pol, A. N., Bloom, F. E., Gautvik, K. M., & Sutcliffe, J. G.

(1998). The Hypocretins: Hypothalamus-Specific Peptides With Neuroexcitatory Activity. *PNAS, 95*(1), 322-327.

De Vry, J., & Jentzsch, K. R. (2004). Partial Agonist-Like Profile Of The Cannabinoid Receptor Antagonist Sr141716a In A Food-Reinforced Operant Paradigm. *Behavioural Pharmacology, 15*(1), 13-20.

Deacon, C. F., Nauck, M. A., Toftnielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995). Both Subcutaneously And Intravenously Administered Glucagon-Like Peptide-I Are Rapidly Degraded From The Nh2-Terminus In Type-Ii Diabetic-Patients And In Healthy-Subjects. *Diabetes, 44*(9), 1126-1131.

Debas, H. T., Farooq, O., & Grossman, M. I. (1975). Inhibition Of Gastric-Emptying Is A Physiological Action Of Cholecystokinin. *Gastroenterology, 68*(5), 1211-1217.

Deblon, N., Veyrat-Durebex, C., Bourgoin, L., Caillon, A., Bussier, A.-L., Petrosino, S., Piscitelli, F., Legros, J.-J., Geenen, V., Foti, M., Wahli, W., Di Marzo, V., & Rohner-Jeanrenaud, F. (2011). Mechanisms Of The Anti-Obesity Effects Of Oxytocin In Diet-Induced Obese Rats. *Plos One, 6*(9).

Defronzo, R. A., Fleck, P. R., Wilson, C. A., Mekki, Q., & Alogliptin Study, G. (2008). Efficacy And Safety Of The Dipeptidyl Peptidase-4 Inhibitor Alogliptin In Patients With Type 2 Diabetes And Inadequate Glycemic Control A Randomized, Double-Blind, Placebo-Controlled Study. *Diabetes Care, 31*(12), 2315-2317.

Defronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & Macconell, L. (2008). Effects Of Exenatide Versus Sitagliptin On Postprandial Glucose, Insulin And Glucagon Secretion, Gastric Emptying, And Caloric Intake: A Randomized, Cross-Over Study. *Current Medical Research And Opinion, 24*(10), 2943-2952.

Defronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005). Effects Of Exenatide (Exendin-4) On Glycemic Control And Weight Over 30 Weeks In Metformin-Treated Patients With Type 2 Diabetes. *Diabetes Care, 28*(5), 1092-1100.

Degen, L., Oesch, S., Casanova, M., Graf, S., Ketterer, S., Drewe, J., & Beglinger, C. (2005). Effect Of Peptide Yy3-36 On Food Intake In Humans. *Gastroenterology, 129*(5), 1430-1436.

Degroot, A., & Nomikos, G. G. (2004). Genetic Deletion And Pharmacological Blockade Of Cb1 Receptors Modulates Anxiety In The Shock-Probe Burying Test. *European Journal Of Neuroscience, 20*(4), 1059-1064.

Della-Zuana, O., Audinot, V., Levenez, V., Ktorza, A., Presse, F., Nahon, J.-L., & Boutin, J. A. (2012). Peripheral Injections Of Melanin-Concentrating Hormone Receptor 1 Antagonist S38151 Decrease Food Intake And Body Weight In Rodent Obesity Models. *Frontiers In Endocrinology, 3*, 160-160.

Derosa, G., & Salvadeo, S. A. T. (2011). *The Role Of Apolipoprotein Apo A-Iv In Eating Behavior And Diet*.

Despres, J.-P., Ross, R., Boka, G., Almeras, N., Lemieux, I., & Investigators, A. D.-L. (2009). Effect Of Rimonabant On The High-Triglyceride/Low-Hdl-Cholesterol Dyslipidemia, Intraabdominal Adiposity, And Liver Fat The Adagio-Lipids Trial. *Arteriosclerosis Thrombosis And Vascular Biology, 29*(3), 416-423.

Despres, J. P., Golay, A., & Sjostrom, L. (2005). Rimonabant Obesity Lipids Study; Effects Of Rimonabant On Metabolic Risk Factors In Overweight Patients With Dyslipidemia. *New England Journal Of Medicine, 353*(20), 2121-2134.

Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988). Determination And Characterization Of A Cannabinoid Receptor In Rat-Brain. *Molecular Pharmacology, 34*(5), 605-613.

Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992). Isolation

And Structure Of A Brain Constituent That Binds To The Cannabinoid Receptor. *Science, 258*(5090), 1946-1949.

Devine, D. P., Leone, P., & Wise, R. A. (1993). Mesolimbic Dopamine Neurotransmission Is Increased By Administration Of M-Opioid Receptor Antagonists. *European Journal Of Pharmacology, 243*(1), 55-64.

Devine, E., & Young, A. A. (1998). Weight Gain In Male And Female Mice With Amylin Gene Knockout. *Diabetes, 47*, A317-A317.

Di Marzo, V. (2008). Cb1 Receptor Antagonism: Biological Basis For Metabolic Effects. *Drug Discovery Today, 13*, 1026-1041.

Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Batkai, S., Jarai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., & Kunos, G. (2001). Leptin-Regulated Endocannabinoids Are Involved In Maintaining Food Intake. *Nature, 410*(6830), 822-825.

Dickson, S. L., Shirazi, R. H., Hansson, C., Bergquist, F., Nissbrandt, H., & Skibicka, K. P. (2012). The Glucagon-Like Peptide 1 (Glp-1) Analogue, Exendin-4, Decreases The Rewarding Value Of Food: A New Role For Mesolimbic Glp-1 Receptors. *Journal Of Neuroscience, 32*(14), 4812-4820.

Dietrich, M. O., & Horvath, T. L. (2012). Limitations In Anti-Obesity Drug Development: The Critical Role Of Hunger-Promoting Neurons. *Nature Reviews Drug Discovery, 11*(9), 675-691.

Dilsaver, S. C., Qamar, A. B., & Delmedico, V. J. (1992). The Efficacy Of Bupropion In Winter Depression - Results Of An Open Trial. *Journal Of Clinical Psychiatry, 53*(7), 252-255.

Dimarzo, V. (2008). Targeting The Endocannabinoid System: To Enhance Or Reduce? *Nature Reviews Drug Discovery, 7*, 438-455.

Dimarzo V, L. A., Cristino L. (2009). The Endocannabinoid System As A Link Between Homestatic And Hedonic Pathways Involved In Eneregy Balance Regulation. *International Journal Of Obesity, 33*, S18-S24.

Dipatrizio, N. V., Astarita, G., Schwartz, G., Li, X., & Piomelli, D. (2011). Endocannabinoid Signal In The Gut Controls Dietary Fat Intake. *Proceedings Of The National Academy Of Sciences Of The United States Of America, 108*(31), 12904-12908.

Donnelly, J. E., Blair, S. N., Jakicic, J. M., Manore, M. M., Rankin, J. W., & Smith, B. K. (2009). Appropriate Physical Activity Intervention Strategies For Weight Loss And Prevention Of Weight Regain For Adults. *Medicine And Science In Sports And Exercise, 41*(2), 459-471.

Dossat, A. M., Lilly, N., Kay, K., & Williams, D. L. (2011). Glucagon-Like Peptide 1 Receptors In Nucleus Accumbens Affect Food Intake. *Journal Of Neuroscience, 31*(41), 14453-14457.

Douketis, J. D., Macie, C., Thabane, L., & Williamson, D. F. (2005). Systematic Review Of Long-Term Weight Loss Studies In Obese Adults: Clinical Significance And Applicability To Clinical Practice. *International Journal Of Obesity, 29*(10), 1153-1167.

Dourish Ct, H. P. (1985). Pharmacological And Biochemical Analyhsis Of Feeding Behaviour. *Brain Research Bulletin, 15*, 369-370.

Dourish, C. T., Hutson, P. H., & Curzon, G. (1985). Low-Doses Of The Putative Serotonin Agonist 8-Hydroxy-2-(Di-N-Propylamino) Tetralin (8-Oh-Dpat) Elicit Feeding In The Rat. *Psychopharmacology, 86*(1-2), 197-204.

Dourish, C. T., Rycroft, W., & Iversen, S. D. (1989). Postponement Of Satiety By Blockade Of Brain Cholecystokinin (Cck-B) Receptors. *Science, 245*(4925), 1509-1511.

Drent, M. L., Zelissen, P. M. J., Koppeschaar, H. P. F., Kruseman, A. C. N., Lutterman, J. A., & Vanderveen, E. A. (1995). The Effect Of Dexfenfluramine On Eating Habits In A Dutch Ambulatory Android Overweight Population With An Overconsumption Of Snacks. *International Journal Of Obesity, 19*(5), 299-304.

Drewnowski, A., Krahn, D. D., Demitrack, M. A., Nairn, K., & Gosnell, B. A. (1995). Naloxone, An Opiate Blocker, Reduces The Consumption Of Sweet High-Fat Foods In Obese And Lean Female Binge Eaters. *The American Journal Of Clinical Nutrition, 61*(6), 1206-1212.

Drucker, D. J. (2006). The Biology Of Incretin Hormones. *Cell Metabolism, 3*(3), 153-165.

Drucker, D. J. (2007). The Role Of Gut Hormones In Glucose Homeostasis. *Journal Of Clinical Investigation, 117*(1), 24-32.

Drucker, D. J., & Asa, S. (1988). Glucagon Gene-Expression In Vertebrate Brain. *Journal Of Biological Chemistry, 263*(27), 13475-13478.

Drucker, D. J., Sherman, S. I., Bergenstal, R. M., & Buse, J. B. (2011). The Safety Of Incretin-Based Therapies-Review Of The Scientific Evidence. *Journal Of Clinical Endocrinology & Metabolism, 96*(7), 2027-2031.

Dryden, S., Frankish, H. M., Wang, Q., Pickavance, L., & Williams, G. (1996). The Serotonergic Agent Fluoxetine Reduces Neuropeptide Y Levels And Neuropeptide Y Secretion In The Hypothalamus Of Lean And Obese Rats. *Neuroscience, 72*(2), 557-566.

Dryden, S., Wang, Q., Frankish, H. M., Pickavance, L., & Williams, G. (1995). The Serotonin (5-Ht) Antagonist Methysergide Increases Neuropeptide-Y (Npy) Synthesis And Secretion In The Hypothalamus Of The Rat. *Brain Research, 699*(1), 12-18.

Dryden, S., Wang, Q. O., Frankish, H. M., & Williams, G. (1996). Differential Effects Of The 5-Ht1b/2c Receptor Agonist Mcpp And The 5-Ht1a Agonist Flesinoxan On Hypothalamic Neuropeptide Y In The Rat: Evidence That Npy May Mediate Serotonin's Effects On Food Intake. *Peptides, 17*(6), 943-949.

Duarte, C., Alonso, R., Bichet, N., Cohen, C., Soubrie, P., & Thiebot, M. H. (2004). Blockade By The Cannabinoid Cb1 Receptor Antagonist, Rimonabant (Sr141716), Of The Potentiation By Quinelorane Of Food-Primed Reinstatement Of Food-Seeking Behavior. *Neuropsychopharmacology, 29*(5), 911-920.

Dube, M. G., Horvath, T. L., Leranth, C., Kalra, P. S., & Kalra, S. P. (1994). Naloxone Reduces The Feeding Evoked By Intracerebroventricular Galanin Injection. *Physiology & Behavior, 56*(4), 811-813.

Dun, S. L., Brailoiu, G. C., Yang, J., Chang, J. K., & Dun, N. J. (2003). Neuropeptide W-Immunoreactivity In The Hypothalamus And Pituitary Of The Rat. *Neuroscience Letters, 349*(2), 71-74.

Dungan Lemko, H. M., Clifton, D. K., Steiner, R. A., & Fraley, G. S. (2008). Altered Response To Metabolic Challenges In Mice With Genetically Targeted Deletions Of Galanin-Like Peptide. *American Journal Of Physiology. Endocrinology And Metabolism, 295*(3), E605-612.

Duxon, M., Stretton, J., Porter, R., Pilleux, J. P., Martin, J. D., & Upton, N. (2001). Evidence That Orexin-A Evoked Grooming, But Not Water Intake, In The Rat Is Mediated By The Orexin-1 (Ox1) Receptor. *British Journal Of Pharmacology, 134*, 131P.

Dwoskin, L. P., Rauhut, A. S., King-Pospisil, K. A., & Bardo, M. T. (2006). Review Of The Pharmacology And Clinical Profile Of Bupropion, An Antidepressant And Tobacco Use Cessation Agent. *Cns Drug Reviews, 12*(3-4), 178-207.

Ebbeling, C. B., Feldman, H. A., Osganian, S. K., Chomitz, V. R., Ellenbogen, S. J., & Ludwig, D. S. (2006). Effects Of Decreasing Sugar-Sweetened Beverage Consumption On Body Weight In Adolescents: A Randomized, Controlled Pilot Study. *Pediatrics, 117*(3), 673-680.

Ebihara, K., Ogawa, Y., Katsuura, G., Numata, Y., Masuzaki, H., Satoh, N., Tamaki, M., Yoshioka, T., Hayase, M., Matsuoka, N., Aizawa-Abe, M., Yoshimasa, Y., & Nakao, K. (1999). Involvement Of Agouti-Related Protein, An

Endogenous Antagonist Of Hypothalamic Melanocortin Receptor, In Leptin Action. *Diabetes, 48*(10), 2028-2033.

Edwards, C. M. B., Abbott, C. R., Sunter, D., Kim, M.-S., Dakin, C. L., Murphy, K. G., Abusnana, S., Taheri, S., Rossi, M., & Bloom, S. R. (2000). Cocaine-And Amphetamine-Regulated Transcript, Glucagon-Like Peptide-1 And Corticotrophin Releasing Factor Inhibit Feeding Via Agouti-Related Protein Independent Pathways In The Rat. *Brain Research, 866*(1-2), 128-134.

Edwards, C. M. B., Stanley, S. A., Davis, R., Brynes, A. E., Frost, G. S., Seal, L. J., Ghatei, M. A., & Bloom, S. R. (2001). Exendin-4 Reduces Fasting And Postprandial Glucose And Decreases Energy Intake In Healthy Volunteers. *American Journal Of Physiology-Endocrinology And Metabolism, 281*(1), E155-E161.

Edwards, G. L., Gedulin, B. R., Jodka, C., Dilts, R. P., Miller, C. C., & Young, A. (1998). Area Postrema (Ap)-Lesions Block The Regulation Of Gastric Emptying By Amylin. *Gastroenterology, 114*(4), A748-A748.

Edwards S, S. R. (1991). Peripherally Administered 5-Hydroxytryptamine Elicits The Full Behavioural Sequence Of Satiety. *Physiology And Behavior, 50*, 1075-1077.

Egan, J. M., Clocquet, A. R., & Elahi, D. (2002). The Insulinotropic Effect Of Acute Exendin-4 Administered To Humans: Comparison Of Nondiabetic State To Type 2 Diabetes. *Journal Of Clinical Endocrinology & Metabolism, 87*(3), 1282-1290.

Egan, J. M., Meneilly, G. S., & Elahi, D. (2003). Effects Of 1-Mo Bolus Subcutaneous Administration Of Exendin-4 In Type 2 Diabetes. *American Journal Of Physiology-Endocrinology And Metabolism, 284*(6), E1072-E1079.

Egecioglu, E., Jerlhag, E., Salome, N., Skibicka, K. P., Haage, D., Bohlooly-Y, M., Andersson, D., Bjursell, M., Perrissoud, D., Engel, J. A., & Dickson, S. L. (2010). Ghrelin Increases Intake Of Rewarding Food In Rodents. *Addiction Biology, 15*(3), 304-311.

Eisenbraun, J., & Ehrlein, H. J. (1996). Effects Of Somatostatin On Luminal Transit And Absorption Of Nutrients In The Proximal Gut Of Minipigs. *Digestive Diseases And Sciences, 41*(5), 894-901.

Eison, A. S., Wright, R. N., & Freeman, R. (1992). Peripheral 5-Carboxamidotryptamine Induces Hindlimb Scratching By Stimulating 5-Ht1a Receptors In Rats. *Life Sciences, 51*(10), PL95-PL99.

Elangbam, C. S. (2010). Drug-Induced Valvulopathy: An Update. *Toxicologic Pathology, 38*(6), 837-848.

Elias, C. F., Aschkenasi, C., Lee, C., Kelly, J., Ahima, R. S., Bjorbaek, C., Flier, J. S., Saper, C. B., & Elmquist, J. K. (1999). Leptin Differentially Regulates Npy And Pomc Neurons Projecting To The Lateral Hypothalamic Area. *Neuron, 23*(4), 775-786.

Ellacott, K. L. J., & Cone, R. D. (2004). The Central Melanocortin System And The Integration Of Short- And Long-Term Regulators Of Energy Homeostasis. *Recent Prog Horm Res, 59*(1), 395-408.

Elmquist, J. K., Ahima, R. S., Elias, C. F., Flier, J. S., & Saper, C. B. (1998). Leptin Activates Distinct Projections From The Dorsomedial And Ventromedial Hypothalamic Nuclei. *Proceedings Of The National Academy Of Sciences Of The United States Of America, 95*(2), 741-746.

Elmquist, J. K., Maratos-Flier, E., Saper, C. B., & Flier, J. S. (1998). Unraveling The Central Nervous System Pathways Underlying Responses To Leptin. *Nature Neuroscience, 1*(6), 445-450.

Elrick, H., Hlad, C. J., Arai, Y., & Stimmler, L. (1964). Plasma Insulin Response To Oral + Intravenous Glucose Administration. *Journal Of Clinical Endocrinology & Metabolism, 24*(10), 1076-+.

Emea. (2006). Guideline On Clinical Investigation Of Medicinal Products Used In Weight Control. Retrieved 16th August, 2013, From Http://Www.Ema.Europa.Eu/Docs/En_GB/Document_Library/Scientific_Guideline/2009/09/WC500003213.Pdf

Emea. (2010). European Medicines Agency Recommends Suspension Of Marketing Authorisation For Sibutramine. Retrieved 2nd Feb, 2011, From Http://Www.Ema.Europa.Eu/Ema/Index.Jsp?Curl=Pages/News_And_Events/News/2010/01/News_Detail_000985.Jsp

Emisphere. (2011). Novo Nordisk Starts Phase I Trial With Long-Acting Oral Glp-1 Analogue.

Emond, M., Schwartz, G. J., Ladenheim, E. E., & Moran, T. H. (1999). Central Leptin Modulates Behavioral And Neural Responsivity To Cck. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 276*(5), R1545-R1549.

Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992). Isolation And Characterization Of Exendin-4, An Exendin-3 Analog, From Heloderma-Suspectum Venom - Further Evidence For An Exendin Receptor On Dispersed Acini From Guinea-Pig Pancreas. *Journal Of Biological Chemistry, 267*(11), 7402-7405.

Erchegyi, J., Grace, C. R. R., Samant, M., Cescato, R., Piccand, V., Riek, R., Reubi, J. C., & Rivier, J. E. (2008). Ring Size Of Somatostatin Analogues (Odt-8) Modulates Receptor Selectivity And Binding Affinity. *Journal Of Medicinal Chemistry, 51*(9), 2668-2675.

Erick Escartin-Perez, R., Monica Cendejas-Trejo, N., Maria Cruz-Martinez, A., Gonzalez-Hernandez, B., Manuel Mancilla-Diaz, J., & Floran-Garduno, B. (2009). Role Of Cannabinoid Cb1 Receptors On Macronutrient Selection And Satiety In Rats. *Physiology & Behavior, 96*(4-5), 646-650.

Erlanson-Albertsson, C. (2011). *The Role Of Enterostatin In Eating Behavior And Diet*.

Erlansonalbertsson, C., & Larsson, A. (1988). A Possible Physiological-Function Of Pancreatic Pro-Colipase Activation Peptide In Appetite Regulation. *Biochimie, 70*(9), 1245-1250.

Erondu, N., Gantz, I., Musser, B., Suryawanshi, S., Mallick, M., Addy, C., Cote, J., Bray, G., Fujioka, K., Bays, H., Hollander, P., Sanabria-Bohorquez, S. M., Eng, W., Langstrom, B., Hargreaves, R. J., Burns, H. D., Kanatani, A., Fukami, T., Macneil, D. J., Gottesdiener, K. M., Amatruda, J. M., Kaufman, K. D., & Heymsfield, S. B. (2006). Neuropeptide Y5 Receptor Antagonism Does Not Induce Clinically Meaningful Weight Loss In Overweight And Obese Adults. *Cell Metabolism, 4*(4), 275-282.

Erreger, K., Davis, A. R., Poe, A. M., Greig, N. H., Stanwood, G. D., & Galli, A. (2012). Exendin-4 Decreases Amphetamine-Induced Locomotor Activity. *Physiology & Behavior, 106*(4), 574-578.

Erspamer, V. (1940). Pharmacological Studies On Enteramine. I Memorandum The Effect Of Acetone Extracts Of Rabbit Stomach Mucous On Blood Pressure And Insulated Surviving Organs. *Naunyn-Schmiedebergs Archiv Fur Experimentelle Pathologie Und Pharmakologie, 196*, 343-365.

Erspamer, V., & Asero, B. (1952). Identification Of Enteramine, The Specific Hormone Of The Enterochromaffin Cell System, As 5-Hydroxytryptamine. *Nature, 169*(4306), 800-801.

Eva, C., Serra, M., Mele, P., Panzica, G., & Oberto, A. (2006). Physiology And Gene Regulation Of The Brain Npyy1 Receptor. *Frontiers In Neuroendocrinology, 27*(3), 308-339.

Fabre, L. F., & Mclendon, D. M. (1978). Double-Blind Placebo-Controlled Study Of Bupropion Hydrochloride (Wellbatrin) In Treatment Of Depressed In-Patients. *Current Therapeutic Research-Clinical And Experimental, 23*(3), 393-402.

Fadel, J., & Deutch, A. Y. (2002). Anatomical Substrates Of Orexin-Dopamine Interactions: Lateral Hypothalamic Projections To The Ventral Tegmental Area. *Neuroscience, 111*(2), 379-387.

Fakhoury, W. K. H., Lereun, C., & Wright, D. (2010). A Meta-Analysis Of Placebo-Controlled Clinical Trials Assessing The Efficacy And Safety Of Incretin-Based Medications In Patients With Type 2 Diabetes. *Pharmacology, 86*(1), 44-57.

Fan, W., Et Al. (1997). Role Of Melanocortinergic Neurons In Feeding And The Agouti Obesity Syndrome. *Nature, 385*, 165- 168.

Fang, J., Wylie-Rosett, J., Cohen, H. W., Kaplan, R. C., & Alderman, M. H. (2003). Exercise, Body Mass Index, Caloric Intake, And Cardiovascular Mortality. *American Journal Of Preventive Medicine, 25*(4), 283-289.

Fann, W. E., Schroeder, D. H., Mehta, N. B., Soroko, F. E., & Maxwell, R. A. (1978). Clinical-Trial Of Bupropion Hcl In Treatment Of Depression. *Current Therapeutic Research-Clinical And Experimental, 23*(2), 222-229.

Fantino, M., Hosotte, J., & Apfelbaum, M. (1986). An Opioid Antagonist, Naltrexone, Reduces Preference For Sucrose In Humans. *American Journal Of Physiology, 251*(1), R91-R96.

Farooqi, I. S., Jebb, S. A., Langmack, G., Lawrence, E., Cheetham, C. H., Prentice, A. M., Hughes, I. A., Mccamish, M. A., & O'rahilly, S. (1999). Effects Of Recombinant Leptin Therapy In A Child With Congenital Leptin Deficiency. *New England Journal Of Medicine, 341*(12), 879-884.

Fava, M., Rush, A. J., Thase, M. E., Clayton, A., Stahl, S. M., Pradko, J. F., & Johnston, J. A. (2005). 15 Years Of Clinical Experience With Bupropion Hcl: From Bupropion To Bupropion Sr To Bupropion Xl. *Primary Care Companion To The Journal Of Clinical Psychiatry, 7*(3), 106-113.

Fda. (1997a). Fda Announces Withdrawal Fenfluramine And Dexfenfluramine (Fen-Phen) (1997 Ed.).

Fda. (1997b). "Fen-Phen" Update (Fenfluramine, Phentermine, Dexfenfluramine). Retrieved 10th Feb, 2011, From Http://Www.Fda.Gov/Drugs/Drugsafety/Postmarketdrugsafetyinformationpatientsandproviders/Ucm180082.Htm

Fda. (2005). Phenylpropanolamine (Ppa) Information Page. Retrieved 16th August, 2013, From Http://Www.Fda.Gov/Drugs/Drugsafety/Informationbydrugclass/Ucm150738.Htm

Fda. (2007). Guidence For Industry Developing Products For Weight Management. Retrieved 16th August, 2013, From Http://Www.Fda.Gov/Downloads/Drugs/Guidencecomplicanceregulatoryinformation/Guidences/Ucm071612.Pdf

Fda. (2011). Meridia (Sibutramine): Market Withdrawal Due To Risk Of Serious Cardiovascular Events. Retrieved 16th August, 2013

Fda. (2012). Lorcaserin Hydrochloride Briefing Document. Retrieved 16th August, 2013

Feifel, D., & Vaccarino, F. J. (1994). Growth Hormone-Regulatory Peptides (Ghrh And Somatostatin) And Feeding - A Model For The Integration Of Central And Peripheral Function. *Neuroscience And Biobehavioral Reviews, 18*(3), 421-433.

Feldberg, W., & Toh, C. C. (1953). Distribution Of 5-Hydroxytryptamine (Serotonin, Enteramine) In The Wall Of The Digestive Tract. *Journal Of Physiology-London, 119*(2-3), 352-362.

Feldman, J. M. (1988). Effect Of The Monoamine-Oxidase Inhibitors Clorgyline And Pargyline On The Hyperphagia Of Obese Mice. *Behavioural Brain Research, 29*(1-2), 147-158.

Feldman , R. S., Meyer, J. S., & Quenzer, L. F. (1997). Principles of neuropsychopharmacology. Massachusetts, USA: Sinauer Associates, Inc.

Ferguson, S. A., & Maier, K. L. (2013). A Review Of Seasonal/Circannual Effects Of Laboratory Rodent Behavior. *Physiology & Behavior, 119*(0), 130-136.

Fernandez-Tome Mp, G. Y., Del Rio J. (1988). Interaction Between Opioid Agonists Or Naloxone And 5-Htp On Feeding Behavior In Food-Deprived Rats. *Pharmacology, Biochemistry And Behavior, 29*, 387-392.

Ferreira, H. S., Oliveira, E., Faustino, T. N., Silva, E. D. E., & Fregoneze, J. B. (2005). Effect Of The Activation Of Central 5-Ht2c Receptors By The 5-Ht2c Agonist Mcpp On Blood Pressure And Heart Rate In Rats. *Brain Research, 1040*(1-2), 64-72.

Ferrer-Lorente, R., Cabot, C., Fernandez-Lopez, J.-A., & Alemany, M. (2007). Effects Of Combined Oleoyl-Estrone And Rimonabant On Overweight Rats. *Journal Of Pharmacological Sciences, 104*(2), 176-182.

Ferris, R. M., & Beaman, O. J. (1983). Bupropion - A New Anti-Depressant Drug, The Mechanism Of Action Of Which Is Not Associated With Down-Regulation Of Postsynaptic Beta-Adrenergic, Serotonergic (5-Ht2), Alpha-2-Adrenergic, Imipramine And Dopaminergic Receptors In Brain. *Neuropharmacology, 22*(11), 1257-1267.

Ferris, R. M., Cooper, B. R., & Maxwell, R. A. (1983). Studies Of Bupropions Mechanism Of Anti-Depressant Activity. *Journal Of Clinical Psychiatry, 44*(5), 74-78.

Ferris, R. M., Maxwell, R. A., Cooper, B. R., & Soroko, F. E. (1982). Neurochemical And Neuro-Pharmacological Investigations Into The Mechanisms Of Action Of Bupropion-Hcl - A New Atypical Anti-Depressant Agent. *Advances In Biochemical Psychopharmacology, 31*, 277-286.

Ferris, R. M., White, H., Russell, A., Beaman, O. J., & Maxwell, R. A. (1978). Effects Of Bupropion Hcl, On Uptake Of Biogenic-Amines And On Inhibition Of Mao. *Federation Proceedings, 37*(3), 481-481.

Ferris, R. M., White, H. L., Cooper, B. R., Maxwell, R. A., Tang, F. L. M., Beaman, O. J., & Russell, A. (1981). Some Neurochemical Properties Of A New Anti-Depressant, Bupropion Hydrochloride (Wellbutrin). *Drug Development Research, 1*(1), 21-35.

Ferry, L., & Johnston, J. A. (2003). Efficacy And Safety Of Bupropion Sr For Smoking Cessation: Data From Clinical Trials And Five Years Of Postmarketing Experience. *International Journal Of Clinical Practice, 57*(3), 224-230.

Feurle, G. E., Hamscher, G., Kusiek, R., Meyer, H. E., & Metzger, J. W. (1992). Identification Of Xenin, A Xenopsin-Related Peptide, In The Human Gastric-Mucosa And Its Effect On Exocrine Pancreatic-Secretion. *Journal Of Biological Chemistry, 267*(31), 22305-22309.

Fidler, M. C., Sanchez, M., Raether, B., Weissman, N. J., Smith, S. R., Shanahan, W. R., Anderson, C. M., & Grp, B. C. T. (2011). A One-Year Randomized Trial Of Lorcaserin For Weight Loss In Obese And Overweight Adults: The Blossom Trial. *Journal Of Clinical Endocrinology & Metabolism, 96*(10), 3067-3077.

Figlewicz, D. P., Bennett, J., Evans, S. B., Kaiyala, K., Sipols, A. J., & Benoit, S. C. (2004). Intraventricular Insulin And Leptin Reverse Place Preference Conditioned With High-Fat Diet In Rats. *Behavioral Neuroscience, 118*(3), 479-487.

Figlewicz, D. P., Nadzan, A. M., Sipols, A. J., Green, P. K., Liddle, R. A., Porte, D., & Woods, S. C. (1992). Intraventricular Cck-8 Reduces Single Meal Size In The Baboon By Interaction With Type-A Cck Receptors. *American Journal Of Physiology, 263*(4), R863-R867.

Filliol, D., Ghozland, S., Chluba, J., Martin, M., Matthes, H. W. D., Simonin, F., Befort, K., Gaveriaux-Ruff, C., Dierich, A., Lemeur, M., Valverde, O., Maldonado, R., & Kieffer, B. L. (2000). Mice Deficient For Delta- And

Gamma-Opioid Receptors Exhibit Opposing Alterations Of Emotional Responses. *Nature Genetics, 25*(2), 195-200.

Fineman, M., Koda, J., & Kolterman, O. (1998). Subcutaneous Administration Of A Human Amylin Analogue Suppresses Postprandial Plasma Glucagon Concentrations In Type 1 Diabetic Patients. *Diabetes, 47*, A89-A89.

Finer, N., Finer, S., & Naoumova, R. P. (1992). Drug-Therapy After Very-Low-Calorie Diets. *American Journal Of Clinical Nutrition, 56*(1), S195-S198.

Finlayson, G., King, N., & Blundell, J. E. (2007). Liking Vs. Wanting Food: Importance For Human Appetite Control And Weight Regulation. *Neuroscience And Biobehavioral Reviews, 31*(7), 987-1002.

Finlayson, Graham, Halford, Jason C. G., King, Neil A., & Blundell, John E. (2007) The regulation of food intake in humans. InWeickert, Martin O. (Ed.) Obesitext - The Source. Endotext.com, South Dartmouth, MA

Fisas, A., Codony, X., Romero, G., Dordal, A., Giraldo, J., Merce, R., Holenz, J., Heal, D., Buschmann, H., & Pauwels, P. J. (2006). Chronic 5-Ht6 Receptor Modulation By E-6837 Induces Hypophagia And Sustained Weight Loss In Diet-Induced Obese Rats. *British Journal Of Pharmacology, 148*(7), 973-983.

Fisler, J. S., Underberger, S. J., York, D. A., & Bray, G. A. (1993). D-Fenfluramine In A Rat Model Of Dietary Fat-Induced Obesity. *Pharmacology Biochemistry And Behavior, 45*(2), 487-493.

Fjellner, B., & Hägermark, O. (1979). Pruritus In Polycythemia Vera: Treatment With Aspirin And Possibility Of Platelet Involvement. *Acta Dermato-Venereologica, 59*(6), 505-512.

Fletcher, P. J., & Burton, M. J. (1984). Effects Of Manipulations Of Peripheral Serotonin On Feeding And Drinking In The Rat. *Pharmacology Biochemistry And Behavior, 20*(6), 835-840.

Fletcher, P. J., Soko, A. D., & Higgins, G. A. (2013). Impulsive Action In The 5-Choice Serial Reaction Time Test In 5-Ht2c Receptor Null Mutant Mice. *Psychopharmacology, 226*(3), 561-570.

Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998). Glucagon-Like Peptide 1 Promotes Satiety And Suppresses Energy Intake In Humans. *Journal Of Clinical Investigation, 101*(3), 515-520.

Flint, A., Raben, A., Ersboll, A. K., Holst, J. J., & Astrup, A. (2001). The Effect Of Physiological Levels Of Glucagon-Like Peptide-1 On Appetite, Gastric Emptying, Energy And Substrate Metabolism In Obesity. *International Journal Of Obesity, 25*(6), 781-792.

Flynn, F. W. (1992). Caudal Brain-Stem Systems Mediate Effects Of Bombesin-Like Peptides On Intake In Rats. *American Journal Of Physiology, 262*(1), R39-R45.

Flynn, F. W. (1997). Bombesin Receptor Antagonists Block The Effects Of Exogenous Bombesin But Not Of Nutrients On Food Intake. *Physiology & Behavior, 62*(4), 791-798.

Flynn, M. C., Plata-Salaman, C. R., & Ffrench-Mullen, J. M. H. (1999). Neuropeptide Y-Related Compounds And Feeding. *Physiology & Behavior, 65*(4-5), 901-905.

Foltin, R. W. (2006). Effects Of Sibutramine On The Appetitive And Consummatory Aspects Of Feeding In Non-Human Primates. *Physiology & Behavior, 87*(2), 280-286.

Foltin, R. W., Brady, J. V., & Fischman, M. W. (1986). Behavioral-Analysis Of Marijuana Effects On Food-Intake In Humans. *Pharmacology Biochemistry And Behavior, 25*(3), 577-582.

Foltin, R. W., Fischman, M. W., & Byrne, M. F. (1988). Effects Of Smoked Marijuana On Food-Intake And Body-Weight Of Humans Living In A Residential Laboratory. *Appetite, 11*(1), 1-14.

Foltin, R. W., Haney, M., Comer, S. D., & Fischman, M. W. (1996). Effect Of Fenfluramine On Food Intake, Mood, And Performance Of Humans Living In A Residential Laboratory. *Physiology & Behavior, 59*(2), 295-305.

Fong, T. M., Guan, X.-M., Marsh, D. J., Shen, C.-P., Sloan Stribling, D., Rosko, K. M., Lao, J., Yu, H., Feng, Y., Xiao, J. C., Van Der Ploeg, L. H. T., Goulet, M. T., Hagmann, W. K., Lin, L. S., Lanza, T. J., Jr., Jewell, J. P., Liu, P., Shah, S. K., Qi, H., Tong, X., Wang, J., Xu, S. S., Francis, B., Strack, A. M., Macintyre, D. E., & Shearman, L. P. (2007). Antiobesity Efficacy Of A Novel Cannabinoid-1 Receptor Inverse Agonist, N- (1s,2s)-3-(4-Chlorophenyl)-2-(3-Cyanophenyl)-1-Methylpropyl -2-Methyl -2-{ 5-(Trifluoromethyl)Pyridin-2-Yl Oxy}Propanamide (Mk-0364), In Rodents. *Journal Of Pharmacology And Experimental Therapeutics, 321*(3), 1013-1022.

Fontaine, K. R. (2001). Weight Loss And Health-Related Quality Of Life. *American Journal Of Managed Care, 7*(9), 926-927.

Fontaine, K. R., Redden, D. T., Wang, C. X., Westfall, A. O., & Allison, D. B. (2003). Years Of Life Lost Due To Obesity. *Jama-Journal Of The American Medical Association, 289*(2), 187-193.

Fossati, R., Apolone, G., Negri, E., Compagnoni, A., La Vecchia, C., Mangano, S., Clivio, L., Garattini, S., & Gen Practice Tobacco, I. (2007). A Double-Blind, Placebo-Controlled, Randomized Trial Of Bupropion For Smoking Cessation In Primary Care. *Archives Of Internal Medicine, 167*(16), 1791-1797.

Foster-Schubert, K. E., Alfano, C. M., Duggan, C. R., Xiao, L., Campbell, K. L., Kong, A., Bain, C. E., Wang, C.-Y., Blackburn, G. L., & Mctiernan, A. (2012). Effect Of Diet And Exercise, Alone Or Combined, On Weight And Body Composition In Overweight-To-Obese Postmenopausal Women. *Obesity, 20*(8), 1628-1638.

Fox, M., French, H., Laporte, J., Blackler, A., & Murphy, D. (2010). The Serotonin 5-Ht2a Receptor Agonist Tcb-2: A Behavioral And Neurophysiological Analysis. *Psychopharmacology, 212*(1), 13-23.

Franks, P. W., Hanson, R. L., Knowler, W. C., Sievers, M. L., Bennett, P. H., & Looker, H. C. (2010). Childhood Obesity, Other Cardiovascular Risk Factors, And Premature Death. *New England Journal Of Medicine, 362*(6), 485-493.

Franz, M. J., Vanwormer, J. J., Crain, A. L., Boucher, J. L., Histon, T., Caplan, W., Bowman, J. D., & Pronk, N. P. (2007). Weight-Loss Outcomes: A Systematic Review And Meta-Analysis Of Weight-Loss Clinical Trials With A Minimum 1-Year Follow-Up. *Journal Of The American Dietetic Association, 107*(10), 1755-1767.

Frassetto, A., Zhang, J., Lao, J. Z., White, A., Metzger, J. M., Fong, T. M., & Chen, R. Z. (2008). Reduced Sensitivity To Diet-Induced Obesity In Mice Carrying A Mutant 5-Ht(6) Receptor. *Brain Research, 1236*, 140-144.

Frederich, R. C., Hamann, A., Anderson, S., Lollmann, B., Lowell, B. B., & Flier, J. S. (1995). Leptin Levels Reflect Body Lipid-Content In Mice - Evidence For Diet-Induced Resistance To Leptin Action. *Nature Medicine, 1*(12), 1311-1314.

Freedland, C. S., Poston, J. S., & Porrino, L. J. (2000). Effects Of Sr141716a, A Central Cannabinoid Receptor Antagonist, On Food-Maintained Responding. *Pharmacology Biochemistry And Behavior, 67*(2), 265-270.

Freedland, C. S., Sharpe, A. L., Samson, H. H., & Porrino, L. J. (2001). Effects Of Sr141716a On Ethanol And Sucrose Self-Administration. *Alcoholism-Clinical And Experimental Research, 25*(2), 277-282.

French, S. J., Murray, B., Rumsey, R. D. E., Sepple, C. P., & Read, N. W. (1993). Preliminary Studies On The Gastrointestinal Responses To Fatty Meals In Obese People. *International Journal Of Obesity, 17*(5), 295-300.

Friedman, J., & Dello Buono, F. (2001). Opioid Antagonists In The Treatment Of Opioid-Induced Constipation And Pruritus. *The Annals Of Pharmacotherapy, 35*(1), 85-91.

Friedman, J. M., & Halaas, J. L. (1998). Leptin And The Regulation Of Body Weight In Mammals. *Nature, 395*(6704), 763-770.

Fujii, R., Yoshida, H., Fukusumi, S., Habata, Y., Hosoya, M., Kawamata, Y., Yano, T., Hinuma, S., Kitada, C., Asami, T., Mori, M., Fujisawa, Y., & Fujino, M. (2002). Identification Of A Neuropeptide Modified With Bromine As An Endogenous Ligand For Gpr7. *Journal Of Biological Chemistry, 277*(37), 34010-34016.

Fujimoto, K., Cardelli, J. A., & Tso, P. (1992). Increased Apolipoprotein-A-Iv In Rat Mesenteric Lymph After Lipid Meal Acts As A Physiological Signal For Satiation. *American Journal Of Physiology, 262*(6), G1002-G1006.

Fujimoto, K., Fukagawa, K., Sakata, T., & Tso, P. (1993). Suppression Of Food-Intake By Apolipoprotein A-Iv Is Mediated Through The Central-Nervous-System In Rats. *Journal Of Clinical Investigation, 91*(4), 1830-1833.

Fujimoto, S., Inui, A., Kiyota, N., Seki, W., Koide, K., Takamiya, S., Uemoto, M., Nakajima, Y., Baba, S., & Kasuga, M. (1997). Increased Cholecystokinin And Pancreatic Polypeptide Responses To A Fat-Rich Meal In Patients With Restrictive But Not Bulimic Anorexia Nervosa. *Biological Psychiatry, 41*(10), 1068-1070.

Funakoshi, A., Miyasaka, K., Shinozaki, H., Masuda, M., Kawanami, T., Takata, Y., & Kono, A. (1995). An Animal-Model Of Congenital Defect Of Gene-Expression Of Cholecystokinin (Cck)-A Receptor. *Biochemical And Biophysical Research Communications, 210*(3), 787-796.

Gadde, K. M. (2007). Combination Therapy Of Zonisamide And Bupropion For Weight Reduction In Obese Women: A Preliminary, Randomized, Open-Label Study. *Journal Of Clinical Psychiatry, 68*(8), 1226-1229.

Gadde, K. M., & Allison, D. B. (2006). Cannabinoid-1 Receptor Antagonist, Rimonabant, For Management Of Obesity And Related Risks. *Circulation, 114*(9), 974-984.

Gadde, K. M., Parker, C. B., Maner, L. G., Wagner, H. R., Logue, E. J., Drezner, M. K., & Krishnan, K. R. R. (2001). Bupropion For Weight Loss: An Investigation Of Efficacy And Tolerability In Overweight And Obese Women. *Obesity Research, 9*(9), 544-551.

Gallate, J. E., Saharov, T., Mallet, P. E., & Mcgregor, I. S. (1999). Increased Motivation For Beer In Rats Following Administration Of A Cannabinoid Cb1 Receptor Agonist. *European Journal Of Pharmacology, 370*(3), 233-240.

Gamber, K. M., Macarthur, H., & Westfall, T. C. (2005). Cannabinoids Augment The Release Of Neuropeptide Y In The Rat Hypothalamus. *Neuropharmacology, 49*(5), 646-652.

Gantz, I., Erondu, N., Mallick, M., Musser, B., Krishna, R., Tanaka, W. K., Snyder, K., Stevens, C., Stroh, M. A., Zhu, H., Wagner, J. A., Macneil, D. J., Heymsfield, S. B., & Amatruda, J. M. (2007). Efficacy And Safety Of Intranasal Peptide Yy3-36 For Weight Reduction In Obese Adults. *J Clin Endocrinol Metab, 92*(5), 1754-1757.

Gantz, I., & Fong, T. M. (2003). The Melanocortin System. *Am J Physiol Endocrinol Metab, 284*(3), E468-474.

Garbutt, J. C. (2010). Efficacy And Tolerability Of Naltrexone In The Management Of Alcohol Dependence. *Current Pharmaceutical Design, 16*(19), 2091-2097.

Garbutt, J. C., West, S. L., Carey, T. S., Lohr, K. N., & Crews, F. T. (1999). Pharmacological Treatment Of Alcohol Dependence - A Review Of The Evidence. *Jama-Journal Of The American Medical Association, 281*(14), 1318-1325.

Gardell Lr, W. C., Chattophadyay S, Cavallaro Ca, Hubbell Cl, Reid Ld. (1997). Combination Of Naltrexone And Fluoxetine On Rats' Propensity To Take Alcoholic Beverage. *Japanese Journal Of Pharmacology, 70*(3), 203-225.

Gardiner, S. M., March, J. E., Kemp, P. A., & Bennett, T. (2008). Autonomic Nervous System-Dependent And -Independent Cardiovascular Effects Of Exendin-4 Infusion In Conscious Rats. *British Journal Of Pharmacology, 154*(1), 60-71.

Gardner, A., & Mallet, P. E. (2006). Suppression Of Feeding, Drinking, And Locomotion By A Putative Cannabinoid Receptor 'Silent Antagonist'. *European Journal Of Pharmacology, 530*(1-2), 103-106.

Gardner, E. A., & Johnston, J. A. (1985). Bupropion - An Antidepressant Without Sexual Pathophysiological Action. *Journal Of Clinical Psychopharmacology, 5*(1), 24-29.

Garfield, A. S., Heisler, L.K. (2009). Pharmacological Targeting Of The Serotonergic System For The Treatment Of Obesity. *The Journal Of Physiology, 587*(1), 49-60.

Gatch, M. B., Negus, S. S., & Mello, N. K. (1998). Antinociceptive Effects Of Monoamine Reuptake Inhibitors Administered Alone Or In Combination With Mu Opioid Agonists In Rhesus Monkeys. *Psychopharmacology, 135*(1), 99-106.

Geiger, J. C. (1933). Fifty years of progress in the prevention of disease: Part i. California and western medicine, 39(5), 327-329.

Georgescu, D., Sears, R. M., Hommel, J. D., Barrot, M., Bolanos, C. A., Marsh, D. J., Bednarek, M. A., Bibb, J. A., Maratos-Flier, E., Nestler, E. J., & Dileone, R. J. (2005). The Hypothalamic Neuropeptide Melanin-Concentrating Hormone Acts In The Nucleus Accumbens To Modulate Feeding Behavior And Forced-Swim Performance. *Journal Of Neuroscience, 25*(11), 2933-2940.

Geracioti, T. D., & Liddle, R. A. (1988). Impaired Cholecystokinin Secretion In Bulimia Nervosa. *New England Journal Of Medicine, 319*(11), 683-688.

Ghaziuddin, N., Welch, K., & Greden, J. (2003). Central Serotonergic Effects Of M-Chlorophenylpiperazine (Mcpp) Among Normal Control Adolescents. *Neuropsychopharmacology, 28*(1), 133-139.

Ghozland, S., Matthes, H. W. D., Simonin, F., Filliol, D., Kieffer, B. L., & Maldonado, R. (2002). Motivational Effects Of Cannabinoids Are Mediated By Mu-Opioid And Kappa-Opioid Receptors. *Journal Of Neuroscience, 22*(3), 1146-1154.

Gibbs, J., Fauser, D. J., Rowe, E. A., Rolls, B. J., Rolls, E. T., & Maddison, S. P. (1979). Bombesin Suppresses Feeding In Rats. *Nature, 282*(5735), 208-210.

Gibbs, J., & Smith, G. P. (1982). Gut Peptides And Food In The Gut Produce Similar Satiety Effects. *Peptides, 3*, 553 - 557.

Gibbs, J., Young, R. C., & Smith, G. P. (1973). Cholecystokinin Decreases Food Intake In Rats. *Journal Of Comparative Physiology And Psychology, 87*(5), 795 - 800.

Gibson, E. L., Kennedy, A. J., & Curzon, G. (1993). D-Fenfluramine-Induced And D-Norfenfluramine-Induced Hypophagia - Differential Mechanisms And Involvement Of Postsynaptic 5-Ht Receptors. *European Journal Of Pharmacology, 242*(1), 83-90.

Giraudo, S. Q., Billington, C. J., & Levine, A. S. (1998). Feeding Effects Of Hypothalamic Injection Of Melanocortin 4 Receptor Ligands. *Brain Research, 809*(2), 302-306.

Giraudo, S. Q., Grace, M. K., Welch, C. C., Billington, C. J., & Levine, A. S. (1993). Naloxone's Anorectic Effect Is Dependant Upon The Relative Palatability Of Food. *Pharmacology Biochemistry And Behavior, 46*(4), 917-921.

Giuliano, C., Robbins, T. W., Nathan, P. J., Bullmore, E. T., & Everitt, B. J. (2012). Inhibition Of Opioid Transmission At The Mu-Opioid Receptor Prevents Both

Food Seeking And Binge-Like Eating. *Neuropsychopharmacology, 37*(12), 2643-2652.

Glaser, B., Zoghlin, G., Pienta, K., & Vinik, A. I. (1988). Pancreatic-Polypeptide Response To Secretin In Obesity - Effects Of Glucose-Intolerance. *Hormone And Metabolic Research, 20*(5), 288-292.

Glass, M. J., Billington, C. J., & Levine, A. S. (1999). Opioids And Food Intake: Distributed Functional Neural Pathways? *Neuropeptides, 33*(5), 360-368.

Glass, M. J., Billington, C. J., & Levine, A. S. (2000). Naltrexone Administered To Central Nucleus Of Amygdala Or Pvn: Neural Dissociation Of Diet And Energy. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 279*(1), R86-R92.

Glass, M. J., Grace, M. K., Cleary, J. P., Billington, C. J., & Levine, A. S. (2001). Naloxone's Effect On Meal Microstructure Of Sucrose And Cornstarch Diets. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 281*(5), R1605-R1612.

Goddard, A. W., Shekhar, A., Whiteman, A. F., & Mcdougle, C. J. (2008). Serotoninergic Mechanisms In The Treatment Of Obsessive-Compulsive Disorder. *Drug Discovery Today, 13*(7-8), 325-332.

Golden, R. N., Rudorfer, M. V., Sherer, M. A., Linnoila, M., & Potter, W. Z. (1988). Bupropion In Depression .1. Biochemical Effects And Clinical-Response. *Archives Of General Psychiatry, 45*(2), 139-143.

Goldstein, A., & Naidu, A. (1989). Multiple Opioid Receptors - Ligand Selectivity Profiles And Binding-Site Signatures. *Molecular Pharmacology, 36*(2), 265-272.

Goldstein, D. J., Rampey, A. H., Roback, P. J., Wilson, M. G., Hamilton, S. H., Sayler, M. E., & Tollefson, G. D. (1995). Efficacy And Safety Of Long-Term Fluoxetine Treatment Of Obesity - Maximizing Success. *Obesity Research, 3*, S481-S490.

Gomez, M. C., Carrasco, M. C., & Redolat, R. (2008). Differential Sensitivity To The Effects Of Nicotine And Bupropion In Adolescent And Adult Male Or Mice During Social Interaction Tests. *Aggressive Behavior, 34*(4), 369-379.

Gomez, R., Navarro, M., Ferrer, B., Trigo, J. M., Bilbao, A., Del Arco, I., Cippitelli, A., Nava, F., Piomelli, D., & De Fonseca, F. R. (2002). A Peripheral Mechanism For Cb1 Cannabinoid Receptor-Dependent Modulation Of Feeding. *Journal Of Neuroscience, 22*(21), 9612-9617.

Goodall, E., & Silverstone, T. (1988). Differential Effect Of D-Fenfluramine And Metergoline On Food-Intake In Human-Subjects. *Appetite, 11*(3), 215-228.

Gorely, T., Morris, J. G., Musson, H., Brown, S., Nevill, A., & Nevill, M. E. (2011). Physical Activity And Body Composition Outcomes Of The Greatfun2run Intervention At 20 Month Follow-Up. *International Journal Of Behavioral Nutrition And Physical Activity, 8*.

Gosnell, B. A., Krahn, D. D., & Majchrzak, M. J. (1990). The Effects Of Morphine On Diet Selection Are Dependent Upon Baseline Diet Preferences. *Pharmacology Biochemistry And Behavior, 37*(2), 207-212.

Gosnell, B. A., & Majchrzak, M. J. (1989). Centrally Administered Opioid Peptides Stimulate Saccharin Intake In Nondeprived Rats. *Pharmacology Biochemistry And Behavior, 33*(4), 805-810.

Grace, C. R. R., Erchegyi, J., Koerber, S. C., Reubi, J. C., Rivier, J., & Riek, R. (2006). Novel Sst(2)-Selective Somatostatin Agonists. Three-Dimensional Consensus Structure By Nmr. *Journal Of Medicinal Chemistry, 49*(15), 4487-4496.

Graff, H., & Stellar, E. (1962). Hyperphagia, Obesity, And Finickiness. *Journal Of Comparative And Physiological Psychology, 55*(4), 418-&.

Grailhe, R., Waeber, C., Dulawa, S. C., Hornung, J. P., Zhuang, X. X., Brunner, D., Geyer, M. A., & Hen, R. (1999). Increased Exploratory Activity And Altered

Response To Lsd In Mice Lacking The 5-Ht5a Receptor. *Neuron, 22*(3), 581-591.

Grandison, L., & Guidotti, A. (1977). Stimulation Of Food-Intake By Muscimol And Beta-Endorphin. *Neuropharmacology, 16*(7-8), 533-536.

Gray, A. M., Spencer, P. S. J., & Sewell, R. D. E. (1998). The Involvement Of The Opioidergic System In The Antinociceptive Mechanism Of Action Of Antidepressant Compounds. *British Journal Of Pharmacology, 124*(4), 669-674.

Greasley, P. J., & Clapham, J. C. (2006). Inverse Agonism Or Neutral Antagonism At G-Protein Coupled Receptors: A Medicinal Chemistry Challenge Worth Pursuing? *European Journal Of Pharmacology, 553*(1–3), 1-9.

Greenway, F. L., Dunayevich, E., Tollefson, G., Erickson, J., Guttadauria, M., Fujioka, K., Cowley, M. A., & Grp, N. B. S. (2009). Comparison Of Combined Bupropion And Naltrexone Therapy For Obesity With Monotherapy And Placebo. *Journal Of Clinical Endocrinology & Metabolism, 94*(12), 4898-4906.

Greenway, F. L., Fujioka, K., & Plodkowski, R. A. (2010). Effect Of Naltrexone Plus Bupropion On Weight Loss In Overweight And Obese Adults (Cor-I): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial (Vol 376, Pg 595, 2010). *Lancet, 376*(9750), 1392-1392.

Greenway, F. L., Whitehouse, M. J., Guttadauria, M., Anderson, J. W., Atkinson, R. L., Fujioka, K., Gadde, K. M., Gupta, A. K., O'neil, P., Schumacher, D., Smith, D., Dunayevich, E., Tollefson, G. D., Weber, E., & Cowley, M. A. (2009). Rational Design Of A Combination Medication For The Treatment Of Obesity. *Obesity, 17*(1), 30-39.

Griebel, G., Stemmelin, J., & Scatton, B. (2005). Effects Of The Cannabinoid Cb1 Receptor Antagonist Rimonabant In Models Of Emotional Reactivity In Rodents. *Biological Psychiatry, 57*(3), 261-267.

Griffond, B., Risold, P. Y., Jacquemard, C., Colard, C., & Fellmann, D. (1999). Insulin-Induced Hypoglycemia Increases Preprohypocretin (Orexin) Mrna In The Rat Lateral Hypothalamic Area. *Neuroscience Letters, 262*(2), 77-80.

Grignaschi, G., & Samanin, R. (1992). Role Of 5-Ht Receptors In The Effect Of D-Fenfluramine On Feeding Patterns In The Rat. *European Journal Of Pharmacology, 212*(2-3), 287-289.

Grignaschi, G., Sironi, F., & Samanin, R. (1995). The 5-Ht1b Receptor Mediates The Effect Of D-Fenfluramine On Eating Caused By Intra-Hypothalamic Injection Of Neuropeptide-Y. *European Journal Of Pharmacology, 274*(1-3), 221-224.

Grill, H. J., & Hayes, M. R. (2009). The Nucleus Tractus Solitarius: A Portal For Visceral Afferent Signal Processing, Energy Status Assessment And Integration Of Their Combined Effects On Food Intake. *International Journal Of Obesity, 33*, S11-S15.

Gropp, E., Shanabrough, M., Borok, E., Xu, A. W., Janoschek, R., Buch, T., Plum, L., Balthasar, N., Hampel, B., Waisman, A., Barsh, G. S., Horvath, T. L., & Bruning, J. C. (2005). Agouti-Related Peptide-Expressing Neurons Are Mandatory For Feeding. *Nature Neuroscience, 8*(10), 1289-1291.

Gross, P. M., Wall, K. M., Pang, J. J., Shaver, S. W., & Wainman, D. S. (1990). Microvascular Specializations Promoting Rapid Interstitial Solute Dispersion In Nucleus Tractus Solitarius. *American Journal Of Physiology - Regulatory, Integrative And Comparative Physiology, 259*(6), R1131-R1138.

Grossman, S. P. (1975). Role Of The Hypothalamus In The Regulation Of Food And Water Intake. *Psychological Review, 82*(3), 200-224.

Guan, X.-M., Chen, H., Dobbelaar, P. H., Dong, Y., Fong, T. M., Gagen, K., Gorski, J., He, S., Howard, A. D., Jian, T., Jiang, M., Kan, Y., Kelly, T. M., Kosinski, J., Lin, L. S., Liu, J., Marsh, D. J., Metzger, J. M., Miller, R., Nargund, R. P., Palyha, O., Shearman, L., Shen, Z., Stearns, R., Strack, A. M., Stribling, S., Tang, Y. S., Wang, S.-P., White, A., Yu, H., & Reitman, M. L. (2010). Regulation Of Energy Homeostasis By Bombesin Receptor Subtype-3: Selective Receptor Agonists For The Treatment Of Obesity. *Cell Metabolism, 11*(2), 101-112.

Guan, X.-M., Metzger, J. M., Yang, L., Raustad, K. A., Wang, S.-P., Spann, S. K., Kosinski, J. A., Yu, H., Shearman, L. P., Faidley, T. D., Palyha, O., Kan, Y., Kelly, T. M., Sebhat, I., Lin, L. S., Dragovic, J., Lyons, K. A., Craw, S., Nargund, R. P., Marsh, D. J., Strack, A. M., & Reitman, M. L. (2011). Antiobesity Effect Of Mk-5046, A Novel Bombesin Receptor Subtype-3 Agonist. *Journal Of Pharmacology And Experimental Therapeutics, 336*(2), 356-364.

Guan, X. M., Yu, H., Palyha, O. C., Mckee, K. K., Feighner, S. D., Sirinathsinghji, D. J., Smith, R. G., Van Der Ploeg, L. H., & Howard, A. D. (1997). Distribution Of Mrna Encoding The Growth Hormone Secretagogue Receptor In Brain And Peripheral Tissues. *Brain Research. Molecular Brain Research, 48*(1), 23-29.

Gueudet, C., Santucci, V., Rinaldicarmona, M., Soubrie, P., & Lefur, G. (1995). The Cb1 Cannabinoid Receptor Antagonist Sr 141716a Affects A(9) Dopamine Neuronal-Activity In The Rat. *Neuroreport, 6*(10), 1421-1425.

Gullestad, L., Bjuro, T., Aaberge, L., Apelland, T., Skardal, R., Kjekshus, E., Nordlander, M., Ablad, B., & Pernow, J. (2003). The Effect Of A Neuropeptide Yy1 Receptor Antagonist In Patients With Angina Pectoris. *European Heart Journal, 24*(12), 1120-1127.

Gundlah, C., Martin, K. F., Heal, D. J., & Auerbach, S. B. (1997). In Vivo Criteria To Differentiate Monoamine Reuptake Inhibitors From Releasing Agents: Sibutramine Is A Reuptake Inhibitor. *Journal Of Pharmacology And Experimental Therapeutics, 283*(2), 581-591.

Guscott, M. R., Egan, E., Cook, G. P., Stanton, J. A., Beer, M. S., Rosahl, T. W., Hartmann, S., Kulagowski, J., Mcallister, G., Fone, K. C. F., & Hutson, P. H. (2003). The Hypothermic Effect Of 5-Ct In Mice Is Mediated Through The 5-Ht7 Receptor. *Neuropharmacology, 44*(8), 1031-1037.

Gutzwiller, J. P., Drewe, J., Goke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999). Glucagon-Like Peptide-1 Promotes Satiety And Reduces Food Intake In Patients With Diabetes Mellitus Type 2. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 276*(5), R1541-R1544.

Gutzwiller, J. P., Drewe, J., Ketterer, S., Hildebrand, P., Krautheim, A., & Beglinger, C. (2000). Interaction Between Cck And A Preload On Reduction Of Food Intake Is Mediated By Cck-A Receptors In Humans. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 279*(1), R189-R195.

Gutzwiller, J. P., Goke, B., Drewe, J., Hildebrand, P., Ketterer, S., Handschin, D., Winterhalder, R., Conen, D., & Beglinger, C. (1999). Glucagon-Like Peptide-1: A Potent Regulator Of Food Intake In Humans. *Gut, 44*(1), 81-86.

Guygrand, B. (1992). Index (International Dexfenfluramine Study) As A Model For Long-Term Pharmacotherapy Of Obesity In The 1990s. *International Journal Of Obesity, 16*, S5-S14.

Guygrand, B. (1995). Clinical Studies With Dexfenfluramine: From Past To Future. *Obesity Research, 3*, S491-S496.

Guygrand, B., Crepaldi, G., Lefebvre, P., Apfelbaum, M., Gries, A., & Turner, P. (1989). International Trial Of Long-Term Dexfenfluramine In Obesity. *Lancet, 2*(8672), 1142-1145.

Hadjimarkou, M. M., Singh, A., Kandov, Y., Israel, Y., Pan, Y. X., Rossi, G. C., Pasternak, G. W., & Bodnar, R. J. (2004). Opioid Receptor Involvement In Food Deprivation-Induced Feeding: Evaluation Of Selective Antagonist And

Antisense Oligodeoxynucleotide Probe Effects In Mice And Rats. *Journal Of Pharmacology And Experimental Therapeutics, 311*(3), 1188-1202.

Hagan, M. M., Holguin, F. D., Cabello, C. E., Hanscom, D. R., & Moss, D. E. (1997). Combined Naloxone And Fluoxetine On Deprivation-Induced Binge Eating Of Palatable Foods In Rats. *Pharmacology Biochemistry And Behavior, 58*(4), 1103-1107.

Hagan, M. M., Rushing, P. A., Pritchard, L. M., Schwartz, M. W., Strack, A. M., Van Der Ploeg, L. H. T., Woods, S. C., & Seeley, R. J. (2000). Long-Term Orexigenic Effects Of Agrp-(83---132) Involve Mechanisms Other Than Melanocortin Receptor Blockade. *Am J Physiol Regul Integr Comp Physiol, 279*(1), R47-52.

Hainerova, I., Torekov, S. S., Ek, J., Finkova, M., Borch-Johnsen, K., Jorgensen, T., Madsen, O. D., Lebl, J., Hansen, T., & Pedersen, O. (2006). Association Between Neuromedin U Gene Variants And Overweight And Obesity. *Journal Of Clinical Endocrinology & Metabolism, 91*(12), 5057-5063.

Halatchev, I. G., Ellacott, K. L. J., Fan, W., & Cone, R. D. (2004). Peptide Yy3-36 Inhibits Food Intake In Mice Through A Melanocortin-4 Receptor-Independent Mechanism

10.1210/En.2003-1754. *Endocrinology, 145*(6), 2585-2590.

Halem, H. A., Taylor, J. E., Dong, J. Z., Shen, Y., Datta, R., Abizaid, A., Diano, S., Horvath, T. L., & Culler, M. D. (2005). A Novel Growth Hormone Secretagogue-1a Receptor Antagonist That Blocks Ghrelin-Induced Growth Hormone Secretion But Induces Increased Body Weight Gain. *Neuroendocrinology, 81*(5), 339-349.

Halford, J. C. (2006). Obesity Drugs In Clinical Development. *Current Opinion In Investigational Drugs, 7*(4), 312-318.

Halford, J. C., & Blundell, J. E. (1993). 5-Hydroxytryptaminergic Drugs Compared On The Behavioral Sequence Associated With Satiety. *British Journal Of Pharmacology, 110*, P95-P95.

Halford, J. C., & Blundell, J. E. (1996a). The 5-Ht1b Receptor Agonist Cp-94,253 Reduces Food Intake And Preserves The Behavioural Satiety Sequence. *Physiology & Behavior, 60*(3), 933-939.

Halford, J. C., & Blundell, J. E. (1996b). Metergoline Antagonizes Fluoxetine-Induced Suppression Of Food Intake But Not Changes In The Behavioural Satiety Sequence. *Pharmacology Biochemistry And Behavior, 54*(4), 745-751.

Halford, J. C., Boyland, E. J., Blundell, J. E., Kirkham, T. C., Harrold, J. A., Halford, J. C. G., Boyland, E. J., Blundell, J. E., Kirkham, T. C., & Harrold, J. A. (2010). Pharmacological Management Of Appetite Expression In Obesity. *Nature Reviews Endocrinology, 6*(5), 255-269.

Halford, J. C., Boyland, E. J., Cooper, S. J., Dovey, T. M., Huda, M. S. B., Dourish, C. T., Dawson, G. R., & Wilding, J. P. H. (2010). The Effects Of Sibutramine On The Microstructure Of Eating Behaviour And Energy Expenditure In Obese Women. *Journal Of Psychopharmacology, 24*(1), 99-109.

Halford, J. C., Boyland, E. J., Lawton, C. L., Blundell, J. E., & Harrold, J. A. (2011). Serotonergic Anti-Obesity Agents Past Experience And Future Prospects. *Drugs, 71*(17), 2247-2255.

Halford, J. C., Cooper, G. D., Dovey, T. M., Ishii, Y., Rodgers, J., & Blundell, J. E. (2003). The Psychopharmacology Of Appetite: Targets For Potential Anti-Obesity Agents. *Current Medicinal Chemistry - Central Nervous System Agents, 3*(4), 283-310.

Halford, J. C., Harrold, J. A., Boyland, E. J., Lawton, C. L., & Blundell, J. E. (2007). Serotonergic Drugs - Effects On Appetite Expression And Use For The Treatment Of Obesity. *Drugs, 67*(1), 27-55.

Halford, J. C., Harrold, J. A., Lawton, C. L., & Blundell, J. E. (2005). Serotonin (5-Ht) Drugs: Effects On Appetite Expression And Use For The Treatment Of Obesity. *Current Drug Targets, 6*(2), 201-213.

Halford, J. C., Heal, D. J., & Blundell, J. E. (1995). Effects In The Rat Of Sibutramine On Food-Intake And The Behavioral Satiety Sequence. *British Journal Of Pharmacology, 114*, P387-P387.

Halford, J. C., Lawton, C. L., & Blundell, J. E. (1997). The 5-Ht2 Receptor Agonist Mk-212 Reduces Food Intake And Increases Resting But Prevents The Behavioural Satiety Sequence. *Pharmacology, Biochemistry, And Behavior, 56*(1), 41-46.

Halford, J. C., Wanninayake, S. C., & Blundell, J. E. (1998). Behavioral Satiety Sequence (Bss) For The Diagnosis Of Drug Action On Food Intake. *Pharmacology, Biochemistry And Behavior, 61*(2), 159-168.

Haller, J., Varga, B., Ledent, C., Barna, I., & Freund, T. F. (2004). Context-Dependent Effects Of Cb1 Cannabinoid Gene Disruption On Anxiety-Like And Social Behaviour In Mice. *European Journal Of Neuroscience, 19*(7), 1906-1912.

Hallschmid, M., Benedict, C., Born, J., Fehm, H.-L., & Kern, W. (2004). Manipulating Central Nervous Mechanisms Of Food Intake And Body Weight Regulation By Intranasal Administration Of Neuropeptides In Man. *Physiology & Behavior*

Special Section On Olfactory Perception, Communication, And The Nose-To-Brain Pathway, 83(1), 55-64.

Hamilton, C. L., & Ciaccia, P. J. (1971). Hypothalamus, Temperature Regulation, And Feeding In Rat. *American Journal Of Physiology, 221*(3), 800-&.

Hanada, R., Teranishi, H., Pearson, J. T., Kurokawa, M., Hosoda, H., Fukushima, N., Fukue, Y., Serino, R., Fujihara, H., Ueta, Y., Ikawa, M., Okabe, M., Murakami, N., Shirai, M., Yoshimatsu, H., Kangawa, K., & Kojima, M. (2004). Neuromedin U Has A Novel Anorexigenic Effect Independent Of The Leptin Signaling Pathway. *10*(10), 1067-1073.

Hancock, A. A., Bennani, Y. L., Bush, E. N., Esbenshade, T. A., Faghih, R., Fox, G. B., Jacobson, P., Knourek-Segel, V., Krueger, K. M., Nuss, M. E., Pan, J. B., Shapiro, R., Witte, D. G., & Yao, B. B. (2004). Antiobesity Effects Of A-331440, A Novel Non-Imidazole Histamine H-3 Receptor Antagonist. *European Journal Of Pharmacology, 487*(1-3), 183-197.

Hancock, A. A., & Brune, M. E. (2005). Assessment Of Pharmacology And Potential Anti-Obesity Properties Of H3 Receptor Antagonists/Inverse Agonists. *Expert Opinion On Investigating Drugs, 14*(3), 223-241.

Hannon-Engel, S. (2012). Regulating Satiety In Bulimia Nervosa: The Role Of Cholecystokinin. *Perspectives In Psychiatric Care, 48*(1), 34-40.

Hansen, B. C., Bjenning, C., & Knudsen, L. B. (2001). Sustained Appetite Suppression And Weight Loss In Obese Rhesus Monkeys Treated With A Long-Acting Glp-1 Derivative, Nn2211. *Diabetologia, 44*, A196-A196.

Hansen, D. L., Toubro, S., Stock, M. J., Macdonald, I. A., & Astrup, A. (1998). Thermogenic Effects Of Sibutramine In Humans. *American Journal Of Clinical Nutrition, 68*(6), 1180-1186.

Hansen, D. L., Toubro, S., Stock, M. J., Macdonald, I. A., & Astrup, A. (1999). The Effect Of Sibutramine On Energy Expenditure And Appetite During Chronic Treatment Without Dietary Restriction. *International Journal Of Obesity, 23*(10), 1016-1024.

Hansen, M. J., Schioth, H. B., & Morris, M. J. (2005). Feeding Responses To A Melanocortin Agonist And Antagonist In Obesity Induced By A Palatable High-Fat Diet. *Brain Research, 1039*(1-2), 137-145.

Hansotia, T., Maida, A., Flock, G., Yamada, Y., Tsukiyama, K., Seino, Y., & Drucker, D. J. (2007). Extrapancreatic Incretin Receptors Modulate Glucose

Homeostasis, Body Weight, And Energy Expenditure. *Journal Of Clinical Investigation, 117*(1), 143-152.

Hao, S. Z., Avraham, Y., Mechoulam, R., & Berry, E. M. (2000). Low Dose Anandamide Affects Food Intake, Cognitive Function, Neurotransmitter And Corticosterone Levels In Diet-Restricted Mice. *European Journal Of Pharmacology, 392*(3), 147-156.

Hara, J., Beuckmann, C. T., Nambu, T., Willie, J. T., Chemelli, R. M., Sinton, C. M., Sugiyama, F., Yagami, K., Goto, K., Yanagisawa, M., & Sakurai, T. (2001). Genetic Ablation Of Orexin Neurons In Mice Results In Narcolepsy, Hypophagia, And Obesity. *Neuron, 30*(2), 345-354.

Hariri, N., & Thibault, L. (2010). High-Fat Diet-Induced Obesity In Animal Models. *Nutrition Research Reviews, 23*(2), 270-299.

Harris, G. C., Wimmer, M., & Aston-Jones, G. (2005). A Role For Lateral Hypothalamic Orexin Neurons In Reward Seeking. *437*(7058), 556-559.

Harris, G. C., Wimmer, M., Randall-Thompson, J. F., & Aston-Jones, G. (2007). Lateral Hypothalamic Orexin Neurons Are Critically Involved In Learning To Associate An Environment With Morphine Reward. *Behavioural Brain Research, 183*(1), 43.

Harrold, J. A., Doyey, T. M., Blundell, J. E., & Halford, J. C. G. (2012). Cns Regulation Of Appetite. *Neuropharmacology, 63*(1), 3-17.

Hart, C. L., Ward, A. S., Haney, M., Comer, S. D., Foltin, R. W., & Fischman, M. W. (2002). Comparison Of Smoked Marijuana And Oral Delta(9)-Tetrahydrocannabinol In Humans. *Psychopharmacology, 164*(4), 407-415.

Hartotruax, N., Stern, W. C., Miller, L. L., Sato, T. L., & Cato, A. E. (1983). Effects Of Bupropion On Body-Weight. *Journal Of Clinical Psychiatry, 44*(5), 183-186.

Hasegawa, H., Meeusen, R., Sarre, S., Diltoer, M., Piacentini, M. F., & Michotte, Y. (2005). Acute Dopamine/Norepinephrine Reuptake Inhibition Increases Brain And Core Temperature In Rats. *Journal Of Applied Physiology, 99*(4), 1397-1401.

Hassanain, M., & Levin, B. E. (2002). Dysregulation Of Hypothalamic Serotonin Turnover In Diet-Induced Obese Rats. *Brain Research, 929*(2), 175-180.

Hayashi, A., Sonoda, R., Kimura, Y., Takasu, T., Suzuki, M., Sasamata, M., & Miyata, K. (2004). Antiobesity Effect Of Ym348, A Novel 5-Ht2c Receptor Agonist, In Zucker Rats. *Brain Research, 1011*(2), 221-227.

Hayashi, A., Suzuki, M., Sasamata, M., & Miyata, K. (2004). Thermogenic Effect Of Ym348, A Novel 5-Ht2c-Receptor Agonist, In Rats. *Journal Of Pharmacy And Pharmacology, 56*(12), 1551-1556.

Hayes, M. R., & Covasa, M. (2006). Dorsal Hindbrain 5-Ht3 Receptors Participate In Control Of Meal Size And Mediate Cck-Induced Satiation. *Brain Research, 1103*, 99-107.

Hayes, M. R., Kanoski, S. E., Alhadeff, A. L., & Grill, H. J. (2011). Comparative Effects Of The Long-Acting Glp-1 Receptor Ligands, Liraglutide And Exendin-4, On Food Intake And Body Weight Suppression In Rats. *Obesity, 19*(7), 1342-1349.

Hayes, M. R., Leichner, T. M., Zhao, S., Lee, G. S., Chowansky, A., Zimmer, D., De Jonghe, B. C., Kanoski, S. E., Grill, H. J., & Bence, K. K. (2011). Intracellular Signals Mediating The Food Intake-Suppressive Effects Of Hindbrain Glucagon-Like Peptide-1 Receptor Activation. *Cell Metabolism, 13*(3), 320-330.

Hayes, M. R., Skibicka, K. P., & Grill, H. J. (2008). Caudal Brainstem Processing Is Sufficient For Behavioral, Sympathetic, And Parasympathetic Responses Driven By Peripheral And Hindbrain Glucagon-Like-Peptide-1 Receptor Stimulation. *Endocrinology, 149*(8), 4059-4068.

Haykal, R. F., & Akiskal, H. S. (1990). Bupropion As A Promising Approach To Rapid Cycling Bipolar-Ii Patients. *Journal Of Clinical Psychiatry, 51*(11), 450-455.

Hays, J. T., Hurt, R. D., Rigotti, N. A., Niaura, R., Gonzales, D., Durcan, M. J., Sachs, D. P. L., Wolter, T. D., Buist, A. S., Johnston, J. A., & White, J. D. (2001). Sustained-Release Bupropion For Pharmacologic Relapse Prevention After Smoking Cessation - A Randomized, Controlled Trial. *Annals Of Internal Medicine, 135*(6), 423-433.

Hayward, M. D., & Low, M. J. (2007). The Contribution Of Endogenous Opioids To Food Reward Is Dependent On Sex And Background Strain. *Neuroscience, 144*(1), 17.

Hayward, M. D., Schaich-Borg, A., Pintar, J. E., & Low, M. J. (2006). Differential Involvement Of Endogenous Opioids In Sucrose Consumption And Food Reinforcement. *Pharmacology Biochemistry And Behavior, 85*(3), 601-611.

Heal, D. J., Aspley, S., Prow, M. R., Jackson, H. C., Martin, K. F., & Cheetham, S. C. (1998). Sibutramine: A Novel Anti-Obesity Drug. A Review Of The Pharmacological Evidence To Differentiate It From D-Amphetamine And D-Fenfluramine. *International Journal Of Obesity, 22*, S18-S28.

Heal, D. J., Cheetham, S. C., Prow, M. R., Martin, K. F., & Buckett, W. R. (1998). A Comparison Of The Effects On Central 5-Ht Function Of Sibutramine Hydrochloride And Other Weight-Modifying Agents. *British Journal Of Pharmacology, 125*(2), 301-308.

Heal, D. J., Gosden, J., & Smith, S. L. (2009). Regulatory Challenges For New Drugs To Treat Obesity And Comorbid Metabolic Disorders. *British Journal Of Clinical Pharmacology, 98*, 861-874.

Heal, D. J., Smith, S. L., Fisas, A., Codony, X., & Buschmann, H. (2008). Selective 5-Ht(6) Receptor Ligands: Progress In The Development Of A Novel Pharmacological Approach To The Treatment Of Obesity And Related Metabolic Disorders. *Pharmacology & Therapeutics, 117*(2), 207-231.

Health, N. I. O. (2000). The Practical Guide Identification, Evaluation, And Treatment Of Overweight And Obesity In Adults. Retrieved May 2013 Http://Www.Nhlbi.Nih.Gov/Guidelines/Obesity/Prctgd_C.Pdf

Hedlund, P. B., Danielson, P. E., Thomas, E. A., Slanina, K., Carson, M. J., & Sutcliffe, J. G. (2003). No Hypothermic Response To Serotonin In 5-Ht7 Receptor Knockout Mice. *Proceedings Of The National Academy Of Sciences Of The United States Of America, 100*(3), 1375-1380.

Hedner, T., Narkiewicz, K., Oparil, S., & Kjeldsen, S. E. (2013). Primary Cardiovascular Prevention By Mediterranean Diet - The Predimed Trial. *Blood Pressure, 22*(3), 129-130.

Heilig, M., Mcleod, S., Brot, M., Heinrichs, S. C., Menzaghi, F., Koob, G. F., & Britton, K. T. (1993). Anxiolytic-Like Action Of Neuropeptide-Y - Mediation By Y1 Receptors In Amydala, And Dissociation From Food-Intake Effects. *Neuropsychopharmacology, 8*(4), 357-363.

Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & Grp, G. S. (2005). Exenatide Versus Insulin Glargine In Patients With Suboptimally Controlled Type 2 Diabetes - A Randomized Trial. *Annals Of Internal Medicine, 143*(8), 559-569.

Heisler, L. K., Chu, H. M., Brennan, T. J., Danao, J. A., Bajwa, P., Parsons, L. H., & Tecott, L. H. (1998). Elevated Anxiety And Antidepressant-Like Responses In Serotonin 5-Ht1a Receptor Mutant Mice. *Proceedings Of The National Academy Of Sciences Of The United States Of America, 95*(25), 15049-15054.

Heisler, L. K., Cowley, M. A., Kishi, T., Tecott, L. H., Fan, W., Low, M. J., Smart, J. L., Rubinstein, M., Tatro, J. B., Zigman, J. M., Cone, R. D., & Elmquist, J. K. (2003). Central Serotonin And Melanocortin Pathways Regulating Energy Homeostasis. *Ann NY Acad Sci, 994*(1), 169-174.

Heisler, L. K., Cowley, M. A., Tecott, L. H., Fan, W., Low, M. J., Smart, J. L., Rubinstein, M., Tatro, J. B., Marcus, J. N., Holstege, H., Lee, C. E., Cone, R. D., & Elmquist, J. K. (2002). Activation Of Central Melanocortin Pathways By Fenfluramine. *Science, 297*(5581), 609-611.

Heisler, L. K., Jobst, E. E., Sutton, G. M., Zhou, L., Borok, E., Thornton-Jones, Z., Liu, H. Y., Zigman, J. M., Balthasar, N., Kishi, T., Lee, C. E., Aschkenasi, C. J., Zhang, C.-Y., Yu, J., Boss, O., Mountjoy, K. G., Clifton, P. G., Lowell, B. B., Friedman, J. M., Horvath, T., Butler, A. A., Elmquist, J. K., & Cowley, M. A. (2006). Serotonin Reciprocally Regulates Melanocortin Neurons To Modulate Food Intake. *Neuron, 51*(2), 239.

Heisler, L. K., Kanarek, R. B., & Gerstein, A. (1997). Fluoxetine Decreases Fat And Protein Intakes But Not Carbohydrate Intake In Male Rats. *Pharmacology Biochemistry And Behavior, 58*(3), 767-773.

Hermann, H., Marsicano, G., & Lutz, B. (2002). Coexpression Of The Cannabinoid Receptor Type 1 With Dopamine And Serotonin Receptors In Distinct Neuronal Subpopulations Of The Adult Mouse Forebrain. *Neuroscience, 109*(3), 451-460.

Herrmann, C., Goke, R., Richter, G., Fehmann, H. C., Arnold, R., & Goke, B. (1995). Glucagon-Like Peptide-1 And Glucose-Dependent Insulin-Releasing Polypeptide Plasma-Levels In Response To Nutrients. *Digestion, 56*(2), 117-126.

Hervey, G. R. (1969). Regulation Of Energy Balance. *Nature, 222*(5194), 629-&.

Herz, A. (1997). Endogenous Opioid Systems And Alcohol Addiction. *Psychopharmacology, 129*(2), 99-111.

Heshmati, H., Caplain, H., Bellisle, F., Mosse, M., Fauveau, C., & Le Fur, G. (2001). Sr141716, A Selective Cannabinoid Cb1 Receptor Antagonist Reduces Hunger, Caloric Intake, And Body Weight In Overweight Or Obese Men. *Obesity Research, 9*, 70S-70S.

Hetherington, A. W., & Ranson, S. W. (1940). Hypothalamic Lesions And Adiposity In The Rat. *Anatomical Record, 78*, 149 - 172.

Heuser, M., Kleiman, I., Popken, O., Nustede, R., & Post, S. (2002). Evidence For Non-Neurotensin Receptor-Mediated Effects Of Xenin (1-25) - Focus On Intestinal Microcirculation. *Regulatory Peptides, 107*(1-3), 23-27.

Hewitt, K. N., Lee, M. D., Dourish, C. T., & Clifton, P. G. (2002). Serotonin 2c Receptor Agonists And The Behavioural Satiety Sequence In Mice. *Pharmacology Biochemistry And Behavior, 71*(4), 691-700.

Heymsfield, S. B., Greenberg, A. S., Fujioka, K., Dixon, R. M., Kushner, R., Hunt, T., Lubina, J. A., Patane, J., Self, B., Hunt, P., & Mccamish, M. (1999). Recombinant Leptin For Weight Loss In Obese And Lean Adults - A Randomized, Controlled, Dose-Escalation Trial. *Jama-Journal Of The American Medical Association, 282*(16), 1568-1575.

Higgins, G. A., Silenieks, L. B., Rossmann, A., Rizos, Z., Noble, K., Soko, A. D., & Fletcher, P. J. (2012). The 5-Ht2c Receptor Agonist Lorcaserin Reduces Nicotine Self-Administration, Discrimination, And Reinstatement: Relationship To Feeding Behavior And Impulse Control. *Neuropsychopharmacology, 37*(5), 1177-1191.

Higgs, S., Cooper, A. J., & Barnes, N. M. (2011). Reversal Of Sibutramine-Induced Anorexia With A Selective 5-Ht2c Receptor Antagonist. *Psychopharmacology, 214*(4), 941-947.

Higgs, S., Williams, C. M., & Kirkham, T. C. (2003). Cannabinoid Influences On Palatability: Microstructural Analysis Of Sucrose Drinking After Delta(9)-Tetrahydrocannabinol, Anandamide, 2-Arachidonoyl Glycerol And Sr141716. *Psychopharmacology, 165*(4), 370-377.

Higuchi, S., Irie, K., Mishima, S., Araki, M., Ohji, M., Shirakawa, A., Akitake, Y., Matsuyama, K., Mishima, K., Mishima, K., Iwasaki, K., & Fujiwara, M. (2010). The Cannabinoid 1-Receptor Silent Antagonist O-2050 Attenuates

Preference For High-Fat Diet And Activated Astrocytes In Mice. *Journal Of Pharmacological Sciences, 112*(3), 369-372.

Hikiji, K. (2004). Local Perfusion Of Mcpp Into The Ventromedial Hypothalamic Nucleus Inhibits Food Intake In Rats. *Journal Of The Osaka City Medical Center, 53*(1-2), 9-15.

Hildebrandt, A. L., Kelly-Sullivan, D. M., & Black, S. C. (2003). Antiobesity Effects Of Chronic Cannabinoid Cb1 Receptor Antagonist Treatment In Diet-Induced Obese Mice. *European Journal Of Pharmacology, 462*(1–3), 125-132.

Hill, J. O., & Astrup, A. (2003). What Diets Should We Be Recommending For Obesity? *Obesity Reviews : An Official Journal Of The International Association For The Study Of Obesity, 4*(2), 77-78.

Hill, M. N., & Gorzalka, B. B. (2005). Is There A Role For The Endocannabinoid System In The Etiology And Treatment Of Melancholic Depression? *Behavioural Pharmacology, 16*(5-6), 333-352.

Hillebrand, J. J. G., De Wied, D., & Adan, R. A. H. (2002). Neuropeptides, Food Intake And Body Weight Regulation: A Hypothalamic Focus. *Peptides, 23*(12), 2283-2306.

Hinton, V., Rosofsky, M., Granger, J., & Geary, N. (1986). Combined Injection Potentiates The Satiety Effects Of Pancreatic Glucagon, Cholecystokinin, And Bombesin. *Brain Research Bulletin, 17*(5), 615-619.

Hirose, N., Murakawa, K., Takada, K., Oi, Y., Suzuki, T., Nagase, H., Cools, A. R., & Koshikawa, N. (2005). Interactions Among Mu- And Delta-Opioid Receptors, Especially Putative Delta1- And Delta2-Opioid Receptors, Promote Dopamine Release In The Nucleus Accumbens. *Neuroscience, 135*(1), 213-225.

Hirosue, Y., Inui, A., Teranishi, A., Miura, M., Nakajima, M., Okita, M., Nakajima, Y., Himori, N., Baba, S., & Kasuga, M. (1993). Cholecystokinin-Octapeptide Analogs Suppress Food-Intake Via Central Cck-A Receptors In Mice. *American Journal Of Physiology, 265*(3), R481-R486.

Ho, J. M., & Blevins, J. E. (2013). Coming Full Circle: Contributions Of Central And Peripheral Oxytocin Actions To Energy Balance. *Endocrinology, 154*(2), 589-596.

Hochol, A., Tortorella, C., Rucinski, M., Ziolkowska, A., Nussdorfer, G. G., & Malendowicz, L. K. (2007). Effects Of Neuropeptides B And W On The Rat Pituitary-Adrenocortical Axis: In Vivo And In Vitro Studies. *International Journal Of Molecular Medicine, 19*(2), 207-211.

Hodge, J., Bow, J. P., Plyler, K. S., Vemuri, V. K., Wisniecki, A., Salamone, J. D., Makriyannis, A., & Mclaughlin, P. J. (2008). The Cannabinoid Cb1 Receptor Inverse Agonist Am 251 And Antagonist Am 4113 Produce Similar Effects On The Behavioral Satiety Sequence In Rats. *Behavioural Brain Research, 193*(2), 298.

Hohmann, J. G., Krasnow, S. M., Teklemichael, D. N., Clifton, D. K., Wynick, D., & Steiner, R. A. (2003). Neuroendocrine Profiles In Galanin-Overexpressing And Knockout Mice. *Neuroendocrinology, 77*(6), 354-366.

Hollander, P., Plodkowski, R., Gupta, A. K., Guttadauria, M., Erickson, J., Kim, D., & Dunayevich, E. (2010). Cor-Diabetes: Naltrexone Sr/Bupropion Sr Combination Therapy Led To Significant And Sustained Weight Loss And Improved Hba1c In Overweight/Obese Subjects With Type 2 Diabetes. *Diabetes, 59*, A15-A15.

Hollander, P. A., Levy, P., Fineman, M., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2003). Pramlintide As An Adjunct To Insulin Therapy Improves Long-Term Glycemic And Weight Control In Patients With Type 2 Diabetes - A 1-Year Randomized Controlled Trial. *Diabetes Care, 26*(3), 784-790.

Holliste.Le. (1971). Hunger And Appetite After Single Doses Of Marihuana, Alcohol, And Dextroamphetamine. *Clinical Pharmacology & Therapeutics, 12*(1), 44-&.

Holst, J. J. (2007). The Physiology Of Glucagon-Like Peptide 1. *Physiological Reviews, 87*(4), 1409-1439.

Holt, R. I. G. (2005). Obesity - An Epidemic Of The Twenty-First Century: An Update For Psychiatrists

10.1177/0269881105058377. *J Psychopharmacol, 19*(6_Suppl), 6-15.

Holtzman, S. G. (1974). Behavioral-Effects Of Separate And Combined Administration Of Naloxone And D-Amphetamine. *Journal Of Pharmacology And Experimental Therapeutics, 189*(1), 51-60.

Hopwood, S. E., & Stamford, J. A. (2001). Multiple 5-Ht1 Autoreceptor Subtypes Govern Serotonin Release In Dorsal And Median Raphe Nuclei. *Neuropharmacology, 40*(4), 508-519.

Horne, R. L., Ferguson, J. M., Pope, H. G., Hudson, J. I., Lineberry, C. G., Ascher, J., & Cato, A. (1988). Treatment Of Bulimia With Bupropion - A Multicenter Controlled Trial. *Journal Of Clinical Psychiatry, 49*(7), 262-266.

Hornung, J. P. (2003). The Human Raphe Nuclei And The Serotonergic System. *Journal Of Chemical Neuroanatomy, 26*(4), 331-343.

Horswill, J. G., Bali, U., Shaaban, S., Keily, J. F., Jeevaratnam, P., Babbs, A. J., Reynet, C., & In, P. W. K. (2007). Psncbam-1, A Novel Allosteric Antagonist At Cannabinoid Cb1 Receptors With Hypophagic Effects In Rats. *British Journal Of Pharmacology, 152*(5), 805-814.

Horvath, T. L., Diano, S., Sotonyi, P., Heiman, M., & Tschop, M. (2001). Minireview: Ghrelin And The Regulation Of Energy Balance--A Hypothalamic Perspective. *Endocrinology, 142*(10), 4163-4169.

Hosoya, M., Moriya, T., Kawamata, Y., Ohkubo, S., Fujii, R., Matsui, H., Shintani, Y., Fukusumi, S., Habata, Y., Hinuma, S., Onda, H., Nishimura, O., & Fujino, M. (2000). Identification And Functional Characterization Of A Novel Subtype Of Neuromedin U Receptor. *Journal Of Biological Chemistry, 275*(38), 29528-29532.

Howard, A. D., Wang, R. P., Pong, S. S., Mellin, T. N., Strack, A., Guan, X. M., Zeng, Z. Z., Williams, D. L., Feighner, S. D., Nunes, C. N., Murphy, B., Stair, J. N., Yu, H., Jiang, Q. P., Clements, M. K., Tan, C. P., Mckee, K. K., Hreniuk, D. L., Mcdonald, T. P., Lynch, K. R., Evans, J. F., Austin, C. P., Caskey, C. T., Van Der Ploeg, L. H. T., & Liu, Q. Y. (2000). Identification Of Receptors For Neuromedin U And Its Role In Feeding. *Nature, 406*(6791), 70-74.

Howard, J. L., Rohrbach, K. W., Pollard, G. T., Mcbennett, S. T., & Jones, C. N. (1978). Comparison Of Bupropion Hcl And Imipramine Hcl In Various Operant Paradigms. *Federation Proceedings, 37*(3), 481-481.

Howlett, A. C. (2002). The Cannabinoid Receptors. *Prostaglandins & Other Lipid Mediators, 68-9*, 619-631.

Hoyer, D., Hannon, J. P., & Martin, G. R. (2002). Molecular, Pharmacological And Functional Diversity Of 5-Ht Receptors. *Pharmacology Biochemistry And Behavior, 71*(4), 533-554.

Huang, X. F., Han, M., South, T., & Storlien, L. (2003). Altered Levels Of Pow, Agrp And Mc4-R Mrna Expression In The Hypothalamus And Other Parts Of The Limbic System Of Mice Prone Or Resistant To Chronic High-Energy Diet-Induced Obesity. *Brain Research, 992*(1), 9-19.

Hughes, R. N., & Syme, L. A. (1972). Role Of Social Isolation And Sex In Determining Effects Of Chlordiazepoxide And Methylphenidate On Exploratory Behavior. *Psychopharmacologia, 27*(4), 359-366.

Hukshorn, C. J., Westerterp-Plantenga, M. S., & Saris, W. H. M. (2003). Pegylated Human Recombinant Leptin (Peg-Ob) Causes Additional Weight Loss In

Severely Energy-Restricted, Overweight Men. *American Journal Of Clinical Nutrition, 77*(4), 771-776.
Hulsey, M. G., Pless, C. M., White, B. D., & Martin, R. J. (1995). Icv Administration Of Anti-Npy Antisense Oligonucleotide - Effects On Feeding-Behavior, Body-Weight, Peptide Content And Peptide Release. *Regulatory Peptides, 59*(2), 207-214.
Hummel, K. P., Dickie, M. M., & Coleman, D. L. (1966). Diabetes A New Mutation In Mouse. *Science, 153*(3740), 1127-&.
Hurren, K. M., & Berlie, H. D. (2011). Lorcaserin: An Investigational Serotonin 2c Agonist For Weight Loss. *American Journal Of Health-System Pharmacy, 68*(21), 2029-2037.
Hurt, R. D., Sachs, D. P. L., Glover, E. D., Offord, K. P., Johnston, J. A., Dale, L. C., Khayrallah, M. A., Schroeder, D. R., Glover, P. N., Sullivan, C. R., Croghan, I. T., & Sullivan, P. M. (1997). A Comparison Of Sustained-Release Bupropion And Placebo For Smoking Cessation. *New England Journal Of Medicine, 337*(17), 1195-1202.
Hustvedt, B. E., & Lovo, A. (1972). Correlation Between Hyperinsulinemia And Hyperphagia In Rats With Ventromedial Hypothalamic-Lesions. *Acta Physiologica Scandinavica, 84*(1), 29-&.
Hutson, P. H., Donohoe, T. P., & Curzon, G. (1988). Infusion Of The 5-Hydroxytryptamine Agonists Ru24969 And Tfmpp Into The Paraventricular Nucleus Of The Hypothalamus Causes Hypophagia. *Psychopharmacology, 95*(4), 550-552.
Hynes, M. D., Lochner, M. A., Bemis, K. G., & Hymson, D. L. (1985). Fluoxetine, A Selective Inhibitor Of Serotonin Uptake, Potentiates Morphine Analgesia Without Altering Its Discriminative Stimulus Properties Or Affinity For Opioid Receptors. *Life Sciences, 36*(24), 2317-2323.
Ibrahim, N., Bosch, M. A., Smart, J. L., Qiu, J., Rubinstein, M., Ronnekleiv, O. K., Low, M. J., & Kelly, M. J. (2003). Hypothalamic Proopiomelanocortin Neurons Are Glucose Responsive And Express K-Atp Channels. *Endocrinology, 144*(4), 1331-1340.
Ida, T., Mori, K., Miyazato, M., Egi, Y., Abe, S., Nakahara, K., Nishihara, M., Kangawa, K., & Murakami, N. (2005). Neuromedin S Is A Novel Anorexigenic Hormone

10.1210/En.2005-0107. *Endocrinology, 146*(10), 4217-4223.
Inc, O. T. (2007). Contrave. Retrieved 6th September 2013, 2013, From Http://Www.Orexigen.Com/Product-Candidates/Contrave.Html
Ingalls, A. M., Dickie, M. M., & Snell, G. D. (1950). Obese, A New Mutation In The House Mouse. *Journal Of Heredity, 41*(12), 317-318.
Inoue, K., Valdez, G. R., Reyes, T. M., Reinhardt, L. E., Tabarin, A., Rivier, J., Vale, W. W., Sawchenko, P. E., Koob, G. F., & Zorrilla, E. P. (2003). Human Urocortin Ii, A Selective Agonist For The Type 2 Corticotropin-Releasing Factor Receptor, Decreases Feeding And Drinking In The Rat. *Journal Of Pharmacology And Experimental Therapeutics, 305*(1), 385-393.
Irwin, N., Hunter, K., & Flatt, P. R. (2008). Comparison Of Independent And Combined Chronic Metabolic Effects Of Gip And Cb1 Receptor Blockade In High-Fat Fed Mice. *Peptides, 29*(6), 1036-1041.
Ishihara, A., Tanaka, T., Kanatani, A., Fukami, T., Ihara, M., & Fukuroda, T. (1998). A Potent Neuropeptide Y Antagonist, 1229u91, Suppressed Spontaneous Food Intake In Zucker Fatty Rats. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 274*(5), R1500-R1504.
Ishii, Y., Blundell, J. E., Halford, J. C., Rodgers, R. J., & Halford, J. C. G. (2003). Palatability, Food Intake And The Behavioural Satiety Sequence In Male Rats. *Physiology & Behavior, 80*(1), 37-47.

Ishii, Y., Blundell, J. E., Halford, J. C. G., & Rodgers, R. J. (2003). Effects Of Systematic Variation In Presatiation And Fasting On The Behavioural Satiety Sequence In Male Rats. *Physiology & Behavior, 79*(2), 227-238.

Ishii, Y., Blundell, J. E., Halford, J. C. G., Upton, N., Porter, R., Johns, A., Jeffrey, P., Summerfield, S., & Rodgers, R. J. (2005). Anorexia And Weight Loss In Male Rats 24 H Following Single Dose Treatment With Orexin-1 Receptor Antagonist Sb-334867. *Behavioural Brain Research, 157*(2), 331-341.

Ishii, Y., Blundell, J. E., Halford, J. C. G., Upton, N., Porter, R., Johns, A., & Rodgers, R. J. (2004). Differential Effects Of The Selective Orexin-1 Receptor Antagonist Sb-334867 And Lithium Chloride On The Behavioural Satiety Sequence In Rats. *Physiology & Behavior, 81*(1), 129-140.

Ishii, Y., Blundell, J. E., Halford, J. C. G., Upton, N., Porter, R., Johns, A., & Rodgers, R. J. (2005). Satiety Enhancement By Selective Orexin-1 Receptor Antagonist Sb-334867: Influence Of Test Context And Profile Comparison With Cck-8s. *Behavioural Brain Research, 160*(1), 11-24.

Islam, A. K., & Bodnar, R. J. (1990). Selective Opioid Receptor Antagonist Effects Upon Intake Of A High-Fat Diet In Rats. *Brain Research, 508*(2), 293-296.

Ivy, A. C., & Oldberg, E. (1928). A Hormone Mechanism For Gall-Bladder Contraction And Evacuation. *American Journal Of Physiology, 86*(3), 599-613.

Iwamoto, E. T. (1981). Locomotor-Activity And Antinociception After Putative-Mu, Putative-Kappa And Putative-Sigma Opioid Receptor Agonists In The Rat - Influence Of Dopaminergic Agonists And Antagonists. *Journal Of Pharmacology And Experimental Therapeutics, 217*(2), 451-460.

Jackson, H. C., & Sewell, R. D. E. (1985a). Are Delta-Opioid Receptors Involved In The Regulation Of Food And Water-Intake. *Neuropharmacology, 24*(9), 885-888.

Jackson, H. C., & Sewell, R. D. E. (1985b). Hyperphagia Induced By 2-Deoxy-D-Glucose In The Presence Of The Delta-Opioid Antagonist Ici 174,864. *Neuropharmacology, 24*(8), 815-817.

Jain, A. K., Kaplan, R. A., Gadde, K. M., Wadden, T. A., Allison, D. B., Brewer, E. R., Leadbetter, R. A., Richard, N., Haight, B., Jamerson, B. D., Buaron, K. S., & Metz, A. (2002). Bupropion Sr Vs. Placebo For Weight Loss In Obese Patients With Depressive Symptoms. *Obesity Research, 10*(10), 1049-1056.

Jakicic, J. M., Marcus, B. H., Lang, W., & Janney, C. (2008). Effect Of Exercise On 24-Month Weight Loss Maintenance In Overweight Women. *Archives Of Internal Medicine, 168*(14), 1550-1559.

Jakicic, J. M., & Otto, A. D. (2005). Physical Activity Considerations For The Treatment And Prevention Of Obesity. *American Journal Of Clinical Nutrition, 82*(1), 226S-229S.

James, W. P. T. (2005). The Scout Study: Risk-Benefit Profile Of Sibutramine In Overweight High-Risk Cardiovascular Patients. *European Heart Journal Supplements, 7*(L), L44-L48.

James, W. P. T., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rossner, S., Saris, W. H. M., Van Gaal, L. F., & Grp, S. S. (2000). Effect Of Sibutramine On Weight Maintenance After Weight Loss: A Randomised Trial. *LANCET, 356*(9248), 2119-2125.

James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., Renz, C. L., & Investigators, S. (2010). Effect Of Sibutramine On Cardiovascular Outcomes In Overweight And Obese Subjects. *New England Journal Of Medicine, 363*(10), 905-917.

Jamshidi, N., & Taylor, D. A. (2001). Anandamide Administration Into The Ventromedial Hypothalamus Stimulates Appetite In Rats. *British Journal Of Pharmacology, 134*(6), 1151-1154.

Janoyan, J. J., Crim, J. L., & Darmani, N. A. (2002). Reversal Of Sr 141716a-Induced Head-Twitch And Ear-Scratch Responses In Mice By Delta(9)-Thc And Other Cannabinoids. *Pharmacology Biochemistry And Behavior, 71*(1-2), 155-162.

Janssen, P., Rotondo, A., Mule, F., & Tack, J. (2013). Review Article: A Comparison Of Glucagon-Like Peptides 1 And 2. *Alimentary Pharmacology & Therapeutics, 37*(1), 18-36.

Jarbe, T. U. C., Andrzejewski, M. E., & Dipatrizio, N. V. (2002). Interactions Between The Cb1 Receptor Agonist Delta(9)-Thc And The Cb1 Receptor Antagonist Sr-141716 In Rats: Open-Field Revisited. *Pharmacology Biochemistry And Behavior, 73*(4), 911-919.

Jarbe, T. U. C., Dipatrizio, N. V., Li, C., & Makriyannis, A. (2003). The Cannabinoid Receptor Antagonist Sr-141716 Does Not Readily Antagonize Open-Field Effects Induced By The Cannabinoid Receptor Agonist (R)-Methanandamide In Rats. *Pharmacology Biochemistry And Behavior, 75*(4), 809-821.

Jarbe, T. U. C., Harris, M. Y., Li, C., Liu, Q., & Makriyannis, A. (2004). Discriminative Stimulus Effects In Rats Of Sr-141716 (Rimonabant), A Cannabinoid Cb1 Receptor Antagonist. *Psychopharmacology, 177*(1-2), 35-45.

Järbe, T. U. C., Lemay, B. J., Olszewska, T., Vemuri, V. K., Wood, J. T., & Makriyannis, A. (2008). Intrinsic Effects Of Am4113, A Putative Neutral Cb1 Receptor Selective Antagonist, On Open-Field Behaviors In Rats. *Pharmacology Biochemistry And Behavior, 91*(1), 84.

Jarbe, T. U. C., Ross, T., Dipatrizio, N. V., Pandarinathan, L., & Makriyannis, A. (2006). Effects Of The Cb1r Agonist Win-55,212-2 And The Cb1r Antagonists Sr-141716 And Am-1387: Open-Field Examination In Rats. *Pharmacology Biochemistry And Behavior, 85*(1), 243-252.

Jarrousse, C., Niel, H., & Bataille, D. (1986). Oxyntomodulin Glucagon-37 Inhibits Gastric Acid Secretion In Response To A Liquid Meal In The Conscious Rat. *Canadian Journal Of Physiology And Pharmacology*(JULY), 108-108.

Jean, A., Conductier, G., Manrique, C., Bouras, C., Berta, P., Hen, R., Charnay, Y., Bockaert, J., & Compan, V. (2007). Anorexia Induced By Activation Of Serotonin 5-Ht4 Receptors Is Mediated By Increases In Cart In The Nucleus Accumbens. *Proceedings Of The National Academy Of Sciences Of The United States Of America, 104*(41), 16335-16340.

Jensen, R. T., Battey, J. F., Spindel, E. R., & Benya, R. V. (2008). International Union Of Pharmacology. Lxviii. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, And Functions In Normal And Disease States. *Pharmacological Reviews, 60*(1), 1-42.

Jerlhag, E., Egecioglu, E., Dickson, S. L., & Engel, J. A. (2010). Ghrelin Receptor Antagonism Attenuates Cocaine- And Amphetamine-Induced Locomotor Stimulation, Accumbal Dopamine Release, And Conditioned Place Preference. *Psychopharmacology, 211*(4), 415-422.

Jerlhag, E., Egecioglu, E., Landgren, S., Salome, N., Heilig, M., Moechars, D., Datta, R., Perrissoud, D., Dickson, S. L., & Engel, J. A. (2009). Requirement Of Central Ghrelin Signaling For Alcohol Reward. *Proceedings Of The National Academy Of Sciences Of The United States Of America, 106*(27), 11318-11323.

Jodka, C., Gedulin, B. R., & Young, A. A. (1998). Exendin-4 Potently Regulates Gastric Emptying In Rats. *Diabetes, 47*, A403-A403.

Jodka, C., Green, B., Young, A., & Gedulin, B. (1996). Amylin Modulation Of Gastric Emptying In Rats Depends Upon An Intact Vagus Nerve. *Diabetes, 45*, 867-867.

Johansson, K., Neovius, K., Desantis, S. M., Rossner, S., & Neovius, M. (2009). Discontinuation Due To Adverse Events In Randomized Trials Of Orlistat, Sibutramine And Rimonabant: A Meta-Analysis. *Obesity Reviews, 10*(5), 564-575.

Johansson, O., Hokfelt, T., & Elde, R. P. (1984). Immunohistochemical Distribution Of Somatostatin-Like Immunoreactivity In The Central Nervous-System Of The Adult-Rat. *Neuroscience, 13*(2), 265-&.

Johnson Ba, A.-D. N., Prihoda Tj. (2000). Combining Ondansetron And Naltrexone Effectively Treates Biologically Predisposed Alcoholics: From Hypotheses To Preliminary Clinical Evidence. *Alcoholism: Clinical And Experimental Research, 24*, 737-742.

Johnson, S. W., & North, R. A. (1992). Opioids Excite Dopamine Neurons By Hyperpolarization Of Local Interneurons. *Journal Of Neuroscience, 12*(2), 483-488.

Johnstone, L. E., Fong, T. M., & Leng, G. (2006). Neuronal Activation In The Hypothalamus And Brainstem During Feeding In Rats. *Cell Metabolism, 4*(4), 313-321.

Jordan, J., Greenway, F. L., Leiter, L. A., Li, Z., Jacobson, P., Murphy, K., Hill, J., Kler, L., & Aftring, R. P. (2008). Stimulation Of Cholecystokinin-A Receptors With Gi181771x Does Not Cause Weight Loss In Overweight Or Obese Patients. *Clinical Pharmacology & Therapeutics, 83*(2), 281-287.

Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., Fiore, M. C., & Baker, T. B. (1999). A Controlled Trial Of Sustained-Release Bupropion, A Nicotine Patch, Or Both For Smoking Cessation. *New England Journal Of Medicine, 340*(9), 685-691.

Jorgensen, H., Riis, M., Knigge, U., Kjaer, A., & Warberg, J. (2003). Serotonin Receptors Involved In Vasopressin And Oxytocin Secretion. *Journal Of Neuroendocrinology, 15*(3), 242-249.

Jureus, A., Cunningham, M. J., Mcclain, M. E., Clifton, D. K., & Steiner, R. A. (2000). Galanin-Like Peptide (Galp) Is A Target For Regulation By Leptin In The Hypothalamus Of The Rat. *Endocrinology, 141*(7), 2703-2706.

Justinova, Z., Solinas, M., Tanda, G., Redhi, G. H., & Goldberg, S. R. (2005). The Endogenous Cannabinoid Anandamide And Its Synthetic Analog R(+)-Methanandamide Are Intravenously Self-Administered By Squirrel Monkeys. *Journal Of Neuroscience, 25*(23), 5645-5650.

Kabemura, T., Chijiiwa, Y., Misawa, T., Harada, N., Kawakami, O., & Nawata, H. (1991). Direct Inhibitory Effect Of Somatostatin On Cck-Induced Contraction Of Smooth Muscle Cells In Guinea-Pig Small Intestine. *Medical Science Research, 19*(18), 583-584.

Kalivas, P. W., Widerlöv, E., Stanley, D., Breese, G., & Prange, A. J. (1983). Enkephalin Action On The Mesolimbic System: A Dopamine-Dependent And A Dopamine-Independent Increase In Locomotor Activity. *Journal Of Pharmacology And Experimental Therapeutics, 227*(1), 229-237.

Kalra, S. P., Dube, M. G., Fournier, A., & Kalra, P. S. (1991). Structure-Function Analysis Of Stimulation Of Food-Intake By Neuropeptide-Y - Effects Of Receptor Agonists. *Physiology & Behavior, 50*(1), 5-9.

Kalra, S. P., Dube, M. G., Pu, S., Xu, B., Horvath, T. L., & Kalra, P. S. (1999). Interacting Appetite-Regulating Pathways In The Hypothalamic Regulation Of Body Weight. *Endocrine Reviews, 20*(1), 68-100.

Kamatchi, G. L., Bhakthavatsalam, P., Chandra, D., & Bapna, J. S. (1984). Inhibition Of Insulin Hyperphagia By Gamma-Aminobutyric Acid Antagonists In Rats. *Life Sciences, 34*(23), 2297-2301.

Kamiji, M. M., & Inui, A. (2007). Neuropeptide Y Receptor Selective Ligands In The Treatment Of Obesity. *Endocrine Reviews, 28*(6), 664-684.

Kanatani, A. M., S. Murai, N. Sugimoto, N. Ito, J. Fukuroda, T. Fukami, T. Morin, N. Macneil, D.J. Van Der Ploeg, L.H.T. Saga, Y. Nishimura, S. Ihara, M. (2000). Role Of The Y1 Receptor In The Regulation Of Neuropeptide Y-

Mediated Feeding: Comparison Of Wild-Type, Y1 Receptor-Deficient And Y5 Receptor Deficient Mice. *Endocrinology, 141*(3), 1011-1016.

Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011). Peripheral And Central Glp-1 Receptor Populations Mediate The Anorectic Effects Of Peripherally Administered Glp-1 Receptor Agonists, Liraglutide And Exendin-4. *Endocrinology, 152*(8), 3103-3112.

Kanoski, S. E., Rupprecht, L. E., Fortin, S. M., De Jonghe, B. C., & Hayes, M. R. (2012). The Role Of Nausea In Food Intake And Body Weight Suppression By Peripheral Glp-1 Receptor Agonists, Exendin-4 And Liraglutide. *Neuropharmacology, 62*(5-6), 1916-1927.

Kapatos, G., & Gold, R. M. (1973). Evidence For Ascending Noradrenergic Mediation Of Hypothalamic Hyperphagia. *Pharmacology Biochemistry And Behavior, 1*(1), 81-87.

Kaplan, J. M., Song, S., & Grill, H. J. (1998). Serotonin Receptors In The Caudal Brainstem Are Necessary And Sufficient For The Anorectic Effect Of Peripherally Administered Mcpp. *Psychopharmacology, 137*(1), 43-49.

Karatayev, O., Barson, J. R., Chang, G.-Q., & Leibowitz, S. F. (2009). Hypothalamic Injection Of Non-Opioid Peptides Increases Gene Expression Of The Opioid Enkephalin In Hypothalamic And Mesolimbic Nuclei: Possible Mechanism Underlying Their Behavioral Effects. *Peptides, 30*(12), 2423-2431.

Karlsson, J., Sjostrom, L., & Sullivan, M. (1998). Swedish Obese Subjects (Sos) - An Intervention Study Of Obesity. Two-Year Follow-Up Of Health-Related Quality Of Life (Hrql) And Eating Behavior After Gastric Surgery For Severe Obesity. *International Journal Of Obesity, 22*(2), 113-126.

Karsak, M., Gaffal, E., Date, R., Wang-Eckhardt, L., Rehnelt, J., Petrosino, S., Starowicz, K., Steuder, R., Schlicker, E., Cravatt, B., Mechoulam, R., Buettner, R., Werner, S., Di Marzo, V., Tueting, T., & Zimmer, A. (2007). Attenuation Of Allergic Contact Dermatitis Through The Endocannabinoid System. *Science, 316*(5830), 1494-1497.

Kashyap, S. R., Bhatt, D. L., Wolski, K., Watanabe, R. M., Abdul-Ghani, M., Abood, B., Pothier, C. E., Brethauer, S., Nissen, S., Gupta, M., Kirwan, J. P., & Schauer, P. R. (2013). Metabolic Effects Of Bariatric Surgery In Patients With Moderate Obesity And Type 2 Diabetes: Analysis Of A Randomized Control Trial Comparing Surgery With Intensive Medical Treatment. *Diabetes Care, 36*(8), 2175-2182.

Kask, A., Rago, L., & Harro, J. (1998). Evidence For Involvement Of Neuropeptide Y Receptors In The Regulation Of Food Intake: Studies With Y-1-Selective Antagonist Bibp3226. *British Journal Of Pharmacology, 124*(7), 1507-1515.

Kastin, A. J., & Akerstrom, V. (2003). Entry Of Exendin-4 Into Brain Is Rapid But May Be Limited At High Doses. *International Journal Of Obesity, 27*(3), 313-318.

Kastin, A. J., Pan, W., Akerstrom, V., Hackler, L., Wang, C., & Kotz, C. M. (2002). Novel Peptide-Peptide Cooperation May Transform Feeding Behavior. *Peptides, 23*(12), 2189-2196.

Katsiki, N., Hatzitolios, A. I., & Mikhailidis, D. P. (2011). Naltrexone Sustained-Release (Sr) Plus Bupropion Sr Combination Therapy For The Treatment Of Obesity: 'A New Kid On The Block'? *Annals Of Medicine, 43*(4), 249-258.

Katsuura, G., Asakawa, A., & Inui, A. (2002). Roles Of Pancreatic Polypeptide In Regulation Of Food Intake. *Peptides, 23*(2), 323-329.

Kaye, W. H., Berrettini, W. H., Gwirtsman, H. E., Chretien, M., Gold, P. W., George, D. T., Jimerson, D. C., & Ebert, M. H. (1987). Reduced Cerebrospinal-Fluid Levels Of Immunoreactive Proopiomelanocortin Related Peptides (Including Beta-Endorphin) In Anorexia-Nervosa. *Life Sciences, 41*(18), 2147-2155.

Kaye, W. H., Gwirtsman, H. E., Brewerton, T. D., George, D. T., & Wurtman, R. J. (1988). Bingeing Behavior And Plasma Amino-Acids - A Possible

Involvement Of Brain-Serotonin In Bulimia Nervosa. *Psychiatry Research, 23*(1), 31-43.

Keesey, R. E. (1986). A Set-Point Theory Of Obesity. *Handbook Of Eating Disorders*, 63-88.

Kelai S, H. N., Aufere G, Beauge F, Hamon M, Lanfumey L. (2006). Cannabinoid-Serotonin Interactions In Alcohol-Preferring Vs. Alcohol-Avoiding Mice. *Jounal Of Neuroschemistry, 99*, 308-320.

Kelly, M. J., Loose, M. D., & Ronnekleiv, O. K. (1990). Opioids Hyperpolarize B-Endorphin Neurons Via M-Receptor Activation Of A Potassium Conductance. *Neuroendocrinology, 52*(3), 268-275.

Kelly, M. W., & Cline, M. A. (2007). Central Amylin Induces Anxiety Related Behaviors While Decreasing Nutrient Absorption In Chicks. *Faseb Journal, 21*(5), A461-A461.

Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D. L., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005). Effects Of Exenatide (Exendin-4) On Glycemic Control Over 30 Weeks In Patients With Type 2 Diabetes Treated With Metformin And A Sulfonylurea. *Diabetes Care, 28*(5), 1083-1091.

Kennedy, A. R., Gettys, T. W., Watson, P., Wallace, P., Ganaway, E., Pan, Q., & Garvey, W. T. (1997). The Metabolic Significance Of Leptin In Humans: Gender-Based Differences In Relationship To Adiposity, Insulin Sensitivity, And Energy Expenditure. *Journal Of Clinical Endocrinology & Metabolism, 82*(4), 1293-1300.

Kennedy, G. C. (1953). The Role Of Depot Fat In The Hypothalamic Control Of Food Intake In The Rat. *Proceedings Of The Royal Society Of London Series B-Biological Sciences, 140*(901), 578-592.

Kennett, G. A., & Clifton, P. G. (2010). New Approaches To The Pharmacological Treatment Of Obesity Can They Break Through The Efficacy Barrier? *Pharmacology Biochemistry And Behavior, 97*(1), 63-83.

Kennett Ga, C. P. (2010). New Approaches To The Pharmacological Treatment Of Obesity: Can They Break Through The Efficacy Barrier? *Pharmacology, Biochemistry & Behavior, 97*, 63-83.

Kennett, G. A., & Curzon, G. (1988). Evidence That Hypophagia Induced By Mcpp And Tfmpp Requires 5-Ht1c And 5-Ht1b Receptors - Hypophagia Induced By Ru-24969 Only Requires 5-Ht1b Receptors. *Psychopharmacology, 96*(1), 93-100.

Kennett, G. A., & Curzon, G. (1991). Potencies Of Antagonists Indicate That 5-Ht1c Receptors Mediate 1-3(Chlorophenyl)Piperazine-Induced Hypophagia. *British Journal Of Pharmacology, 103*(4), 2016-2020.

Kennett, G. A., Dourish, C. T., & Curzon, G. (1987). 5-Ht1b Agonists Induce Anorexia At A Postsynaptic Site. *European Journal Of Pharmacology, 141*(3), 429-435.

Kennett, G. A., Wood, M. D., Bright, F., Trail, B., Riley, G., Holland, V., Avenell, K. Y., Stean, T., Upton, N., Bromidge, S., Forbes, I. T., Brown, A. M., Middlemiss, D. N., & Blackburn, T. P. (1997). Sb 242084, A Selective And Brain Penetrant 5-Ht2c Receptor Antagonist. *Neuropharmacology, 36*(4-5), 609-620.

Keranen, A.-M., Savolainen, M. J., Reponen, A. H., Kujari, M.-L., Lindeman, S. M., Bloigu, R. S., & Laitinen, J. H. (2009). The Effect Of Eating Behavior On Weight Loss And Maintenance During A Lifestyle Intervention. *Preventive Medicine, 49*(1), 32-38.

Kernan, W. N., Viscoli, C. M., Brass, L. M., Broderick, J. P., Brott, T., Feldmann, E., Morgenstern, L. B., Wilterdink, J. L., & Horwitz, R. I. (2000). Phenylpropanolamine And The Risk Of Hemorrhagic Stroke. *New England Journal Of Medicine, 343*(25), 1826-1832.

Kieffer, T. J., & Habener, J. L. (1999). The Glucagon-Like Peptides. *Endocrine Reviews, 20*(6), 876-913.

Kieffer, T. J., Mcintosh, C. H. S., & Pederson, R. A. (1995). Degradation Of Glucose-Dependent Insulinotropic Polypeptide And Truncated Glucagon-Like Peptide-1 In-Vitro And In-Vivo By Dipeptidyl Peptidase-Iv. *Endocrinology, 136*(8), 3585-3596.

Kim, D., Macconell, L., Zhuang, D., Kothare, P. A., Trautmann, M., Fineman, M., & Taylor, K. (2007). Effects Of Once-Weekly Dosing Of A Long-Acting Release Formulation Of Exenatide On Glucose Control And Body Weight In Subjects With Type 2 Diabetes. *Diabetes Care, 30*(6), 1487-1493.

Kim, W., & Egan, J. M. (2008). The Role Of Incretins In Glucose Homeostasis And Diabetes Treatment. *Pharmacological Reviews, 60*(4), 470-512.

Kimura T, O. T., Watanabe K, Yoshimura H, Yamamoto I. (1998). Anandamide, An Endogenous Cannabinoid Receptor Ligand, Also Interacts With 5-Hydroxytryptamine (5-Ht) Receptor. *Biol Pharm Bull, 21*(3), 224-226.

King, A., De Wit, H., Riley, R. C., Cao, D., Niaura, R., & Hatsukami, D. (2006). Efficacy Of Naltrexone In Smoking Cessation: A Preliminary Study And An Examination Of Sex Differences. *Nicotine & Tobacco Research, 8*(5), 671-682.

King, A. C., Cao, D., Zhang, L., & O'malley, S. S. (2013). Naltrexone Reduction Of Long-Term Smoking Cessation Weight Gain In Women But Not Men: A Randomized Controlled Trial. *Biological Psychiatry, 73*(9), 924-930.

King, B. M., Castellanos, F. X., Kastin, A. J., Berzas, M. C., Mauk, M. D., Olson, G. A., & Olson, R. D. (1979). Naloxone-Induced Suppression Of Food-Intake In Normal And Hypothalamic Obese Rats. *Pharmacology Biochemistry And Behavior, 11*(6), 729-732.

King, B. M., Cook, J. T., Rossiter, K. N., & Rollins, B. L. (2003). Obesity-Inducing Amygdala Lesions: Examination Of Anterograde Degeneration And Retrograde Transport. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 284*(4), R965-R982.

King, B. M., Sam, H., Arceneaux, E. R., & Kass, J. M. (1994). Effect On Food Intake And Body Weight Of Lesions In And Adjacent To The Posterodorsal Amygdala In Rats. *Physiol Behav, 55*(5), 963-966.

King, S. J., Isaacs, A. M., O'farrell, E., & Abizaid, A. (2011). Motivation To Obtain Preferred Foods Is Enhanced By Ghrelin In The Ventral Tegmental Area. *Hormones And Behavior, 60*(5), 572-580.

Kinsey, S. G., O'neal, S. T., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2011). Inhibition Of Endocannabinoid Catabolic Enzymes Elicits Anxiolytic-Like Effects In The Marble Burying Assay. *Pharmacology Biochemistry And Behavior, 98*(1), 21-27.

Kinzig, K. P., D'alessio, D. A., & Seeley, R. J. (2002). The Diverse Roles Of Specific Glp-1 Receptors In The Control Of Food Intake And The Response To Visceral Illness. *Journal Of Neuroscience, 22*(23), 10470-10476.

Kinzig, K. P., Figueriedo, H., Murphy, E. K., Herman, J. P., Sakai, R. R., D'alessio, D. A., & Seeley, R. J. (2002). Multiple Roles Of Glucagon - Like Peptide - 1 In Response To Interoceptive And Exteroceptive Stressors. *Society For Neuroscience Abstract Viewer And Itinerary Planner, 2002*.

Kirkham, T. C. (1990). Enhanced Anorectic Potency Of Naloxone In Rats Sham Feeding 30% Sucrose: Reversal By Repeated Naloxone Administration. *Physiology & Behavior, 47*(3), 419-426.

Kirkham, T. C. (2008). Taranabant Cuts The Fat: New Hope For Cannabinoid-Based Obesity Therapies. *Cell Metabolism, 7*(1), 1.

Kirkham, T. C. (2009). Cannabinoids And Appetite: Food Craving And Food Pleasure. *International Review Of Psychiatry, 21*(2), 163-171.

Kirkham, T. C., & Blundell, J. E. (1984). Dual Action Of Naloxone On Feeding Revealed By Behavioral-Analysis - Separate Effects On Initiation And Termination Of Eating. *Appetite, 5*(1), 45-52.

Kirkham, T. C., & Blundell, J. E. (1986). Effect Of Naloxone And Naltrexone On The Development Of Satiation Measured In The Runway - Comparisons With D-Amphetamine And D-Fenfluramine. *Pharmacology Biochemistry And Behavior, 25*(1), 123-128.

Kirkham, T. C., & Blundell, J. E. (1987). Effects Of Naloxone And Naltrexone On Meal Patterns Of Freely-Feeding Rats. *Pharmacology Biochemistry And Behavior, 26*(3), 515-520.

Kirkham, T. C., & Cooper, S. J. (1988). Naloxone Attenuation Of Sham Feeding Is Modified By Manipulation Of Sucrose Concentration. *Physiology & Behavior, 44*(4–5), 491-494.

Kirkham, T. C., Walsh, C. A., Gibbs, J., Smith, G. P., Leban, J., & Mcdermed, J. (1994). A Novel Bombesin Receptor Antagonist Selectively Blocks The Satiety Action Of Peripherally Administered Bombesin. *Pharmacology Biochemistry And Behavior, 48*(3), 809-811.

Kirkham, T. C., & Williams, C. M. (2001). Synergistic Effects Of Opioid And Cannabinoid Antagonists On Food Intake. *Psychopharmacology, 153*(2), 267-270.

Kirkham, T. C., Williams, C. M., Fezza, F., & Di Marzo, V. (2002). Endocannabinoid Levels In Rat Limbic Forebrain And Hypothalamus In Relation To Fasting, Feeding And Satiation: Stimulation Of Eating By 2-Arachidonoyl Glycerol. *British Journal Of Pharmacology, 136*(4), 550-557.

Kissileff, H. R., Pi-Sunyer, F. X., Thornton, J., & Smith, G. P. (1981). C-Terminal Octapeptide Of Cholecystokinin Decreases Food Intake In Man. *The American Journal Of Clinical Nutrition, 34*, 154 - 160.

Kitchener, S. J., & Dourish, C. T. (1994). An Examination Of The Behavioural Specificity Of Hypophagia Induced By 5-Ht1b, 5-Ht1c, And 5-Ht2 Receptor Agonists Using The Post-Prandial Satiety Sequence In Rats. *Psychopharmacology, 113*, 369 - 377.

Klein, S., Sheard, N. F., Pi-Sunyer, X., Daly, A., Wylie-Rosett, J., Kulkarni, K., & Clark, N. G. (2004). Weight Management Through Lifestyle Modification For The Prevention And Management Of Type 2 Diabetes: Rationale And Strategies. A Statement Of The American Diabetes Association, The North American Association For The Study Of Obesity, And The American Society For Clinical Nutrition. *The American Journal Of Clinical Nutrition, 80*(2), 257-263.

Kleinman, R., Ohning, G., Wong, H., Watt, P., Walsh, J., & Brunicardi, F. C. (1994). Regulatory Role Of Intraislet Somatostatin On Insulin-Secretion In The Isolated-Perfused Human Pancreas. *Pancreas, 9*(2), 172-178.

Kluver, H., & Bucy, P. C. (1939). Preliminary Analysis Of Functions Of The Temporal Lobes In Monkeys. *Archives Of Neurology & Psychiatry, 42*(6), 979-000.

Knauf, C., Cani, P. D., Ait-Belgnaoui, A., Benani, A., Dray, C., Cabou, C., Colom, A., Uldry, M., Rastrelli, S., Sabatier, E., Godet, N., Waget, A., Penicaud, L., Valet, P., & Burcelin, R. (2008). Brain Glucagon-Like Peptide 1 Signaling Controls The Onset Of High-Fat Diet-Induced Insulin Resistance And Reduces Energy Expenditure. *Endocrinology, 149*(10), 4768-4777.

Knudsen, L. B. (2010). Liraglutide: The Therapeutic Promise From Animal Models. *International Journal Of Clinical Practice, 64*, 4-11.

Koch, J. E. (2001). Delta(9)-Thc Stimulates Food Intake In Lewis Rats - Effects On Chow, High-Fat And Sweet High-Fat Diets. *Pharmacology Biochemistry And Behavior, 68*(3), 539-543.

Koch, J. E., & Bodnar, R. J. (1994). Selective Alterations In Macronutrient Intake Of Food-Deprived Or Glucoprivic Rats By Centrally-Administered Opioid Receptor Subtype Antagonists In Rats. *Brain Research, 657*(1-2), 191-201.

Koda, S., Date, Y., Murakami, N., Shimbara, T., Hanada, T., Toshinai, K., Niijima, A., Furuya, M., Inomata, N., Osuye, K., & Nakazato, M. (2005). The Role Of

The Vagal Nerve In Peripheral Pyy3-36-Induced Feeding Reduction In Rats. *Endocrinology, 146*(5), 2369-2375.

Koe, B. K., Nielsen, J. A., Macor, J. E., & Heym, J. (1992). Biochemical And Behavioral-Studies Of The 5-Ht(1b) Receptor Agonist, Cp-94,253. *Drug Development Research, 26*(3), 241-250.

Koegler, F. H., Enriori, P. J., Billes, S. K., Takahashi, D. L., Martin, M. S., Clark, R. L., Evans, A. E., Grove, K. L., Cameron, J. L., & Cowley, M. A. (2005). Peptide Yy(3-36) Inhibits Morning, But Not Evening, Food Intake And Decreases Body Weight In Rhesus Macaques. *Diabetes, 54*(11), 3198-3204.

Koegler, F. H., & Ritter, S. (1998). Galanin Injection Into The Nucleus Of The Solitary Tract Stimulates Feeding In Rats With Lesions Of The Paraventricular Nucleus Of The Hypothalamus. *Physiology & Behavior, 63*(4), 521-527.

Kohno, D., Gao, H.-Z., Muroya, S., Kikuyama, S., & Yada, T. (2003). Ghrelin Directly Interacts With Neuropeptide-Y-Containing Neurons In The Rat Arcuate Nucleus: Ca2+ Signaling Via Protein Kinase A And N-Type Channel-Dependent Mechanisms And Cross-Talk With Leptin And Orexin. *Diabetes, 52*(4), 948-956.

Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999). Ghrelin Is A Growth-Hormone-Releasing Acylated Peptide From Stomach. *Nature, 402*(6762), 656-660.

Kokkotou, E., Jeon, J. Y., Wang, X., Marino, F. E., Carlson, M., Trombly, D. J., & Maratos-Flier, E. (2005). Mice With Mch Ablation Resist Diet-Induced Obesity Through Strain-Specific Mechanisms. *American Journal Of Physiology - Regulatory, Integrative And Comparative Physiology, 289*(1), R117-R124.

Kolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. D. (2005). Pharmacokinetics, Pharmacodynamics, And Safety Of Exenatide In Patients With Type 2 Diabetes Mellitus. *American Journal Of Health-System Pharmacy, 62*(2), 173-181.

Konkle, A. T. M., Sreter, K. B., Baker, S. L., & Bielajew, C. (2003). Chronic Paroxetine Infusion Influences Macronutrient Selection In Male Sprague-Dawley Rats. *Pharmacology Biochemistry And Behavior, 74*(4), 883-890.

Koopmans, H. S., & Sclafani, A. (1981). Control Of Body-Weight By Lower Gut Signals. *International Journal Of Obesity, 5*(5), 491-495.

Kopelman, P. (2007). Health Risks Associated With Overweight And Obesity. *Obesity Reviews, 8*, 13-17.

Kopelman, P., Bryson, A., Hickling, R., Rissanen, A., Rossner, S., Toubro, S., & Valensi, P. (2007). Cetilistat (Atl-962), A Novel Lipase Inhibitor: A 12-Week Randomized, Placebo-Controlled Study Of Weight Reduction In Obese Patients. *International Journal Of Obesity, 31*(3), 494-499.

Kopelman, P., Groot, G. D. H., Rissanen, A., Rossner, S., Toubro, S., Palmer, R., Hallam, R., Bryson, A., & Hickling, R. I. (2010). Weight Loss, Hba(1c) Reduction, And Tolerability Of Cetilistat In A Randomized, Placebo-Controlled Phase 2 Trial In Obese Diabetics: Comparison With Orlistat (Xenical). *Obesity, 18*(1), 108-115.

Korner, J., Savontaus, E., Chua, S. C., Leibel, R. L., & Wardlaw, S. L. (2001). Leptin Regulation Of Agrp And Npy Mrna In The Rat Hypothalamus. *Journal Of Neuroendocrinology, 13*(11), 959-966.

Korotkova, T. M., Sergeeva, O. A., Eriksson, K. S., Haas, H. L., & Brown, R. E. (2003). Excitation Of Ventral Tegmental Area Dopaminergic And Nondopaminergic Neurons By Orexins/Hypocretins. *J. Neurosci., 23*(1), 7-11.

Kotz, C. M., Grace, M. K., Billington, C. J., & Levine, A. S. (1993). The Effect Of Norbinaltorphimine, B-Funaltrexamine And Naltrindole On Npy-Induced Feeding. *Brain Research, 631*(2), 325-328.

Kotz, C. M., Grace, M. K., Briggs, J., Levine, A. S., & Billington, C. J. (1995). Effects Of Opioid Antagonists Naloxone And Naltrexone On Neuropeptide Y-Induced Feeding And Brown Fat Thermogenesis In The Rat - Neural Site Of Action. *Journal Of Clinical Investigation, 96*(1), 163-170.

Kotz, C. M., Grace, M. K., Briggs, J. E., Billington, C. J., & Levine, A. S. (1996). Naltrexone Induces Arcuate Nucleus Neuropeptide Y Gene Expression In The Rat. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 271*(1), R289-R294.

Koulischer, D., Moroder, L., & Deschodtlanckman, M. (1982). Degradation Of Cholecystokinin Octapeptide, Related Fragments And Analogs By Human And Rat Plasma Invitro. *Regulatory Peptides, 4*(3), 127-139.

Kovacs, E. M. R., Lejeune, M., & Westerterp-Plantenga, M. S. (2003). The Effects Of Enterostatin Intake On Food Intake And Energy Expenditure. *British Journal Of Nutrition, 90*(1), 207-214.

Kowalski, T. J., Spar, B. D., Markowitz, L., Maguire, M., Golovko, A., Yang, S., Farley, C., Cook, J. A., Tetzloff, G., Hoos, L., Del Vecchio, R. A., Kazdoba, T. M., Mccool, M. F., Hwa, J. J., Hyde, L. A., Davis, H., Vassileva, G., Hedrick, J. A., & Gustafson, E. L. (2005). Transgenic Overexpression Of Neuromedin U Promotes Leanness And Hypophagia In Mice. *Journal Of Endocrinology, 185*(1), 151-164.

Koylu, E. O., Couceyro, P. R., Lambert, P. D., & Kuhar, M. J. (1998). Cocaine- And Amphetamine-Regulated Transcript Peptide Immunohistochemical Localization In The Rat Brain. *Journal Of Comparative Neurology, 391*(1), 115-132.

Krasnow, S. M., Fraley, G. S., Schuh, S. M., Baumgartner, J. W., Clifton, D. K., & Steiner, R. A. (2003). A Role For Galanin-Like Peptide In The Integration Of Feeding, Body Weight Regulation, And Reproduction In The Mouse. *Endocrinology, 144*(3), 813-822.

Kreymann, B., Williams, G., Ghatei, M. A., & Bloom, S. R. (1987). Glucagonlike Peptide-1 7-36 - A Physiological Incretin In Man. *LANCET, 2*(8571), 1300-1304.

Krishna, R., Gumbiner, B., Stevens, C., Musser, B., Mallick, M., Suryawanshi, S., Maganti, L., Zhu, H., Han, T. H., Scherer, L., Simpson, B., Cosgrove, D., Gottesdiener, K., Amatruda, J., Rolls, B. J., Blundell, J., Bray, G. A., Fujioka, K., Heymsfield, S. B., Wagner, J. A., & Herman, G. A. (2009). Potent And Selective Agonism Of The Melanocortin Receptor 4 With Mk-0493 Does Not Induce Weight Loss In Obese Human Subjects: Energy Intake Predicts Lack Of Weight Loss Efficacy. *Clinical Pharmacology & Therapeutics, 86*(6), 659-666.

Krishnan-Sarin, S., Meandzija, B., & O'malley, S. (2003). Naltrexone And Nicotine Patch In Smoking Cessation: A Preliminary Study. *Nicotine & Tobacco Research, 5*(6), 851-857.

Kriska, A. M., Saremi, A., Hanson, R. L., Bennett, P. H., Kobes, S., Williams, D. E., & Knowler, W. C. (2003). Physical Activity, Obesity, And The Incidence Of Type 2 Diabetes In A High-Risk Population. *American Journal Of Epidemiology, 158*(7), 669-675.

Kristensen, P., Judge, M. E., Thim, L., Ribel, U., Christjansen, K. N., Wulff, B. S., Clausen, J. T., Jensen, P. B., Madsen, O. D., Vrang, N., Larsen, P. J., & Hastrup, S. (1998). Hypothalamic Cart Is A New Anorectic Peptide Regulated By Leptin. *Nature, 393*, 72 - 76.

Kublaoui, B. M., Gemelli, T., Tolson, K. P., Wang, Y., & Zinn, A. R. (2008). Oxytocin Deficiency Mediates Hyperphagic Obesity Of Sim1 Haploinsufficient Mice. *Molecular Endocrinology, 22*(7), 1723-1734.

Kumanyika, S. K. (2008). Environmental Influences On Childhood Obesity: Ethnic And Cultural Influences In Context. *Physiology & Behavior, 94*(1), 61-70.

Kunos, G., Osei-Hyiaman, D., Bátkai, S., Sharkey, K. A., & Makriyannis, A. (2009). Should Peripheral Cb1 Cannabinoid Receptors Be Selectively Targeted For Therapeutic Gain? *Trends In Pharmacological Sciences, 30*(1), 1.

Kuraishi, Y., Yageta, Y., Konno, M., Andoh, T., Yamaguchi-Miyamoto, T., & Nojima, H. (2008). Intracisternal, But Not Intrathecal, Injection Of Naloxone Inhibits Cutaneous Itch-Related Response In Mice. *Biological And Pharmaceutical Bulletin, 31*(11), 2143-2145.

Kuraishi, Y., Yamaguchi, T., & Miyamoto, T. (2000). Itch-Scratch Responses Induced By Opioids Through Central Mu Opioid Receptors In Mice. *Journal Of Biomedical Science, 7*(3), 248-252.

Kurtz, T. W., Morris, R. C., & Pershadsingh, H. A. (1989). The Zucker Fatty Rat As A Genetic Model Of Obesity And Hypertension. *Hypertension, 13*(6), 896-901.

Lachey, J. L., D'alessio, D. A., Rinaman, L., Elmquist, J. K., Drucker, D. J., & Seeley, R. J. (2005). The Role Of Central Glucagon-Like Peptide-1 In Mediating The Effects Of Visceral Illness: Differential Effects In Rats And Mice. *Endocrinology, 146*(1), 458-462.

Laizure, S. C., Devane, C. L., Stewart, J. T., Dommisse, C. S., & Lai, A. A. (1985). Pharmacokinetics Of Bupropion And Its Major Basic Metabolites In Normal Subjects After A Single Dose. *Clinical Pharmacology & Therapeutics, 38*(5), 586-589.

Lalonde, J., Samson, P., Poulin, S., Deshaies, Y., & Richard, D. (2004). Additive Effects Of Leptin And Topiramate In Reducing Fat Deposition In Lean And Obese Ob/Ob Mice. *Physiology & Behavior, 80*(4), 415-420.

Lam, D. D., Garfield, A. S., Marston, O. J., Shaw, J., & Heisler, L. K. (2010). Brain Serotonin System In The Coordination Of Food Intake And Body Weight. *Pharmacology Biochemistry And Behavior, 97*(1), 84-91.

Lam, D. D., Przydzial, M. J., Ridley, S. H., Yeo, G. S. H., Rochford, J. J., O'rahilly, S., & Heisler, L. K. (2008). Serotonin 5-Ht2c Receptor Agonist Promotes Hypophagia Via Downstream Activation Of Melanocortin 4 Receptors. *Endocrinology, 149*(3), 1323-1328.

Lamb, R. J., & Griffiths, R. R. (1990). Self-Administration In Baboons And The Discriminative Stimulus Effects In Rats Of Bupropion, Nomifensine, Diclofensine And Imipramine. *Psychopharmacology, 102*(2), 183-190.

Lambert, P. D., Couceyro, P. R., Mcgirr, K. M., Vechia, S. E. D., Smith, Y., & Kuhar, M. J. (1998). Cart Peptides In The Central Control Of Feeding And Interactions With Neuropeptide Y. *Synapse, 29*(4), 293-298.

Lamont, B. J., & Drucker, D. J. (2008). Differential Antidiabetic Efficacy Of Incretin Agonists Versus Dpp-4 Inhibition In High Fat-Fed Mice. *Diabetes, 57*(1), 190-198.

Lamota, L., Javier Bermudez-Silva, F., Marco, E.-M., Llorente, R., Gallego, A., Rodriguez De Fonseca, F., & Viveros, M.-P. (2008). Effects Of Adolescent Nicotine And Sr 147778 (Surinabant) Administration On Food Intake, Somatic Growth And Metabolic Parameters In Rats. *Neuropharmacology, 54*(1), 194-205.

Lanfumey, L., & Hamon, M. (2004). 5-Ht1 Receptors. *CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), 3*(1), 1-10.

Lang, A., & Froelicher, E. S. (2006). Management Of Overweight And Obesity In Adults: Behavioral Intervention For Long-Term Weight Loss And Maintenance. *European Journal Of Cardiovascular Nursing : Journal Of The Working Group On Cardiovascular Nursing Of The European Society Of Cardiology, 5*(2), 102-114.

Lang, R., Berger, A., Santic, R., Geisberger, R., Hermann, A., Herzog, H., & Kofler, B. (2005). Pharmacological And Functional Characterization Of Galanin-Like Peptide Fragments As Potent Galanin Receptor Agonists. *Neuropeptides, 39*(3), 179-184.

Larhammar, D. (1996). Structural Diversity Of Receptors For Neuropeptide Y, Peptide Yy And Pancreatic Polypeptide. *Regulatory Peptides, 65*(3), 165-174.

Larm, J. A., & Gundlach, A. L. (2000). Galanin-Like Peptide (Galp) Mrna Expression Is Restricted To Arcuate Nucleus Of Hypothalamus In Adult Male Rat Brain. *Neuroendocrinology, 72*(2), 67-71.

Larsen, P. J., Fledelius, C., Knudsen, L. B., & Tang-Christensen, M. (2001). Systemic Administration Of The Long-Acting Glp-1 Derivative Nn2211 Induces Lasting And Reversible Weight Loss In Both Normal And Obese Rats. *Diabetes, 50*(11), 2530-2539.

Larsen, P. J., & Hunter, R. G. (2006). The Role Of Cart In Body Weight Homeostasis. *Peptides, 27*(8), 1981-1986.

Larsen, P. J., Tangchristensen, M., & Jessop, D. S. (1997). Central Administration Of Glucagon-Like Peptide-1 Activates Hypothalamic Neuroendocrine Neurons In The Rat. *Endocrinology, 138*(10), 4445-4455.

Larsen, P. J., Vrang, N., Petersen, P. C., & Kristensen, P. (2000). Chronic Intracerebroventricular Administration Of Recombinant Cart (42 - 89) Peptide Inhibits Food Intake And Causes Weight Loss In Lean And Obese Zucker (Fa/Fa) Rats. *Obesity Research, 8*(8).

Lauritsen, K. B., Moody, A. J., Christensen, K. C., & Jensen, S. L. (1980). Gastric-Inhibitory Polypeptide (Gip) And Insulin Release After Small Bowel Resection In Man. *Scandinavian Journal Of Gastroenterology, 15*(7), 833-840.

Lawrence, C. B., Baudoin, F. M. H., & Luckman, S. M. (2002). Centrally Administered Galanin-Like Peptide Modifies Food Intake In The Rat: A Comparison With Galanin. *Journal Of Neuroendocrinology, 14*(11), 853-860.

Lawrence, C. B., Snape, A. C., Baudoin, F. M. H., & Luckman, S. M. (2002). Acute Central Ghrelin And Gh Secretagogues Induce Feeding And Activate Brain Appetite Centers. *Endocrinology, 143*(1), 155-162.

Lawton, C. L., Wales, J. K., Hill, A. J., & Blundell, J. E. (1995). Serotoninergic Manipulation, Meal-Induced Satiety And Eating Pattern - Effect Of Fluoxetine In Obese Female Subjects. *Obesity Research, 3*(4), 345-356.

Le Ad, S. E. (1994). Interaction Between Opiate And 5-Ht3 Receptor Antagonists In The Regulation Of Alcohol Intake. *Alcohol And Alcoholism, 2*(Supplement), 545-549.

Le, A. D., & Sellers, E. M. (1994). Interaction Between Opiate And 5-Ht3 Receptor Antagonists In The Regulation Of Alcohol Intake. *Alcohol And Alcoholism (Oxford, Oxfordshire). Supplement, 2*, 545-549.

Le Foll, B., & Goldberg, S. R. (2005). Cannabinoid Cb1 Receptor Antagonists As Promising New Medications For Drug Dependence. *Journal Of Pharmacology And Experimental Therapeutics, 312*(3), 875-883.

Le Roux, C. W., Aylwin, S. J. B., Batterham, R. L., Borg, C. M., Coyle, F., Prasad, V., Shurey, S., Ghatei, M. A., Patel, A. G., & Bloom, S. R. (2006). Gut Hormone Profiles Following Bariatric Surgery Favor An Anorectic State, Facilitate Weight Loss, And Improve Metabolic Parameters. *Annals Of Surgery, 243*(1), 108-114.

Lean, M. E. J., Han, T. S., & Seidell, J. C. (1998). Impairment Of Health And Quality Of Life In People With Large Waist Circumference. *LANCET, 351*(9106), 853-856.

Leckstrom, A., Kim, E. R., Wong, D., & Mizuno, T. M. (2009). Xenin, A Gastrointestinal Peptide, Regulates Feeding Independent Of The Melanocortin Signaling Pathway. *Diabetes, 58*(1), 87-94.

Ledent, C., Valverde, O., Cossu, C., Petitet, F., Aubert, L. F., Beslot, F., Bohme, G. A., Imperato, A., Pedrazzini, T., Roques, B. P., Vassart, G., Fratta, W., & Parmentier, M. (1999). Unresponsiveness To Cannabinoids And Reduced Addictive Effects Of Opiates In Cb1 Receptor Knockout Mice. *Science, 283*(5400), 401-404.

Lee, J., Martin, E., Paulino, G., De Lartigue, G., & Raybould, H. E. (2011). Effect Of Ghrelin Receptor Antagonist On Meal Patterns In Cholecystokinin Type 1 Receptor Null Mice. *Physiology & Behavior, 103*(2), 181-187.

Lee, M. D., & Clifton, P. G. (1992). Partial Reversal Of Fluoxetine Anorexia By The 5-Ht Antagonist Metergoline. *Psychopharmacology, 107*(2-3), 359-364.

Lee, M. D., Kennett, G. A., Dourish, C. T., & Clifton, P. G. (2002). 5-Ht(1b) Receptors Modulate Components Of Satiety In The Rat: Behavioural And Pharmacological Analyses Of The Selective Serotonin(1b) Agonist Cp-94,253. *Psychopharmacologia, 164*(1), 49-60.

Lee, M. D., & Simansky, K. J. (1997). Cp-94,253: A Selective Serotonin(1b) (5-Ht1b) Agonist That Promotes Satiety. *Psychopharmacology, 131*(3), 264-270.

Lee, M. D., Somerville, E. M., Kennett, G. A., Dourish, C. T., & Clifton, P. G. (2004). Reduced Hypophagic Effects Of D-Fenfluramine And The 5-Ht2c Receptor Agonist Mcpp In 5-Ht1b Receptor Knockout Mice. *Psychopharmacology, 176*(1), 39-49.

Lee, M. W., & Fujioka, K. (2009). Naltrexone For The Treatment Of Obesity: Review And Update. *Expert Opinion On Pharmacotherapy, 10*(11), 1841-1845.

Leibig. (1843). *Animal Chemistry: Or Organic Chemistry In Its Application To Physiology And Pathology*. Boston: John Owen.

Leibowitz, S. F., Hammer, N. J., & Chang, K. (1981). Hypothalamic Paraventricular Nucleus Lesions Produce Overeating And Obesity In The Rat. *Physiology & Behavior, 27*(6), 1031-1040.

Leibowitz, S. F., & Hor, L. (1982). Endorphinergic And Alpha-Noradrenergic Systems In The Paraventricular Nucleus - Effects On Eating Behavior. *Peptides, 3*(3), 421-428.

Leibowitz, S. F., & Kim, T. (1992). Impact Of A Galanin Antagonist On Exogenous Galanin And Natural Patterns Of Fat Ingestion. *Brain Research, 599*(1), 148-152.

Lerman, C., Niaura, R., Collins, B. N., Wileyto, P., Hawk, L., Epstein, L. H., Audrain-Mcgovern, J., & Pinto, A. (2004). Effect Of Bupropion On Depression Symptoms In A Smoking Cessation Clinical Trial. *Psychology Of Addictive Behaviors, 18*(4), 362-366.

Leventhal, L., Kirkham, T. C., Cole, J. L., & Bodnar, R. J. (1995). Selective Actions Of Central M And K Opioid Antagonists Upon Sucrose Intake In Sham-Fed Rats. *Brain Research, 685*(1–2), 205-210.

Levine, A. S., & Billington, C. J. (2004). Opioids As Agents Of Reward-Related Feeding: A Consideration Of The Evidence. *Physiology & Behavior, 82*(1), 57-61.

Levine, A. S., Kneip, J., Grace, M., & Morley, J. E. (1983). Effect Of Centrally Administered Neurotensin On Multiple Feeding Paradigms. *Pharmacology Biochemistry And Behavior, 18*(1), 19-23.

Levine, A. S., & Morley, J. E. (1982). Peripherally Administered Somatostatin Reduces Feeding By A Vagal Mediated Mechanism. *Pharmacology Biochemistry And Behavior, 16*(6), 897-902.

Levine, A. S., & Morley, J. E. (1984). Neuropeptide-Y - A Potent Inducer Of Consummatory Behavior In Rats. *Peptides, 5*(6), 1025-1029.

Levine, A. S., Rogers, B., Kneip, J., Grace, M., & Morley, J. E. (1983). Effect Of Centrally Administered Corticotropin Releasing-Factor (Crf) On Multiple Feeding Paradigms. *Neuropharmacology, 22*(3), 337-339.

Levine, A. S., Winsky-Sommerer, R., Huitron-Resendiz, S., Grace, M. K., & De Lecea, L. (2005). Injection Of Neuropeptide W Into Paraventricular Nucleus Of Hypothalamus Increases Food Intake. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 288*(6), R1727-R1732.

Li, Z. P., Hong, K., Yip, I., Huerta, S., Bowerman, S., Walker, J., Wang, H. J., Elashoff, R., Go, V. L. W., & Heber, D. (2003). Body Weight Loss With Phentermine Alone Versus Phentermine And Fenfluramine With Very-Low-Calorie Diet In An Outpatient Obesity Management Program: A Retrospective Study. *Current Therapeutic Research-Clinical And Experimental, 64*(7), 447-460.

Li, Z. P., Maglione, M., Tu, W. L., Mojica, W., Arterburn, D., Shugarman, L. R., Hilton, L., Suttorp, M., Solomon, V., Shekelle, P. G., & Morton, S. C. (2005). Meta-Analysis: Pharmacologic Treatment Of Obesity. *Annals Of Internal Medicine, 142*(7), 532-546.

Liang, N. C., Bello, N. T., & Moran, T. H. (2013). Additive Feeding Inhibitory And Aversive Effects Of Naltrexone And Exendin-4 Combinations. *International Journal Of Obesity, 37*(2), 272-278.

Licinio, J., Caglayan, S., Ozata, M., Yildiz, B. O., De Miranda, P. B., O'kirwan, F., Whitby, R., Liang, L. Y., Cohen, P., Bhasin, S., Krauss, R. M., Veldhuis, J. D., Wagner, A. J., Depaoli, A. M., Mccann, S. M., & Wong, M. L. (2004). Phenotypic Effects Of Leptin Replacement On Morbid Obesity, Diabetes Mellitus, Hypogonadism, And Behavior In Leptin-Deficient Adults. *Proceedings Of The National Academy Of Sciences Of The United States Of America, 101*(13), 4531-4536.

Lieverse, R. J., Jansen, J. B. M., Masclee, A. A. M., & Lamers, C. (1995). Satiety Effects Of A Physiological Dose Of Cholecystokinin In Humans. *Gut, 36*(2), 176-179.

Lin, L., Chen, J., & York, D. A. (1997). Chronic Icv Enterostatin Preferentially Reduced Fat Intake And Lowered Body Weight. *Peptides, 18*(5), 657-661.

Lin, L., Park, M., & York, D. A. (2007). Enterostatin Inhibition Of Dietary Fat Intake Is Modulated Through The Melanocortin System. *Peptides, 28*(3), 643-649.

Lin, L., Park, M. J., Hulver, M., & York, D. A. (2006). Different Metabolic Responses To Central And Peripheral Injection Of Enterostatin. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 290*(4), R909-R915.

Lin, L., Thomas, S. R., Kilroy, G., Schwartz, G. J., & York, D. A. (2003). Enterostatin Inhibition Of Dietary Fat Intake Is Dependent On Cck-A Receptors. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 285*(2), R321-R328.

Lin, L., & York, D. A. (1997). Enterostatin Actions In The Amygdala And Pvn To Suppress Feeding In The Rat. *Peptides, 18*(9), 1341-1347.

Lin, L., & York, D. A. (1998). Chronic Ingestion Of Dietary Fat Is A Prerequisite For Inhibition Of Feeding By Enterostatin. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 275*(2), R619-R623.

Lin, L., & York, D. A. (2005). 5-Ht1b Receptors Modulate The Feeding Inhibitory Effects Of Enterostatin. *Brain Research, 1062*(1-2), 26-31.

Lin, L., York, D. A., & Bray, G. A. (1994). Enterostatin Induced Anorexia Is Not Related To Gastric Emptying In Rats. *International Journal Of Obesity, 18*(SUPPL. 2), 101-101.

Lineberry, C. G., Johnston, J. A., Raymond, R. N., Samara, B., Feighner, J. P., Harto, N. E., Granacher, R. P., Weisler, R. H., Carman, J. S., & Boyer, W. F. (1990). A Fixed-Dose (300 Mg) Efficacy Study Of Bupropion And Placebo In Depressed Outpatients. *Journal Of Clinical Psychiatry, 51*(5), 194-199.

Little, T. J., Horowitz, M., & Feinle-Bisset, C. (2005). Role Of Cholecystokinin In Appetite Control And Body Weight Regulation. *Obesity Reviews, 6*(4), 297-306.

Littman, A. J., Kristal, A. R., & White, E. (2005). Effects Of Physical Activity Intensity, Frequency, And Activity Type On 10-Y Weight Change In Middle-Aged Men And Women. *International Journal Of Obesity, 29*(5), 524-533.

Liu, Y. L., Connoley, I. P., Harrison, J., Heal, D. J., & Stock, M. J. (2002). Comparison Of The Thermogenic And Hypophagic Effects Of Sibutramine's Metabolite 2 And Other Monoamine Reuptake Inhibitors. *European Journal Of Pharmacology, 452*(1), 49-56.

Liu, Y. L., Connoley, I. P., Heal, D. J., & Stock, M. J. (2004). Pharmacological Characterisation Of The Thermogenic Effect Of Bupropion. *European Journal Of Pharmacology, 498*(1-3), 219-225.

Liu, Y. L., Connoley, I. P., Wilson, C. A., & Stock, M. J. (2005). Effects Of The Cannabinoid Cb1 Receptor Antagonist Sr141716 On Oxygen Consumption And Soleus Muscle Glucose Uptake In Lep(Ob)/Lep(Ob) Mice. *International Journal Of Obesity, 29*(2), 183-187.

Lockie, S. H., Czyzyk, T. A., Chaudhary, N., Perez-Tilve, D., Woods, S. C., Oldfield, B. J., Statnick, M. A., & Tschoep, M. H. (2011). Cns Opioid Signaling Separates Cannabinoid Receptor 1-Mediated Effects On Body Weight And Mood-Related Behavior In Mice. *Endocrinology, 152*(10), 3661-3667.

Loewe, S., & Muischnek, H. (1926). Uber Kombinationswirkunger: I. Mitteilung: Hiltsmittel Der Fragstellung. *Naunyn-Schmiedebergs Archives Of Pharmacology, 114*(313-326).

Loke, Y. K., Derry, S., & Pritchard-Copley, A. (2002). Appetite Suppressants And Valvular Heart Disease - A Systematic Review. *BMC Clinical Pharmacology, 2*, 6-6.

Long, S. J., Sutton, J. A., Amaee, W. B., Giouvanoudi, A., Spyrou, N. M., Rogers, P. J., & Morgan, L. V. (1999). No Effect Of Glucagon-Like Peptide-1 On Short-Term Satiety And Energy Intake In Man. *British Journal Of Nutrition, 81*(4), 273-279.

Lopez-Alonso, V. E., Mancilla-Diaz, J. M., Rito-Domingo, M., Gonzalez-Hernandez, B., & Escartin-Perez, R. E. (2007). The Effects Of 5-Ht1a And 5-Ht2creceptor Agonists On Behavioral Satiety Sequence In Rats. *Neuroscience Letters, 416*(3), 285.

Lopez, C. A., Guesdon, B., Baraboi, E.-D., Roffarello, B. M., Hetu, M., & Richard, D. (2011). Involvement Of The Opioid System In The Orexigenic And Hedonic Effects Of Melanin-Concentrating Hormone. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 301*(4), R1105-R1111.

Lotter, E. C., Krinsky, R., Mckay, J. M., Treneer, C. M., Porte, D., & Woods, S. C. (1981). Somatostatin Decreases Food-Intake Of Rats And Baboons. *Journal Of Comparative And Physiological Psychology, 95*(2), 278-287.

Lowe, M. R., & Butryn, M. L. (2007). Hedonic Hunger: A New Dimension Of Appetite? *Physiology & Behavior, 91*(4), 432-439.

Lowy, M. T., & Yim, G. K. W. (1981). The Anorexic Effect Of Naltrexone Is Independent Of Its Suppressant Effect On Water-Intake. *Neuropharmacology, 20*(9), 883-886.

Lucas, J. J., Yamamoto, A., Scearce-Levie, K., Saudou, F., & Hen, R. (1998). Absence Of Fenfluramine-Induced Anorexia And Reduced C-Fos Induction In The Hypothalamus And Central Amygdaloid Complex Of Serotonin 1b Receptor Knock-Out Mice. *Journal Of Neuroscience, 18*(14), 5537-5544.

Lucki, I., Kreider, M. S., & Simansky, K. J. (1988). Reduction Of Feeding-Behavior By The Serotonin Uptake Inhibitor Sertraline. *Psychopharmacology, 96*(3), 289-295.

Ludwig, D. S., Tritos, N. A., Mastaitis, J. W., Kulkarni, R., Kokkotou, E., Elmquist, J., Lowell, B., Flier, J. S., & Maratos-Flier, E. (2001). Melanin-Concentrating Hormone Overexpression In Transgenic Mice Leads To Obesity And Insulin Resistance. *J. Clin. Invest., 107*(3), 379-386.

Luft, R. (1989). Minkowski,Oskar - Discovery Of The Pancreatic Origin Of Diabetes, 1889. *Diabetologia, 32*(7), 399-401.

Lund, P. K., Goodman, R. H., Jacobs, J. W., & Habener, J. F. (1980). Glucagon Precursors Identified By Immunoprecipitation Of Products Of Cell-Free Translation Of Messenger-Rna. *Diabetes, 29*(7), 583-586.

Luppino, F. S., De Wit, L. M., Bouvy, P. F., Stijnen, T., Cuijpers, P., Penninx, B. W. J. H., & Zitman, F. G. (2010). Overweight, Obesity, And Depression A Systematic Review And Meta-Analysis Of Longitudinal Studies. *Archives Of General Psychiatry, 67*(3), 220-229.

Luque, C. A., & Rey, J. A. (1999). Sibutramine: A Serotonin-Norepinephrine Reuptake-Inhibitor For The Treatment Of Obesity. *Annals Of Pharmacotherapy, 33*(9), 968-978.

Luttinger, D., King, R. A., Sheppard, D., Strupp, J., Nemeroff, C. B., & Prange, A. J. (1982). The Effect Of Neurotensin On Food-Consumption In The Rat. *European Journal Of Pharmacology, 81*(3), 499-503.

Lutz, T. (2009). Control Of Food Intake And Eneregy Expenditure By Amylin - Therapeutic Implications. *International Journal Of Obesity, 33*, S24-S27.

Lutz, T. A. (2005). Pancreatic Amylin As A Centrally Acting Satiating Hormone. *Current Drug Targets, 6*(2), 181-189.

Lutz, T. A. (2010). The Role Of Amylin In The Control Of Energy Homeostasis. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 298*(6), R1475-R1484.

Lutz, T. A. (2013). The Interaction Of Amylin With Other Hormones In The Control Of Eating. *Diabetes Obesity & Metabolism, 15*(2), 99-111.

Lutz, T. A., Delprete, E., & Scharrer, E. (1994). Reduction Of Food-Intake In Rats By Intraperitoneal Injection Of Low-Doses Of Amylin. *Physiology & Behavior, 55*(5), 891-895.

Lutz, T. A., Senn, M., Althaus, J., Del Prete, E., Ehrensperger, F., & Scharrer, E. (1998). Lesion Of The Area Postrema Nucleus Of The Solitary Tract (Ap/Nts) Attenuates The Anorectic Effects Of Amylin And Calcitonin Gene-Related Peptide (Cgrp) In Rats. *Peptides, 19*(2), 309-317.

Maccioni, P., Pes, D., Carai, M. A. M., Gessa, G. L., & Colombo, G. (2008). Suppression By The Cannabinoid Cb(1) Receptor Antagonist, Rimonabant, Of The Reinforcing And Motivational Properties Of A Chocolate-Flavoured Beverage In Rats. *Behavioural Pharmacology, 19*(3), 197-209.

Mack, C., Hoyt, J., Moore, C., Jodka, C., & Sams-Dodd, F. (2003). Sustained Reduction In Food Intake And Body Weight In High-Fat-Fed Rats During 28-Day Amylin Infusion. *Diabetes, 52*, A389-A389.

Mack, C., Laugero, K., Liu, Q., Jodka, C., Young, A., & Parkes, D. (2006). Therapeutic Applications Of Incretin Mimetics For Metabolic Diseases: Preclinical Studies. *Drug Development Research, 67*(7), 553-558.

Mack, C. M., Moore, C. X., Jodka, C. M., Bhavsar, S., Wilson, J. K., Hoyt, J. A., Roan, J. L., Vu, C., Laugero, K. D., Parkes, D. G., & Young, A. A. (2006). Antiobesity Action Of Peripheral Exenatide (Exendin-4) In Rodents: Effects On Food Intake, Body Weight, Metabolic Status And Side-Effect Measures. *International Journal Of Obesity, 30*(9), 1332-1340.

Mack, C. M., Soares, C. J., Wilson, J. K., Athanacio, J. R., Turek, V. F., Trevaskis, J. L., Roth, J. D., Smith, P. A., Gedulin, B., Jodka, C. M., Roland, B. L., Adams, S. H., Lwin, A., Herich, J., Laugero, K. D., Vu, C., Pittner, R., Paterniti, J. R., Jr., Hanley, M., Ghosh, S., & Parkes, D. G. (2010). Davalintide (Ac2307), A Novel Amylin-Mimetic Peptide: Enhanced Pharmacological Properties Over Native Amylin To Reduce Food Intake And Body Weight. *International Journal Of Obesity, 34*(2), 385-395.

Mackenzie, R. G., Hoebel, B. G., Ducret, R. P., & Trulson, M. E. (1979). Hyperphagia Following Intra-Ventricular Para-Chlorophenylalanine-Methyl, Leucine-Methyl Or Tryptophan-Methyl Esters - Lack Of Correlation With

Whole Brain-Serotonin Levels. *Pharmacology Biochemistry And Behavior, 10*(6), 951-955.

Macleod, J. J. R. (1924). Insulin. *Physiological Reviews, 4*(1), 21-68.

Macneil, D. J. (2007). Npyy1 And Y5 Receptor Selective Antagonists As Anti-Obesity Drugs. *Current Topics In Medicinal Chemistry, 7*(17), 1721-1733.

Macneil, D. J. (2013). The Role Of Melanin-Concentrating Hormone And Its Receptors In Energy Homeostasis. *Frontiers In Endocrinology, 4*, 49-49.

Macor, J. E., Burkhart, C. A., Heym, J. H., Ives, J. L., Lebel, L. A., Newman, M. E., Nielsen, J. A., Ryan, K., Schulz, D. W., Torgersen, L. K., & Koe, B. K. (1990). 3-(1,2,5,6-Tetrahydropyrid-4-Yl)Pyrrolo 3,2-B Pyrid-5-One - A Potent And Selective Serotonin (5-Ht1b) Agonist And Rotationally Restricted Phenolic Analog Of 5-Methoxy-3-(1,2,5,6-Tetrahydropyrid-4-Yl)Indole. *Journal Of Medicinal Chemistry, 33*(8), 2087-2093.

Macphail, R. C., & Gollub, L. R. (1974). Independence Of Effects Of D-Amphetamine And Food-Deprivation Or Body-Weight On Food-Consumption Of Rats. *Psychopharmacologia, 34*(2), 163-172.

Maekawa, F., Quah, H. M. A., Tanaka, K., & Ohki-Hamazaki, H. (2004). Leptin Resistance And Enhancement Of Feeding Facilitation By Melanin-Concentrating Hormone In Mice Lacking Bombesin Receptor Subtype-3. *Diabetes, 53*(3), 570-576.

Maekawa, T., Nojima, H., Kuraishi, Y., & Aisaka, K. (2006). The Cannabinoid Cb2 Receptor Inverse Agonist Jte-907 Suppresses Spontaneous Itch-Associated Responses Of Nc Mice, A Model Of Atopic Dermatitis. *European Journal Of Pharmacology, 542*(1-3), 179-183.

Maeno, H., Yamada, K., Santo-Yamada, Y., Aoki, K., Sun, Y. J., Sato, E., Fukushima, T., Ogura, H., Araki, T., Kamichi, S., Kimura, I., Yamano, M., Maeno-Hikichi, Y., Watase, K., Aoki, S., Kiyama, H., Wada, E., & Wada, K. J. (2004). Comparison Of Mice Deficient In The High- Or Low-Affinity Neurotensin Receptors, Ntsr1 Or Ntsr2, Reveals A Novel Function For Ntsr2 In Thermal Nociception. *Brain Research, 998*(1), 122-129.

Magdalena Farias, M., Cuevas, A. M., & Rodriguez, F. (2011). Set-Point Theory And Obesity. *Metabolic Syndrome And Related Disorders, 9*(2), 85-89.

Maggio, C. A., Haraczkiewicz, E., & Vasselli, J. R. (1988). Diet Composition Alters The Satiety Effect Of Cholecystokinin In Lean And Obese Zucker Rats. *Physiology & Behavior, 43*(4), 485-491.

Maggio, C. A., Presta, E., Filippo Bracco, E., Vasselli, J. R., Kissileff, H. R., Pfohl, D. N., & Hashim, S. A. (1985). Naltrexone And Human Eating Behavior: A Dose-Ranging Inpatient Trial In Moderately Obese Men. *Brain Research Bulletin, 14*(6), 657-661.

Maggs, D., Shen, L., Strobel, S., Brown, D., Kolterman, O., & Weyer, C. (2003). Effect Of Pramlintide On A(1c) And Body Weight In Insulin-Treated African Americans And Hispanics With Type 2 Diabetes: A Pooled Post Hoc Analysis. *Metabolism-Clinical And Experimental, 52*(12), 1638-1642.

Magnan, J., Paterson, S. J., Tavani, A., & Kosterlitz, H. W. (1982). The Binding Spectrum Of Narcotic Analgesic Drugs With Different Agonist And Antagonist Properties. *Naunyn-Schmiedebergs Archives Of Pharmacology, 319*(3), 197-205.

Mahler, S. V., Smith, K.S., & Berridge, K.C. (2007). Endocannabinoid Hedonic Hotspot For Sensory Pleasure: Anandamide In Nucleus Accumbens Shell Enhances 'Liking' Of A Sweet Reward. *NEUROPSYCHOPHARMACOLOGY, 32*, 2267-2278.

Majeed, N. H., Lason, W., Przewlocka, B., & Przewlocki, R. (1985). Differential Modulation Of The Beta-Endorphin And Dynorphin Systems By Serotonergic Stimulation In The Rat. *Neuropeptides, 5*(4-6), 563-566.

Makimura, H., Mizuno, T. M., Mastaitis, J. W., Agami, R., & Mobbs, C. V. (2002). Reducing Hypothalamic Agrp By Rna Interference Increases Metabolic Rate

And Decreases Body Weight Without Influencing Food Intake. *Bmc Neuroscience, 3*(1), 18 - 24.

Makowski, C. T., Gwinn, K. M., & Hurren, K. M. (2011). Naltrexone/Bupropion: An Investigational Combination For Weight Loss And Maintenance. *Obesity Facts, 4*(6), 489-494.

Malcolm, R., O'neil, P. M., Sexauer, J. D., Riddle, F. E., Currey, H. S., & Counts, C. (1985). A Controlled Trial Of Naltrexone In Obese Humans. *International Journal Of Obesity, 9*(5), 347-353.

Malik, S., Mcglone, F., Bedrossian, D., & Dagher, A. (2008). Ghrelin Modulates Brain Activity In Areas That Control Appetitive Behavior. *Cell Metabolism, 7*(5), 400-409.

Malmstrom, R. E. (2002). Pharmacology Of Neuropeptide Y Receptor Antagonists - Focus On Cardiovascular Functions. *European Journal Of Pharmacology, 447*(1), 11-30.

Man, P. S., & Lawrence, C. B. (2008). The Effects Of Galanin-Like Peptide On Energy Balance, Body Temperature And Brain Activity In The Mouse And Rat Are Independent Of The Galr2/3 Receptor. *Journal Of Neuroendocrinology, 20*(1), 128-137.

Manberg, P. J., Youngblood, W. W., Nemeroff, C. B., Rossor, M. N., Iversen, L. L., Prange, A. J., & Kizer, J. S. (1982). Regional Distribution Of Neurotensin In Human-Brain. *Journal Of Neurochemistry, 38*(6), 1777-1780.

Mansour, A., Khachaturian, H., Lewis, M. E., Akil, H., & Watson, S. J. (1988). Anatomy Of Cns Opioid Receptors. *Trends In Neurosciences, 11*(7), 308-314.

Mantzoros, C., Flier, J. S., Lesem, M. D., Brewerton, T. D., & Jimerson, D. C. (1997). Cerebrospinal Fluid Leptin In Anorexia Nervosa: Correlation With Nutritional Status And Potential Role In Resistance To Weight Gain. *Journal Of Clinical Endocrinology & Metabolism, 82*(6), 1845-1851.

Manzanares, J., Corchero, J., Romero, J., Fernandez-Ruiz, J. J., Ramos, J. A., & Fuentes, J. A. (1999). Pharmacological And Biochemical Interactions Between Opioids And Cannabinoids. *Trends In Pharmacological Sciences, 20*(7), 287-294.

Marbury, T. C., Angelo, J. E., Gulley, R. M., Krosnick, A., Sugimoto, D. H., & Zellner, S. R. (1996). A Placebo-Controlled, Dose-Response Study Of Dexfenfluramine In The Treatment Of Obese Patients. *Current Therapeutic Research-Clinical And Experimental, 57*(9), 663-674.

Marco, E. M., Romero-Zerbo, S. Y., Viveros, M.-P., & Bermudez-Silva, F. J. (2012). The Role Of The Endocannabinoid System In Eating Disorders: Pharmacological Implications. *Behavioural Pharmacology, 23*(5-6), 526-536.

Marek, G. J., & Aghajanian, G. K. (1998). 5-Hydroxytryptamine-Induced Excitatory Postsynaptic Currents In Neocortical Layer V Pyramidal Cells: Suppression By Mu-Opiate Receptor Activation. *Neuroscience, 86*(2), 485-497.

Margetic, S., Gazzola, C., Pegg, G. G., & Hill, R. A. (2002). Leptin: A Review Of Its Peripheral Actions And Interactions. *International Journal Of Obesity, 26*(11), 1407-1433.

Margules, D. L., Moisset, B., Lewis, M. J., Shibuya, H., & Pert, C. B. (1978). Beta-Endorphin Is Associated With Overeating In Genetically Obese Mice (Ob-Ob) And Rats (Fa-Fa). *Science, 202*(4371), 988-991.

Mark, E. J., Patalas, E. D., Chang, H. T., Evans, R. J., & Kessler, S. C. (1997). Fatal Pulmonary Hypertension Associated With Short-Term Use Of Fenfluramine And Phentermine. *New England Journal Of Medicine, 337*(9), 602-606.

Marks, D. L., & Cone, R. D. (2001). Central Melanocortins And The Regulation Of Weight During Acute And Chronic Disease. *Recent Prog Horm Res, 56*(1), 359-376.

Markskaufman, R., & Balmagiya, T. (1985). Acute Effects Of Naltrexone On Energy-Balance And Thermoregulation In Rats. *Nutrition Reports International, 32*(2), 337-347.

Markskaufman, R., Balmagiya, T., & Gross, E. (1984). Modifications In Food-Intake And Energy-Metabolism In Rats As A Function Of Chronic Naltrexone Infusions. *Pharmacology Biochemistry And Behavior, 20*(6), 911-916.

Markskaufman, R., & Kanarek, R. B. (1981). Modifications Of Nutrient Selection Induced By Naloxone In Rats. *Psychopharmacology, 74*(4), 321-324.

Marrazzi, M. A., Bacon, J. P., Kinzie, J., & Luby, E. D. (1995). Naltrexone Use In The Treatment Of Anorexia Nervosa And Bulimia Nervosa*. *International Clinical Psychopharmacology, 10*(3), 163-172.

Marsh, D. J., Hollopeter, G., Kafer, K. E., & Palmiter, R. D. (1998). Role Of The Y5 Neuropeptide Y Receptor In Feeding And Obesity. *Nature Medicine, 4*(6), 718-721.

Marsicano, G., & Lutz, B. (2006). Neuromodulatory Functions Of The Endocannabinoid System. *Journal Of Endocrinological Investigation, 29*(3 Suppl), 27-46.

Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J. R., Hofmann, C., Zieglgansberger, W., Di Marzo, V., & Lutz, B. (2002). The Endogenous Cannabinoid System Controls Extinction Of Aversive Memories. *Nature, 418*(6897), 530-534.

Martellotta, M. C., Cossu, G., Fattore, L., Gessa, G. L., & Fratta, W. (1998). Self-Administration Of The Cannabinoid Receptor Agonist Win 55,212-2 In Drug-Naive Mice. *Neuroscience, 85*(2), 327-330.

Martens, E. A., Lemmens, S. G., & Westerterp-Plantenga, M. S. (2013). Protein Leverage Affects Energy Intake Of High-Protein Diets In Humans. *American Journal Of Clinical Nutrition, 97*(1), 86-93.

Martin, C. K., Redman, L. M., Zhang, J., Sanchez, M., Anderson, C. M., Smith, S. R., & Ravussin, E. (2011). Lorcaserin, A 5-Ht2c Receptor Agonist, Reduces Body Weight By Decreasing Energy Intake Without Influencing Energy Expenditure. *Journal Of Clinical Endocrinology & Metabolism, 96*(3), 837-845.

Martin, J. R., Bos, M., Jenck, F., Moreau, J. L., Mutel, V., Sleight, A. J., Wichmann, J., Andrews, J. S., Berendsen, H. H. G., Broekkamp, C. L. E., Ruigt, G. S. F., Kohler, C., & Van Delft, A. M. L. (1998). 5-Ht2c Receptor Agonists: Pharmacological Characteristics And Therapeutic Potential. *Journal Of Pharmacology And Experimental Therapeutics, 286*(2), 913-924.

Martin, P., Massol, J., Colin, J. N., Lacomblez, L., & Puech, A. J. (1990). Antidepressant Profile Of Bupropion And 3 Metabolites In Mice. *Pharmacopsychiatry, 23*(4), 187-194.

Martin, W. R., Wikler, A., Eades, C. G., & Pescor, F. T. (1963). Tolerance To And Physical-Dependence On Morphine In Rats. *Psychopharmacologia, 4*(4), 247-260.

Martinez, V., Barquist, E., Rivier, J., & Tache, Y. (1998). Central Crf Inhibits Gastric Emptying Of A Nutrient Solid Meal In Rats: The Role Of Crf(2) Receptors. *American Journal Of Physiology-Gastrointestinal And Liver Physiology, 274*(5), G965-G970.

Mashiko, S., Moriya, R., Ishihara, A., Gomori, A., Matsushita, H., Egashira, S., Iwaasa, H., Takahashi, T., Haga, Y., Fukami, T., & Kanatani, A. (2009). Synergistic Interaction Between Neuropeptide Y(1) And Y(5) Receptor Pathways In Regulation Of Energy Homeostasis. *European Journal Of Pharmacology, 615*(1-3), 113-117.

Matejek, N., Weimann, E., Witzel, C., Molenkamp, G., Schwidergall, S., & Bohles, H. (1999). Hypoleptinaemia In Patients With Anorexia Nervosa And In Elite Gymnasts With Anorexia Athletica. *International Journal Of Sports Medicine, 20*(7), 451-456.

Matias, I., & Di Marzo, V. (2007). Endocannabinoids And The Control Of Energy Balance. *Trends In Endocrinology And Metabolism, 18*(1), 27-37.

Matson, C. A., Reid, D. F., Cannon, T. A., & Ritter, R. C. (2000). Cholecystokinin And Leptin Act Synergistically To Reduce Body Weight. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 278*(4), R882-R890.

Matson, C. A., Wiater, M. F., Kuijper, J. L., & Weigle, D. S. (1997). Synergy Between Leptin And Cholecystokinin (Cck) To Control Daily Caloric Intake. *Peptides, 18*(8), 1275-1278.

Matsuda, K., Shimakura, S.-I., Maruyama, K., Miura, T., Uchiyama, M., Kawauchi, H., Shioda, S., & Takahashi, A. (2006). Central Administration Of Melanin-Concentrating Hormone (Mch) Suppresses Food Intake, But Not Locomotor Activity, In The Goldfish, Carassius Auratus. *Neuroscience Letters, 399*(3), 259-263.

Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990). Structure Of A Cannabinoid Receptor And Functional Expression Of The Cloned Cdna. *Nature, 346*(6284), 561-564.

Matsumoto, Y., Watanabe, T., Adachi, Y., Itoh, T., Ohtaki, T., Onda, H., Kurokawa, T., Nishimura, O., & Fujino, M. (2002). Galanin-Like Peptide Stimulates Food Intake In The Rat. *Neuroscience Letters, 322*(1), 67-69.

Mayer, J. (1955). Regulation Of Energy Intake And The Body Weight: The Glucostatic Theory And The Lipostatic Hypothesis. *Annals Of The New York Academy Of Sciences, 63*, 15 - 43.

Mazella, J., Beraud-Dufour, S., Devader, C., Massa, F., & Coppola, T. (2012). Neurotensin And Its Receptors In The Control Of Glucose Homeostasis. *Frontiers In Endocrinology, 3*, 143-143.

Mccann, U. D., Yuan, J., Hatzidimitriou, G., & Ricaurte, G. A. (1997). Selective Serotonin Reuptake Inhibitors Dissociate Fenfluramine's Anorectic And Neurotoxic Effects: Importance Of Dose, Species And Drug. *Journal Of Pharmacology And Experimental Therapeutics, 281*(3), 1487-1498.

Mccarthy, P. S., Dettmar, P. W., Lynn, A. G., & Sanger, D. J. (1981). Anorectic Actions Of The Opiate Antagonist Naloxone. *Neuropharmacology, 20*(12B), 1347-1349.

Mcgavigan, A. K., & Murphy, K. G. (2012). Gut Hormones: The Future Of Obesity Treatment? *British Journal Of Clinical Pharmacology, 74*(6), 911-919.

Mcguirk, J., Muscat, R., & Willner, P. (1992). Effects Of Chronically Administered Fluoxetine And Fenfluramine On Food Intake, Body Weight And The Behavioural Satiety Sequence. *Psychopharmacology, 106*, 401-407.

Mcguirk, J., & Silverstone, T. (1990). The Effect Of The 5-Ht Reuptake Inhibitor Fluoxetine On Food-Intake And Body-Weight In Healthy Male-Subjects. *International Journal Of Obesity, 14*(4), 361-372.

Mcintosh, C., Arnold, R., Bothe, E., Becker, H., Kobberling, J., & Creutzfeldt, W. (1978). Gastrointestinal Somatostatin In Man And Dog. *Metabolism-Clinical And Experimental, 27*(9), 1317-1320.

Mckay, L. D., Kenney, N. J., Edens, N. K., Williams, R. H., & Woods, S. C. (1981). Intracerebroventricular Beta-Endorphin Increases Food-Intake Of Rats. *Life Sciences, 29*(14), 1429-1434.

Mckay, N. J., Kanoski, S. E., Hayes, M. R., & Daniels, D. (2011). Glucagon-Like Peptide-1 Receptor Agonists Suppress Water Intake Independent Of Effects On Food Intake. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 301*(6), R1755-R1764.

Mclaughlin, C. L., & Baile, C. A. (1981). Obese Mice And The Satiety Effects Of Cholecystokinin, Bombesin And Pancreatic Polypeptide. *Physiology & Behavior, 26*(3), 433-437.

Mclaughlin, C. L., & Baile, C. A. (1984). Increased Sensitivity Of Zucker Obese Rats To Naloxone Is Present At Weaning. *Physiology & Behavior, 32*(6), 929-933.

Mclaughlin, P. J. (2012). Reports Of The Death Of Cb1 Antagonists Have Been Greatly Exaggerated: Recent Preclinical Findings Predict Improved Safety In The Treatment Of Obesity. *Behavioural Pharmacology, 23*(5-6), 537-550.

Mclaughlin, P. J., Qian, L., Wood, J. T., Wisniecki, A., Winston, K. M., Swezey, L. A., Ishiwari, K., Betz, A. J., Pandarinathan, L., Xu, W., Makriyannis, A., & Salamone, J. D. (2006). Suppression Of Food Intake And Food-Reinforced Behavior Produced By The Novel Cb1 Receptor Antagonist/Inverse Agonist Am 1387. *Pharmacology Biochemistry And Behavior, 83*(3), 396-402.

Mclaughlin, P. J., Winston, K., Swezey, L., Wisniecki, A., Aberman, J., Tardif, D. J., Betz, A. J., Ishiwari, K., Makriyannis, A., & Salamone, J. D. (2003). The Cannabinoid Cb1 Antagonists Sr 141716a And Am 251 Suppress Food Intake And Food-Reinforced Behavior In A Variety Of Tasks In Rats. *Behavioural Pharmacology, 14*(8), 583-588.

Mclaughlin, P. J., Winston, K. M., Limebeer, C. L., Parker, L. A., Makriyannis, A., & Salamone, J. D. (2005). The Cannabinoid Cb1 Antagonist Am 251 Produces Food Avoidance And Behaviors Associated With Nausea But Does Not Impair Feeding Efficiency In Rats. *Psychopharmacology, 180*(2), 286-293.

Mclaughlin Pj, W. K., Swezey La, Vemuri Vk, Makriyannis A, Salamone Jd. (2010). Detailed Analysis Of Food-Reinforced Operant Lever Pressing Distinguishes Effects Of A Cannabinoid Cb1 Inverse Agonist And Dopamine D1 And D2 Antagonists. *Pharmacology, Biochemistry & Behavior, 96*, 75-81.

Mcmahon, F. G., Fujioka, K., Singh, B. N., Mendel, C. M., Rowe, E., Rolston, K., Johnson, F., & Mooradian, A. D. (2000). Efficacy And Safety Of Sibutramine In Obese White And African American Patients With Hypertension - A 1-Year, Double-Blind, Placebo-Controlled, Multicenter Trial. *Archives Of Internal Medicine, 160*(14), 2185-2191.

Mcmahon, L. R., & Wellman, P. J. (1998). Pvn Infusion Of Glp-1-(7-36) Amide Suppresses Feeding But Does Not Induce Aversion Or Alter Locomotion In Rats. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 274*(1), R23-R29.

Mcminn, J. E., Sindelar, D. K., Havel, P. J., & Schwartz, M. W. (2000). Leptin Deficiency Induced By Fasting Impairs The Satiety Response To Cholecystokinin. *Endocrinology, 141*(12), 4442-4448.

Mcminn, J. E., Wilkinson, C. W., Havel, P. J., Woods, S. C., & Schwartz, M. W. (2000). Effect Of Intracerebroventricular Alpha-Msh On Food Intake, Adiposity, C-Fos Induction, And Neuropeptide Expression. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 279*(2), R695-R703.

Meeran, K., O'shea, D., Edwards, C. M. B., Turton, M. D., Heath, M. M., Gunn, I., Abusnana, S., Rossi, M., Small, C. J., Goldstone, A. P., Taylor, G. M., Sunter, D., Steere, J., Choi, S. J., Ghatei, M. A., & Bloom, S. R. (1999). Repeated Intracerebroventricular Administration Of Glucagon-Like Peptide-1-(7-36) Amide Or Exendin-(9-39) Alters Body Weight In The Rat. *Endocrinology, 140*(1), 244-250.

Meereis-Schwanke, K., Klonowski-Stumpe, H., Herberg, L., & Niederau, C. (1998). Long-Term Effects Of Cck-Agonist And -Antagonist On Food Intake And Body Weight In Zucker Lean And Obese Rats. *Peptides, 19*(2), 291-299.

Meguid, M. M., Fetissov, S. O., Blaha, V., & Yang, Z. J. (2000). Dopamine And Serotonin Vmn Release Is Related To Feeding Status In Obese And Lean Zucker Rats. *Neuroreport, 11*(10), 2069-2072.

Meier, J. J., Gallwitz, B., & Nauck, M. A. (2003). Glucagon-Like Peptide 1 And Gastric Inhibitory Polypeptide - Potential Applications In Type 2 Diabetes Mellitus. *Biodrugs, 17*(2), 93-102.

Melander, T., Hokfelt, T., Rokaeus, A., Cuello, A. C., Oertel, W. H., Verhofstad, A., & Goldstein, M. (1986). Coexistence Of Galanin-Like Immunoreactivity With Catecholamines, 5-Hydroxytryptamine, Gaba And Neuropeptides In The Rat Cns. *Journal Of Neuroscience, 6*(12), 3640-3654.

Melis, T., Succu, S., Sanna, F., Boi, A., Argiolas, A., & Melis, M. R. (2007). The Cannabinoid Antagonist Sr 141716a (Rimonabant) Reduces The Increase Of Extra-Cellular Dopamine Release In The Rat Nucleus Accumbens Induced By A Novel High Palatable Food. *Neuroscience Letters, 419*(3), 231-235.

Mellinkoff, S. M., Frankland, M., Boyle, D., & Greipel, M. (1956). Relationship Between Serum Amino Acid Concentration And Fluctuations In Appetite. *Journal Of Applied Physiology, 8*(5), 535-538.

Mencarelli, M., Verti, B., Savia, G., Marzullo, P., Walker, G., Di Blasio, A., & Liuzzi, A. (2004). Human Leptin Gene Polymorphism And Metabolic Syndrome In Severely Obese Patients. *International Journal Of Obesity, 28*, S109-S109.

Mentlein, R., Gallwitz, B., & Schmidt, W. E. (1993). Dipeptidylpeptidase-Iv Hydrolyzes Gastric-Inhibitory Polypeptide, Glucagon-Like Peptide-1(7-36)Amide, Peptide Histidine Methionine And Is Responsible For Their Degradation In Human Serum. *European Journal Of Biochemistry, 214*(3), 829-835.

Mercer, J. G., Hoggard, N., Williams, L. M., Lawrence, C. B., Hannah, L. T., Morgan, P. J., & Trayhurn, P. (1996). Coexpression Of Leptin Receptor And Preproneuropeptide Y Mrna In Arcuate Nucleus Of Mouse Hypothalamus. *Journal Of Neuroendocrinology, 8*(10), 733-735.

Mercer, J. G., & Speakman, J. R. (2001). Hypothalamic Neuropeptide Mechanisms For Regulating Energy Balance: From Rodent Models To Human Obesity. *Neuroscience And Biobehavioral Reviews, 25*(2), 101-116.

Merchenthaler, I., Lane, M., & Shughrue, P. (1999). Distribution Of Pre-Pro-Glucagon And Glucagon-Like Peptide-1 Receptor Messenger Rnas In The Rat Central Nervous System. *Journal Of Comparative Neurology, 403*(2), 261-280.

Mhra. (2008a). Rimonabant (Acomplia): Depression; Psychiatric Adverse Reactions. Retrieved 16th August, 2013

Mhra. (2008b). Rimonabant: European Suspension Of Marketing Authorization. *Drug Safety Update.* Volume 2, Issue 4. Retrieved 8th Feb, 2010, From Http://Www.Mhra.Gov.Uk/Safetyinformation/Drugsafetyupdate/CON87927

Michelakis, E. D., & Weir, E. K. (2001). Anorectic Drugs And Pulmonary Hypertension From The Bedside To The Bench. *American Journal Of The Medical Sciences, 321*(4), 292-299.

Miller, D. K., Sumithran, S. P., & Dwoskin, L. P. (2002). Bupropion Inhibits Nicotine-Evoked H-3 Overflow From Rat Striatal Slices Preloaded With H-3 Dopamine And From Rat Hippocampal Slices Preloaded With H-3 Norepinephrine. *Journal Of Pharmacology And Experimental Therapeutics, 302*(3), 1113-1122.

Miller, K. J. (2005). Serotonin 5-Ht2c Receptor Agonists: For The Treatment Of Obesity. *Molecular Interventions, 5*(5), 282-291.

Miller, L., & Griffith, J. (1983). A Comparison Of Bupropion, Dextroamphetamine, And Placebo In Mixed-Substance Abusers. *Psychopharmacology, 80*(3), 199-205.

Miller, N. E., Bailey, C. J., & Stevenson, J. A. F. (1950). Decreased Hunger But Increased Food Intake Resulting From Hypothalamic Lesions. *Science, 112*(2905), 256-259.

Millington, G. W. M. (2007). The Role Of Proopiomelanocortin (Pomc) Neurones In Feeding Behaviour. *Nutrition & Metabolism, 4*.

Minamino, N., Kangawa, K., & Matsuo, H. (1983). Neuromedin-B - A Novel Bombesin-Like Peptide Identified In Porcine Spinal-Cord. *Biochemical And Biophysical Research Communications, 114*(2), 541-548.

Mingrone, G., Panunzi, S., De Gaetano, A., Guidone, C., Iaconelli, A., Leccesi, L., Nanni, G., Pomp, A., Castagneto, M., Ghirlanda, G., & Rubino, F. (2012). Bariatric Surgery Versus Conventional Medical Therapy For Type 2 Diabetes. *New England Journal Of Medicine, 366*(17), 1577-1585.

Minozzi, S., Amato, L., Vecchi, S., Davoli, M., Kirchmayer, U., & Verster, A. (2011). Oral Naltrexone Maintenance Treatment For Opioid Dependence. *Cochrane Database Of Systematic Reviews*(2).

Mitchell, J. E., Morley, J. E., Levine, A. S., Hatsukami, D., Gannon, M., & Pfohl, D. (1987). High-Dose Naltrexone Therapy And Dietary Counseling For Obesity. *Biological Psychiatry, 22*(1), 35-42.

Miyamoto, T., Nojima, H., Shinkado, T., Nakahashi, T., & Kuraishi, Y. (2002). Itch-Associated Response Induced By Experimental Dry Skin In Mice. *The Japanese Journal Of Pharmacology, 88*(3), 285-292.

Modell, J. G., Rosenthal, N. E., Harriett, A. E., Krishen, A., Asgharian, A., Foster, V. J., Metz, A., Rockett, C. B., & Wightman, D. S. (2005). Seasonal Affective Disorder And Its Prevention By Anticipatory Treatment With Bupropion Xl. *Biological Psychiatry, 58*(8), 658-667.

Mogi, K., Yonezawa, T., Chen, D. S., Li, J. Y., Sawasaki, T., & Nishihara, M. (2003). Correlation Between Spontaneous Feeding Behavior And Neuropeptide Y Profile In The Third Ventricular Cerebrospinal Fluid Of Goats. *Domestic Animal Endocrinology, 25*(2), 175-182.

Molina-Holgado F, M.-H. E., Leret Ml, Gonzalez Mi, Reader Ta. (1993). Distribution Of Indoleamines And [3h]Paroxetine Binding In Rat Brain Regions Following Acute Or Perinetal Delta9-Tetrahydrocannabinol Treatments. *Neurochemical Research, 18*(11), 1183-1191.

Mollet, A., Gilg, S., Riediger, T., & Lutz, T. A. (2004). Infusion Of The Amylin Antagonist Ac 187 Into The Area Postrema Increases Food Intake In Rats. *Physiology & Behavior, 81*(1), 149-155.

Mondal, M. S., Nakazato, M., Date, Y., Murakami, N., Yanagisawa, M., & Matsukura, S. (1999). Widespread Distribution Of Orexin In Rat Brain And Its Regulation Upon Fasting. *Biochemical And Biophysical Research Communications, 256*(3), 495-499.

Mondal, M. S., Yamaguchi, H., Date, Y., Shimbara, T., Toshinai, K., Shimomura, Y., Mori, M., & Nakazato, M. (2003). A Role For Neuropeptide W In The Regulation Of Feeding Behavior. *Endocrinology, 144*(11), 4729-4733.

Mondal, M. S., Yamaguchi, H., Date, Y., Toshinai, K., Kawagoe, T., Tsuruta, T., Kageyama, H., Kawamura, Y., Shioda, S., Shimomura, Y., Mori, M., & Nakazato, M. (2006). Neuropeptide W Is Present In Antral G Cells Of Rat, Mouse, And Human Stomach. *Journal Of Endocrinology, 188*(1), 49-57.

Monnikes, H., Heymannmonnikes, I., & Tache, Y. (1992). Crf In The Paraventricular Nucleus Of The Hypothalamus Induces Dose-Related Behavioral Profile In Rats. *Brain Research, 574*(1-2), 70-76.

Montague, C. T., Farooqi, I. S., Whitehead, J. P., Soos, M. A., Rau, H., Wareham, N. J., Sewter, C. P., Digby, J. E., Mohammed, S. N., & Hurst Et, A. (1997). Congenital Leptin Deficiency Is Associated With Severe Early-Onset Obesity In Humans. *Nature, 387*(6636), 903-908.

Montgomery, A. M. J., & Willner, P. (1988). Fenfluramine Disrupts The Behavioural Satiety Sequence. *1988, 94*, 397-401.

Moran, T. (2009). Gut Peptides In The Control Of Food Intake. *International Journal Of Obesity, 33*, S7-S10.

Moran, T. H. (2000). Cholecystokinin And Satiety: Current Perspectives. *Nutrition, 16*(10), 858-865.

Moran, T. H., & Bi, S. (2006). Hyperphagia And Obesity In Oletf Rats Lacking Cck-1 Receptors. *Philosophical Transactions Of The Royal Society B-Biological Sciences, 361*(1471), 1211-1218.

Moran, T. H., & Dailey, M. J. (2009). Gut Peptides: Targets For Antiobesity Drug Development? *Endocrinology, 150*(6), 2526-2530.

Moran, T. H., Moody, T. W., Hostetler, A. M., Robinson, P. H., Goldrich, M., & Mchugh, P. R. (1988). Distribution Of Bombesin Binding-Sites In The Rat Gastrointestinal-Tract. *Peptides, 9*(3), 643-649.

Moran, T. H., Smedh, U., Kinzig, K. P., Scott, K. A., Knipp, S., & Ladenheim, E. E. (2004). Peptide Yy (3-36) Inhibits Gastric Emptying And Produces Acute Reductions In Food Intake In Rhesus Monkeys. *Am J Physiol Regul Integr Comp Physiol*, 00535.02004.

Moreau, J. L., Griebel, G., Jenck, F., Martin, J. R., Widmer, U., & Haefely, W. E. (1992). Behavioral Profile Of The 5ht1a Receptor Antagonist (S)-Uh-301 In Rodents And Monkeys. *Brain Research Bulletin, 29*(6), 901-904.

Moreira, F. A., & Crippa, J. A. S. (2009). The Psychiatric Side-Effects Of Rimonabant. *Revista Brasileira De Psiquiatria, 31*(2), 145-153.

Moriya, R., Mashiko, S., Ishihara, A., Takahashi, T., Murai, T., Ito, J., Mitobe, Y., Oda, Z., Iwaasa, H., Takehiro, F., & Kanatani, A. (2009). Comparison Of Independent And Combined Chronic Anti-Obese Effects Of Npy Y2 Receptor Agonist, Pyy(3-36), And Npy Y5 Receptor Antagonist In Diet-Induced Obese Mice. *Peptides, 30*(7), 1318-1322.

Morley, J. E., Baranetsky, N. G., Wingert, T. D., Carlson, H. E., Hershman, J. M., Melmed, S., Levin, S. R., Jamison, K. R., Weitzman, R., Chang, R. J., & Varner, A. A. (1980). Endocrine Effects Of Naloxone-Induced Opiate Receptor Blockade. *Journal Of Clinical Endocrinology & Metabolism, 50*(2), 251-257.

Morley, J. E., & Flood, J. F. (1991). Amylin Decreases Food-Intake In Mice. *Peptides, 12*(4), 865-869.

Morley, J. E., & Levine, A. S. (1981). Dynorphin-(1-13) Induces Spontaneous Feeding In Rats. *Life Sciences, 29*(18), 1901-1903.

Morley, J. E., & Levine, A. S. (1982). Corticotropin Releasing-Factor, Grooming And Ingestive Behavior. *Life Sciences, 31*(14), 1459-1464.

Morris, M. J., & Nguyen, T. (2001). Does Neuropeptide Y Contribute To The Anorectic Action Of Amylin? *Peptides, 22*(3), 541-546.

Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006). Central Nervous System Control Of Food Intake And Body Weight. *Nature, 443*(7109), 289-295.

Morton, G. J., Thatcher, B. S., Reidelberger, R. D., Ogimoto, K., Wolden-Hanson, T., Baskin, D. G., Schwartz, M. W., & Blevins, J. E. (2012). Peripheral Oxytocin Suppresses Food Intake And Causes Weight Loss In Diet-Induced Obese Rats. *American Journal Of Physiology-Endocrinology And Metabolism, 302*(1), E134-E144.

Mountjoy, K. G., & Wong, J. (1997). Obesity, Diabetes And Functions For Proopiomelanocortin-Derived Peptides. *Molecular And Cellular Endocrinology, 128*(1-2), 171-177.

Mueller, T. D., Sullivan, L. M., Habegger, K., Yi, C.-X., Kabra, D., Grant, E., Ottaway, N., Krishna, R., Holland, J., Hembree, J., Perez-Tilve, D., Pfluger, P. T., Deguzman, M. J., Siladi, M. E., Kraynov, V. S., Axelrod, D. W., Dimarchi, R., Pinkstaff, J. K., & Tschoep, M. H. (2012). Restoration Of Leptin Responsiveness In Diet-Induced Obese Mice Using An Optimized Leptin Analog In Combination With Exendin-4 Or Fgf21. *Journal Of Peptide Science, 18*(6), 383-393.

Mul, J. D., La Fleur, S. E., Toonen, P. W., Afrasiab-Middelman, A., Binnekade, R., Schetters, D., Verheij, M. M. M., Sears, R. M., Homberg, J. R., Schoffelmeer, A. N. M., Adan, R. A. H., Dileone, R. J., De Vries, T. J., &

Cuppen, E. (2011). Chronic Loss Of Melanin-Concentrating Hormone Affects Motivational Aspects Of Feeding In The Rat. *Plos One, 6*(5).
Mula, M., & Sander, J. W. (2007). Negative Effects Of Antiepileptic Drugs On Mood In Patients With Epilepsy. *Drug Safety, 30*(7), 555-567.
Mulder, G. J. (1839). Uber Die Zusammensetzung Einiger Thierischen

Substanzen. *J Prakt Chem., 16*, 129-152.
Muley, M. P., Joshi, M. A., & Manekar, M. S. (1984). Effect Of Bupropion On Dopamine And 5-Hydroxytryptamine-Mediated Behavior In Mice. *Journal Of Pharmacy And Pharmacology, 36*(3), 208-210.
Munro, S., Thomas, K. L., & Abushaar, M. (1993). Molecular Characterization Of A Peripheral Receptor For Cannabinoids. *Nature, 365*(6441), 61-65.
Munzberg, H., Bjornholm, M., Bates, S. H., & Myers, M. G. (2005). Leptin Receptor Action And Mechanisms Of Leptin Resistance. *Cellular And Molecular Life Sciences, 62*(6), 642-652.
Muraki, Y., Yamanaka, A., Tsujino, N., Kilduff, T. S., Goto, K., & Sakurai, T. (2004). Serotonergic Regulation Of The Orexin/Hypocretin Neurons Through The 5-Ht1a Receptor. *Journal Of Neuroscience, 24*(32), 7159-7166.
Muroya, S., Funahashi, H., Yamanaka, A., Kohno, D., Uramura, K., Nambu, T., Shibahara, M., Kuramochi, M., Takigawa, M., Yanagisawa, M., Sakurai, T., Shioda, S., & Yada, T. (2004). Orexins (Hypocretins) Directly Interact With Neuropeptide Y, Pomc And Glucose-Responsive Neurons To Regulate Ca2+ Signaling In A Reciprocal Manner To Leptin: Orexigenic Neuronal Pathways In The Mediobasal Hypothalamus. *European Journal Of Neuroscience, 19*(6), 1524-1534.
Murphy, B., Nunes, C. N., Ronan, J. J., Harper, C. M., Beall, M. J., Hanaway, M., Fairhurst, A. M., Van Der Ploeg, L. H. T., Macintyre, D. E., & Mellin, T. N. (1998). Melanocortin Mediated Inhibition Of Feeding Behavior In Rats. *Neuropeptides, 32*(6), 491-497.
Muscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008). Separate Impact Of Obesity And Glucose Tolerance On The Incretin Effect In Normal Subjects And Type 2 Diabetic Patients. *Diabetes, 57*(5), 1340-1348.
Musso, D. L., Mehta, N. B., Soroko, F. E., Ferris, R. M., Hollingsworth, E. B., & Kenney, B. T. (1993). Synthesis And Evaluation Of The Antidepressant Activity Of The Enantiomers Of Bupropion. *Chirality, 5*(7), 495-500.
Muurahainen, N. E., Kissileff, H. R., & Pisunyer, F. X. (1993). Intravenous-Infusion Of Bombesin Reduces Food-Intake In Humans. *American Journal Of Physiology, 264*(2), R350-R354.
Myers, M. G., Cowley, M. A., & Muenzberg, H. (2008). Mechanisms Of Leptin Action And Leptin Resistance *Annual Review Of Physiology* (Vol. 70, Pp. 537-556).
Myers, R. D., Wooten, M. H., Ames, C. D., & Nyce, J. W. (1995). Anorexic Action Of A New Potential Neuropeptide-Y Antagonist [D-Tyr(27,36), D-Thr(32)]-Npy(27-36) Infused Into The Hypothalamus Of The Rat. *Brain Research Bulletin, 37*(3), 237-245.
Nagase, H., Nakajima, A., Sekihara, H., York, D. A., & Bray, G. A. (2002). Regulation Of Feeding Behavior, Gastric Emptying, And Sympathetic Nerve Activity To Interscapular Brown Adipose Tissue By Galanin And Enterostatin: The Involvement Of Vagal-Central Nervous System Interactions. *Journal Of Gastroenterology, 37*, 118-127.
Nahon, J. L. (1994). The Melanin-Concentrating Hormone - From The Peptide To The Gene. *Critical Reviews In Neurobiology, 8*(4), 221-262.
Nakahara, K., Katayama, T., Maruyama, K., Ida, T., Mori, K., Miyazato, M., Kangawa, K., & Murakami, N. (2010). Comparison Of Feeding Suppression

By The Anorexigenic Hormones Neuromedin U And Neuromedin S In Rats. *Journal Of Endocrinology, 207*(2), 185-193.

Nakashima, Y., Ida, T., Sato, T., Nakamura, Y., Takahashi, T., Mori, K., Miyazato, M., Kangawa, K., Kusukawa, J., & Kojima, M. (2010). Neuromedin U Is Necessary For Normal Gastrointestinal Motility And Is Regulated By Serotonin. In H. Vaudry & S. Shioda (Eds.), *Phylogenetic Aspects Of Neuropeptides: From Invertebrates To Humans* (Vol. 1200, Pp. 104-111).

Nakazato, M., Hanada, R., Murakami, N., Date, Y., Mondal, M. S., Kojima, M., Yoshimatsu, H., Kangawa, K., & Matsukura, S. (2000). Central Effects Of Neuromedin U In The Regulation Of Energy Homeostasis. *Biochemical And Biophysical Research Communications, 277*(1), 191-194.

Nakazato, M., Murakami, N., Date, Y., Kojima, M., Matsuo, H., Kangawa, K., & Matsukura, S. (2001). A Role For Ghrelin In The Central Regulation Of Feeding. *Nature, 409*(6817), 194-198.

Nakazi, M., Bauer, U., Nickel, T., Kathmann, M., & Schlicker, E. (2000). Inhibition Of Serotonin Release In The Mouse Brain Via Presynaptic Cannabinoid Cb1 Receptors. *Naunyn-Schmiedebergs Archives Of Pharmacology, 361*(1), 19-24.

Narita, M., Nagumo, Y., Hashimoto, S., Narita, M., Khotib, J., Miyatake, M., Sakurai, T., Yanagisawa, M., Nakamachi, T., Shioda, S., & Suzuki, T. (2006). Direct Involvement Of Orexinergic Systems In The Activation Of The Mesolimbic Dopamine Pathway And Related Behaviors Induced By Morphine

10.1523/Jneurosci.2761-05.2006. *J. Neurosci., 26*(2), 398-405.

Naslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J. E., Holst, J. J., Rossner, S., & Hellstrom, P. M. (1999). Energy Intake And Appetite Are Suppressed By Glucagon-Like Peptide-1 (Glp-1) In Obese Men. *International Journal Of Obesity, 23*(3), 304-311.

Naslund, E., Gutniak, M., Skogar, S., Rossner, S., & Hellstrom, P. M. (1998). Glucagon-Like Peptide 1 Increases The Period Of Postprandial Satiety And Slows Gastric Emptying In Obese Men. *American Journal Of Clinical Nutrition, 68*(3), 525-530.

Nathan, P. J., & Bullmore, E. T. (2009). From Taste Hedonics To Motivational Drive: Central M-Opioid Receptors And Binge-Eating Behaviour. *The International Journal Of Neuropsychopharmacology, 12*(07), 995-1008.

Nathan, P. J., O'neill, B. V., Bush, M. A., Koch, A., Tao, W. X., Maltby, K., Napolitano, A., Brooke, A. C., Skeggs, A. L., Herman, C. S., Larkin, A. L., Ignar, D. M., Richards, D. B., Williams, P. M., & Bullmore, E. T. (2012). Opioid Receptor Modulation Of Hedonic Taste Preference And Food Intake: A Single-Dose Safety, Pharmacokinetic, And Pharmacodynamic Investigation With Gsk1521498, A Novel M-Opioid Receptor Inverse Agonist. *The Journal Of Clinical Pharmacology, 52*(4), 464-474.

Nauck, M., Stockmann, F., Ebert, R., & Creutzfeldt, W. (1986). Reduced Incretin Effect In Type-2 (Non-Insulin-Dependent) Diabetes. *Diabetologia, 29*(1), 46-52.

Nauck, M. A., Hompesch, M., Filipczak, R., Le, T. D. T., Zdravkovic, M., & Gumprecht, J. (2006). Five Weeks Of Treatment With The Glp-1 Analogue Liraglutide Improves Glycaemic Control And Lowers Body Weight In Subjects With Type 2 Diabetes. *Experimental And Clinical Endocrinology & Diabetes, 114*(8), 417-423.

Navarro, M., Carrera, M. R. A., Fratta, W., Valverde, O., Cossu, G., Fattore, L., Chowen, J. A., Gomez, R., Del Arco, I., Villanua, M. A., Maldonado, R., Koob, G. F., & De Fonseca, F. R. (2001). Functional Interaction Between Opioid And Cannabinoid Receptors In Drug Self-Administration. *Journal Of Neuroscience, 21*(14), 5344-5350.

Navarro, M., Defonseca, F. R., Alvarez, E. A., Chowen, J. A., Zueco, J. A., Gomez, R., Eng, J., & Blazquez, E. (1996). Colocalization Of Glucagon-Like Peptide-1 (Glp-1) Receptors, Glucose Transporter Glut-2, And Glucokinase Mrnas In Rat Hypothalamic Cells: Evidence For A Role Of Glp-1 Receptor Agonists As An Inhibitory Signal For Food And Water Intake. *Journal Of Neurochemistry, 67*(5), 1982-1991.

Navarro, M., Hernandez, E., Munoz, R. M., Delarco, I., Villanua, M. A., Carrera, M. R. A., & Defonseca, F. R. (1997). Acute Administration Of The Cb1 Cannabinoid Receptor Antagonist Sr 141716a Induces Anxiety-Like Responses In The Rat. *Neuroreport, 8*(2), 491-496.

Nayebi, A. R. M., & Charkhpour, M. (2006). Role Of 5-Ht1a And 5-Ht2 Receptors Of Dorsal And Median Raphe Nucleus In Tolerance To Morphine Analgesia In Rats. *Pharmacology Biochemistry And Behavior, 83*(2), 203-207.

Neary, N. M., Goldstone, A. P., & Bloom, S. R. (2004). Appetite Regulation: From The Gut To The Hypothalamus. *Clinical Endocrinology, 60*(2), 153-160.

Neel, J., V. (1999). The 'Thrifty Genotype' In 1998. *Nutrition Review, 57*(5), S2-S9.

Neill, J. C., & Cooper, S. J. (1989). Selective Reduction By Serotonergic Agents Of Hypertonic Saline Consumption In Rats - Evidence For Possible 5-Ht 1c Receptor Mediation. *Psychopharmacology, 99*(2), 196-201.

Netterimages.Com. (2010). Http://Www.Cellbiol.Net/Ste/Alpobesity2.Php.

Neumeister, A., Bain, E., Nugent, A. C., Carson, R. E., Bonne, O., Luckenbaugh, D. A., Eckelman, W., Herscovitch, P., Charney, D. S., & Drevets, W. C. (2004). Reduced Serotonin Type 1(A) Receptor Binding In Panic Disorder. *Journal Of Neuroscience, 24*(3), 589-591.

Neurosearch. (2011). Tesofensine – A Promising Weight Loss Candidate. Retrieved 16th August, 2013

Nhmrc. (2003). Clinical Practice Guidelines For The Management Of Overweight And Obesity In Adults.

Nichols, D. E., & Nichols, C. D. (2008). Serotonin Receptors. *Chemical Reviews, 108*(5), 1614-1641.

Nielsen, J. A., Chapin, D. S., Johnson, J. L., & Torgersen, L. K. (1992). Sertraline, A Serotonin-Uptake Inhibitor, Reduces Food-Intake And Body-Weight In Lean Rats And Genetically-Obese Mice. *American Journal Of Clinical Nutrition, 55*(1), S185-S188.

Nielsen, J. A., Shannon, N. J., Bero, L., & Moore, K. E. (1986). Effects Of Acute And Chronic Bupropion On Locomotor-Activity And Dopaminergic-Neurons. *Pharmacology Biochemistry And Behavior, 24*(4), 795-799.

Nielsen, L. L., Young, A. A., & Parkes, D. G. (2004). Pharmacology Of Exenatide (Synthetic Exendin-4): A Potential Therapeutic For Improved Glycemic Control Of Type 2 Diabetes. *Regulatory Peptides, 117*(2), 77-88.

Niemeier, H. M., Leahey, T., Reed, K. P., Brown, R. A., & Wing, R. R. (2012). An Acceptance-Based Behavioral Intervention For Weight Loss: A Pilot Study. *Behavior Therapy, 43*(2), 427-435.

Nissen, S. E., Nicholls, S. J., Wolski, K., Rodes-Cabau, J., Cannon, C. P., Deanfield, J. E., Despres, J.-P., Kastelein, J. J. P., Steinhubl, S. R., Kapadia, S., Yasin, M., Ruzyllo, W., Gaudin, C., Job, B., Hu, B., Bhatt, D. L., Lincoff, A. M., Tuzcu, E. M., & For The, S. I. (2008). Effect Of Rimonabant On Progression Of Atherosclerosis In Patients With Abdominal Obesity And Coronary Artery Disease: The Stradivarius Randomized Controlled Trial. *JAMA, 299*(13), 1547-1560.

Nobelprize.Org. (2013). The Discovery Of Insulin. From Http://Www.Nobelprize.Org/Educational/Medicine/Insulin/Discovery-Insulin.Html

Nogueiras, R., Perez-Tilve, D., Veyrat-Durebex, C., Morgan, D. A., Varela, L., Haynes, W. G., Patterson, J. T., Disse, E., Pfluger, P. T., Lopez, M., Woods, S. C., Dimarchi, R., Dieguez, C., Rahmouni, K., Rohner-Jeanrenaud, F., &

Tschoep, M. H. (2009). Direct Control Of Peripheral Lipid Deposition By Cns Glp-1 Receptor Signaling Is Mediated By The Sympathetic Nervous System And Blunted In Diet-Induced Obesity. *Journal Of Neuroscience, 29*(18), 5916-5925.

Nomikos, G. G., Damsma, G., Wenkstern, D., & Fibiger, H. C. (1992). Effects Of Chronic Bupropion On Interstitial Concentrations Of Dopamine In Rat Nucleus-Accumbens And Striatum. *NEUROPSYCHOPHARMACOLOGY, 7*(1), 7-14.

Nonogaki, K., Abdallah, L., Goulding, E. H., Bonasera, S. J., & Tecott, L. H. (2003). Hyperactivity And Reduced Energy Cost Of Physical Activity In Serotonin 5-Ht2c Receptor Mutant Mice. *Diabetes, 52*(2), 315-320.

Nonogaki, K., Strack, A. M., Dallman, M. F., & Tecott, L. H. (1998). Leptin-Independent Hyperphagia And Type 2 Diabetes In Mice With A Mutated Serotonin 5-Ht2c Receptor Gene. *Nature Medicine, 4*(10), 1152-1156.

Norrelund, H., Hansen, T. K., Orskov, H., Hosoda, H., Kojima, M., Kangawa, K., Weeke, J., Moller, N., Christiansen, J. S., & Jorgensen, J. O. L. (2002). Ghrelin Immunoreactivity In Human Plasma Is Suppressed By Somatostatin. *Clinical Endocrinology, 57*(4), 539-546.

O'malley, S. S., Krishnan-Sarin, S., Farren, C., Sinha, R., & Kreek, M. J. (2002). Naltrexone Decreases Craving And Alcohol Self-Administration In Alcohol-Dependent Subjects And Activates The Hypothalamo-Pituitary-Adrenocortical Axis. *Psychopharmacology, 160*(1), 19-29.

O'neil, P. M., Smith, S. R., Weissman, N. J., Fidler, M. C., Sanchez, M., Zhang, J., Raether, B., Anderson, C. M., & Shanahan, W. R. (2012). Randomized Placebo-Controlled Clinical Trial Of Lorcaserin For Weight Loss In Type 2 Diabetes Mellitus: The Bloom-Dm Study. *Obesity, 20*(7), 1426-1436.

Ohki-Hamazaki, H., Iwabuchi, M., & Maekawa, F. (2005). Development And Function Of Bombesin-Like Peptides And Their Receptors. *International Journal Of Developmental Biology, 49*(2-3), 293-300.

Ohtaki, T., Kumano, S., Ishibashi, Y., Ogi, K., Matsui, H., Harada, M., Kitada, C., Kurokawa, T., Onda, H., & Fujino, M. (1999). Isolation And Cdna Cloning Of A Novel Galanin-Like Peptide (Galp) From Porcine Hypothalamus. *Journal Of Biological Chemistry, 274*(52), 37041-37045.

Okumura, T., Fukagawa, K., Tso, P., Taylor, I. L., & Pappas, T. N. (1996). Apolipoprotein A-Iv Acts In The Brain To Inhibit Gastric Emptying In The Rat. *American Journal Of Physiology-Gastrointestinal And Liver Physiology, 270*(1), G49-G53.

Okumura, T., Pappas, T. N., & Taylor, I. L. (1994). Intracisternal Injection Of Pancreatic Polypeptide Stimulates Gastric Emptying In Rats. *Neuroscience Letters, 178*(1), 167-170.

Ollmann, M. M., Lamoreux, M. L., Wilson, B. D., & Barsh, G. S. (1998). Interaction Of Agouti Protein With The Melanocortin 1 Receptor In Vitro And In Vivo. *Genes & Development, 12*(3), 316-330.

Ollmann, M. M., Wilson, B. D., Yang, Y.-K., Kerns, J. A., Chen, Y., Gantz, I., & Barsh, G. S. (1997). Antagonism Of Central Melanocortin Receptors In Vitro And In Vivo By Agouti-Related Protein. *Science, 278*(5335), 135-138.

Olszewski, P. K., Klockars, A., Olszewska, A. M., Fredriksson, R., Schioth, H. B., & Levine, A. S. (2010). Molecular, Immunohistochemical, And Pharmacological Evidence Of Oxytocin's Role As Inhibitor Of Carbohydrate But Not Fat Intake. *Endocrinology, 151*(10), 4736-4744.

Olszewski, P. K., & Levine, A. S. (2007). Central Opioids And Consumption Of Sweet Tastants: When Reward Outweighs Homeostasis. *Physiology & Behavior, 91*(5), 506-512.

Omalley, S. S., Jaffe, A. J., Chang, G., Schottenfeld, R. S., Meyer, R. E., & Rounsaville, B. (1992). Naltrexone And Coping Skills Therapy For Alcohol

Dependence - A Controlled-Study. *Archives Of General Psychiatry, 49*(11), 881-887.

Onaivi, E. S., Green, M. R., & Martin, B. R. (1990). Pharmacological Characterization Of Cannabinoids In The Elevated Plus Maze. *Journal Of Pharmacology And Experimental Therapeutics, 253*(3), 1002-1009.

Orexigen Theapreutics, P. (2009). Orexigen(R) Therapeutics Phase 2b Trial For Empatic(Tm) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators In Obese Patients. Retrieved 11th September 2013, 2013, From Http://Ir.Orexigen.Com/Phoenix.Zhtml?C=207034&P=Irol-Newsarticle&Id=1336796

Orexigen Theapreutics, P. (2010). Contrave (Naltrexone Sr/Bupropion Sr Combination) Advisory Committee Briefing Document. Retrieved 11th September 2013, 2013, From Http://Www.Fda.Gov/Downloads/Advisorycommittees/Committeesmeetingmaterials/Drugs/Endocrinologicandmetabolicdrugsadvisorycommittee/UCM235672.Pdf+Contrave&Client=Fdagov&Site=Fdagov&Lr=&Proxystylesheet=Fdagov&Output=Xml_No_Dtd&Ie=UTF-8&Access=P&Oe=UTF-8

Orexigen Theapreutics, P. (2011). Orexigen And Fda Identify A Clear And Feasible Path To Approval For Contrave®. Retrieved 11th September 2013, 2013, From Http://Ir.Orexigen.Com/Phoenix.Zhtml?C=207034&P=Irol-Newsarticle&Id=1608571

Orskov, C., Rabenhoj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994). Tissue And Plasma-Concentrations Of Amidated And Glycine-Extended Glucagon-Like Peptide-I In Humans. *Diabetes, 43*(4), 535-539.

Ortiz, A. A., Milardo, L. F., Decarr, L. B., Buckholz, T. M., Mays, M. R., Claus, T. H., Livingston, J. N., Mahle, C. D., & Lumb, K. J. (2007). A Novel Long-Acting Selective Neuropeptide Y2 Receptor Polyethylene Glycol-Conjugated Peptide Agonist Reduces Food Intake And Body Weight And Improves Glucose Metabolism In Rodents. *Journal Of Pharmacology And Experimental Therapeutics, 323*(2), 692-700.

Ortmann, R. (1985). The Conditioned Place Preference Paradigm In Rats - Effect Of Bupropion. *Life Sciences, 37*(21), 2021-2027.

Osaka, T., Tsukamoto, A., Koyama, Y., & Inoue, S. (2008). Central And Peripheral Administration Of Amylin Induces Energy Expenditure In Anesthetized Rats. *Peptides, 29*(6), 1028-1035.

Osei-Hyiaman, D., Depetrillo, M., Pacher, P., Liu, J., Radaeva, S., Batkai, S., Harvey-White, J., Mackie, K., Offertaler, L., Wang, L., & Kunos, G. (2005). Endocannabinoid Activation At Hepatic Cb1 Receptors Stimulates Fatty Acid Synthesis And Contributes To Diet-Induced Obesity. *Journal Of Clinical Investigation, 115*(5), 1298-1305.

Oshea, D., Morgan, D. G. A., Meeran, K., Edwards, C. M. B., Turton, M. D., Choi, S. J., Heath, M. M., Gunn, I., Taylor, G. M., Howard, J. K., Bloom, C. I., Small, C. J., Haddo, O., Ma, J. J., Callinan, W., Smith, D. M., Ghatei, M. A., & Bloom, S. R. (1997). Neuropeptide Y Induced Feeding In The Rat Is Mediated By A Novel Receptor. *Endocrinology, 138*(1), 196-202.

Ostrowski, N. L., Rowland, N., Foley, T. L., Nelson, J. L., & Reid, L. D. (1981). Morphine Antagonists And Consummatory Behaviors. *Pharmacology Biochemistry And Behavior, 14*(4), 549-559.

Owens, M. J., & Nemeroff, C. B. (1991). Physiology And Pharmacology Of Corticotropin-Releasing Factor. *Pharmacological Reviews, 43*(4), 425-473.

Owyang, C. (1996). Physiological Mechanisms Of Cholecystokinin Action On Pancreatic Secretion. *American Journal Of Physiology-Gastrointestinal And Liver Physiology, 271*(1), G1-G7.

Padwal, R. (2009). Contrave, A Bupropion And Naltrexone Combination Therapy For The Potential Treatment Of Obesity. *Current Opinion In Invesigational Drugs, 10*, 1117-1125.

Padwal, R., Li, S. K., & Lau, D. C. W. (2003). Long-Term Pharmacotherapy For Overweight And Obesity: A Systematic Review And Meta-Analysis Of Randomized Controlled Trials. *International Journal Of Obesity, 27*(12), 1437-1446.

Pagano, C., Rossato, M., & Vettor, R. (2008). Endocannabinoids, Adipose Tissue And Lipid Metabolism. *Journal Of Neuroendocrinology, 20*, 124-129.

Pang, Z. P., & Han, W. (2012). Regulation Of Synaptic Functions In Central Nervous System By Endocrine Hormones And The Maintenance Of Energy Homoeostasis. *Bioscience Reports, 32*(5), 423-432.

Papakostas, G. I., Fava, M., & Thase, M. E. (2008). Treatment Of Ssri-Resistant Depression: A Meta-Analysis Comparing Within-Versus Across-Class Switches. *Biological Psychiatry, 63*(7), 699-704.

Parenti, M., Tirone, F., Olgiati, V. R., & Groppetti, A. (1983). Presence Of Opiate Receptors On Striatal Serotoninergic Nerve-Terminals. *Brain Research, 280*(2), 317-322.

Park, M., Lin, L., Thomas, S., Braymer, H. D., Smith, P. M., Harrison, D. H. T., & York, D. A. (2004). The F-1-Atpase Beta-Subunit Is The Putative Enterostatin Receptor. *Peptides, 25*(12), 2127-2133.

Park, S., Peng, X. D., Frohman, L. A., & Kineman, R. D. (2005). Expression Analysis Of Hypothalamic And Pituitary Components Of The Growth Hormone Axis In Fasted And Streptozotocin-Treated Neuropeptide Y (Npy)-Intact (Npy+/+) And Npy-Knockout (Npy-/-) Mice. *Neuroendocrinology, 81*(6), 360-371.

Parker, H. E., Reimann, F., & Gribble, F. M. (2010). Molecular Mechanisms Underlying Nutrient-Stimulated Incretin Secretion. *Expert Reviews In Molecular Medicine, 12*.

Parker, J. A., & Bloom, S. R. (2012). Hypothalamic Neuropeptides And The Regulation Of Appetite. *Neuropharmacology, 63*(1), 18-30.

Parkes, D., Jodka, C., Smith, P., Nayak, S., Rinehart, L., Gingerich, R., Chen, K., & Young, A. (2001). Pharmacokinetic Actions Of Exendin-4 In The Rat: Comparison With Glucagon-Like Peptide-1. *Drug Development Research, 53*(4), 260-267.

Parkes, D. G., Pittner, R., Jodka, C., Smith, P., & Young, A. (2001). Insulinotropic Actions Of Exendin-4 And Glucagon-Like Peptide-1 In Vivo And In Vitro. *Metabolism-Clinical And Experimental, 50*(5), 583-589.

Parkinson, J. R. C., Chaudhri, O. B., Kuo, Y.-T., Field, B. C. T., Herlihy, A. H., Dhillo, W. S., Ghatei, M. A., Bloom, S. R., & Bell, J. D. (2009). Differential Patterns Of Neuronal Activation In The Brainstem And Hypothalamus Following Peripheral Injection Of Glp-1, Oxyntomodulin And Lithium Chloride In Mice Detected By Manganese-Enhanced Magnetic Resonance Imaging (Memri). *Neuroimage, 44*(3), 1022-1031.

Parkinson, J. R. C., Dhillo, W. S., Small, C. J., Chaudhri, O. B., Bewick, G. A., Pritchard, I., Moore, S., Ghatei, M. A., & Bloom, S. R. (2008). Pyy3-36 Injection In Mice Produces An Acute Anorexigenic Effect Followed By A Delayed Orexigenic Effect Not Observed With Other Anorexigenic Gut Hormones. *American Journal Of Physiology-Endocrinology And Metabolism, 294*(4), E698-E708.

Parks, C. L., Robinson, P. S., Sibille, E., Shenk, T., & Toth, M. (1998). Increased Anxiety Of Mice Lacking The Serotonin(1a) Receptor. *Proceedings Of The National Academy Of Sciences Of The United States Of America, 95*(18), 10734-10739.

Passarelli, F., & Costa, T. (1989). Mu-Opioid And Delta-Opioid Receptors Inhibit Serotonin Release In Rat Hippocampus. *Journal Of Pharmacology And Experimental Therapeutics, 248*(1), 299-305.

Patel, S., & Hillard, C. J. (2006). Pharmacological Evaluation Of Cannabinoid Receptor Ligands In A Mouse Model Of Anxiety: Further Evidence For An Anxiolytic Role For Endogenous Cannabinoid Signaling. *Journal Of Pharmacology And Experimental Therapeutics, 318*(1), 304-311.

Patel, Y. C. (1999). Somatostatin And Its Receptor Family. *Frontiers In Neuroendocrinology, 20*(3), 157-198.

Paterson, N. E., Fedolak, A., Olivier, B., Hanania, T., Ghavami, A., & Caldarone, B. (2010). Psychostimulant-Like Discriminative Stimulus And Locomotor Sensitization Properties Of The Wake-Promoting Agent Modafinil In Rodents. *Pharmacology Biochemistry And Behavior, 95*(4), 449-456.

Paulik, M., Hamilton, B., Hommel, J., Holt, L., Herring, C., Stroup, A. E., Mebrahtu, M., Elangbam, C., Danger, D., Way, J. M., Weng, S., Roller, S., Al-Barazanji, K., Becherer, D., Jespers, L., & Feldman, P. (2011). A Combination Of A Long-Acting Pyy And Exendin-4 Causes Synergistic Weight Loss, Glucose Lowering And Normalization Of Metabolic Parameters In Obese And Diabetic Mice. *Obesity, 19*, S156-S156.

Pavon, F. J., Bilbao, A., Hernandez-Folgado, L., Cippitelli, A., Jagerovic, N., Abellan, G., Rodriguez-Franco, M. I., Serrano, A., Macias, M., Gomez, R., Navarro, M., Goya, P., & De Fonseca, F. R. (2006). Antiobesity Effects Of The Novel In Vivo Neutral Cannabinoid Receptor Antagonist 5-(4-Chlorophenyl)-1-(2,4-Dichlorophenyl)-3-Hexyl-1h-1,2,4-Triazole-Lh 21. *Neuropharmacology, 51*(2), 358-366.

Pederson, R. A., Schubert, H. E., & Brown, J. C. (1975). Gastric Inhibitory Polypeptide - Physiologic Release And Insulinotropic Action In Dog. *Diabetes, 24*(12), 1050-1056.

Peier, A., Kosinski, J., Cox-York, K., Qian, Y., Desai, K., Feng, Y., Trivedi, P., Hastings, N., & Marsh, D. J. (2009). The Antiobesity Effects Of Centrally Administered Neuromedin U And Neuromedin S Are Mediated Predominantly By The Neuromedin U Receptor 2 (Nmur2). *Endocrinology, 150*(7), 3101-3109.

Peier, A. M., Desai, K., Hubert, J., Du, X., Yang, L., Qian, Y., Kosinski, J. R., Metzger, J. M., Pocai, A., Nawrocki, A. R., Langdon, R. B., & Marsh, D. J. (2011). Effects Of Peripherally Administered Neuromedin U On Energy And Glucose Homeostasis. *Endocrinology, 152*(7), 2644-2654.

Pelletier, G., & Simard, J. (1991). Dopaminergic Regulation Of Pre-Pronpy Messenger-Rna Levels In The Rat Arcuate Nucleus. *Neuroscience Letters, 127*(1), 96-98.

Pennock, R. L., & Hentges, S. T. (2011). Differential Expression And Sensitivity Of Presynaptic And Postsynaptic Opioid Receptors Regulating Hypothalamic Proopiomelanocortin Neurons. *Journal Of Neuroscience, 31*(1), 281-288.

Perez-Tilve, D., Gonzalez-Matias, L., Alvarez-Crespo, M., Leiras, R., Tovar, S., Dieguez, C., & Mallo, F. (2007). Exendin-4 Potently Decreases Ghrelin Levels In Fasting Rats. *Diabetes, 56*(1), 143-151.

Perrine, S. A., Hoshaw, B. A., & Unterwald, E. M. (2006). Delta Opioid Receptor Ligands Modulate Anxiety-Like Behaviors In The Rat. *British Journal Of Pharmacology, 147*(8), 864-872.

Pertwee, R. G. (2005). Inverse Agonism And Neutral Antagonism At Cannabinoid Cbi Receptors. *Life Sciences, 76*(12), 1307-1324.

Pertwee, R. G. (2009). Emerging Strategies For Exploiting Cannabinoid Receptor Agonists As Medicines. *British Journal Of Pharmacology, 156*(3), 397-411.

Peters, A. (2010). Incretin-Based Therapies: Review Of Current Clinical Trial Data. *American Journal Of Medicine, 123*, S28-S37.

Phan, N. Q., Bernhard, J. D., Luger, T. A., & Ständer, S. (2010). Antipruritic Treatment With Systemic M-Opioid Receptor Antagonists: A Review. *Journal Of The American Academy Of Dermatology, 63*(4), 680-688.

Pi-Sunyer, F., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & Grp, R.-N. A. S. (2006). Effect Of Rimonabant, A Cannabinoid-1 Receptor Blocker, On Weight And Cardiometabolic Risk Factors In Overweight Or Obese Patients - Rio-North America: A Randomized Controlled Trial. *Jama-Journal Of The American Medical Association, 295*(7), 761-775.

Pickel, V. M., Chan, J., Kash, T. L., Rodriguez, J. J., & Mackie, K. (2004). Compartment-Specific Localization Of Cannabinoid 1 (Cb1) And Mu-Opioid Receptors In Rat Nucleus Accumbens. *Neuroscience, 127*(1), 101-112.

Pietras, T. A., & Rowland, N. E. (2002). Effect Of Opioid And Cannabinoid Receptor Antagonism On Orphanin Fq-Induced Hyperphagia In Rats. *European Journal Of Pharmacology, 442*(3), 237-239.

Pijl, H., Koppeschaar, H. P. F., Willekens, F. L. A., Dekamp, I. O., Veldhuis, H. D., & Meinders, A. E. (1991). Effect Of Serotonin Reuptake Inhibition By Fluoxetine On Body-Weight And Spontaneous Food Choice In Obesity. *International Journal Of Obesity, 15*(3), 237-242.

Pinder, R. M., Brogden, R. N., Sawyer, P. R., Speight, T. M., & Avery, G. S. (1975). Fenfluramine - Review Of Its Pharmacological Properties And Therapeutic Efficacy In Obesity. *Drugs, 10*(4), 241-323.

Pinelli, N. R., & Hurren, K. M. (2011). Efficacy And Safety Of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared With Exenatide Twice Daily And Sitagliptin In Type 2 Diabetes Mellitus: A Systematic Review And Meta-Analysis. *Annals Of Pharmacotherapy, 45*(7-8), 850-860.

Piomelli, D. (2003). The Molecular Logic Of Endocannabinoid Signalling. *Nature Reviews Neuroscience, 4*(11), 873-884.

Pisunyer, X., Kissileff, H. R., Thornton, J., & Smith, G. P. (1982). C-Terminal Octapeptide Of Cholecystokinin Decreases Food-Intake In Obese Men. *Physiology & Behavior, 29*(4), 627-630.

Pittner, R. A., Albrandt, K., Beaumont, K., Gaeta, L. S. L., Koda, J. E., Moore, C. X., Rittenhouse, J., & Rink, T. J. (1994). Molecular Physiology Of Amylin. *Journal Of Cellular Biochemistry, 55*, 19-28.

Plamondon, H., & Merali, Z. (1994). Push-Pull Perfusion Reveals Meal-Dependent Changes In The Release Of Bombesin-Like Peptides In The Rat Paraventricular Nucleus. *Brain Research, 668*(1-2), 54-61.

Plodkowski, R. A., Nguyen, Q., Sundaram, U., Nguyen, L., Chau, D. L., & Jeor, S. S. (2009). Bupropion And Naltrexone: A Review Of Their Use Individually And In Combination For The Treatment Of Obesity. *Expert Opinion On Pharmacotherapy, 10*(6), 1069-1081.

Pocai, A. (2012). Unraveling Oxyntomodulin, Glp1's Enigmatic Brother. *Journal Of Endocrinology, 215*(3), 335-346.

Poindexter, G. S., Bruce, M. A., Leboulluec, K. L., Monkovic, I., Martin, S. W., Parker, E. M., Iben, L. G., Mcgovern, R. T., Ortiz, A. A., Stanley, J. A., Mattson, G. K., Kozlowski, M., Arcuri, M., & Antal-Zimanyi, I. (2002). Dihydropyridine Neuropeptide Yy1 Receptor Antagonists. *Bioorganic & Medicinal Chemistry Letters, 12*(3), 379-382.

Poirier, B., Bidouard, J. P., Cadrouvele, C., Marniquet, X., Staels, B., O'connor, S. E., Janiak, P., & Herbert, J. M. (2005). The Anti-Obesity Effect Of Rimonabant Is Associated With An Improved Serum Lipid Profile. *Diabetes Obesity & Metabolism, 7*(1), 65-72.

Pollock, J. D., & Rowland, N. (1981). Peripherally Administered Serotonin Decreases Food-Intake In Rats. *Pharmacology Biochemistry And Behavior, 15*(2), 179-183.

Polonsky, K. S., Given, B. D., & Van Cauter, E. (1988). Twenty-Four-Hour Profiles And Pulsatile Patterns Of Insulin Secretion In Normal And Obese Subjects. *The Journal Of Clinical Investigation, 81*(2), 442-448.

Poncelet, M., Maruani, J., Calassi, R., & Soubrie, P. (2003). Overeating, Alcohol And Sucrose Consumption Decrease In Cb1 Receptor Deleted Mice. *Neuroscience Letters, 343*(3), 216-218.

Pories, W. (2011). Bariatric Surgery For Severe Obesity. U.S. Department Of Health And Human Services.

Pories, W. J., Swanson, M. S., Macdonald, K. G., Long, S. B., Morris, P. G., Brown, B. M., Barakat, H. A., Deramon, R. A., Israel, G., Dolezal, J. M., & Dohm, L. (1995). Who Would Have Thought It - An Operation Proves To Be The Most Effective Therapy For Adult-Onset Diabetes-Mellitus. *Annals Of Surgery, 222*(3), 339-352.

Porsolt, R. D., Bertin, A., & Jalfre, M. (1978). Behavioral Despair In Rats And Mice - Strain Differences And Effects Of Imipramine. *European Journal Of Pharmacology, 51*(3), 291-294.

Porter, R. A., Chan, W. N., Coulton, S., Johns, A., Hadley, M. S., Widdowson, K., Jerman, J. C., Brough, S. J., Coldwell, M., Smart, D., Jewitt, F., Jeffrey, P., & Austin, N. (2001). 1,3-Biarylureas As Selective Non-Peptide Antagonists Of The Orexin-1 Receptor. *Bioorganic & Medicinal Chemistry Letters, 11*(14), 1907-1910.

Potes, C. S., Turek, V. F., Cole, R. L., Vu, C., Roland, B. L., Roth, J. D., Riediger, T., & Lutz, T. A. (2010). Noradrenergic Neurons Of The Area Postrema Mediate Amylin's Hypophagic Action. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 299*(2), R623-R631.

Powell, A. G., Apovian, C. M., & Aronne, L. J. (2011). New Drug Targets For The Treatment Of Obesity. *Clinical Pharmacology & Therapeutics, 90*(1), 40-51.

Powley, T. L., & Plocher, T. A. (1980). Hypophysectomy Blocks The Weight-Gain And Obesity Produced By Goldthioglucose Lesions. *Behavioral And Neural Biology, 28*(3), 300-318.

Pratley, R. E., & Gilbert, M. (2008). Targeting Incretins In Type 2 Diabetes: Role Of Glp-1 Receptor Agonists And Dpp-4 Inhibitors. *The Review Of Diabetic Studies : RDS, 5*(2), 73-94.

Pratley, R. E., Jauffret-Kamel, S., Galbreath, E., & Holmes, D. (2006). Twelve-Week Monotherapy With The Dpp-4 Inhibitor Vildagliptin Improves Glycemic Control In Subjects With Type 2 Diabetes. *Hormone And Metabolic Research, 38*(6), 423-428.

Price, C. J., Samson, W. K., & Ferguson, A. V. (2008). Neuropeptide W Influences The Excitability Of Neurons In The Rat Hypothalamic Arcuate Nucleus. *Neuroendocrinology, 88*(2), 88-94.

Pringle, A., Jennings, K., Line, S., Bannerman, D., Higgs, S., & Sharp, T. (2008). Mice Overexpressing The 5-Hydroxytryptamine Transporter Show No Alterations In Feeding Behaviour And Increased Non-Feeding Responses To Fenfluramine. *Psychopharmacology, 200*(2), 291.

Pritchett, C. E., & Hajnal, A. (2012). Glucagon-Like Peptide-1 Regulation Of Carbohydrate Intake Is Differentially Affected By Obesogenic Diets. *Obesity, 20*(2), 313-317.

Proietto, J., Rissanen, A., Harp, J. B., Erondu, N., Yu, Q., Suryawanshi, S., Jones, M. E., Johnson-Levonas, A. O., Heymsfield, S. B., Kaufman, K. D., & Amatruda, J. M. (2010). A Clinical Trial Assessing The Safety And Efficacy Of The Cb1r Inverse Agonist Taranabant In Obese And Overweight Patients: Low-Dose Study. *International Journal Of Obesity, 34*(8), 1243-1254.

Prolor. (2011). Prolor Biotech Reports Positive Preclinical Results In Weight Loss Study Of Its Long-Acting Anti-Obesity Drug Candidate. Retrieved 6th September 2013, 2013, From Http://Www.Prnewswire.Com/News-

Releases/Prolor-Biotech-Reports-Positive-Preclinical-Results-In-Weight-Loss-Study-Of-Its-Long-Acting-Anti-Obesity-Drug-Candidate-123214973.Html

Qin, J., Feng, M., Wang, C., Ye, Y., Wang, P. S., & Liu, C. (2009). Oxytocin Receptor Expressed On The Smooth Muscle Mediates The Excitatory Effect Of Oxytocin On Gastric Motility In Rats. *Neurogastroenterology And Motility, 21*(4), 430-438.

Qu, D. Q., Ludwig, D. S., Gammeltoft, S., Piper, M., Pelleymounter, M. A., Cullen, M. J., Mathes, W. F., Przypek, J., Kanarek, R., & Maratosflier, E. (1996). A Role For Melanin-Concentrating Hormone In The Central Regulation Of Feeding Behaviour. *Nature, 380*(6571), 243-247.

Ramboz, S., Oosting, R., Amara, D. A., Kung, H. F., Blier, P., Mendelsohn, M., Mann, J. J., Brunner, D., & Hen, R. (1998). Serotonin Receptor 1a Knockout: An Animal Model Of Anxiety-Related Disorder. *Proceedings Of The National Academy Of Sciences Of The United States Of America, 95*(24), 14476-14481.

Ramnanan, C. J., Edgerton, D. S., Rivera, N., Irimia-Dominguez, J., Farmer, B., Neal, D. W., Lautz, M., Donahue, E. P., Meyer, C. M., Roach, P. J., & Cherrington, A. D. (2010). Molecular Characterization Of Insulin-Mediated Suppression Of Hepatic Glucose Production In Vivo. *Diabetes, 59*(6), 1302-1311.

Ramos-Alvarez, I., Martin-Duce, A., Moreno-Villegas, Z., Sanz, R., Aparicio, C., Portal-Nunez, S., Mantey, S. A., Jensen, R. T., & Gonzalez, N. (2013). Bombesin Receptor Subtype-3 (Brs-3), A Novel Candidate As Therapeutic Molecular Target In Obesity And Diabetes. *Molecular And Cellular Endocrinology, 367*(1-2), 109-115.

Ramos, E. J. B., Meguid, M. M., Campos, A. C. L., & Coelho, J. C. U. (2005). Neuropeptide Y, [Alpha]-Melanocyte-Stimulating Hormone, And Monoamines In Food Intake Regulation. *Nutrition, 21*(2), 269-279.

Randall, P. A., Vemuri, V. K., Segovia, K. N., Torres, E. F., Hosmer, S., Nunes, E. J., Santerre, J. L., Makriyannis, A., & Salamone, J. D. (2010). The Novel Cannabinoid Cb1 Antagonist Am6545 Suppresses Food Intake And Food-Reinforced Behavior. *Pharmacology Biochemistry And Behavior, 97*(1), 179-184.

Ranganath, L. R., Beety, J. M., Morgan, L. M., Wright, J. W., Howland, R., & Marks, V. (1996). Attenuated Glp-1 Secretion In Obesity: Cause Or Consequence? *Gut, 38*(6), 916-919.

Raposinho, P. D., Castillo, E., D'alleves, V., Broqua, P., Pralong, F. P., & Aubert, M. L. (2000). Chronic Blockade Of The Melanocortin 4 Receptor Subtype Leads To Obesity Independently Of Neuropeptide Y Action, With No Adverse Effects On The Gonadotropic And Somatotropic Axes. *Endocrinology, 141*(12), 4419-4427.

Rapport, M. M., Green, A. A., & Page, I. H. (1948). Serum Vasoconstrictor (Serotonin) .4. Isolation And Characterization. *Journal Of Biological Chemistry, 176*(3), 1243-1251.

Rasmussen, E. B., & Huskinson, S. L. (2008). Effects Of Rimonabant On Behavior Maintained By Progressive Ratio Schedules Of Sucrose Reinforcement In Obese Zucker (Fa/Fa) Rats. *Behavioural Pharmacology, 19*(7), 735-742.

Ratner, R. E., Maggs, D., Nielsen, L. L., Stonehouse, A. H., Poon, T., Zhang, B., Bicsak, T. A., Brodows, R. G., & Kim, D. D. (2006). Long-Term Effects Of Exenatide Therapy Over 82 Weeks On Glycaemic Control And Weight In Over-Weight Metformin-Treated Patients With Type 2 Diabetes Mellitus. *Diabetes Obesity & Metabolism, 8*(4), 419-428.

Rauhut, A. S., Neugebauer, N., Dwoskin, L. P., & Bardo, M. T. (2003). Effect Of Bupropion On Nicotine Self-Administration In Rats. *Psychopharmacology, 169*(1), 1-9.

Raun, K., Von Voss, P., Gotfredsen, C. F., Golozoubova, V., Rolin, B., & Knudsen, L. B. (2007). Liraglutide, A Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight And Food Intake In Obese Candy-Fed Rats, Whereas A Dipeptidyl Peptidase-Iv Inhibitor, Vildagliptin, Does Not. *Diabetes, 56*(1), 8-15.

Raun, K., Von Voss, P., & Knudsen, L. B. (2007). Liraglutide, A Once-Daily Human Glucagon-Like Peptide-1 Analog, Minimizes Food Intake In Severely Obese Minipigs. *Obesity, 15*(7), 1710-1716.

Ravinet Trillou, C., Arnone, M., Delgorge, C., Gonalons, N., Keane, P., Maffrand, J.-P., & Soubrie, P. (2003). Anti-Obesity Effect Of Sr141716, A Cb1 Receptor Antagonist, In Diet-Induced Obese Mice. *American Journal Of Physiology. Regulatory, Integrative And Comparative Physiology, 284*(2), R345-353.

Ravinet Trillou, C., Delgorge, C., Menet, C., Arnone, M., & Soubrie, P. (2004). Cb1 Cannabinoid Receptor Knockout In Mice Leads To Leanness, Resistance To Diet-Induced Obesity And Enhanced Leptin Sensitivity. *International Journal Of Obesity And Related Metabolic Disorders : Journal Of The International Association For The Study Of Obesity, 28*(4), 640-648.

Ravussin, E., Smith, S. R., Mitchell, J. A., Shringarpure, R., Shan, K., Maier, H., Koda, J. E., & Weyer, C. (2009). Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach To Obesity Pharmacotherapy. *Obesity, 17*(9), 1736-1743.

Raynor, K., Kong, H. Y., Chen, Y., Yasuda, K., Yu, L., Bell, G. I., & Reisine, T. (1994). Pharmacological Characterization Of The Cloned Kappa-Opioid, Delta-Opioid, And Mu-Opioid Receptors. *Molecular Pharmacology, 45*(2), 330-334.

Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study, G. (2006). Efficacy And Safety Of The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin As Monotherapy In Patients With Type 2 Diabetes Mellitus. *Diabetologia, 49*(11), 2564-2571.

Reda, T. K., Geliebter, A., & Pi-Sunyer, F. X. (2002). Amylin, Food Intake, And Obesity. *Obesity Research, 10*(10), 1087-1091.

Redolat, R., Gomez, M. C., Vicens, P., & Carrasco, M. C. (2005). Bupropion Effects On Aggressiveness And Anxiety In Of1 Male Mice. *Psychopharmacology, 177*(4), 418-427.

Redolat, R., Vidal, J., Gomez, M. C., & Carrasco, M. C. (2005). Effects Of Acute Bupropion Administration On Locomotor Activity In Adolescent And Adult Mice. *Behavioural Pharmacology, 16*(1), 59-62.

Reidelberger, R., Haver, A., Apenteng, B., Anders, K., & Steenson, S. (2011a). Effects Of Leptin Replacement Alone And With Exendin-4 On Food Intake And Body Weight In Weight-Reduced Diet-Induced Obese Rats. *Obesity, 19*, S178-S178.

Reidelberger, R. D., Haver, A. C., Apenteng, B. A., Anders, K. L., & Steenson, S. M. (2011b). Effects Of Exendin-4 Alone And With Peptide Yy3-36 On Food Intake And Body Weight In Diet-Induced Obese Rats. *Obesity, 19*(1), 121-127.

Reidelberger, R. D., Haver, A. C., Arnelo, U., Smith, D. D., Schaffert, C. S., & Permert, J. (2004). Amylin Receptor Blockade Stimulates Food Intake In Rats. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 287*(3), R568-R574.

Reilly, J. J., & Kelly, J. (2011). Long-Term Impact Of Overweight And Obesity In Childhood And Adolescence On Morbidity And Premature Mortality In Adulthood: Systematic Review. *International Journal Of Obesity, 35*(7), 891-898.

Reinehr, T., Enriori, P. J., Harz, K., Cowley, M. A., & Roth, C. L. (2006). Pancreatic Polypeptide In Obese Children Before And After Weight Loss. *International Journal Of Obesity, 30*(10), 1476-1481.

Remaury, A., Vita, N., Gendreau, S., Jung, M., Arnone, M., Poncelet, M., Culouscou, J. M., Le Fur, G., Soubrie, P., Caput, D., Shire, D., Kopf, M., & Ferrara, P. (2002). Targeted Inactivation Of The Neurotensin Type 1 Receptor Reveals Its Role In Body Temperature Control And Feeding Behavior But Not In Analgesia. *Brain Research, 953*(1-2), 63-72.

Rezvani, A. H., Overstreet, D. H., Mason, G. A., Janowsky, D. S., Hamedi, M., Clark, E., & Yang, Y. (2000). Combination Pharmacotherapy: A Mixture Of Small Doses Of Naltrexone, Fluoxetine, And A Thyrotropin-Releasing Hormone Analogue Reduces Alcohol Intake In Three Strains Of Alcohol-Preferring Rats. *Alcohol And Alcoholism, 35*(1), 76-83.

Rhythm. (2011). Rm-493: Mc4r Peptide Therapeutic

A New Drug Class For The Treatment Of Obesity And Diabetes. Retrieved 16th August, 2013

Richardson, J. D., Aanonsen, L., & Hargreaves, K. M. (1997). Sr 141716a, A Cannabinoid Receptor Antagonist, Produces Hyperalgesia In Untreated Mice. *European Journal Of Pharmacology, 319*(2-3), R3-R4.

Rickels, K., & Rynn, M. (2002). Pharmacotherapy Of Generalized Anxiety Disorder. *Journal Of Clinical Psychiatry, 63*, 9-16.

Riddle, M. C., Henry, R. R., Poon, T. H., Zhang, B., Mac, S. M., Holcombe, J. H., Kim, D. D., & Maggs, D. G. (2006). Exenatide Elicits Sustained Glycaemic Control And Progressive Reduction Of Body Weight In Patients With Type 2 Diabetes Inadequately Controlled By Sulphonylureas With Or Without Metformin. *Diabetes-Metabolism Research And Reviews, 22*(6), 483-491.

Rigotti, N. A., Thorndike, A. N., Durcan, M. J., White, J. D., Johnston, J. A., Niaura, R., Gonzales, D., Sachs, D. P. L., Hayes, J. T., & Hurt, R. D. (2000). Smokers Taking Bupropion Gain Less Weight After Smoking Cessation: A Gender-Related Effect. *Journal Of General Internal Medicine, 15*, 93-93.

Rinaldicarmona, M., Barth, F., Heaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D., Ferrara, P., Soubrie, P., Breliere, J. C., & Lefur, G. (1994). Sr141716a, A Potent And Selective Antagonist Of The Brain Cannabinoid Receptor. *FEBS Letters, 350*(2-3), 240-244.

Rinaman, L. (1999a). A Functional Role For Central Glucagon-Like Peptide-1 Receptors In Lithium Chloride-Induced Anorexia. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 277*(5), R1537-R1540.

Rinaman, L. (1999b). Interoceptive Stress Activates Glucagon-Like Peptide-1 Neurons That Project To The Hypothalamus. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 277*(2), R582-R590.

Rinaman, L. (2010). Ascending Projections From The Caudal Visceral Nucleus Of The Solitary Tract To Brain Regions Involved In Food Intake And Energy Expenditure. *Brain Research, 1350*, 18-34.

Rios, C., Gomes, I., & Devi, L. A. (2006). Mu Opioid And Cb1 Cannabinoid Receptor Interactions: Reciprocal Inhibition Of Receptor Signaling And Neuritogenesis. *British Journal Of Pharmacology, 148*(4), 387-395.

Rocca, A. S., & Brubaker, P. L. (1999). Role Of The Vagus Nerve In Mediating Proximal Nutrient-Induced Glucagon-Like Peptide-1 Secretion. *Endocrinology, 140*(4), 1687-1694.

Rodgers, R., Holch, P., & Tallett, A. (2010). Behavioural Satiety Sequence (Bss): Separating Wheat From Chaff In The Behavioural Pharmacology Of Appetite. *Pharmacology, Biochemistry And Behavior, 97*(1), 3-14.

Rodgers, R. J., Evans, P. M., & Murphy, A. (2005). Anxiogenic Profile Of Am-251, A Selective Cannabinoid Cb1 Receptor Antagonist, In Plus-Maze-Naive And Plus-Maze-Experienced Mice. *Behavioural Pharmacology, 16*(5-6), 405-413.

Rodgers, R. J., Halford, J. C. G., De Souza, R. L. N., De Souza, A. L. C., Piper, D. C., Arch, J. R. S., & Blundell, J. E. (2000). Dose-Response Effects Of Orexin-A On Food Intake And The Bahavioural Satiety Sequence In Rats. *Regulatory Peptides, 96*(1-2), 71-84.

Rodgers, R. J., Halford, J. C. G., De Souza, R. L. N., De Souza, A. L. C., Piper, D. C., Arch, J. R. S., Upton, N., Porter, R. A., Johns, A., & Blundell, J. E. (2001). Sb-334867, A Selective Orexin-1 Receptor Antagonist, Enhances Behavioural Satiety And Blocks The Hyperphagic Effect Of Orexin-A In Rats. *European Journal Of Neuroscience, 13*(7), 1444-1452.

Rodgers, R. J., Haller, J., Halasz, J., & Mikics, E. (2003). 'One-Trial Sensitization' To The Anxiolytic-Like Effects Of Cannabinoid Receptor Antagonist Sr141716a In The Mouse Elevated Plus-Maze. *European Journal Of Neuroscience, 17*(6), 1279-1286.

Rodgers, R. J., Ishii, Y., Halford, J. C. G., & Blundell, J. E. (2002). Orexins And Appetite Regulation. *Neuropeptides, 36*(5), 303-325.

Rodgers, R. J., Tschoep, M. H., & Wilding, J. P. H. (2012). Anti-Obesity Drugs: Past, Present And Future. *Disease Models & Mechanisms, 5*(5), 621-626.

Rodriguez De Fonseca, F., Carrera, M. R. A., Navarro, M., Koob, G. F., & Weiss, F. (1997). Activation Of Corticotropin-Releasing Factor In The Limbic System During Cannabinoid Withdrawal. *Science (Washington D C), 276*(5321), 2050-2054.

Rodriguez, J. J., Mackie, K., & Pickel, V. M. (2001). Ultrastructural Localization Of The Cb1 Cannabinoid Receptor In Mu-Opioid Receptor Patches Of The Rat Caudate Putamen Nucleus. *Journal Of Neuroscience, 21*(3), 823-833.

Rodriquez De Fonseca, F., Navarro, M., Alvarez, E., Roncero, I., Chowen, J. A., Maestre, O., Gomez, R., Munoz, R. M., Eng, J., & Blazquez, E. (2000). Peripheral Versus Central Effects Of Glucagon-Like Peptide-1 Receptor Agonists On Satiety And Body Weight Loss In Zucker Obese Rats. *Metabolism Clinical And Experimental, 49*(6), 709-717.

Rogers, P., Mckibbin, P. E., & Williams, G. (1991). Acute Fenfluramine Administration Reduces Neuropeptide-Y Concentrations In Specific Hypothalamic Regions Of The Rat - Possible Implications For The Anorectic Effect Of Fenfluramine. *Peptides, 12*(2), 251-255.

Rolls, B. J., Morris, E. L., & Roe, L. S. (2002). Portion Size Of Food Affects Energy Intake In Normal-Weight And Overweight Men And Women. *American Journal Of Clinical Nutrition, 76*(6), 1207-1213.

Rolls, B. J., Shide, D. J., Thorwart, M. L., & Ulbrecht, J. S. (1998). Sibutramine Reduces Food Intake In Non-Dieting Women With Obesity. *Obesity Research, 6*(1), 1-11.

Rosenstock, J., Hollander, P., Chevalier, S., Iranmanesh, A., & Grp, S. S. (2008). Serenade: The Study Evaluating Rimonabant Efficacy In Drug-Naive Diabetic Patients Effects Of Monotherapy With Rimonabant, The First Selective Cb1 Receptor Antagonist, On Glycemic Control, Body Weight, And Lipid Profile In Drug-Naive Type 2 Diabetes. *Diabetes Care, 31*(11), 2169-2176.

Rosenstock, J., Hollander, P., Gadde, K. M., Sun, X., Strauss, R., Leung, A., & Grp, O. B. D. S. (2007). A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess The Efficacy And Safety Of Topiramate Controlled Release In The Treatment Of Obese Type 2 Diabetic Patients. *Diabetes Care, 30*(6), 1480-1486.

Roses, A. D. (2009). Stimulation Of Cholecystokinin-A Receptors With Gl181771x: A Failed Clinical Trial That Did Not Test The Pharmacogenetic Hypothesis For Reduction Of Food Intake. *Clinical Pharmacology & Therapeutics, 85*(4), 362-365.

Rossner, S., Sjostrom, L., Noack, R., Meinders, A. E., Noseda, G., & European Orlistat Obesity Study, G. (2000). Weight Loss, Weight Maintenance, And

Improved Cardiovascular Risk Factors After 2 Years Treatment With Orlistat For Obesity. *Obesity Research, 8*(1), 49-61.

Roth, J. D., Coffey, T., Jodka, C. M., Maier, H., Athanacio, J. R., Mack, C. M., Weyer, C., & Parkes, D. G. (2007). Combination Therapy With Amylin And Peptide Yy 3-36 In Obese Rodents: Anorexigenic Synergy And Weight Loss Additivity. *Endocrinology, 148*(12), 6054-6061.

Roth, J. D., Erickson, M. R., Chen, S., & Parkes, D. G. (2012). Glp-1r And Amylin Agonism In Metabolic Disease: Complementary Mechanisms And Future Opportunities. *British Journal Of Pharmacology, 166*(1), 121-136.

Roth, J. D., Hughes, H., Kendall, E., Baron, A. D., & Anderson, C. M. (2006). Antiobesity Effects Of The Beta-Cell Hormone Amylin In Diet-Induced Obese Rats: Effects On Food Intake, Body Weight, Composition, Energy Expenditure, And Gene Expression. *Endocrinology, 147*(12), 5855-5864.

Roth, J. D., Roland, B. L., Cole, R. L., Trevaskis, J. L., Weyer, C., Koda, J. E., Anderson, C. M., Parkes, D. G., & Baron, A. D. (2008). Leptin Responsiveness Restored By Amylin Agonism In Diet-Induced Obesity: Evidence From Nonclinical And Clinical Studies. *Proceedings Of The National Academy Of Sciences Of The United States Of America, 105*(20), 7257-7262.

Roth, J. D., & Rowland, N. E. (1998). Efficacy Of Administration Of Dexfenfluramine And Phentermine, Alone And In Combination, On Ingestive Behavior And Body Weight In Rats. *Psychopharmacology, 137*(1), 99-106.

Roth, J. D., Trevaskis, J. L., Turek, V. F., & Parkes, D. G. (2010). "Weighing In" On Synergy: Preclinical Research On Neurohormonal Anti-Obesity Combinations. *Brain Research, 1350*, 86-94.

Roth, J. D., Trevaskis, J. L., Wilson, J., Lei, C., Athanacio, J., Mack, C., Kesty, N. C., Coffey, T., Weyer, C., & Parkes, D. G. (2008). Antiobesity Effects Of The Beta-Cell Hormone Amylin In Combination With Phentermine Or Sibutramine In Diet-Induced Obese Rats. *International Journal Of Obesity, 32*(8), 1201-1210.

Rowe, W., Viau, V., Meaney, M. J., & Quirion, R. (1995). Stimulation Of Crh-Mediated Acth-Secretion By Central Administration Of Neurotensin - Evidence For The Participation Of The Paraventricular Nucleus. *Journal Of Neuroendocrinology, 7*(2), 109-117.

Rowe, W. B., Nicot, A., Sharma, S., Gully, D., Walker, C. D., Rostene, W. H., Meaney, M. J., & Quirion, R. (1997). Central Administration Of The Neurotensin Receptor Antagonist, Sr48892, Modulates Diurnal And Stress-Related Hypothalamic-Pituitary-Adrenal Activity. *Neuroendocrinology, 66*(2), 75-85.

Rowland, N. E., & Carlton, J. (1986). Neurobiology Of An Anorectic Drug - Fenfluramine. *Progress In Neurobiology, 27*(1), 13-62.

Rowland, N. E., Crews, E. C., & Gentry, R. M. (1997). Comparison Of Fos Induced In Rat Brain By Glp-1 And Amylin. *Regulatory Peptides, 71*(3), 171-174.

Rowland, N. E., Mukherjee, M., & Robertson, K. (2001). Effects Of The Cannabinoid Receptor Antagonist Sr 141716, Alone And In Combination With Dexfenfluramine Or Naloxone, On Food Intake In Rats. *Psychopharmacology, 159*(1), 111-116.

Rubino, D., Apovian, C. M., Still, C. D., Mignon, L., Burns, C., Harris-Collazo, R., Dunayevich, E., & Kim, D. D. (2010). Naltrexone Sr/Bupropion Sr Combination (Nb) Therapy Shifts Subjects From The Obese To The Non-Obese Body Mass Index (Bmi) Classes: From The Cor-Ii Phase 3, Double-Blind, Placebo-Controlled, 56-Week Study. *Obesity, 18*, S156-S156.

Rubino, T., Patrini, G., Massi, P., Fuzio, D., Vigano, D., Giagnoni, G., & Parolaro, D. (1998). Cannabinoid-Precipitated Withdrawal: A Time-Course Study Of The Behavioral Aspect And Its Correlation With Cannabinoid Receptors And G

Protein Expression. *Journal Of Pharmacology And Experimental Therapeutics, 285*(2), 813-819.

Rudski, J. M., Grace, M., Kuskowski, M. A., Billington, C. J., & Levine, A. S. (1996). Behavioral Effects Of Naloxone On Neuropeptide Y-Induced Feeding. *Pharmacology Biochemistry And Behavior, 54*(4), 771-777.

Ruiu, S., Pinna, G. A., Marchese, G., Mussinu, J. M., Saba, P., Tambaro, S., Casti, P., Vargiu, R., & Pani, L. (2003). Synthesis And Characterization Of Ness 0327: A Novel Putative Antagonist Of The Cb1 Cannabinoid Receptor. *Journal Of Pharmacology And Experimental Therapeutics, 306*(1), 363-370.

Rukwied, R., Watkinson, A., Mcglone, F., & Dvorak, M. (2003). Cannabinoid Agonists Attenuate Capsaicin-Induced Responses In Human Skin. *Pain, 102*(3), 283-288.

Rumsfeld, J. S., & Nallamothu, B. K. (2008). The Hope And Fear Of Rimonabant. *JAMA, 299*(13), 1601-1602.

Rushing, P. A., Hagan, M. M., Seeley, R. J., Lutz, T. A., D'alessio, D. A., Air, E. L., & Woods, S. C. (2001). Inhibition Of Central Amylin Signaling Increases Food Intake And Body Adiposity In Rats. *Endocrinology, 142*(11), 5035-5038.

Rushing, P. A., Hagan, M. M., Seeley, R. J., Lutz, T. A., & Woods, S. C. (2000). Amylin: A Novel Action In The Brain To Reduce Body Weight. *Endocrinology, 141*(2), 850-853.

Russell-Jones, D. (2009). Molecular, Pharmacological And Clinical Aspects Of Liraglutide, A Once-Daily Human Glp-1 Analogue. *Molecular And Cellular Endocrinology, 297*(1-2), 137-140.

Rutkowska, M. (2004). The Effect Of Am 251, A Cannabinoid Cb1 Receptor Antagonist, On Food Intake In Rats. *Acta Poloniae Pharmaceutica, 61*(5), 401-403.

Sachs, G. S., Lafer, B., Stoll, A. L., Banov, M., Thibault, A. B., Tohen, M., & Rosenbaum, J. F. (1994). A Double-Blind Trial Of Bupropion Versus Desipramine For Bipolar Depression. *Journal Of Clinical Psychiatry, 55*(9), 391-393.

Sagredo O, R. J., Fernandez-Ruiz J, Lopez Rodriguez Ml, De Miguel R. (2006). Chronic Delta9-Tetrahydrocannabinol Administration Affects Serotonin Levels In The Rat Frontal Cortex. *Naunyn-Schmiedeberg's Arch Pharmacol, 372*, 313-327.

Sahr, A. E., Sindelar, D. K., Alexander-Chacko, J. T., Eastwood, B. J., Mitch, C. H., & Statnick, M. A. (2008). Activation Of Mesolimbic Dopamine Neurons During Novel And Daily Limited Access To Palatable Food Is Blocked By The Opioid Antagonist Ly255582. *Am J Physiol Regul Integr Comp Physiol, 295*(2), R463-471.

Sahu, A., Carraway, R. E., & Wang, Y. P. (2001). Evidence That Neurotensin Mediates The Central Effect Of Leptin On Food Intake In Rat. *Brain Research, 888*(2), 343-347.

Sainsbury, A., Cooney, G. J., & Herzog, H. (2002). Hypothalamic Regulation Of Energy Homeostasis. *Best Practice & Research Clinical Endocrinology & Metabolism, 16*(4), 623-637.

Sainsbury, A., Schwarzer, C., Couzens, M., Jenkins, A., Oakes, S. R., Ormandy, C. J., & Herzog, H. (2002). Y4 Receptor Knockout Rescues Fertility In Ob/Ob Mice. *Genes Dev., 16*(9), 1077-1088.

Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., Williams, S. C., Richardson, J. A., Kozlowski, G. P., Wilson, S., Arch, J. R. S., Buckingham, R. E., Haynes, A. C., Carr, S. A., Annan, R. S., Mcnulty, D. E., Liu, W. S., Terrett, J. A., Elshourbagy, N. A., Bergsma, D. J., & Yanagisawa, M. (1998). Orexins And Orexin Receptors: A Family Of Hypothalamic Neuropeptides And G Protein-Coupled Receptors That Regulate Feeding Behavior. *Cell, 92*(4), 573-585.

Salamone, J. D., Mclaughlin, P. J., Sink, K., Makriyannis, A., & Parker, L. A. (2007). Cannabinoid Cb1 Receptor Inverse Agonists And Neutral Antagonists: Effects On Food Intake, Food-Reinforced Behavior And Food Aversions. *Physiology & Behavior, 91*(4), 383-388.

Saltiel, A. R., & Kahn, C. R. (2001). Insulin Signalling And The Regulation Of Glucose And Lipid Metabolism. *Nature, 414*(6865), 799-806.

Samanin, R., Mennini, T., Bendotti, C., Barone, D., Caccia, S., & Garattini, S. (1989). Evidence That Central 5-Ht2 Receptors Do Not Play An Important Role In The Anorectic Activity Of D-Fenfluramine In The Rat. *Neuropharmacology, 28*(5), 465-469.

Samanin, R., Mennini, T., Ferraris, A., Bendotti, C., Borsini, F., & Garattini, S. (1979). Meta-Chlorophenylpiperazine - Central Serotonin Agonist Causing Powerful Anorexia In Rats. *Naunyn-Schmiedebergs Archives Of Pharmacology, 308*(2), 159-163.

Sanchis-Segura, C., Cline, B. H., Marsicano, G., Lutz, B., & Spanagel, R. (2004). Reduced Sensitivity To Reward In Cb1 Knockout Mice. *Psychopharmacology, 176*(2), 223-232.

Sanger, D. J., & Mccarthy, P. S. (1981a). Endorphinergic Mechanisms And Ingestive Behavior. *Neuroscience Letters*(SUPPL. 7), S447-S447.

Sanger, D. J., & Mccarthy, P. S. (1981b). Increased Food And Water-Intake Produced In Rats By Opiate Receptor Agonists. *Psychopharmacology, 74*(3), 217-220.

Sanger, D. J., & Mccarthy, P. S. (1982). A Comparison Of The Effects Of Opiate Antagonists On Operant And Ingestive Behavior. *Pharmacology Biochemistry And Behavior, 16*(6), 1013-1015.

Sanger, D. J., Mccarthy, P. S., & Metcalf, G. (1981). The Effects Of Opiate Antagonists On Food-Intake Are Stereospecific. *Neuropharmacology, 20*(1), 45-47.

Santamaria, A., & Arias, H. R. (2010). Neurochemical And Behavioral Effects Elicited By Bupropion And Diethylpropion In Rats. *Behavioural Brain Research, 211*(1), 132-139.

Sargent, B. J., & Moore, N. A. (2009). New Central Targets For The Treatment Of Obesity. *British Journal Of Clinical Pharmacology, 68*(6), 852-860.

Sargent, P. A., Sharpley, A. L., Williams, C., Goodall, E. M., & Cowen, P. J. (1997). 5-Ht2c Receptor Activation Decreases Appetite And Body Weight In Obese Subjects. *Psychopharmacology, 133*(3), 309-312.

Saris, W. H. M., Astrup, A., Prentice, A. M., Zunft, H. J. F., Formiguera, X., Verboeket-Van De Venne, W., Raben, A., Poppitt, S. D., Seppelt, B., Johnston, S., Vasilaras, T. H., & Keogh, G. F. (2000). Randomized Controlled Trial Of Changes In Dietary Carbohydrate/Fat Ratio And Simple Vs Complex Carbohydrates On Body Weight And Blood Lipids: The Carmen Study. *International Journal Of Obesity, 24*(10), 1310-1318.

Saudou, F., Amara, D. A., Dierich, A., Lemeur, M., Ramboz, S., Segu, L., Buhot, M. C., & Hen, R. (1994). Enhanced Aggressive-Behavior In Mice Lacking 5-Ht1b Receptor. *Science, 265*(5180), 1875-1878.

Sayegh, A. I. (2013). The Role Of Bombesin And Bombesin-Related Peptides In The Short-Term Control Of Food Intake. In Y. X. Tao (Ed.), *G Protein-Coupled Receptors In Energy Homeostasis And Obesity Pathogensis* (Vol. 114, Pp. 343-370).

Scalera, G., & Tarozzi, G. (1998). Somatostatin Administration Modifies Food Intake, Body Weight, And Gut Motility In Rat. *Peptides, 19*(6), 991-997.

Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012). Bariatric Surgery Versus Intensive Medical Therapy In Obese Patients With Diabetes. *New England Journal Of Medicine, 366*(17), 1567-1576.

Scheen, A. J., Finer, N., Hollander, P., Jensen, M. D., Van Goal, L. F., & Grp, R. I.-D. S. (2006). Efficacy And Tolerability Of Rimonabant In Overweight Or Obese Patients With Type 2 Diabetes: A Randomised Controlled Study. *Lancet, 368*(9548), 1660-1672.

Schick, R. R., Samsami, S., Zimmermann, J. P., Eberl, T., Endres, C., Schusdziarra, V., & Classen, M. (1993). Effect Of Galanin On Food-Intake In Rats - Involvement Of Lateral And Ventromedial Hypothalamic Sites. *American Journal Of Physiology, 264*(2), R355-R361.

Schick, R. R., Schusdziarra, V., Nussbaumer, C., & Classen, M. (1991). Neuropeptide-Y And Food-Intake In Fasted Rats - Effect Of Naloxone And Site Of Action. *Brain Research, 552*(2), 232-239.

Schick, R. R., Zimmermann, J. P., Walde, T. V., & Schusdziarra, V. (2003). Peptides That Regulate Food Intake - Glucagon-Like Peptide 1-(7-36) Amide Acts At Lateral And Medial Hypothalamic Sites To Suppress Feeding In Rats. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 284*(6), R1427-R1435.

Schlosburg, J. E., O'neal, S. T., Conrad, D. H., & Lichtman, A. H. (2011). Cb1 Receptors Mediate Rimonabant-Induced Pruritic Responses In Mice: Investigation Of Locus Of Action. *Psychopharmacology, 216*(3), 323-331.

Schoffelmeer, A. N. M., Hogenboom, F., Wardeh, G., & De Vries, T. J. (2006). Interactions Between Cb1 Cannabinoid And Mu Opioid Receptors Mediating Inhibition Of Neurotransmitter Release In Rat Nucleus Accumbens Core. *Neuropharmacology, 51*(4), 773-781.

Schreiber, R., & De Vry, J. (2002). Role Of 5-Ht(2c) Receptors In The Hypophagic Effect Of M-Cpp, Org 37684 And Cp-94,253 In The Rat. *Progress In Neuro-Psychopharmacology & Biological Psychiatry, 26*(3), 441-449.

Schreiber, R., Selbach, K., Asmussen, M., Hesse, D., & De Vry, J. (2000). Effects Of Serotonin(1/2) Receptor Agonists On Dark-Phase Food And Water Intake In Rats. *Pharmacology Biochemistry And Behavior, 67*(2), 291-305.

Schwartz, G. J. (2000). The-Role Of Gastrointestinal Vagal Afferents In The Control Of Food Intake: Current Prospects. *Nutrition, 16*(10), 866-873.

Schwartz, M. W., Figlewicz, D. P., Baskin, D. G., Woods, S. C., & Porte, D. (1992). Insulin In The Brain - A Hormonal Regulator Of Energy-Balance. *Endocrine Reviews, 13*(3), 387-414.

Schwartz, M. W., Woods, S. C., Porte Jr., D., Seeley, R. J., & Baskin, D. G. (2000). Central Nervous System Control Of Food Intake. *Nature, 404*, 661 - 671.

Sciolino, N. R., Zhou, W., & Hohmann, A. G. (2011). Enhancement Of Endocannabinoid Signaling With Jzl184, An Inhibitor Of The 2-Arachidonoylglycerol Hydrolyzing Enzyme Monoacylglycerol Lipase, Produces Anxiolytic Effects Under Conditions Of High Environmental Aversiveness In Rats. *Pharmacological Research, 64*(3), 226-234.

Scott, K. A., & Moran, T. H. (2007). The Glp-1 Agonist Exendin-4 Reduces Food Intake In Nonhuman Primates Through Changes In Meal Size. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 293*(3), R983-R987.

Scott, V., Kimura, N., Stark, J. A., & Luckman, S. M. (2005). Intravenous Peptide Yy3-36 And Y2 Receptor Antagonism In The Rat: Effects On Feeding Behaviour. *Journal Of Neuroendocrinology, 17*(7), 452-457.

Scrocchi, L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996). Diabetes In Mice With A Targeted Disruption Of The Glp-1 Receptor Gene. *Diabetes, 45*, 71-71.

Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996). Glucose Intolerance But Normal Satiety In Mice With A Null Mutation In The Glucagon-Like Peptide 1 Receptor Gene. *Nature Medicine, 2*(11), 1254-1258.

Seeley, R. J., Blake, K., Rushing, P. A., Benoit, S., Eng, J., Woods, S. C., & D'alessio, D. (2000). The Role Of Cns Glucagon-Like Peptide-1 (7-36) Amide Receptors In Mediating The Visceral Illness Effects Of Lithium Chloride. *Journal Of Neuroscience, 20*(4), 1616-1621.

Sekino, A., Ohata, H., Mano-Otagiri, A., Arai, K., & Shibasaki, T. (2004). Both Corticotropin-Releasing Factor Receptor Type 1 And Type 2 Are Involved In Stress-Induced Inhibition Of Food Intake In Rats. *Psychopharmacology, 176*(1), 30-38.

Serra, G., & Fratta, W. (2007). A Possible Role For The Endocannabinoid System In The Neurobiology Of Depression. *Clinical Practice And Epidemiology In Mental Health : CP & EMH, 3*, 25-25.

Serrano, A., Del Arco, I., Javier Pavon, F., Macias, M., Perez-Valero, V., & Rodriguez De Fonseca, F. (2008). The Cannabinoid Cb1 Receptor Antagonist Sr141716a (Rimonabant) Enhances The Metabolic Benefits Of Long-Term Treatment With Oleoylethanolamide In Zucker Rats. *Neuropharmacology, 54*(1), 226-234.

Sesso, H. D., Paffenbarger, R. S., & Lee, I. M. (2000). Physical Activity And Coronary Heart Disease In Men - The Harvard Alumni Health Study. *Circulation, 102*(9), 975-980.

Settle, E. C., Stahl, S. M., Batey, S. R., Johnston, J. A., & Ascher, J. A. (1999). Safety Profile Of Sustained-Release Bupropion In Depression: Results Of Three Clinical Trials. *Clinical Therapeutics, 21*(3), 454-463.

Shacham, S., Marantz, Y., Senderowitz, H., Orbach, P., Sharadendu, A., Becker, O., & Noiman, S. (2005). Novel 5-Ht6 Receptor Antagonists For The Treatment Of Obesity. *Obesity Research, 13*, A192-A192.

Shargill, N. S., Tsujii, S., Bray, G. A., & Erlansonalbertsson, C. (1991). Enterostatin Suppresses Food-Intake Following Injection Into The 3rd Ventricle Of Rats. *Brain Research, 544*(1), 137-140.

Shearman, L., Rosko, K., Camacho, R., Stribling, S., Zhou, D., Kuca, S., Strack, A., & Macintyre, D. E. (2003). Chronic Effects Of Cannabinoid 1 (Cb1) Receptor Inverse Agonist, Am251, On Indices Of Energy Balance And Gastrointestinal Motility In Mice. *International Journal Of Obesity, 27*(Supplement 1), S56-S56.

Shide, D. J., & Rolls, B. J. (1995). Information About The Fat Content Of Preloads Influences Energy Intake In Healthy Women. *Journal Of The American Dietetic Association, 95*(9), 993-998.

Shiiya, T., Nakazato, M., Mizuta, M., Date, Y., Mondal, M. S., Tanaka, M., Nozoe, S. I., Hosoda, H., Kangawa, K., & Matsukura, S. (2002). Plasma Ghrelin Levels In Lean And Obese Humans And The Effect Of Glucose On Ghrelin Secretion. *Journal Of Clinical Endocrinology & Metabolism, 87*(1), 240-244.

Shimada, M., Tritos, N. A., Lowell, B. B., . Flier, J. S., Maratos-Flier, E. (1998). Mice Lacking Melanin-Concentrating Hormone Are Hypophagic And Lean. *Nature, 396*, 670 - 674.

Shimomura, Y., Harada, M., Goto, M., Sugo, T., Matsumoto, Y., Abe, M., Watanabe, T., Asami, T., Kitada, C., Mori, M., Onda, H., & Fujino, M. (2002). Identification Of Neuropeptide W As The Endogenous Ligand For Orphan G-Protein-Coupled Receptors Gpr7 And Gpr8. *Journal Of Biological Chemistry, 277*(39), 35826-35832.

Shionogi. (2011). Double-Blind, Multi-Center, Randomized Study To Assess The Efficacy And Safety Of Velneperit (S-2367) And Orlistat Administered Individually Or Combined With A Reduced Calorie Diet (Rcd) In Obese Subjects. Http://Clinicaltrials.Gov/Ct2/Show/NCT01126970?Term=Obesity&No_Unk=Y&Type=Intr&Rank=738

Shopsin, B. (1983). Bupropions Prophylactic Efficacy In Bipolar Affective-Illness. *Journal Of Clinical Psychiatry, 44*(5), 163-169.

Shutter, J. R., Graham, M., Kinsey, A. C., Scully, S., Luthy, R., & Stark, K. L. (1997). Hypothalamic Expression Of Art, A Novel Gene Related To Agouti, Is Up-Regulated In Obese And Diabetic Mutant Mice. *Genes & Development, 11*(5), 593-602.

Sidhpura, N., Redfern, P., Rowley, H., Heal, D., & Wonnacott, S. (2007). Comparison Of The Effects Of Bupropion And Nicotine On Locomotor Activation And Dopamine Release In Vivo. *Biochemical Pharmacology, 74*(8), 1292-1298.

Siegel, G. J., Agranoff, B.W., Albers, R. W., Fisher, S. K., and Uhler, M. D. (1999) Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th edition. Philadelphia: Lippincott-Raven.

Sileno, A. P., Brandt, G. C., Spann, B. M., & Quay, S. C. (2005). Lower Mean Weight After 14 Days Intravenous Administration Peptide Yy3-36 (Pyy3-36) In Rabbits. *30*(1), 68-72.

Siler, T. M., Vandenbe.G, Yen, S. S. C., Brazeau, P., Vale, W., & Guillemi.R. (1973). Inhibition Of Growth-Hormone Release In Humans By Somatostatin. *Journal Of Clinical Endocrinology & Metabolism, 37*(4), 632-634.

Silva, A. P., Cavadas, C., & Grouzmann, E. (2002). Neuropeptide Y And Its Receptors As Potential Therapeutic Drug Targets. *Clinica Chimica Acta, 326*(1-2), 3-25.

Silvestre, R. A., Rodriguez-Gallardo, J., Jodka, C., Parkes, D. G., Pittner, R. A., Young, A. A., & Marco, J. (2001). Selective Amylin Inhibition Of The Glucagon Response To Arginine Is Extrinsic To The Pancreas. *American Journal Of Physiology-Endocrinology And Metabolism, 280*(3), E443-E449.

Simansky, K. J. (1996). Serotonergic Control Of The Organization Of Feeding And Satiety. *Behavioral Brain Research, 73*, 37 - 42.

Simansky, K. J., & Nicklous, D. M. (2002). Parabrachial Infusion Of D-Fenfluramine Reduces Food Intake - Blockade By The 5-Ht1b Antagonist Sb-216641. *Pharmacology Biochemistry And Behavior, 71*(4), 681-690.

Simansky, K. J., & Vaidya, A. H. (1990). Behavioral Mechanisms For The Anorectic Action Of The Serotonin (5-Ht) Uptake Inhibitor Sertraline In Rats - Comparison With Directly Acting 5-Ht Agonists. *Brain Research Bulletin, 25*(6), 953-960.

Simiand, J., Keane, M., Keane, P. E., & Soubrie, P. (1998). Sr 141716, A Cb1 Cannabinoid Receptor Antagonist, Selectively Reduces Sweet Food Intake In Marmoset. *Behavioural Pharmacology, 9*(2), 179-181.

Simiand, J., Keane, M., Keane, P. E., & Soubrié, P. (1998). Sr 141716, A Cb1 Cannabinoid Receptor Antagonist, Selectively Reduces Sweet Food Intake In Marmoset. *Behavioural Pharmacology, 9*(2), 179-181.

Simone, D. A., Bodnar, R. J., Goldman, E. J., & Pasternak, G. W. (1985). Involvement Of Opioid Receptor Subtypes In Rat-Feeding Behavior. *Life Sciences, 36*(9), 829-833.

Sink, K. S., Mclaughlin, P. J., Wood, J. A. T., Brown, C., Fan, P., Vemuri, V. K., Pang, Y., Olzewska, T., Thakur, G. A., Makriyannis, A., Parker, L. A., & Salamone, J. D. (2008). The Novel Cannabinoid Cb1 Receptor Neutral Antagonist Am4113 Suppresses Food Intake And Food-Reinforced Behavior But Does Not Induce Signs Of Nausea In Rats. *Neuropsychopharmacology, 33*(4), 946-955.

Sink, K. S., Segovia, K. N., Sink, J., Randall, P. A., Collins, L. E., Correa, M., Markus, E. J., Vemuri, V. K., Makriyannis, A., & Salamone, J. D. (2010). Potential Anxiogenic Effects Of Cannabinoid Cb1 Receptor Antagonists/Inverse Agonists In Rats: Comparisons Between Am4113, Am251, And The Benzodiazepine Inverse Agonist Fg-7142. *European Neuropsychopharmacology, 20*(2), 112-122.

Sink Ks, S. K., Nunes Ej, Collins Le, Vemuri Vk, Thakur G, Makriyannis A, Salamone Jd. (2009). Intracerebroventricular Administration Of Cannabinoid

Cb1 Receptor Antagonist Am251 And Am4113 Fails To Alter Food-Reinforced Behavior In Rats. *Psychopharmacology, 206*, 2230232.

Sipols, A. J., Bayer, J., Bennett, R., & Figlewicz, D. P. (2002). Intraventricular Insulin Decreases Kappa Opioid-Mediated Sucrose Intake In Rats. *Peptides, 23*(12), 2181-2187.

Sjostrom, L., Lindroos, A. K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjostrom, C. D., Sullivan, M., Wedel, H., & Swedish Obese Subjects Study, S. (2004). Lifestyle, Diabetes, And Cardiovascular Risk Factors 10 Years After Bariatric Surgery. *New England Journal Of Medicine, 351*(26), 2683-2693.

Sjostrom, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P. F., & Krempf, M. (1998). Randomised Placebo-Controlled Trial Of Orlistat For Weight Loss And Prevention Of Weight Regain In Obese Patients. *Lancet, 352*(9123), 167-172.

Skelly, M. J., Guy, E. G., Howlett, A. C., & Pratt, W. E. (2010). Cb1 Receptors Modulate The Intake Of A Sweetened-Fat Diet In Response To Mu-Opioid Receptor Stimulation Of The Nucleus Accumbens. *Pharmacology Biochemistry And Behavior, 97*(1), 144-151.

Skibicka, K. P., Hansson, C., Alvarez-Crespo, M., Friberg, P. A., & Dickson, S. L. (2011). Ghrelin Directly Targets The Ventral Tegmental Area To Increase Food Motivation. *Neuroscience, 180*, 129-137.

Slemmer, J. E., Martin, B. R., & Damaj, M. I. (2000). Bupropion Is A Nicotinic Antagonist. *Journal Of Pharmacology And Experimental Therapeutics, 295*(1), 321-327.

Sloth, B., Holst, J. J., Flint, A., Gregersen, N. T., & Astrup, A. (2007). Effects Of Pyy1-36 And Pyy3-36 On Appetite, Energy Intake, Energy Expenditure, Glucose And Fat Metabolism In Obese And Lean Subjects. *Am J Physiol Endocrinol Metab, 292*(4), E1062-1068.

Smart, D., Sabido-David, C., Brough, S. J., Jewitt, F., Johns, A., Porter, R. A., & Jerman, J. C. (2001). Sb-334867-A: The First Selective Orexin-1 Receptor Antagonist. *British Journal Of Pharmacology, 132*(6), 1179-1182.

Smith, F. J., Campfield, L. A., Moschera, J. A., Bailon, P. S., & Burn, P. (1998). Brain Administration Of Ob Protein (Leptin) Inhibits Neuropeptide-Y-Induced Feeding In Ob/Ob Mice. *Regulatory Peptides, 75-6*, 433-439.

Smith, I. G., Goulder, M. A., & Sibutramine Clin Study, T. (2001). Randomized Placebo-Controlled Trial Of Long-Term Treatment With Sibutramine In Mild To Moderate Obesity. *Journal Of Family Practice, 50*(6), 505-512.

Smith, R. J., See, R. E., & Aston-Jones, G. (2009). Orexin/Hypocretin Signaling At The Orexin 1 Receptor Regulates Cue-Elicited Cocaine-Seeking. *European Journal Of Neuroscience, 30*(3), 493-503.

Smith, S. R., Aronne, L. J., Burns, C. M., Kesty, N. C., Halseth, A. L., & Weyer, C. (2008). Sustained Weight Loss Following 12-Month Pramlintide Treatment As An Adjunct To Lifestyle Intervention In Obesity. *Diabetes Care, 31*(9), 1816-1823.

Smith, S. R., Prosser, W. A., Donahue, D. J., Morgan, M. E., Anderson, C. M., Shanahan, W. R., & Grp, A. P. D. S. (2009). Lorcaserin (Apd356), A Selective 5-Ht2c Agonist, Reduces Body Weight In Obese Men And Women. *Obesity, 17*(3), 494-503.

Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., Shanahan, W. R., Behav, M., & Lorcaserin, O. (2010). Multicenter, Placebo-Controlled Trial Of Lorcaserin For Weight Management. *New England Journal Of Medicine, 363*(3), 245-256.

Snyder, S. H. (1977). Opiate Receptors And Internal Opiates. *Scientific American, 236*(3), 44-56.

Solinas, M., & Goldberg, S. R. (2005). Motivational Effects Of Cannabinoids And Opioids On Food Reinforcement Depend On Simultaneous Activation Of

Cannabinoid And Opioid Systems. *Neuropsychopharmacology, 30*(11), 2035-2045.

Somerville, E. M., Horwood, J. M., Lee, M. D., Kennett, G. A., & Clifton, P. G. (2007). 5-Ht2c Receptor Activation Inhibits Appetitive And Consummatory Components Of Feeding And Increases Brain C-Fos Immunoreactivity In Mice. *European Journal Of Neuroscience, 25*(10), 3115-3124.

Soroko, F. E., Mehta, N. B., Maxwell, R. A., Ferris, R. M., & Schroeder, D. H. (1977). Bupropion Hydrochloride (+/-) Alpha-Tert-Butylamino-3-Chloropropiophenone Hcl) - Novel Antidepressant Agent. *Journal Of Pharmacy And Pharmacology, 29*(12), 767-770.

Sowden, G. L., Weinshenker, D., & Swoap, S. J. (2006). Peripheral Oxyntomodulin Increases Heart Rate In Mice, Independent Of Insulin And Catecholamines. *Faseb Journal, 20*(4), A313-A313.

Spindel, E. (1986). Mammalian Bombesin-Like Peptides. *Trends In Neurosciences, 9*(3), 130-133.

Stacher, G., Steinringer, H., Schmierer, G., Schneider, C., & Winklehner, S. (1982). Cholecystokinin Octapeptide Decreases Intake Of Solid Food In Man. *Peptides, 3*(2), 133-136.

Stahl, S. M., Pradko, J. F., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S. (2004). A Review Of The Neuropharmacology Of Bupropion, A Dual Norepinephrine And Dopamine Reuptake Inhibitor. *Prim Care Companion J Clin Psychiatry, 6*(4), 159–166.

Stairs, D. J., & Dworkin, S. I. (2008). Rate-Dependent Effects Of Bupropion On Nicotine Self-Administration And Food-Maintained Responding In Rats. *Pharmacology Biochemistry And Behavior, 90*(4), 701-711.

Stan, S., Delvin, E., Lambert, M., Seidman, E., & Levy, E. (2003). Apo A-Iv: An Update On Regulation And Physiologic Functions. *Biochimica Et Biophysica Acta-Molecular And Cell Biology Of Lipids, 1631*(2), 177-187.

Ständer, S., Böckenholt, B., Schürmeyer-Horst, F., Weishaupt, C., Heuft, G., Luger, T. A., & Schneider, G. (2009). Treatment Of Chronic Pruritus With The Selective Serotonin Re-Uptake Inhibitors Paroxetine And Fluvoxamine: Results Of An Open-Labelled, Two-Arm Proof-Of-Concept Study. *Acta Dermato-Venereologica, 89*(1), 45-51.

Stander, S., Schmelz, M., Metze, D., Luger, T., & Rukwied, R. (2005). Distribution Of Cannabinoid Receptor 1 (Cb1) And 2 (Cb2) On Sensory Nerve Fibers And Adnexal Structures In Human Skin. *Journal Of Dermatological Science, 38*(3), 177-188.

Stanley, B. G., Kyrkouli, S. E., Lampert, S., & Leibowitz, S. F. (1986). Neuropeptide Y Chronically Injected Into The Hypothalamus: A Powerful Neurochemical Inducer Of Hyperphagia And Obesity. *Peptides, 7*, 1189 - 1192.

Stanley, B. G., & Leibowitz, S. F. (1984). Neuropeptide Y: Stimulation Of Feeding And Drinking By Injection Into The Paraventricular Nucleus. *Life Sciences, 35*, 2635 - 2642.

Steensland, P., Simms, J. A., Nielsen, C. K., Holgate, J., Bito-Onon, J. J., & Bartlett, S. E. (2010). The Neurokinin 1 Receptor Antagonist, Ezlopitant, Reduces Appetitive Responding For Sucrose And Ethanol. *Plos One, 5*(9).

Stein, L. J., & Woods, S. C. (1981). Cholecystokinin And Bombesin Act Independently To Decrease Food-Intake In The Rat. *Peptides, 2*(4), 431-436.

Steinert, R. E., Poller, B., Castelli, M. C., Drewe, J., & Beglinger, C. (2010). Oral Administration Of Glucagon-Like Peptide 1 Or Peptide Yy 3-36 Affects Food Intake In Healthy Male Subjects. *American Journal Of Clinical Nutrition, 92*(4), 810-817.

Stellar, E. (1954). The Physiology Of Motivation. *Psychological Review, 61*(1), 5 - 22.

Stengel, A., Goebel, M., Million, M., Stenzel-Poore, M. P., Kobelt, P., Moennikes, H., Tache, Y., & Wang, L. (2009). Corticotropin-Releasing Factor-Overexpressing Mice Exhibit Reduced Neuronal Activation In The Arcuate Nucleus And Food Intake In Response To Fasting. *Endocrinology, 150*(1), 153-160.

Stengel, A., Goebel, M., Wang, L., Rivier, J., Kobelt, P., Monnikes, H., & Tache, Y. (2010). Selective Central Activation Of Somatostatin Receptor 2 Increases Food Intake, Grooming Behavior And Rectal Temperature In Rats. *Journal Of Physiology And Pharmacology, 61*(4), 399-407.

Stephen M. Stahl., J. F. P., Barbara R. Haight., Jack G. Modell, M.D., Carol B. Rockett., And Susan Learned-Coughlin. (2004). A Review Of The Neuropharmacology Of Bupropion, A Dual Norepinephrine And Dopamine Reuptake Inhibitor. *Prim Care Companion J Clin Psychiatry, 6*(4), 159–166.

Stiedl, O., Misane, I., Koch, M., Pattij, T., Meyer, M., & Ogren, S. O. (2007). Activation Of The Brain 5-Ht2c Receptors Causes Hypolocomotion Without Anxiogenic-Like Cardiovascular Adjustments In Mice. *Neuropharmacology, 52*(3), 949-957.

Stinus, L., Koob, G. F., Ling, N., Bloom, F. E., & Le Moal, M. (1980). Locomotor Activation Induced By Infusion Of Endorphins Into The Ventral Tegmental Area: Evidence For Opiate-Dopamine Interactions. *Proceedings Of The National Academy Of Sciences, 77*(4), 2323-2327.

Stoeckel, L. E., Weller, R. E., Giddings, M., & Cox, J. E. (2008). Peptide Yy Levels Are Associated With Appetite Suppression In Response To Long-Chain Fatty Acids. *Physiology & Behavior, 93*(1-2), 289.

Stolakis, V., Kalafatakis, K., Botis, J., Zarros, A., & Liapi, C. (2010). The Regulatory Role Of Neurotensin On The Hypothalamic-Anterior Pituitary Axons: Emphasis On The Control Of Thyroid-Related Functions. *Neuropeptides, 44*(1), 1-7.

Stricker-Krongrad, A., Souquet, A., & Burlet, C. (1995). Effects Of Sibutramine On Feeding Behaviour In Obese And Lean Zucker Rats. *Int. J. Obes, 19*(Suppl 2), 398.

Strohmayer, A. J., & Smith, G. P. (1987). A Sex Difference In The Effect Of Cck-8 On Food And Water-Intake In Obese (Ob Ob) And Lean (+/+) Mice. *Peptides, 8*(5), 845-848.

Stubbs, J., Whybrow, S., Teixeira, P., Blundell, J., Lawton, C., Westenhoefer, J., Engel, D., Shepherd, R., Mcconnon, A., Gilbert, P., & Raats, M. (2011). Problems In Identifying Predictors And Correlates Of Weight Loss And Maintenance: Implications For Weight Control Therapies Based On Behaviour Change. *Obesity Reviews, 12*(9), 688-708.

Stutz, A. M., Morrison, C. D., & Argyropoulos, G. (2005). The Agouti-Related Protein And Its Role In Energy Homeostasis. *Peptides, 26*(10), 1771-1781.

Suckow, R. F., Smith, T. M., Perumal, A. S., & Cooper, T. B. (1986). Pharmacokinetics Of Bupropion And Metabolites In Plasma And Brain Of Rats, Mice, And Guinea-Pigs. *Drug Metabolism And Disposition, 14*(6), 692-697.

Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995). 2-Arachidonoylgylcerol - A Possible Endogenous Cannabinoid Receptor-Ligand In Brain. *Biochemical And Biophysical Research Communications, 215*(1), 89-97.

Svec, F., Thompson, H., Corll, C., & Porter, J. (2002). Levels Of Hypothalamic Neurotransmitters In Lean And Obese Zucker Rats. *Nutritional Neuroscience, 5*(5), 321-326.

Swaney, J. B., Braithwaite, F., & Eder, H. A. (1977). Characterization Of Apolipoproteins Of Rat Plasma Lipoproteins. *Biochemistry, 16*(2), 271-278.

Sweet, D. C. L., A.S. And Kotz, C.M. (2004). Functional Opioid Pathways Are Necessary For Hypocretin-1(Orexin -A)- Induced Feeding. *Peptides, 25*, 307-314.

Szayna, M., Doyle, M. E., Betkey, J. A., Holloway, H. W., Spencer, R. G. S., Greig, N. H., & Egan, J. M. (2000). Exendin-4 Decelerates Food Intake, Weight Gain, And Fat Deposition In Zucker Rats. *Endocrinology, 141*(6), 1936-1941.

Tachibana, T., Cline, M. A., Sugahara, K., Ueda, H., & Hiramatsu, K. (2009). Central Administration Of Somatostatin Stimulates Feeding Behavior In Chicks. *General And Comparative Endocrinology, 161*(3), 354-359.

Taha, S. A. (2010). Preference Or Fat? Revisiting Opioid Effects On Food Intake. *Physiology & Behavior, 100*(5), 429-437.

Takahashi, N., Okumura, T., Yamada, H., & Kohgo, Y. (1999). Stimulation Of Gastric Acid Secretion By Centrally Administered Orexin-A In Conscious Rats. *Biochemical And Biophysical Research Communications, 254*(3), 623-627.

Takeda. (2010). Amylin And Takeda Announce Decision To Advance Development Of Pramlintide/Metreleptin Combination Treatment For Obesity. Retrieved 11th September 2013, 2013, From Http://Www.Takeda.Com/News/2010/20100223_3746.Html

Takeda. (2011). Amylin And Takeda Discontinue Development Of Pramlintide/Metreleptin Combination Treatment For Obesity Following Commercial Reassessment Of The Program. Retrieved 11th September 2013, 2013, From Http://Www.Takeda.Com/News/2011/20110805_3889.Html

Takenoya, F., Kageyama, H., Shiba, K., Date, Y., Nakazato, M., & Shioda, S. (2010). Neuropeptide W: A Key Player In The Homeostatic Regulation Of Feeding And Energy Metabolism? In H. Vaudry & S. Shioda (Eds.), *Phylogenetic Aspects Of Neuropeptides: From Invertebrates To Humans* (Vol. 1200, Pp. 162-169).

Takenoya, F., Kitamura, S., Kageyama, H., Nonaka, N., Seki, M., Itabashi, K., Date, Y., Nakazato, M., & Shioda, S. (2008). Neuronal Interactions Between Neuropeptide W- And Orexin- Or Melanin-Concentrating Hormone-Containing Neurons In The Rat Hypothalamus. *Regulatory Peptides, 145*(1-3), 159-164.

Tallett, A. (2009). *Individual And Combined Effects Of Cannabinoid, Opioid, And Monoaminergic Compounds On Food Intake, Behaviour And Weight Gain In Rats.* University Of Leeds, UK.

Tallett, A. J., Blundell, J. E., & Rodgers, R. J. (2007a). Acute Anorectic Response To Cannabinoid Cb1 Receptor Antagonist/Inverse Agonist Am 251 In Rats: Indirect Behavioural Mediation. *Behavioural Pharmacology, 18*, 591-600.

Tallett, A. J., Blundell, J. E., & Rodgers, R. J. (2007b). Grooming, Scratching And Feeding: Role Of Response Competition In Acute Anorectic Response To Rimonabant In Male Rats. *Psychopharmacology, 195*(1), 27-39.

Tallett, A. J., Blundell, J. E., & Rodgers, R. J. (2007c). On The Behavioural Selectivity Of Rimonabant-Induced Anorexia In Rats. *Behavioural Pharmacology, 18*, S95-S95.

Tallett, A. J., Blundell, J. E., & Rodgers, R. J. (2008a). Behaviourally-Selective Hypophagic Effects Of Naloxone In Non-Deprived Male Rats Presented With Palatable Food. *Behavioural Brain Research, 187*(2), 417-427.

Tallett, A. J., Blundell, J. E., & Rodgers, R. J. (2008b). Endogenous Opioids And Cannabinoids: System Interactions In The Regulation Of Appetite, Grooming And Scratching. *Physiology & Behavior, 94*(3), 422-431.

Tallett, A. J., Blundell, J. E., & Rodgers, R. J. (2009a). Effects Of Acute Low-Dose Combined Treatment With Naloxone And Am 251 On Food Intake, Feeding

Behaviour And Weight Gain In Rats. *Pharmacology Biochemistry And Behavior, 91*(3), 358-366.

Tallett, A. J., Blundell, J. E., & Rodgers, R. J. (2009b). Night And Day: Diurnal Differences In The Behavioural Satiety Sequence In Male Rats. *Physiology & Behavior, 97*(1), 125-130.

Tallett, A. J., Blundell, J. E., & Rodgers, R. J. (2009c). Sibutramine-Induced Anorexia: Potent, Dose-Dependent And Behaviourally-Selective Profile In Male Rats. *Behavioural Brain Research, 198*(2), 359-365.

Tallett, A. J., Blundell, J. E., & Rodgers, R. J. (2010a). Effects Of Acute Low-Dose Combined Treatment With Rimonabant And Sibutramine On Appetite And Weight Gain In Rats. *Pharmacology Biochemistry And Behavior, 97*(1), 92-100.

Tallett, A. J., Blundell, J. E., & Rodgers, R. J. (2010b). Sibutramine & Naloxone: Infra-Additive Interaction In The Regulation Of Appetite? *Behavioural Brain Research, 207*(1), 174-181.

Talsania, T., Anini, Y., Siu, S., Drucker, D. J., & Brubaker, P. L. (2005). Peripheral Exendin-4 And Peptide Yy3-36 Synergistically Reduce Food Intake Through Different Mechanisms In Mice. *Endocrinology, 146*(9), 3748-3756.

Tam, J., Cinar, R., Liu, J., Godlewski, G., Wesley, D., Jourdan, T., Szanda, G., Mukhopadhyay, B., Chedester, L., Liow, J.-S., Innis, R. B., Cheng, K., Rice, K. C., Deschamps, J. R., Chorvat, R. J., Mcelroy, J. F., & Kunos, G. (2012). Peripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity By Reversing Leptin Resistance. *Cell Metabolism, 16*(2), 167-179.

Tan, T. M., Field, B. C. T., Minnion, J. S., Cuenco-Shillito, J., Chambers, E. S., Zac-Varghese, S., Brindley, C. J., Mt-Isa, S., Fiorentino, F., Ashby, D., Ward, I., Ghatei, M. A., & Bloom, S. R. (2012). Pharmacokinetics, Adverse Effects And Tolerability Of A Novel Analogue Of Human Pancreatic Polypeptide, Pp 1420. *British Journal Of Clinical Pharmacology, 73*(2), 232-239.

Tanaka, H., Yoshida, T., Miyamoto, N., Motoike, T., Kurosu, H., Shibata, K., Yamanaka, A., Williams, S. C., Richardson, J. A., Tsujino, N., Garry, M. G., Lerner, M. R., King, D. S., O'dowd, B. F., Sakurai, T., & Yanagisawa, M. (2003). Characterization Of A Family Of Endogenous Neuropeptide Ligands For The G Protein-Coupled Receptors Gpr7 And Gpr8. *Proceedings Of The National Academy Of Sciences Of The United States Of America, 100*(10), 6251-6256.

Tanda, G., & Goldberg, S. R. (2003). Cannabinoids: Reward, Dependence, And Underlying Neurochemical Mechanisms - A Review Of Recent Preclinical Data. *Psychopharmacology, In Press*.

Tanda, G., Pontieri, F. E., & Dichiara, G. (1997). Cannabinoid And Heroin Activation Of Mesolimbic Dopamine Transmission By A Common Mu 1 Opioid Receptor Mechanism. *Science, 276*(5321), 2048-2050.

Tangchristensen, M., Larsen, P. J., Goke, R., Finkjensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996). Central Administration Of Glp-1-(7-36) Amide Inhibits Food And Water Intake In Rats. *American Journal Of Physiology-Regulatory Integrative And Comparative Physiology, 271*(4), R848-R856.

Tartaglia, L. A. (1997). The Leptin Receptor. *Journal Of Biological Chemistry, 272*(10), 6093-6096.

Tashkin, D. P., Kanner, R., Bailey, W., Buist, S., Anderson, P., Nides, M. A., Gonzales, D., Dozier, G., Patel, M. K., & Jamerson, B. D. (2001). Smoking Cessation In Patients With Chronic Obstructive Pulmonary Disease: A Double-Blind, Placebo-Controlled, Randomised Trial. *Lancet, 357*(9268), 1571-1575.

Taskinen, M. R., Rosenstock, J., Tamminen, I., Kubiak, R., Patel, S., Dugi, K. A., & Woerle, H. J. (2011). Safety And Efficacy Of Linagliptin As Add-On Therapy To Metformin In Patients With Type 2 Diabetes: A Randomized, Double-

Blind, Placebo-Controlled Study. *Diabetes Obesity & Metabolism, 13*(1), 65-74.
Tate, C. G. (2012). A Crystal Clear Solution For Determining G-Protein-Coupled Receptor Structures. *Trends In Biochemical Sciences, 37*(9), 343-352.
Tatemoto, K., & Mutt, V. (1980). Isolation Of 2 Novel Candidate Hormones Using A Chemical Method For Finding Naturally-Occurring Polypeptides. *Nature, 285*(5764), 417-418.
Tatemoto, K., Rokaeus, A., Jornvall, H., Mcdonald, T. J., & Mutt, V. (1983). Galanin - A Novel Biologically-Active Peptide From Porcine Intestine. *FEBS Letters, 164*(1), 124-128.
Tecott, L. H., Sun, L. M., Akana, S. F., Strack, A. M., Lowenstein, D. H., Dallman, M. F., & Julius, D. (1995). Eating Disorder And Epilepsy In Mice Lacking 5-Ht2c Serotonin Receptors. *Nature, 374*(6522), 542-546.
Teitelbaum, P. (1957). Random And Food-Directed Activity In Hyperphagic And Normal Rats. *Journal Of Comparative And Physiological Psychology, 50*(5), 486-490.
Teitelbaum, P., & Epstein, A. N. (1962). The Lateral Hypothalamic Syndrome - Recovery Of Feeding And Drinking After Lateral Hypothalamic-Lesions. *Psychological Review, 69*(2), 74-90.
Teitelbaum, P., & Stellar, E. (1954). Recovery From The Failure To Eat Produced By Hypothalamic Lesions. *Science, 120*(3126), 894-895.
Tella, S. R., Ladenheim, B., & Cadet, J. L. (1997). Differential Regulation Of Dopamine Transporter After Chronic Self-Administration Of Bupropion And Nomifensine. *Journal Of Pharmacology And Experimental Therapeutics, 281*(1), 508-513.
Tepperman, F. S., Hirst, M., & Smith, P. (1983). Brain And Serum Levels Of Naloxone Following Peripheral Administration. *Life Sciences, 33*(11), 1091-1096.
Terra, S., & Tsunoda, S. (1998). Opioid Antagonists In The Treatment Of Pruritus From Cholestatic Liver Disease. *The Annals Of Pharmacotherapy, 32*(11), 1228-1230.
Teskey, G. C., Kavaliers, M., & Hirst, M. (1984). Social-Conflict Activates Opioid Analgesic And Ingestive Behaviors In Male-Mice. *Life Sciences, 35*(3), 303-315.
Thanos, P. K., Ramalhete, R. C., Michaelides, M., Piyis, Y. K., Wang, G.-J., & Volkow, N. D. (2008). Leptin Receptor Deficiency Is Associated With Upregulation Of Cannabinoid 1 Receptors In Limbic Brain Regions. *Synapse, 62*(9), 637-642.
Thiele, T. E., Seeley, R. J., D'alessio, D., Eng, J., Bernstein, I. L., Woods, S. C., & Van Dijk, G. (1998). Central Infusion Of Glucagon-Like Peptide-1-(7-36) Amide (Glp-1) Receptor Antagonist Attenuates Lithium Chloride-Induced C-Fos Induction In Rat Brainstem. *Brain Research, 801*(1-2), 164-170.
Thomas, S., & Schauer, P. (2010). Bariatric Surgery And The Gut Hormone Response. *Nutrition In Clinical Practice, 25*(2), 175-182.
Thompson, R. G., Pearson, L., Schoenfeld, S. L., Kolterman, O. G., & Pramlintide Type 2 Diabet, G. (1998). Pramlintide, A Synthetic Analog Of Human Amylin, Improves The Metabolic Profile Of Patients With Type 2 Diabetes Using Insulin. *Diabetes Care, 21*(6), 987-993.
Thornton-Jones Zd, V. S., Clifton Pg. (2005). The Cannabinoid Cb1 Receptor Antagonist Sr141716a Reduces Appetitive And Consummatory Responses For Food. *Psychopharmacology, 179*, 452-460.
Tiesjema, B., La Fleur, S. E., Luijendijk, M. C. M., Brans, M. A. D., Lin, E.-J. D., During, M. J., & Adan, R. A. (2007). Viral Mediated Neuropeptide Y Expression In The Rat Paraventricular Nucleus Results In Obesity. *Obesity, 15*(10), 2424-2435.

Tirelli, E., Laviola, G., & Adriani, W. (2003). Ontogenesis Of Behavioral Sensitization And Conditioned Place Preference Induced By Psychostimulants In Laboratory Rodents. *Neuroscience And Biobehavioral Reviews, 27*(1-2), 163-178.

Tizzano, J. P., Stribling, D. S., Perez-Tilve, D., Strack, A., Frassetto, A., Chen, R. Z., Fong, T. M., Shearman, L., Krieter, P. A., Tschop, M. H., Skolnick, P., & Basile, A. S. (2008). The Triple Uptake Inhibitor (1r, 5s)-(+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo 3.1.0 Hexane Hydrochloride (Dov 21947) Reduces Body Weight And Plasma Triglycerides In Rodent Models Of Diet-Induced Obesity. *Journal Of Pharmacology And Experimental Therapeutics, 324*(3), 1111-1126.

Toll, B. A., Leary, V., Wu, R., Salovey, P., Meandzija, B., & O'malley, S. S. (2008). A Preliminary Investigation Of Naltrexone Augmentation Of Bupropion To Stop Smoking With Less Weight Gain. *Addictive Behaviors, 33*(1), 173-179.

Tong, Y., & Pelletier, G. (1992). Role Of Dopamine In The Regulation Of Proopiomelanocortin (Pomc) Mrna Levels In The Arcuate Nucleus And Pituitary Gland Of The Female Rat As Studied By In Situ Hybridization. *Molecular Brain Research, 15*(1–2), 27-32.

Tonstad, S., Farsang, C., Klaene, G., Lewis, K., Manolis, A., Perruchoud, A. P., Silagy, C., Van Spiegel, P. I., Astbury, C., Hider, A., & Sweet, R. (2003). Bupropion Sr For Smoking Cessation In Smokers With Cardiovascular Disease: A Multicentre, Randomised Study. *European Heart Journal, 24*(10), 946-955.

Toplak, H., Hamann, A., Moore, R., Masson, E., Gorska, M., Vercruysse, F., Sun, X., Fitchet, M., & Grp, O.-S. (2007). Efficacy And Safety Of Topiramate In Combination With Metformin In The Treatment Of Obese Subjects With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study. *International Journal Of Obesity, 31*(1), 138-146.

Topol, E. J., Bousser, M.-G., Fox, K. A. A., Creager, M. A., Despres, J.-P., Easton, J. D., Hamm, C. W., Montalescot, G., Steg, P. G., Pearson, T. A., Cohen, E., Gaudin, C., Job, B., Murphy, J. H., Bhatt, D. L., & Investigators, C. (2010). Rimonabant For Prevention Of Cardiovascular Events (Crescendo): A Randomised, Multicentre, Placebo-Controlled Trial. *Lancet, 376*(9740), 517-523.

Torgersen, L. K., Macor, J. E., & Nielsen, J. A. (1990). Cp-93129 A Potent And Selective 5ht-1b Agonist Inhibits Food Intake In Rats. *Society For Neuroscience Abstracts, 16*(2), 1035-1035.

Tork, I. (1990). Anatomy Of The Serotonergic System. *Annals Of The New York Academy Of Sciences, 600*, 9-33.

Towell, A., Muscat, R., & Willner, P. (1988). Behavioral Microanalysis Of The Role Of Dopamine In Amphetamine Anorexia. *Pharmacology Biochemistry And Behavior, 30*(3), 641-648.

Trenchard, E., & Silverstone, T. (1983). Naloxone Reduces The Food Intake Of Normal Human Volunteers. *Appetite, 4*(1), 43-50.

Trevaskis, J., Lei, C., Coffey, T., Baron, A., Parkes, D., & Roth, J. (2008). Triple Peptide Administration Of Amylin, Leptin And Pyy(3-36) In Diet Induced Obese Rats: Magnitude And Mechanism Of Weight Loss. *Diabetes, 57*, A57-A57.

Trevaskis, J. L., Coffey, T., Cole, R., Lei, C., Wittmer, C., Walsh, B., Weyer, C., Koda, J., Baron, A. D., Parkes, D. G., & Roth, J. D. (2008). Amylin-Mediated Restoration Of Leptin Responsiveness In Diet-Induced Obesity: Magnitude And Mechanisms. *Endocrinology, 149*(11), 5679-5687.

Trevaskis, J. L., Lei, C., Koda, J. E., Weyer, C., Parkes, D. G., & Roth, J. D. (2010). Interaction Of Leptin And Amylin In The Long-Term Maintenance Of Weight Loss In Diet-Induced Obese Rats. *Obesity, 18*(1), 21-26.

Trevaskis, J. L., Turek, V. F., Griffin, P. S., Wittmer, C., Parkes, D. G., & Roth, J. D. (2010). Multi-Hormonal Weight Loss Combinations In Diet-Induced Obese Rats: Therapeutic Potential Of Cholecystokinin? *Physiology & Behavior, 100*(2), 187-195.

Tritos, N. A., Elmquist, J. K., Mastaitis, J. W., Flier, J. S., & Maratos-Flier, E. (1998). Characterization Of Expression Of Hypothalamic Appetite-Regulating Peptides In Obese Hyperleptinemic Brown Adipose Tissue-Deficient (Uncoupling Protein-Promoter-Driven Diphtheria Toxin A) Mice. *Endocrinology, 139*(11), 4634-4641.

Tritos, N. A., Vicent, D., Gillette, J., Ludwig, D. S., Flier, E. S., & Maratos-Flier, E. (1998). Functional Interactions Between Melanin-Concentrating Hormone, Neuropeptide Y, And Anorectic Neuropeptides In The Rat Hypothalamus. *Diabetes, 47*(11), 1687-1692.

Trivedi, P., Yu, H., Macneil, D. J., Van Der Ploeg, L. H. T., & Guan, X. M. (1998). Distribution Of Orexin Receptor Mrna In The Rat Brain. *FEBS Letters, 438*(1-2), 71-75.

Trojniar, W., & Wise, R. A. (1991). Facilitory Effect Of Delta-9-Tetrahydrocannabinol On Hypothalamically Induced Feeding. *Psychopharmacology, 103*(2), 172-176.

Trulson, M. E., & Jacobs, B. L. (1979). Raphe Unit-Activity In Freely Moving Cats - Correlation With Level Of Behavioral Arousal. *Brain Research, 163*(1), 135-150.

Tschop, M., Castaneda, T. R., Joost, H. G., Thone-Reineke, C., Ortmann, S., Klaus, S., Hagan, M. M., Chandler, P. C., Oswald, K. D., Benoit, S. C., Seeley, R. J., Kinzig, K. P., Moran, T. H., Beck-Sickinger, A. G., Koglin, N., Rodgers, R. J., Blundell, J. E., Ishii, Y., Beattie, A. H., Holch, P., Allison, D. B., Raun, K., Madsen, K., Wulff, B. S., Stidsen, C. E., Birringer, M., Kreuzer, O. J., Schindler, M., Arndt, K., Rudolf, K., Mark, M., Deng, X. Y., Withcomb, D. C., Halem, H., Taylor, J., Dong, J., Datta, R., Culler, M., Craney, S., Flora, D., Smiley, D., & Heiman, M. L. (2004). Physiology: Does Gut Hormone Pyy3-36 Decrease Food Intake In Rodents? *Nature, 430*(6996).

Tschop, M., Smiley, D. L., & Heiman, M. L. (2000). Ghrelin Induces Adiposity In Rodents. *Nature, 407*(6806), 908-913.

Tschop, M., Weyer, C., Tataranni, P. A., Devanarayan, V., Ravussin, E., & Heiman, M. L. (2001). Circulating Ghrelin Levels Are Decreased In Human Obesity. *Diabetes, 50*(4), 707-709.

Tsujino, N., & Sakurai, T. (2009). Orexin/Hypocretin: A Neuropeptide At The Interface Of Sleep, Energy Homeostasis, And Reward System. *Pharmacological Reviews, 61*(2), 162-176.

Tucci, S. A., Rogers, E. K., Korbonits, M., & Kirkham, T. C. (2004). The Cannabinoid Cb1 Receptor Antagonist Sr141716 Blocks The Orexigenic Effects Of Intrahypothalamic Ghrelin. *British Journal Of Pharmacology, 143*(5), 520-523.

Turek, V. F., Trevaskis, J. L., Levin, B. E., Dunn-Meynell, A. A., Irani, B., Gu, G., Wittmer, C., Griffin, P. S., Vu, C., Parkes, D. G., & Roth, J. D. (2010). Mechanisms Of Amylin/Leptin Synergy In Rodent Models. *Endocrinology, 151*(1), 143-152.

Turk, M. W., Yang, K., Hravnak, M., Sereika, S. M., Ewing, L. J., & Burke, L. E. (2009). Randomized Clinical Trials Of Weight Loss Maintenance A Review. *Journal Of Cardiovascular Nursing, 24*(1), 58-80.

Turton, M. D., Oshea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., Wilding, J. P. H., Smith, D. M., Ghatei, M. A., Herbert, J., & Bloom, S. R. (1996). A Role For Glucagon-Like Peptide-1 In The Central Regulation Of Feeding. *Nature, 379*(6560), 69-72.

Twarog, B. M., Page, I. H., & Bailey, H. (1953). Serotonin Content Of Some Mammalian Tissues And Urine And A Method For Its Determination. *American Journal Of Physiology, 175*(1), 157-161.

Tzavara, E. T., Davis, R. J., Perry, K. W., Li, X., Salhoff, C., Bymaster, F. P., Witkin, J. M., & Nomikos, G. G. (2003). The Cb1 Receptor Antagonist Sr141716a Selectively Increases Monoaminergic Neurotransmission In The Medial Prefrontal Cortex: Implications For Therapeutic Actions. *British Journal Of Pharmacology, 138*(4), 544-553.

Ueno, H., Yamaguchi, H., Mizuta, M., & Nakazato, M. (2008). The Role Of Pyy In Feeding Regulation. *Regulatory Peptides, 145*(1-3), 12.

Ueno, N., Inui, A., Iwamoto, M., Kaga, T., Asakawa, A., Okita, M., Fujimiya, M., Nakajima, Y., Ohmoto, Y., & Ohnaka Et, A. (1999). Decreased Food Intake And Body Weight In Pancreatic Polypeptide-Overexpressing Mice. *Gastroenterology, 117*(6), 1427-1432.

Ufsc. (2010). Carbohydrates, Lipids, And Proteins. Retrieved 11th September 2013, 2013, From Http://Www.Cristina.Prof.Ufsc.Br/V2/Digestorio/Mcardle_Carbohydrates_Lipids_Proteins_Chp1_Connection.Pdf

Uhe, A. M., Szmukler, G. I., Collier, G. R., Hansky, J., Odea, K., & Young, G. P. (1992). Potential Regulators Of Feeding-Behavior In Anorexia-Nervosa. *American Journal Of Clinical Nutrition, 55*(1), 28-32.

Ukai, M., & Holtzman, S. G. (1988). Effects Of Beta-Funaltrexamine On Ingestive Behaviors In The Rat. *European Journal Of Pharmacology, 153*(2-3), 161-165.

Unger, R. H., Ohneda, A., Valverde, I., Eisentra.Am, & Exton, J. (1968). Characterization Of Responses Of Circulating Glucagon-Like Immunoreactivity To Intraduodenal And Intravenous Administration Of Glucose. *Journal Of Clinical Investigation, 47*(1), 48-&.

Ungerstedt, U. (1970). Is Interruption Of The Nigrostriatal Dopamine System Producing The Lateral Hypothalamus Syndrome. *Acta Physiologica Scandinavica, 80*(4), 35A-36A.

Usala, T., Clavenna, A., Zuddasa, A., & Bonati, M. (2008). Randomised Controlled Trials Of Selective Serotonin Reuptake Inhibitors In Treating Depression In Children And Adolescents: A Systematic Review And Meta-Anatysis. *European Neuropsychopharmacology, 18*(1), 62-73.

Vaccarino, F. J., Amalric, M., Swerdlow, N. R., & Koob, G. F. (1986). Blockade Of Amphetamine But Not Opiate-Induced Locomotion Following Antagonism Of Dopamine Function In The Rat. *Pharmacology Biochemistry And Behavior, 24*(1), 61-65.

Vaccarino, F. J., Feifel, D., Rivier, J., & Vale, W. (1990). Central Injections Of Growth Hormone-Releasing Factor Antiserum Attenuate The Increased Feeding Associated With Dark Onset Feeding In Rats. *Society For Neuroscience Abstracts, 16*(1), 267-267.

Valassi, E., Scacchi, M., & Cavagnini, F. (2008). Neuroendocrine Control Of Food Intake. *Nutrition Metabolism And Cardiovascular Diseases, 18*(2), 158-168.

Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981). Characterization Of A 41-Residue Ovine Hypothalamic Peptide That Stimulates Secretion Of Corticotropin And Beta-Endorphin. *Science, 213*(4514), 1394-1397.

Valentino, M. A., Lin, J. E., & Waldman, S. A. (2010). Central and peripheral molecular targets for antiobesity pharmacotherapy. Clinical Pharmacology & Therapeutics, 87(6), 652-662

Van Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., Rossner, S., & Grp, R. I.-E. S. (2005). Effects Of The Cannabinoid-1 Receptor Blocker Rimonabant On Weight Reduction And Cardiovascular Risk Factors In Overweight Patients: 1-Year Experience From The Rio-Europe Study. *Lancet, 365*(9468), 1389-1397.

Van Itallie, T. B. (1990). The Glucostatic Theory 1953 - 1988: Roots And Branches. *International Journal Of Obesity, 14*(Suppl. 3), 1 - 10.

Vandenbroeck., G., Clemens,. (2007). Foresight Tackling Obesities: Future Choices — Obesity System Atlas. Http://Www.Bis.Gov.Uk/Assets/Foresight/Docs/Obesity/11.Pdf.

Vanrossum, J., & Simons, F. (1969). Locomotor Activity And Anorexogenic Action. *Psychopharmacologia, 14*(3), 248-&.

Varga, B., Kassai, F., & Gyertyan, I. (2012). Interactions Of Cb1 And Mglu(5) Receptor Antagonists In Food Intake, Anxiety And Memory Models In Rats. *Pharmacology Biochemistry And Behavior, 103*(2), 425-430.

Vemuri, V. K., Janero, D. R., & Makriyannis, A. (2008). Pharmacotherapeutic Targeting Of The Endocannabinoid Signaling System: Drugs For Obesity And The Metabolic Syndrome. *Physiology & Behavior, 93*(4-5), 671-686.

Verbalis, J. G., Mccann, M. J., Mchale, C. M., & Stricker, E. M. (1986). Oxytocin Secretion In Response To Cholecystokinin And Food - Differentiation Of Nausea From Satiety. *Science, 232*(4756), 1417-1419.

Verdich, C., Flint, A., Gutzwiller, J. P., Naslund, E., Beglinger, C., Hellstrom, P. M., Long, S. J., Morgan, L. M., Holst, J. J., & Astrup, A. (2001). A Meta-Analysis Of The Effect Of Glucagon-Like Peptide-1 (7-36) Amide On Ad Libitum Energy Intake In Humans. *Journal Of Clinical Endocrinology & Metabolism, 86*(9), 4382-4389.

Vergoni, A. V., Schioth, H. B., & Bertolini, A. (2000). Melanocortins And Feeding Behavior. *Biomedecine & Pharmacotherapy, 54*(3), 129-134.

Verty, A. N. A., Lockie, S. H., Stefanidis, A., & Oldfield, B. J. (2013). Anti-Obesity Effects Of The Combined Administration Of Cb1 Receptor Antagonist Rimonabant And Melanin-Concentrating Hormone Antagonist Snap-94847 In Diet-Induced Obese Mice. *International Journal Of Obesity, 37*(2), 279-287.

Verty, A. N. A., Mcfarlane, J. R., Mcgregor, I. S., & Mallet, P. E. (2004). Evidence For An Interaction Between Cb1 Cannabinoid And Melanocortin Mcr-4 Receptors In Regulating Food Intake. *Endocrinology, 145*(7), 3224-3231.

Verty, A. N. A., Mcgregor, I. S., & Mallet, P. E. (2004a). Consumption Of High Carbohydrate, High Fat, And Normal Chow Is Equally Suppressed By A Cannabinoid Receptor Antagonist In Non-Deprived Rats. *Neuroscience Letters, 354*(3), 217-220.

Verty, A. N. A., Mcgregor, I. S., & Mallet, P. E. (2004b). The Doparnine Receptor Antagonist Sch 23390 Attenuates Feeding Induced By Delta(9)-Tetrahydrocannobinol. *Brain Research, 1020*(1-2), 188-195.

Verty, A. N. A., Singh, M. E., Mcgregor, S. I., & Mallet, P. E. (2003). The Cannabinoid Receptor Antagonist Sr 141716 Attenuates Overfeeding Induced By Systemic Or Intracranial Morphine. *Psychopharmacology, 168*, 314-323.

Vettor, R., Fabris, R., Pagano, C., & Federspil, G. (2002). Neuroendocrine Regulation Of Eating Behavior. *Journal Of Endocrinological Investigation, 25*(10), 836-854.

Vezina, P., Kalivas, P. W., & Stewart, J. (1987). Sensitization Occurs To The Locomotor Effects Of Morphine And The Specific M Opioid Receptor Agonist, Dago, Administered Repeatedly To The Ventral Tegmental Area But Not To The Nucleus Accumbens. *Brain Research, 417*(1), 51-58.

Vickers, S. P., Benwell, K. R., Porter, R. H., Bickerdike, M. J., Kennett, G. A., & Dourish, C. T. (2000). Comparative Effects Of Continuous Infusion Of Mcpp, Ro 60-0175 And D-Fenfluramine On Food Intake, Water Intake, Body Weight And Locomotor Activity In Rats. *British Journal Of Pharmacology, 130*(6), 1305-1314.

Vickers, S. P., & Clifton, P. G. (2012). Animal Models To Explore The Effects Of Cns Drugs On Food Intake And Energy Expenditure. *Neuropharmacology, 63*(1), 124-131.

Vickers, S. P., Clifton, P. G., & Dourish, C. T. (1996). Behavioural Evidence That D-Fenfluramine-Induced Anorexia In The Rat Is Not Mediated By The 5-Ht1a Receptor Subtype *Psychopharmacology, 125*, 168-175.

Vickers, S. P., Clifton, P. G., Dourish, C. T., & Tecott, L. H. (1999). Reduced Satiating Effect Of D-Fenfluramine In Serotonin 5-Ht2c Receptor Mutant Mice. *Psychopharmacology, 143*, 309 - 314.

Vickers, S. P., & Dourish, C. T. (2004). Serotonin Receptor Ligands And The Treatment Of Obesity. *Current Opinion In Investigational Drugs (London, England : 2000), 5*(4), 377-388.

Vickers, S. P., Dourish, C. T., & Kennett, G. A. (2001). Evidence That Hypophagia Induced By D-Fenfluramine And D-Norfenfluramine In The Rat Is Mediated By 5-Ht2c Receptors. *Neuropharmacology, 41*(2), 200-209.

Vickers, S. P., Easton, N., Webster, L. J., Wyatt, A., Bickerdike, M. J., Dourish, C. T., & Kennett, G. A. (2003). Oral Administration Of The 5-Ht2c Receptor Agonist, Mcpp, Reduces Body Weight Gain In Rats Over 28 Days As A Result Of Maintained Hypophagia. *Psychopharmacology, 167*(3), 274 - 280.

Vickers, S. P., Jackson, H. C., & Cheetham, S. C. (2011). The Utility Of Animal Models To Evaluate Novel Anti-Obesity Agents. *British Journal Of Pharmacology, 164*(4), 1248-1262.

Vickers, S. P., Webster, L. J., Wyatt, A., Dourish, C. T., & Kennett, G. A. (2003). Preferential Effects Of The Cannabinoid Cb, Receptor Antagonist, Sr 141716, On Food Intake And Body Weight Gain Of Obese (Fa/Fa) Compared To Lean Zucker Rats. *Psychopharmacology, 167*(1), 103-111.

Vilsboll, T., Agerso, H., Krarup, T., & Holst, J. J. (2003). Similar Elimination Rates Of Glucagon-Like Peptide-1 In Obese Type 2 Diabetic Patients And Healthy Subjects. *Journal Of Clinical Endocrinology & Metabolism, 88*(1), 220-224.

Vilsboll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001). Reduced Postprandial Concentrations Of Intact Biologically Active Gluccagon-Like Peptide 1 In Type 2 Diabetic Patients. *Diabetes, 50*(3), 609-613.

Vilsboll, T., Krarup, T., Sonne, J., Madsbad, S., Volund, A., Juul, A. G., & Holst, J. J. (2003). Incretin Secretion In Relation To Meal Size And Body Weight In Healthy Subjects And People With Type 1 And Type 2 Diabetes Mellitus. *Journal Of Clinical Endocrinology & Metabolism, 88*(6), 2706-2713.

Vilsboll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courreges, J.-P., Verhoeven, R., Buganova, I., & Madsbad, S. (2007). Liraglutide, A Long-Acting Human Glucagon-Like Peptide-1 Analog, Given As Monotherapy Significantly Improves Glycemic Control And Lowers Body Weight Without Risk Of Hypoglycemia In Patients With Type 2 Diabetes. *Diabetes Care, 30*(6), 1608-1610.

Vincent, J. P., Mazella, J., & Kitabgi, P. (1999). Neurotensin And Neurotensin Receptors. *Trends In Pharmacological Sciences, 20*(7), 302-309.

Vittoz, N. M., Schmeichel, B., & Berridge, C. W. (2008). Hypocretin/Orexin Preferentially Activates Caudomedial Ventral Tegmental Area Dopamine Neurons. *European Journal Of Neuroscience, 28*(8), 1629-1640.

Vivus. (2008). Qnexa Meets Primary Endpoint By Demonstrating Superior Weight Loss Over Components And Placebo In The 28-Week Equate Study (Ob-301). Retrieved 16th August, 2013

Vivus. (2009). Vivus Announces Positive Results From Two Phase 3 Studies; Obese Patients On Qnexa Achieve Average Weight Loss Up To 14.7% And Significant Improvements In Co-Morbidities. Retrieved 16th August, 2013

Vivus. (2010). Fda Issues Complete Response Letter To Vivus Regarding New Drug Application For Qnexa(R). Retrieved 16th August, 2013

Volkoff, H., & Peter, R. E. (2001). Interactions Between Orexin A, Npy And Galanin In The Control Of Food Intake Of The Goldfish, Carassius Auratus. *Regulatory Peptides, 101*(1-3), 59-72.

Volkow, N. D., & O'brien, C. P. (2007). Issues For Dsm-V: Should Obesity Be Included As A Brain Disorder? *Am J Psychiatry, 164*(5), 708-710.

Volkow, N. D., & Wise, R. A. (2005). How Can Drug Addiction Help Us Understand Obesity. *Nature Neuroscience, 8*(5), 555-560.

Volpicelli, J. R., Alterman, A. I., Hayashida, M., & O'brien, C. P. (1992). Naltrexone In The Treatment Of Alcohol Dependence. *Archives Of General Psychiatry, 49*(11), 876-880.

Vrang, N. (2006). Anatomy Of Hypothalamic Cart Neurons. *Peptides, 27*(8), 1970-1980.

W., P. (1845). *Chemistry, Meteorology And The Function Of Digestion.* London: Churchill.

Wada, E., Watase, K., Yamada, K., Ogura, H., Yamano, M., Inomata, Y., Eguchi, J., Yamamoto, K., Sunday, M. E., Maeno, H., Mikoshiba, K., Ohkihamazaki, H., & Wada, K. (1997). Generation And Characterization Of Mice Lacking Gastrin-Releasing Peptide Receptor. *Biochemical And Biophysical Research Communications, 239*(1), 28-33.

Wada, E., Wray, S., Key, S., & Battey, J. (1992). Comparison Of Gene-Expression For 2 Distinct Bombesin Receptor Subtypes In Postnatal Rat Central-Nervous-System. *Molecular And Cellular Neuroscience, 3*(5), 446-460.

Wadden, T. (2004). *Handbook Of Obesity Treatment*: Guilford Press.

Wadden, T., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'neil, P. M., Perri, M. G., Pi-Sunyer, F. X., Rock, C. L., Erickson, J. S., Maier, H. N., Kim, D. D., & Dunayevich, E. (2011). Weight Loss With Naltrexone Sr/Bupropion Sr Combination Therapy As An Adjunct To Behavior Modification: The Cor-Bmod Trial. *Obesity, 19*(1), 110-120.

Wadden, T., Klein, S., Greenway, F. L., Erickson, J., Kim, D. D., Dunayevich, E., & Pl-Sunyer, F. X. (2009). Naltrexone Plus Bupropion Combination Causes Significant Weight Loss: A 56-Week Phase 3 Study. *Diabetes, 58*, A10-A10.

Wadden, T., Webb, V. L., Moran, C. H., & Bailer, B. A. (2012). Lifestyle Modification For Obesity New Developments In Diet, Physical Activity, And Behavior Therapy. *Circulation, 125*(9), 1157-1170.

Waldhoer, M., Bartlett, S. E., & Whistler, J. L. (2004). Opioid Receptors. *Annual Review Of Biochemistry, 73*, 953-990.

Waldmeier, P. C. (1982). Effects Of Anti-Depressant Drugs On Dopamine Uptake And Metabolism. *Journal Of Pharmacy And Pharmacology, 34*(6), 391-394.

Wallingford, N., Perroud, B., Gao, Q., Coppola, A., Gyengesi, E., Liu, Z.-W., Gao, X.-B., Diament, A., Haus, K. A., Shariat-Madar, Z., Mahdi, F., Wardlaw, S. L., Schmaier, A. H., Warden, C. H., & Diano, S. (2009). Prolylcarboxypeptidase Regulates Food Intake By Inactivating Alpha-Msh In Rodents. *Journal Of Clinical Investigation, 119*(8), 2291-2303.

Wallis, C. J., & Lal, H. (1998). A Discriminative Stimulus Produced By 1-(3-Chlorophenyl)Piperazine (Mcpp) As A Putative Animal Model Of Anxiety. *Progress In Neuro-Psychopharmacology & Biological Psychiatry, 22*(3), 547-565.

Walsh, A. E. S., Smith, K. A., Oldman, A. D., Williams, C., Goodall, E. M., & Cowen, P. J. (1994). M-Chlorophenylpiperazine Decreases Food-Intake In A Test Meal. *Psychopharmacology, 116*(1), 120-122.

Wang, G.-J., Volkow, N. D., Logan, J., Pappas, N. R., Wong, C. T., Zhu, W., Netusil, N., & Fowler, J. S. (2001). Brain Dopamine And Obesity. *The Lancet, 357*(9253), 354-357.

Wang, J., & Leibowitz, K. L. (1997). Central Insulin Inhibits Hypothalamic Galanin And Neuropeptide Y Gene Expression And Peptide Release In Intact Rats. *Brain Research, 777*(1-2), 231-236.

Wang, L., Saint-Pierre, D. H., & Tache, Y. (2002). Peripheral Ghrelin Selectively Increases Fos Expression In Neuropeptide Y - Synthesizing Neurons In Mouse Hypothalamic Arcuate Nucleus. *Neuroscience Letters, 325*(1), 47-51.

Wang, L., Stengel, A., Goebel, M., Martinez, V., Gourcerol, G., Rivier, J., & Tache, Y. (2011). Peripheral Activation Of Corticotropin-Releasing Factor Receptor 2 Inhibits Food Intake And Alters Meal Structures In Mice. *Peptides, 32*(1), 51-59.

Wang, X., Horswill, J. G., Whalley, B. J., & Stephens, G. J. (2011). Effects Of The Allosteric Antagonist 1-(4-Chlorophenyl)-3- 3-(6-Pyrrolidin-1-Ylpyridin-2-Yl)Phenyl Urea (Psncbam-1) On Cb1 Receptor Modulation In The Cerebellum. *Molecular Pharmacology, 79*(4), 758-767.

Wannamethee, S. G., & Shaper, A. G. (2001). Physical Activity In The Prevention Of Cardiovascular Disease - An Epidemiological Perspective. *Sports Medicine, 31*(2), 101-114.

Ward, A. S., Comer, S. D., Haney, M., Fischman, M. W., & Foltin, R. W. (1999). Fluoxetine-Maintained Obese Humans: Effect On Food Intake And Body Weight. *Physiology & Behavior, 66*(5), 815-821.

Ward, S. J., Lefever, T. W., Jackson, C., Tallarida, R. J., & Walker, E. A. (2008). Effects Of A Cannabinoid(1) Receptor Antagonist And Serotonin(2c) Receptor Agonist Alone And In Combination On Motivation For Palatable Food: A Dose-Addition Analysis Study In Mice. *Journal Of Pharmacology And Experimental Therapeutics, 325*(2), 567-576.

Ward, S. J., & Raffa, R. B. (2011). Rimonabant Redux And Strategies To Improve The Future Outlook Of Cb1 Receptor Neutral-Antagonist/Inverse-Agonist Therapies. *Obesity, 19*(7), 1325-1334.

Wardlaw, S. L., Kim, J., & Sobieszczyk, S. (1996). Effect Of Morphine On Proopiomelanocortin Gene Expression And Peptide Levels In The Hypothalamus. *Molecular Brain Research, 41*(1–2), 140-147.

Warner, C., & Shoaib, M. (2005). How Does Bupropion Work As A Smoking Cessation Aid? *Addiction Biology, 10*(3), 219-231.

Waters, S. M., & Krause, J. E. (2000). Distribution Of Galanin-1,-2 And-3 Receptor Messenger Rnas In Central And Peripheral Rat Tissues. *Neuroscience, 95*(1), 265-271.

Webber, K. H., Tate, D. F., Ward, D. S., & Bowling, J. M. (2010). Motivation And Its Relationship To Adherence To Self-Monitoring And Weight Loss In A 16-Week Internet Behavioral Weight Loss Intervention. *Journal Of Nutrition Education And Behavior, 42*(3), 161-167.

Webster, L. J. E. A. (2001). Effect Of The Mc4 Agonist Mtii On Food Intake And Thebehavioural Satiety Sequence In The Mouse. *Journal Of Psychopharmacology, 15*(3, Suppl.), J11.

Weingarten, H. P., Chang, P. K., & Jarvie, K. R. (1983). Reactivity Of Normal And Vmh-Lesion Rats To Quinine-Adulterated Foods - Negative Evidence For Negative Finickiness. *Behavioral Neuroscience, 97*(2), 221-233.

Weintraub, M., Rubio, A., Golik, A., Byrne, L., & Scheinbaum, M. L. (1991). Sibutramine In Weight Control - A Dose-Ranging, Efficacy Study. *Clinical Pharmacology & Therapeutics, 50*(3), 330-337.

Weir, M. A., Beyea, M. M., Gomes, T., Juurlink, D. N., Mamdani, M., Blake, P. G., Wald, R., & Garg, A. X. (2011). Orlistat And Acute Kidney Injury: An Analysis Of 953 Patients. *Archives Of Internal Medicine, 171*(7), 703-704.

Weiskrantz, L. (1956). Behavioral Changes Associated With Ablation Of The Amygdaloid Complex In Monkeys. *J Comp Physiol Psychol, 49*(4), 381-391.

Weiss, S. M. (1995). *Pharmacological And Behavioural Examination Of The Defensive Reactions Of Labratory Mice To The Cals Of The Tawny Owl.* (Phd), University Of Leeds, UK.

Weisshaar, E., Ziethen, B., & Gollnick, H. (1997). Can A Serotonin Type 3 (5-Ht3) Receptor Antagonist Reduce Experimentally-Induced Itch? *Inflammation Research, 46*(10), 412-416.

Weisstaub, N. V., Zhou, M., Lira, A., Lambe, E., Gonzalez-Maeso, J., Hornung, J.-P., Sibille, E., Underwood, M., Itohara, S., Dauer, W. T., Ansorge, M. S., Morelli, E., Mann, J. J., Toth, M., Aghajanian, G., Sealfon, S. C., Hen, R., & Gingrich, J. A. (2006). Cortical 5-Ht2a Receptor Signaling Modulates Anxiety-Like Behaviors In Mice. *Science, 313*(5786), 536-540.

Welch, R. M., Lai, A. A., & Schroeder, D. H. (1987a). Pharmacological Significance Of The Species-Differences In Bupropion Metabolism. *Xenobiotica, 17*(3), 287-298.

Welch, R. M., Lai, A. A., & Schroeder, D. H. (1987b). Pharmacological Significance Of The Species Differences In Bupropion Metabolism. *Xenobiotica, 17*(3), 287-298.

Wender, P. H., & Reimherr, F. W. (1990). Bupropion Treatment Of Attention-Deficit Hyperactivity Disorder In Adults. *American Journal Of Psychiatry, 147*(8), 1018-1020.

Werner, N. A., & Koch, J. E. (2003). Effects Of The Cannabinoid Antagonists Am281 And Am630 On Deprivation-Induced Intake In Lewis Rats. *Brain Research, 967*(1-2), 290-292.

White, M. A., & Grilo, C. M. (2013). Bupropion For Overweight Women With Binge-Eating Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. *Journal Of Clinical Psychiatry, 74*(4), 400-406.

Who. (1999). Pharmaceuticals Newsletter. *No. 5 & 6.* Retrieved 8th Feb, 2011, From Http://Apps.Who.Int/Medicinedocs/En/D/Js2270e/3.2.Html

Who. (2013). Obesity And Overweight Fact Sheet, No. 311. Http://Www.Who.Int/Mediacentre/Factsheets/Fs311/En/

Wieczorek, I., Schulz, C., Jarry, H., & Lehnert, H. (2001). The Effects Of The Selective Serotonin Reuptake-Inhibitor Fluvoxamine On Body Weight In Zucker Rats Are Mediated By Corticotropin-Releasing Hormone. *International Journal Of Obesity, 25*(10), 1566-1569.

Wierup, N., Richards, W. G., Bannon, A. W., Kuhar, M. J., Ahren, B., & Sundler, F. (2005). Cart Knock Out Mice Have Impaired Insulin Secretion And Glucose Intolerance, Altered Beta Cell Morphology And Increased Body Weight. *Regulatory Peptides, 129*(1-3), 203-211.

Wikberg, J. E. S., & Mutulis, F. (2008). Targeting Melanocortin Receptors: An Approach To Treat Weight Disorders And Sexual Dysfunction. *Nature Reviews Drug Discovery, 7*(4), 307-323.

Wilcox, C. S., Oskooilar, N., Erickson, J. S., Billes, S. K., Katz, B. B., Tollefson, G., & Dunayevich, E. (2010). An Open-Label Study Of Naltrexone And Bupropion Combination Therapy For Smoking Cessation In Overweight And Obese Subjects. *Addictive Behaviors, 35*(3), 229-234.

Wilding, J. P. H., Gilbey, S. G., Bailey, C. J., Batt, R. A. L., Williams, G., Ghatei, M. A., & Bloom, S. R. (1993). Increased Neuropeptide-Y Messenger-Ribonucleic-Acid (Messenger-Rna) And Decreased Neurotensin Messenger-Rna In The Hypothalamus Of The Obese (Ob/Ob) Mouse. *Endocrinology, 132*(5), 1939-1944.

Wilens, T. E., Haight, B. R., Horrigan, J. P., Hudziak, J. J., Rosenthal, N. E., Connor, D. F., Hampton, K. D., Richard, N. E., & Modell, J. G. (2005). Bupropion Xl In Adults With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled Study. *Biological Psychiatry, 57*(7), 793-801.

Wiley, J. L., Breivogel, C. S., Mahadevan, A., Pertwee, R. G., Cascio, M. G., Bolognini, D., Huffman, J. W., Walentiny, D. M., Vann, R. E., Razdan, R. K., & Martin, B. R. (2011). Structural And Pharmacological Analysis Of O-2050, A Putative Neutral Cannabinoid Cb1 Receptor Antagonist. *European Journal Of Pharmacology, 651*(1-3), 96-105.

Wiley, J. L., Burston, J. J., Leggett, D. C., Alekseeva, O. O., Razdan, R. K., Mahadevan, A., & Martin, B. R. (2005). Cb1 Cannabinoid Receptor-Mediated Modulation Of Food Intake In Mice. *British Journal Of Pharmacology, 145*(3), 293-300.

Williams, C. M., & Kirkham, T. C. (1999). Anandamide Induces Overeating: Mediation By Central Cannabinoid (Cb1) Receptors. *Psychopharmacology, 143*(3), 315-317.

Williams, C. M., & Kirkham, T. C. (2002). Reversal Of Delta(9)-Thc Hyperphagia By Sr141716 And Naloxone But Not Dexfenfluramine. *Pharmacology Biochemistry And Behavior, 71*(1-2), 333-340.

Williams, C. M., Rogers, P. J., & Kirkham, T. C. (1998). Hyperphagia In Pre-Fed Rats Following Oral Delta(9)-Thc. *Physiology & Behavior, 65*(2), 343-346.

Williams, D. L., Baskin, D. G., & Schwartz, M. W. (2009). Evidence That Intestinal Glucagon-Like Peptide-1 Plays A Physiological Role In Satiety. *Endocrinology, 150*(4), 1680-1687.

Williams, G., Bing, C., Cai, X. J., Harrold, J. A., King, P. J., & Liu, X. H. (2001). The Hypothalamus And The Control Of Energy Homeostasis; Different Circuits, Different Purposes. *Physiology & Behavior, 74*(4-5), 683-701.

Williams, K. A. (2001). Synergistic Effects Of Opioid And Cannabinoid Antagonists On Food Intake. *Psychopharmacology, 153*(2), 267-270.

Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996). Gastric Emptying Glucose Responses, And Insulin Secretion After A Liquid Test Meal: Effects Of Exogenous Glucagon-Like Peptide-1 (Glp-1)-(7-36) Amide In Type 2 (Noninsulin-Dependent) Diabetic Patients. *Journal Of Clinical Endocrinology & Metabolism, 81*(1), 327-332.

Willner P, M. J., Phillips G, Muscat R. (1990). Behavioural Analysis Of The Anorectic Effects Of Fluoxetine And Fenfluramine. *Psychopharmacology, 102*, 273-277.

Wing, R. R., & Hill, J. O. (2001). Successful Weight Loss Maintenance. *Annual Review Of Nutrition, 21*, 323-341.

Wirth, M. M., Olszewski, P. K., Yu, C., Levine, A. S., & Giraudo, S. Q. (2001). Paraventricular Hypothalamic Alpha-Melanocyte-Stimulating Hormone And Mtii Reduce Feeding Without Causing Aversive Effects. *Peptides, 22*(1), 129-134.

Wise, S. D. (1992). Clinical-Studies With Fluoxetine In Obesity. *American Journal Of Clinical Nutrition, 55*(1), S181-S184.

Wisse, B. E., & Schwartz, M. W. (2001). Role Of Melanocortins In Control Of Obesity. *Lancet, 358*(9285), 857-859.

Wolfe, B. E., Metzger, E. D., & Stollar, C. (1997). The Effects Of Dieting On Plasma Tryptophan Concentration And Food Intake In Healthy Women. *Physiology & Behavior, 61*(4), 537-541.

Wolff, M. C., & Leander, J. D. (2000). A Comparison Of The Behavioural Effects Of 5-Ht2a And 5-Ht2c Receptor Agonists In The Pigeon. *Behavioural Pharmacology, 11*(5), 355-364.

Wolkowitz, O. M., Doran, A. R., Cohen, M. R., Cohen, R. M., Wise, T. N., & Pickar, D. (1988). Single-Dose Naloxone Acutely Reduces Eating In Obese Humans - Behavioral And Biochemical Effects. *Biological Psychiatry, 24*(4), 483-487.

Woods, S. C., & Porte, D. (1974). Neural Control Of Endocrine Pancreas. *Physiological Reviews, 54*(3), 596-619.

Woolley, M. L., Bentley, J. C., Sleight, A. J., Marsden, C. A., & Fone, K. C. F. (2001). A Role For 5-Ht(6) Receptors In Retention Of Spatial Learning In The Morris Water Maze. *Neuropharmacology, 41*(2), 210-219.

Woolley, M. L., Marsden, C. A., & Fone, K. C. F. (2004). 5-Ht6 Receptors. *Current Drug Targets - CNS And Neurological Disorders, 3*(1), 59-79.

Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001). Ghrelin Enhances Appetite And Increases Food Intake In Humans. *Journal Of Clinical Endocrinology & Metabolism, 86*(12), 5992-5995.

Wren, A. M., Small, C. J., Ward, H. L., Murphy, K. G., Dakin, C. L., Taheri, S., Kennedy, A. R., Roberts, G. H., Morgan, D. G. A., Ghatei, M. A., & Bloom, S. R. (2000). The Novel Hypothalamic Peptide Ghrelin Stimulates Food Intake And Growth Hormone Secretion. *Endocrinology, 141*(11), 4325-4328.

Wright, G., Galloway, L., Kim, J., Dalton, M., Miller, L., & Stern, W. (1985). Bupropion In The Long-Term Treatment Of Cyclic Mood Disorders - Mood Stabilizing Effects. *Journal Of Clinical Psychiatry, 46*(1), 22-25.

Wu, C. L., Hung, C. R., Chang, F. Y., Pau, K. Y. F., & Wang, P. S. (2003). Pharmacological Effects Of Oxytocin On Gastric Emptying And Intestinal Transit Of A Non-Nutritive Liquid Meal In Female Rats. *Naunyn-Schmiedebergs Archives Of Pharmacology, 367*(4), 406-413.

Wu, Y.-K., Yeh, C.-F., Ly, T. W., & Hung, M.-S. (2011). A New Perspective Of Cannabinoid 1 Receptor Antagonists: Approaches Toward Peripheral Cb1r Blockers Without Crossing The Blood-Brain Barrier. *Current Topics In Medicinal Chemistry, 11*(12), 1421-1429.

Wyatt, H. R. (2013). Update On Treatment Strategies For Obesity. *Journal Of Clinical Endocrinology & Metabolism, 98*(4), 1299-1306.

Wynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R. (2006). Oxyntomodulin Increases Energy Expenditure In Addition To Decreasing Energy Intake In Overweight And Obese Humans: A Randomised Controlled Trial. *International Journal Of Obesity, 30*(12), 1729-1736.

Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., & Bloom, S. R. (2005). Subcutaneous Oxyntomodulin Reduces Body Weight In Overweight And Obese Subjects - A Double-Blind, Randomized, Controlled Trial. *Diabetes, 54*(8), 2390-2395.

Wyrwicka, W., & Dobrzecka, C. (1960). Relationship Between Feeding And Satiation Centers Of The Hypothalamus. *Science, 132*(3430), 805-806.

Xanthakos, S. A., & Inge, T. H. (2006). Nutritional Consequences Of Bariatric Surgery. *Current Opinion In Clinical Nutrition And Metabolic Care, 9*(4), 489-496.

Xu Y, J. J., Kohno D, Williams Kw, Lee Ce, Choi Mj, Anderson Jg, Heisler Lk, Zigman Jm, Lowell Bb, Elmquist Jk. (2008). 5-Ht2crs Expressed By Pro-Opiomelanocortin Neurons Regulate Energy Homeostasis. . *Neuron, 60*, 582-589.

Yadav Vk, O. F., Suda N, Liu Z-W, Gao X-B, Confavreux C, Klemenhagen Kc, Tanaka Kf, Gingrich Ja, Guo Xe, Tecott Lh, Mann Jj, Hen R, Horvath Tl, Karsenty G. (2009). A Serotonin-Dependent Mechanism Explains The Leptin Regulation Of Bone Mass, Appetite And Energy Expenditure. *Cell, 138*, 976-989.

Yamada, H., Okumura, T., Motomura, W., Kobayashi, Y., & Kohgo, Y. (2000). Inhibition Of Food Intake By Central Injection Of Anti-Orexin Antibody In Fasted Rats. *Biochemical And Biophysical Research Communications, 267*(2), 527-531.

Yamada, J., Sugimoto, Y., & Yamada, S. (2004). Involvement Of Dopamine Receptors In The Anti-Immobility Effects Of Dopamine Re-Uptake Inhibitors In The Forced Swimming Test. *European Journal Of Pharmacology, 504*(3), 207-211.

Yamada, Y., Post, S. R., Wang, K., Tager, H. S., Bell, G. I., & Seino, S. (1992). Cloning And Functional-Characterization Of A Family Of Human And Mouse Somatostatin Receptors Expressed In Brain, Gastrointestinal-Tract, And Kidney. *Proceedings Of The National Academy Of Sciences Of The United States Of America, 89*(1), 251-255.

Yamamoto, A., & Sugimoto, Y. (2010). Involvement Of Peripheral Mu Opioid Receptors In Scratching Behavior In Mice. *European Journal Of Pharmacology, 649*(1-3), 336-341.

Yamamoto, Y., Ueta, Y., Serino, R., Nomura, M., Shibuya, I., & Yamashita, H. (2000). Effects Of Food Restriction On The Hypothalamic Prepro-Orexin Gene Expression In Genetically Obese Mice. *Brain Research Bulletin, 51*(6), 515-521.

Yamamoto, Y., Ueta, Y., Yamashita, H., Asayama, K., & Shirahata, A. (2002). Expressions Of The Prepro-Orexin And Orexin Type 2 Receptor Genes In Obese Rat. *Peptides, 23*(9), 1689-1696.

Yang, J., Brown, M. S., Liang, G., Grishin, N. V., & Goldstein, J. L. (2008). Identification Of The Acyltransferase That Octanoylates Ghrelin, An Appetite-Stimulating Peptide Hormone. *Cell, 132*(3), 387-396.

Yen, T. T., Wong, D. T., & Bemis, K. G. (1987). Reduction Of Food-Consumption And Body-Weight Of Normal And Obese Mice By Chronic Treatment With Fluoxetine - A Serotonin Reuptake Inhibitor. *Drug Development Research, 10*(1), 37-45.

Yeomans, M. R., & Gray, R. W. (2002). Opioid Peptides And The Control Of Human Ingestive Behaviour. *Neuroscience & Biobehavioral Reviews, 26*(6), 713-728.

Yeomans, M. R., & Wright, P. (1991). Lower Pleasantness Of Palatable Foods In Nalmefene-Treated Human Volunteers. *Appetite, 16*(3), 249-259.

Yoneda, M., Raybould, H., & Tache, Y. (1991). Central Action Of Somatostatin Analog, Sms-201-995, To Stimulate Gastric-Acid Secretion In Rats. *Peptides, 12*(3), 401-406.

York, D. A., & Park, M. (2006). *Enterostatin, A Peptide Regulator Of Dietary Fat Ingestion*.

Yoshimichi, G., Lo, C. C., Tamashiro, K. L. K., Ma, L., Lee, D. M., Begg, D. P., Liu, M., Sakai, R. R., Woods, S. C., Yoshimatsu, H., & Tso, P. (2012). Effect Of Peripheral Administration Of Cholecystokinin On Food Intake In Apolipoprotein Aiv Knockout Mice. *American Journal Of Physiology-Gastrointestinal And Liver Physiology, 302*(11), G1336-G1342.

Yoshioka, M., Matsumoto, M., Togashi, H., Smith, C. B., & Saito, H. (1993). Opioid Receptor Regulation Of 5-Hydroxytryptamine Release From The Rat Hippocampus Measured By Invivo Microdialysis. *Brain Research, 613*(1), 74-79.

Young, A. A., Bhavsar, S. P., Lachappell, R., & Watkins, J. J. (1998). Exendin-4 Is More Potent Than Glp-1 In Lowering Plasma Glucose In Diabetic Mice. *Diabetologia, 41*, A176-A176.

Young, A. A., Gedulin, B. R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., & Denaro, M. (1999). Glucose-Lowering And Insulin-Sensitizing Actions Of Exendin-4 - Studies In Obese Diabetic (Ob/Ob, Db/Db) Mice, Diabetic Fatty Zucker Rats, And Diabetic Rhesus Monkeys (Macaca Mulatta). *Diabetes, 48*(5), 1026-1034.

Young, A. A., Jodka, C., Pittner, R., Parkes, D., & Gedulin, B. R. (2005). Dose-Response For Inhibition By Amylin Of Cholecystokinin-Stimulated Secretion Of Amylase And Lipase In Rats. *Regulatory Peptides, 130*(1-2), 19-26.

Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002). Effect Of 6-Week Course Of Glucagon-Like Peptide 1 On Glycaemic Control, Insulin Sensitivity, And Beta-Cell Function In Type 2 Diabetes: A Parallel-Group Study. *Lancet, 359*(9309), 824-830.

Zarrindast, M. R., & Abolfathiaraghi, F. (1992). Effects Of Bupropion On Core Body-Temperature Of Mice. *Psychopharmacology, 106*(2), 248-252.

Zarrindast, M. R., Hodjati, M. R., Pejhan, A., & Soleimannejad, E. (1996). Bupropion Induces Sniffing: A Possible Dopaminergic Mechanism. *European Neuropsychopharmacology, 6*(4), 299-303.

Zarrindast, M. R., & Hosseininia, T. (1988). Anorectic And Behavioral-Effects Of Bupropion. *General Pharmacology-The Vascular System, 19*(2), 201-204.

Zarrindast, M. R., & Minaian, A. (1991). Different Effects Of Direct And Indirect Dopamine Receptor Agonists On Immobility Time In Reserpine-Treated Mice. *General Pharmacology-The Vascular System, 22*(6), 1017-1021.

Zeng, H., Gragerov, A., Hohmann, J. G., Pavlova, M. N., Schimpf, B. A., Xu, H., Wu, L.-J., Toyoda, H., Zhao, M.-G., Rohde, A. D., Gragerova, G., Onrust, R., Bergmann, J. E., Zhuo, M., & Gaitanaris, G. A. (2006). Neuromedin U Receptor 2-Deficient Mice Display Differential Responses In Sensory Perception, Stress, And Feeding. *Molecular And Cellular Biology, 26*(24), 9352-9363.

Zentaris, Æ. (2009). Æterna Zentaris: New Data Published On Its Ghrelin Antagonist Compound, Aezs-123 (Jmv2959), Supports Its Use In Alcohol Addiction. Retrieved 6th September 2013, 2013, From Http://Www.Aezsinc.Com/En/Page.Php?P=60&Q=323

Zhang, G., Bai, H., Zhang, H., Dean, C., Wu, Q., Li, J., Guariglia, S., Meng, Q., & Cai, D. (2011). Neuropeptide Exocytosis Involving Synaptotagmin-4 And Oxytocin In Hypothalamic Programming Of Body Weight And Energy Balance. *Neuron, 69*(3), 523-535.

Zhang, J., Frassetto, A., Huang, R.-R. C., Lao, J. Z., Pasternak, A., Wang, S.-P., Metzger, J. M., Strack, A. M., Fong, T. M., & Chen, R. Z. (2006). The Mu-Opioid Receptor Subtype Is Required For The Anorectic Effect Of An Opioid Receptor Antagonist. *European Journal Of Pharmacology, 545*(2-3), 147-152.

Zhang, L., Nguyen, A. D., Lee, I. C. J., Yulyaningsih, E., Riepler, S. J., Stehrer, B., Enriquez, R. F., Lin, S., Shi, Y. C., Baldock, P. A., Sainsbury, A., & Herzog, H. (2012). Npy Modulates Pyy Function In The Regulation Of Energy Balance And Glucose Homeostasis. *Diabetes Obesity & Metabolism, 14*(8), 727-736.

Zhang, M., Gosnell, B. A., & Kelley, A. E. (1998). Intake Of High-Fat Food Is Selectively Enhanced By Muopioid Receptor Stimulation Within The Nucleus Accumbens. *Journal Of Pharmacology And Experimental Therapeutics, 285*(2), 908-914.

Zhang, M., Han, L., & Xu, Y. (2012). Roles Of Cocaine- And Amphetamine-Regulated Transcript In The Central Nervous System. *Clinical And Experimental Pharmacology And Physiology, 39*(6), 586-592.

Zhang, M., & Kelley, A. E. (2000). Enhanced Intake Of High-Fat Food Following Striatal Mu-Opioid Stimulation: Microinjection Mapping And Fos Expression. *Neuroscience, 99*(2), 267-277.

Zhang, Q., Li, H., & Guo, F. (2011). Amygdala, An Important Regulator For Food Intake. *Frontiers In Biology, 6*(1), 82-85.

Zhang, Y. Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994). Positional Cloning Of The Mouse Obese Gene And Its Human Homolog. *Nature, 372*(6505), 425-432.

Zheng, D. H., Wooter, M. H., Zhou, Q., & Dohm, G. L. (1996). The Effect Of Exercise On Ob Gene Expression. *Biochemical And Biophysical Research Communications, 225*(3), 747-750.

Zheng, H. Y., Patterson, L. M., & Berthoud, H. R. (2005). Orexin-A Projections To The Caudal Medulla And Orexin-Induced C-Fos Expression, Food Intake, And Autonomic Function. *Journal Of Comparative Neurology, 485*(2), 127-142.

Zhou, J., Roane, D. S., Li, X. C., Bogacka, I., Li, B., Ryan, D. H., & Martin, R. J. (2003). Short-Term Food Restriction And Refeeding Alter Expression Of Genes Likely Involved In Brain Glucosensing. *Experimental Biology And Medicine, 228*(8), 943-950.

Zigman, J. M., & Elmquist, J. K. (2003). Mini Review: From Anorexia To Obesity-The Yin And Yang Of Body Weight Control. *Endocrinology., 144*(9), 3749-3756.

Zoeller, R. T., Tan, S. W., & Tyl, R. W. (2007). General Background On The Hypothalamic-Pituitary-Thyroid (Hpt) Axis. *Critical Reviews In Toxicology, 37*(1-2), 11-53.

Zorrilla, E. P., Iwasaki, S., Moss, J. A., Chang, J., Otsuji, J., Inoue, K., Meijler, M. M., & Janda, K. D. (2006). Vaccination Against Weight Gain. *Proceedings Of The National Academy Of Sciences Of The United States Of America, 103*(35), 13226-13231.

Zorrilla, E. P., & Koob, G. F. (2004). The Therapeutic Potential Of Crf1 Antagonists For Anxiety. *Expert Opinion On Investigational Drugs, 13*(7), 799-828.

Zorrilla, E. P., Reinhardt, L. E., Valdez, G. R., Inoue, K., Rivier, J. E., Vale, W. W., & Koob, G. F. (2004). Human Urocortin 2, A Corticotropin-Releasing Factor (Crf)(2) Agonist, And Ovine Crf, A Crf1 Agonist, Differentially Alter Feeding And Motor Activity. *Journal Of Pharmacology And Experimental Therapeutics, 310*(3), 1027-1034.

Zuger, D., Forster, K., Lutz, T. A., & Riediger, T. (2013). Amylin And Glp-1 Target Different Populations Of Area Postrema Neurons That Are Both Modulated By Nutrient Stimuli. *Physiology & Behavior, 112-113*, 61-69.

Zung, W. W. K., Brodie, H. K. H., Fabre, L., Mclendon, D., & Garver, D. (1983). Comparative Efficacy And Safety Of Bupropion And Placebo In The Treatment Of Depression. *Psychopharmacology, 79*(4), 343-347.

Table of Contents - Appendices

Appendices

The Appendices contain additional statistical information from each study, and are numbered according to individual Experiments. Please refer to Section 3.10 of the Chapter 3 (General Methodology) for specific statistical analysis details.

Appendix 1 Statistical details for Experiment 1 (Chapter 4) – The Effects of Acute Polytherapy with Rimonabant (1.5 mg/kg) and Naloxone (0.1 and 0.01 mg/kg) on Food Intake, the Microstructure of Feeding Behaviour and Bodyweight Gain in Male Rats.

Appendix 1.1 Bonferroni Post Hoc Tests for Habituation Week Food Intake.

Only significant differences are displayed. (MD = mean difference; SE = standard error)

Habituation Trial		Bonferroni Post Hoc Tests
1	3	MD = -6.17, SE = 1.662, **p ≤ 0.05**
	5	MD = -8.51, SE = 1.84, **p ≤ 0.05**
2	5	MD = -4.44, SE = 0.916, **p ≤ 0.05**

Appendix 1.2 3 x 2 way ANOVA results for Total (1-hour) Behavioural Measures.

A Mauchly's value is not provided for the main effect of rimonabant because this factor has only two levels. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Behaviour	Main Effect of Rimonabant	Main effect of Naloxone		Rimonabant x Naloxone Interaction	
	F value df (1,9)	**Mauchly's W**	**F value** df (2,18)	**Mauchly's W**	**F value** df (2,18)
Food Intake	58.49, **p ≤ 0.001**	0.97, NS	2.28, NS	0.64, NS	1.46, NS
Eat Frequency	3.94, NS	1.00, NS	1.71, NS	0.40, **p ≤ 0.05**	0.50, NS (1.25, 11.28)
Eat Duration	31.13, **p ≤ 0.001**	0.93, NS	1.48, NS	0.78, NS	1.08, NS
Eat Bout Length	8.24, **p ≤ 0.05**	0.84, NS	0.03, NS	0.96, NS	0.53, NS
Eat Rate	1.19, NS	0.69, NS	0.27, NS	0.61, NS	0.15, NS
Eat Latency	2.56, NS	0.81, NS	3.87, **p ≤ 0.05**	0.74, NS	3.13, NS
Food ID Latency	0.59, NS	0.76, NS	1.21, NS	0.67, NS	0.88, NS
Locomotion Frequency	3.19, NS	0.95, NS	1.11, NS	0.93, NS	0.40, NS
Locomotion Duration	7.27, **p ≤ 0.05**	0.94, NS	3.00, NS	0.82, NS	0.61, NS
Rear Frequency	0.10, NS	0.86, NS	0.38, NS	0.93, NS	0.19, NS
Rear Duration	0.33, NS	0.79, NS	0.28, NS	0.77, NS	0.05, NS
Groom Frequency	21.73, **p ≤ 0.001**	0.56, NS	5.45, **p ≤ 0.05**	0.88, NS	1.17, NS
Groom Duration	37.88, **p ≤ 0.001**	0.37, **p ≤ 0.05**	5.70, **p ≤ 0.05**	0.70, NS	3.42, p ≤ 0.06 (1.23, 11.07)
Scratch Frequency	75.90, **p ≤ 0.001**	0.49, NS	2.64, NS	0.81, NS	1.33, NS
Scratch Duration	56.57, **p ≤ 0.001**	0.91, NS	2.29, NS	0.96, NS	1.35, NS
Rest Frequency	0.34, NS	0.57, NS	0.18, NS	0.80, NS	0.27, NS
Rest Duration	0.22, NS	0.94, NS	2.00, NS	0.89, NS	0.67, NS
Sniff Frequency	0.32, NS	0.95, NS	0.09, NS	0.72, NS	0.84, NS
Sniff Duration	0.03, NS	0.95, NS	0.31, NS	0.80, NS	0.98, NS

Appendix 1.3 Bonferroni Post Hoc Tests for Significant Main Effects of Rimonabant.

Values represent significant differences between vehicle and rimonabant 1.5mg/kg. (MD = mean difference; SE = standard error)

Behaviour	Bonferroni Post Hoc Tests
Food Intake	MD = 5.69, SD = 0.74, **p ≤ 0.001**
Eat Duration	MD = 270.96, SE = 48.57, **p ≤ 0.001**
Eat Bout Length	MD = 6.50, SE = 2.23, **p ≤ 0.05**
Locomotion Duration	MD = 88.49, SE = 32.82, **p ≤ 0.05**
Groom Frequency	MD = -13.96, SE = 3.00, **p ≤ 0.001**
Groom Duration	MD = -257.76, SE = 41.88, **p ≤ 0.001**
Scratch Frequency	MD = -54.03, SE = 6.20, **p ≤ 0.001**
Scratch Duration	MD = -194.12, SE = 25.81, **p ≤ 0.001**

Appendix 1.4 Bonferroni Post Hoc Tests for Significant Main Effects of Naloxone.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour	Bonferroni Post Hoc Tests
Groom Frequency	0.1mg/kg: MD = 11.92, SE = 2.47, **p ≤ 0.01**
Groom Duration	0.1mg/kg: MD = 204.03, SE = 54.13, **p ≤ 0.05**

Appendix 1.5 Periodic (Timebin) Behavioural Analyses.

Behaviour	Main Effect of Time	Time x Rimonabant Interaction	Time x Naloxone Interaction	Time x Rimonabant x Naloxone Interaction
	F Value df (11,99)	**F Value** df (11,99)	**F Value** df (22,198)	**F Value** df (22,198)
Eat Frequency	90.55, **p ≤ 0.001**	0.98, NS	0.64, NS	1.17, NS
Eat Duration	36.09, **p ≤ 0.001**	4.61, **p ≤ 0.001**	0.88, NS	0.45, NS
Locomotion Frequency	71.97, **p ≤ 0.001**	1.87, p ≤ 0.06	1.14, NS	0.57, NS
Locomotion Duration	65.85, **p ≤ 0.001**	2.04, **p ≤ 0.05**	0.96, NS	0.72, NS
Rear Frequency	49.94, **p ≤ 0.001**	2.58, **p ≤ 0.01**	0.75, NS	0.44, NS
Rear Duration	10.28, **p ≤ 0.001**	2.07, **p ≤ 0.05**	1.04, NS	0.65, NS
Groom Frequency	3.77, **p ≤ 0.001**	2.94, **p ≤ 0.01**	0.64, NS	0.73, NS
Groom Duration	2.12, **p ≤ 0.05**	1.96, **p ≤ 0.05**	0.55, NS	1.23, NS
Scratch Frequency	17.60, **p ≤ 0.001**	13.92, **p ≤ 0.001**	1.21, NS	0.55, NS
Scratch Duration	1.98, **p ≤ 0.05**	2.85, **p ≤ 0.01**	0.88, NS	0.68, NS
Rest Frequency	17.10, **p ≤ 0.001**	0.58, NS	0.94, NS	0.81, NS
Rest Duration	35.77, **p ≤ 0.001**	0.84, NS	1.04, NS	0.63, NS
Sniff Frequency	10.97, **p ≤ 0.001**	2.59, **p ≤ 0.01**	1.21, NS	0.99, NS
Sniff Duration	10.40, **p ≤ 0.001**	2.68, **p ≤ 0.01**	1.18, NS	1.11, NS

Appendix 1.6 Follow up ANOVAs for the Significant Time x Rimonabant Interactions for Eat Duration, Locomotion Duration, and Groom Duration.

The time x rimonabant interaction was followed up with 3 x 2 (rimonabant x naloxone) ANOVA's within each timebin to determine where there was a significant main effect of rimonabant.

Timebin	Main Effect of Rimonabant F Value df (1,9)		
	Eat Duration	**Locomotion Duration**	**Groom Duration**
1 (0-5 min)	10.29, **$p \leq 0.05$**	0.60, NS	10.26, **$p \leq 0.05$**
2 (5-10 min)	23.23, **$p \leq 0.001$**	0.87, NS	5.54, **$p \leq 0.05$**
3 (10-15 min)	17.04, **$p \leq 0.01$**	0.97, NS	1.70, NS
4 (15-20 min)	2.38, NS	19.12, **$p \leq 0.01$**	6.53, **$p \leq 0.05$**
5 (20-25 min)	0.58, NS	14.74, **$p \leq 0.01$**	2.02, NS
6 (25-30 min)	0.50, NS	5.45, **$p \leq 0.05$**	9.95, **$p \leq 0.05$**
7 (30-35 min)	0.00, NS	0.10, NS	3.70, NS
8 (35-40 min)	0.25, NS	11.54, **$p \leq 0.01$**	22.13, **$p \leq 0.001$**
9 (40-45 min)	0.13, NS	3.12, NS	3.13, NS
10 (45-50 min)	9.23, **$p \leq 0.05$**	0.82, NS	3.15, NS
11 (50-55 min)	0.04, NS	7.56, **$p \leq 0.05$**	2.03, NS
12 (55-60 min)	2.25, NS	0.35, NS	2.59, NS

Appendix 1.7 Follow up ANOVAs for the Significant Time x Rimonabant Interactions for Scratch Duration, Sniff Duration and Rear Duration

The time x rimonabant interaction was followed up with 3 x 2 (rimonabant x naloxone) ANOVA's within each timebin to determine where there was a significant main effect of rimonabant.

Timebin	Main Effect of Rimonabant F Value df (1,9)		
	Scratch Duration	**Sniff Duration**	**Rear Duration**
1 (0-5 min)	62.59, **$p \leq 0.001$**	0.69, NS	6.75, **$p \leq 0.05$**
2 (5-10 min)	56.65, **$p \leq 0.001$**	8.95, **$p \leq 0.05$**	3.41, NS
3 (10-15 min)	25.79, **$p \leq 0.001$**	6.06, **$p \leq 0.05$**	8.07, **$p \leq 0.05$**
4 (15-20 min)	24.52, **$p \leq 0.001$**	0.60, NS	5.83, **$p \leq 0.05$**
5 (20-25 min)	18.71, **$p \leq 0.01$**	0.04, NS	1.63, NS
6 (25-30 min)	38.15, **$p \leq 0.001$**	1.26, NS	0.78, NS
7 (30-35 min)	13.27, **$p \leq 0.01$**	0.86, NS	0.47, NS
8 (35-40 min)	27.83, **$p \leq 0.001$**	3.95, NS	5.87, **$p \leq 0.05$**
9 (40-45 min)	5.98, **$p \leq 0.05$**	4.46, NS	0.11, NS
10 (45-50 min)	25.85, **$p \leq 0.001$**	1.50, NS	0.30, NS
11 (50-55 min)	23.86, **$p \leq 0.001$**	0.99, NS	0.01, NS
12 (55-60 min)	0.99, NS	0.02, NS	0.22, NS

Appendix 1.8 Follow up ANOVAs for the Significant Time x Rimonabant Interactions for Rear Frequency, Groom Frequency, Scratch Frequency and Sniff Frequency

The time x rimonabant interaction was followed up with 3 x 2 (rimonabant x naloxone) ANOVA's within each timebin to determine where there was a significant main effect of rimonabant.

Timebin	Main Effect of Rimonabant F Value df (1,9)			
	Rear Frequency	**Groom Frequency**	**Scratch Frequency**	**Sniff Frequency**
1 (0-5 min)	4.99, **$p \leq 0.06$**	15.27, **$p \leq 0.01$**	51.26, **$p \leq 0.001$**	0.74, NS
2 (5-10 min)	2.11, NS	15.13, **$p \leq 0.01$**	66.96, **$p \leq 0.001$**	15.14, **$p \leq 0.01$**
3 (10-15 min)	1.50, NS	4.80, $p \leq 0.06$	58.04, **$p \leq 0.001$**	19.63, **$p \leq 0.01$**

4 (15-20 min)	9.01, **p ≤ 0.05**	3.72, NS	74.19, **p ≤ 0.001**	0.00, NS
5 (20-25 min)	0.39, NS	7.41, **p ≤ 0.05**	29.23, **p ≤ 0.001**	0.40, NS
6 (25-30 min)	0.15, NS	11.45, **p ≤ 0.01**	45.93, **p ≤ 0.001**	0.35, NS
7 (30-35 min)	0.30, NS	11.36, **p ≤ 0.01**	61.57, **p ≤ 0.001**	0.03, NS
8 (35-40 min)	5.30, **p ≤ 0.05**	13.82, **p ≤ 0.01**	29.91, **p ≤ 0.001**	2.30, NS
9 (40-45 min)	0.12, NS	6.27, **p ≤ 0.05**	10.83, **p ≤ 0.01**	0.87, NS
10 (45-50 min)	0.18, NS	12.91, **p ≤ 0.01**	17.87, **p ≤ 0.01**	0.66, NS
11 (50-55 min)	0.78, NS	1.59, NS	45.29, **p ≤ 0.001**	4.05, NS
12 (55-60 min)	1.24, NS	1.50, NS	5.47, **p ≤ 0.05**	0.00, NS

Appendix 1.9 Bonferroni Post Hoc Tests for Main Effect of Rimonabant on Eat Duration in Timebins 1-3 and 10.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Main Effect of Rimonabant
	F Value df (1,9)
1 (0-5 min)	MD = 45.67, SE = 14.24, **p ≤ 0.05**
2 (5-10 min)	MD = 73.74, SE = 15.30, **p ≤ 0.001**
3 (10-15 min)	MD = 69.69, SE = 16.89, **p ≤ 0.01**
10 (45-50 min)	MD = 34.40, SE = 11.33, **p ≤ 0.05**

Appendix 1.10 Bonferroni Post Hoc Tests for Main Effect of Rimonabant on Locomotion Duration in Timebins 4-6, 8 and 11.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Main Effect of Rimonabant
	F Value df (1,9)
4 (15-20 min)	MD = 16.10, SE = 3.68, **p ≤ 0.01**
5 (20-25 min)	MD = 16.20, SE = 4.22, **p ≤ 0.01**
6 (25-30 min)	MD = 7.45, SE = 3.19, **p ≤ 0.05**
8 (35-40 min)	MD = 11.62, SE = 3.42, **p ≤ 0.01**
11 (50-55 min)	MD = 8.55, SE = 3.11, **p ≤ 0.05**

Appendix 1.11 Bonferroni Post Hoc Tests for Main Effect of Rimonabant on Groom Duration and Frequency in Timebins 1, 2, and 4-10.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Main Effect of Rimonabant (1.5mg/kg) F Value df (1,9)	
	Groom Duration	**Groom Frequency**
1 (0-5 min)	MD = -18.54, SE = 5.79, **p ≤ 0.05**	MD = -1.32, SE = 0.34, **p ≤ 0.01**
2 (5-10 min)	MD = -19.35, SE = 8.22, **p ≤ 0.05**	MD = -2.64, SE = 0.68, **p ≤ 0.01**
4 (15-20 min)	MD = -32.32, SE = 12.65, **p ≤ 0.05**	
5 (20-25 min)		MD = -1.12, SE = 0.41, **p ≤ 0.05**
6 (25-30 min)	MD = -26.75, SE = 8.48, **p ≤ 0.05**	MD = -1.48, SE = 0.44, **p ≤ 0.01**
7 (30-35 min)		MD = -1.13, SE = 0.33, **p ≤ 0.01**
8 (35-40 min)	MD = -52.74, SE = 11.21, **p ≤ 0.001**	MD = -2.12, SE = 0.57, **p ≤ 0.01**
9 (40-45 min)		MD = -1.02, SE = 0.41, **p ≤ 0.05**
10 (45-50 min)		MD = -1.13, SE = 0.31, **p ≤ 0.01**

Appendix 1.12 Bonferroni Post Hoc Tests for Main Effect of Rimonabant on Scratch Duration and Frequency in Timebins 1-12.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Main Effect of Rimonabant F Value df (1,9)	
	Scratch Duration	**Scratch Frequency**
1 (0-5 min)	MD = -11.91, SE = 1.51, **p ≤ 0.001**	MD = -8.20, SE = 1.15, **p ≤ 0.001**
2 (5-10 min)	MD = -16.56, SE = 2.20, **p ≤ 0.001**	MD = -7.47, SE = 0.91, **p ≤ 0.001**
3 (10-15 min)	MD = -19.20, SE = 3.78, **p ≤ 0.001**	MD = -6.49, SE = 0.85, **p ≤ 0.001**
4 (15-20 min)	MD = -24.42, SE = 4.93, **p ≤ 0.001**	MD = -6.60, SE = 0.77, **p ≤ 0.001**
5 (20-25 min)	MD = -18.16, SE = 4.20, **p ≤ 0.01**	MD = -3.93, SE = 0.73, **p ≤ 0.001**
6 (25-30 min)	MD = -23.46, SE = 3.80, **p ≤ 0.001**	MD = -4.67, SE = 0.69, **p ≤ 0.001**
7 (30-35 min)	MD = -18.56, SE = 5.09, **p ≤ 0.01**	MD = -4.19, SE = 0.53, **p ≤ 0.001**
8 (35-40 min)	MD = -17.43, SE = 3.30, **p ≤ 0.001**	MD = -3.50, SE = 0.64, **p ≤ 0.001**
9 (40-45 min)	MD = -14.52, SE = 5.94, **p ≤ 0.05**	MD = -2.26, SE = 0.69, **p ≤ 0.01**
10 (45-50 min)	MD = -14.38, SE = 2.83, **p ≤ 0.001**	MD = -3.27, SE = 0.77, **p ≤ 0.01**
11 (50-55 min)	MD = -11.26, SE = 2.31, **p ≤ 0.001**	MD = -2.64, SE = 0.39, **p ≤ 0.001**
12 (55-60 min)		MD = -1.64, SE = 0.70, **p ≤ 0.05**

Appendix 1.13 Bonferroni Post Hoc Tests for Main Effect of Rimonabant on Sniff Duration and Frequency in Timebins 2 and 3.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Main Effect of Rimonabant F Value df (1,9)	
	Sniff Duration	**Sniff Frequency**
2 (5-10 min)	MD = -30.86, SE = 10.32, **p ≤ 0.05**	MD = -6.17, SE = 1.59, **p ≤ 0.01**
3 (10-15 min)	MD = -31.26, SE = 12.70, **p ≤ 0.05**	MD = -7.14, SE = 1.61, **p ≤ 0.01**

Appendix 1.14 Bonferroni Post Hoc Tests for Main Effect of Rimonabant on Rear Duration and Frequency in Timebins 1, 3, 4 and 8.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Main Effect of Rimonabant F Value df (1,9)	
	Rear Duration	**Rear Frequency**
1 (0-5 min)	MD = -10.66, SE = 4.10, **p ≤ 0.05**	
3 (10-15 min)	MD = -11.93, SE = 4.20, **p ≤ 0.05**	
4 (15-20 min)	MD = -12.32, SE = 5.10, **p ≤ 0.05**	MD = -3.04, SE = 1.01, **p ≤ 0.05**
8 (35-40 min)	MD = -12.88, SE = 5.32, **p ≤ 0.05**	MD = -2.30, SE = 1.00, **p ≤ 0.05**

Appendix 2 Statistical details for Experiment 2 (Chapter 4) – Statistical details for Experiment 1 (Chapter 4) – The Effects with Acute Polytherapy of Rimonabant (1.5 mg/kg) and Naloxone (0.5 mg/kg) on Food Intake, the Microstructure of Feeding Behaviour and Bodyweight Gain in Male Rats.

Appendix 2.1 Bonferroni Post Hoc Tests for Habituation Week Food Intake.

Only significant differences are displayed. (MD = mean difference; SE = standard error)

Habituation Trial		Bonferroni Post Hoc Tests
1	3	MD = -4.29, SE = 1.02, **p ≤ 0.05**
	4	MD = -9.37, SE = 0.99, **p ≤ 0.001**
	5	MD = -8.00, SE = 2.05, **p ≤ 0.05**
2	4	MD = -6.03, SE = 0.99, **p ≤ 0.05**
3	4	MD = -5.09, SE = 0.58, **p ≤ 0.001**

Appendix 2.2 3 x 2 way ANOVA results for Total (1-hour) Behavioural Measures.

Mauchly's values are not provided because both factors have only two levels.

Behaviour	Main Effect of Rimonabant	Main effect of Naloxone	Rimonabant x Naloxone Interaction
	F value df (1,9)	**F value** df (2,18)	**F value** df (2,18)
Food Intake	43.34, **p ≤ 0.001**	1.45, NS	0.03, NS
Eat Frequency	5.53, **p ≤ 0.05**	1.44, NS	0.94, NS
Eat Duration	29.06, **p ≤ 0.001**	0.69, NS	0.03, NS
Eat Bout Length	4.17, NS	0.33, NS	0.62, NS
Eat Rate	0.06, NS	0.15, NS	0.24, NS
Eat Latency	3.87, NS	0.24, NS	0.63, NS
Food ID Latency	1.37, NS	2.16, NS	0.69, NS
Locomotion Frequency	9.86, **p ≤ 0.05**	1.29, NS	0.42, NS
Locomotion Duration	15.95, **p ≤ 0.01**	2.30, NS	0.26, NS
Rear Frequency	4.92, p ≤ 0.06	0.01, NS	0.49, NS
Rear Duration	3.08, NS	0.11, NS	0.46, NS
Groom Frequency	25.12, **p ≤ 0.001**	0.37, NS	0.10, NS
Groom Duration	61.50, **p ≤ 0.001**	2.95, NS	2.32, NS
Scratch Frequency	58.67, **p ≤ 0.001**	0.09, NS	0.62, NS
Scratch Duration	60.88, **p ≤ 0.001**	0.36, NS	0.27, NS
Rest Frequency	0.47, NS	0.00, NS	0.21, NS
Rest Duration	0.29, NS	2.24, NS	1.31, NS
Sniff Frequency	3.66, NS	0.12, NS	1.33, NS
Sniff Duration	5.90, **p ≤ 0.05**	0.00, NS	1.61, NS

Appendix 2.3 Bonferroni Post Hoc Tests for Significant Main Effects of Rimonabant.

Values represent significant differences between vehicle and rimonabant 1.5mg/kg. (MD = mean difference; SE = standard error)

Behaviour	Bonferroni Post Hoc Tests
Food Intake	MD = 7.17, SD = 1.09, **$p \leq 0.001$**
Eat Frequency	MD = 11.35, SE = 4.83, **$p \leq 0.05$**
Eat Duration	MD = 262.96, SE = 48.78, **$p \leq 0.001$**
Locomotion Frequency	MD = 40.40, SE = 12.87, **$p \leq 0.05$**
Locomotion Duration	MD = 75.89, SE = 19.00, **$p \leq 0.01$**
Groom Frequency	MD = -21.75, SE = 4.34, **$p \leq 0.001$**
Groom Duration	MD = -420.82, SE = 53.66, **$p \leq 0.001$**
Scratch Frequency	MD = -66.10, SE = 8.63, **$p \leq 0.001$**
Scratch Duration	MD = -262.44, SE = 33.63, **$p \leq 0.001$**
Sniff Duration	MD = 246.81, SE = 101.62, **$p \leq 0.05$**

Appendix 2.4 Periodic (Timebin) Behavioural Analyses.

Behaviour	Main Effect of Time	Time x Rimonabant Interaction	Time x Naloxone Interaction	Time x Rimonabant x Naloxone Interaction
	F Value df (11,99)	**F Value** df (11,99)	**F Value** df (22,198)	**F Value** df (22,198)
Eat Frequency	43.54, **$p \leq 0.001$**	1.95, **$p \leq 0.05$**	0.72, NS	1.34, NS
Eat Duration	13.08, **$p \leq 0.001$**	4.00, **$p \leq 0.001$**	0.72, NS	2.43, **$p \leq 0.01$**
Locomotion Frequency	73.43, **$p \leq 0.001$**	1.19, NS	0.87, NS	0.99, NS
Locomotion Duration	49.23, **$p \leq 0.001$**	0.95, NS	0.67, NS	0.92, NS
Rear Frequency	50.93, **$p \leq 0.001$**	0.88, NS	1.46, NS	2.03, NS
Rear Duration	9.24, **$p \leq 0.001$**	1.34, NS	1.55, NS	1.74, NS
Groom Frequency	1.83, $p \leq 0.06$	1.59, NS	1.20, NS	0.90, NS
Groom Duration	1.74, NS	1.09, NS	1.19, NS	0.61, NS
Scratch Frequency	8.56, **$p \leq 0.001$**	7.74, **$p \leq 0.001$**	0.36, NS	0.24, NS
Scratch Duration	2.16, **$p \leq 0.05$**	1.34, NS	0.94, NS	0.64, NS
Rest Frequency	10.37, **$p \leq 0.001$**	0.33, NS	1.13, NS	0.51, NS
Rest Duration	18.99, **$p \leq 0.001$**	0.50, NS	2.88, **$p \leq 0.01$**	0.73, NS
Sniff Frequency	54.02, **$p \leq 0.001$**	1.45, NS	0.84, NS	1.72, NS
Sniff Duration	5.79, **$p \leq 0.001$**	1.85, $p \leq 0.06$	1.27, NS	1.26, NS

Appendix 2.5 Follow up ANOVAs for the Significant Time x Rimonabant Interactions for Eat Frequency and Scratch Frequency.

The time x rimonabant interaction was followed up with 2 x 2 (rimonabant x naloxone) ANOVA's within each timebin to determine where there was a significant main effect of rimonabant.

Timebin	Main Effect of Rimonabant **F Value** df (1,9)	
	Eat Frequency	**Scratch Frequency**
1 (0-5 min)	3.69, NS	42.78, **$p \leq 0.001$**
2 (5-10 min)	10.73, **$p \leq 0.01$**	66.13, **$p \leq 0.001$**
3 (10-15 min)	3.44, NS	36.27, **$p \leq 0.001$**
4 (15-20 min)	3.89, NS	30.89, **$p \leq 0.001$**
5 (20-25 min)	2.54, NS	11.56, **$p \leq 0.001$**
6 (25-30 min)	0.01, NS	21.96, **$p \leq 0.001$**
7 (30-35 min)	2.25, NS	18.49, **$p \leq 0.001$**
8 (35-40 min)	0.01, NS	46.45, **$p \leq 0.001$**

9 (40-45 min)	0.68, NS	13.97, **$p \leq 0.001$**
10 (45-50 min)	0.02, NS	108.17, **$p \leq 0.001$**
11 (50-55 min)	0.28, NS	14.61, **$p \leq 0.001$**
12 (55-60 min)	0.00, NS	12.90, **$p \leq 0.001$**

Appendix 2.6 Bonferroni Post Hoc Tests for Main Effect of Rimonabant on Eat Frequency in Timebin 2.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Main Effect of Rimonabant
	F Value df (1,9)
2 (5-10 min)	MD = 3.25, SE = 0.99, **$p \leq 0.01$**

Appendix 2.7 Bonferroni Post Hoc Tests for Main Effect of Rimonabant on Scratch Frequency in Timebins 1-12.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Main Effect of Rimonabant
	F Value df (1,9)
1 (0-5 min)	MD = -10.75, SE = 1.64, **$p \leq 0.001$**
2 (5-10 min)	MD = -8.25, SE = 1.01, **$p \leq 0.001$**
3 (10-15 min)	MD = -7.45, SE = 1.24, **$p \leq 0.001$**
4 (15-20 min)	MD = -6.60, SE = 1.19, **$p \leq 0.001$**
5 (20-25 min)	MD = -5.15, SE = 1.52, **$p \leq 0.01$**
6 (25-30 min)	MD = -5.55, SE = 1.18, **$p \leq 0.001$**
7 (30-35 min)	MD = -4.85, SE = 1.13, **$p \leq 0.01$**
8 (35-40 min)	MD = -5.10, SE = 0.75, **$p \leq 0.001$**
9 (40-45 min)	MD = -3.75, SE = 1.00, **$p \leq 0.01$**
10 (45-50 min)	MD = -4.55, SE = 0.44, **$p \leq 0.001$**
11 (50-55 min)	MD = -2.85, SE = 0.75, **$p \leq 0.01$**
12 (55-60 min)	MD = -2.35, SE = 0.65, **$p \leq 0.01$**

Appendix 2.8 Follow up ANOVAs for the Significant Time x Naloxone Interactions for Rest Duration.

The time x rimonabant interaction was followed up with 2 x 2 (rimonabant x naloxone) ANOVA's within each timebin to determine where there was a significant main effect of naloxone.

Timebin	Main Effect of Naloxone
	F Value df (1,9)
1 (0-5 min)	1.00, NS
2 (5-10 min)	0.93, NS
3 (10-15 min)	1.55, NS
4 (15-20 min)	0.11, NS
5 (20-25 min)	0.99, NS
6 (25-30 min)	0.78, NS
7 (30-35 min)	0.01, NS
8 (35-40 min)	0.11, NS
9 (40-45 min)	4.79, $p \leq 0.06$
10 (45-50 min)	6.02, **$p \leq 0.05$**
11 (50-55 min)	1.99, NS
12 (55-60 min)	3.64, NS

Appendix 2.9 Bonferroni Post Hoc Tests for Main Effect of Naloxone on Eat Frequency in Timebin 10.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Main Effect of Naloxone (0.5mg/kg)
	F Value df (1,9)
10 (45-50 min)	MD = -77.01, SE = 31.38, **$p \leq 0.05$**

Appendix 2.10 Follow up 2 way (Rimonabant x Naloxone) ANOVAs for the Significant Time x Rimonabant x Naloxone Interactions for Eat Duration.

Timebin	Main Effect of Rimonabant	Main Effect of Naloxone	Rimonabant x Naloxone Interaction
	F Value df (1,9)	**F Value** df (11,99)	**F Value** df (11,99)
1 (0-5 min)	14.95, **$p \leq 0.01$**	0.44, NS	1.85, NS
2 (5-10 min)	27.34, **$p \leq 0.001$**	1.58, NS	1.58, NS
3 (10-15 min)	18.76, **$p \leq 0.01$**	0.00, NS	1.83, NS
4 (15-20 min)	6.59, **$p \leq 0.05$**	1.50, NS	9.98, **$p \leq 0.05$**
5 (20-25 min)	3.88, NS	0.01, NS	0.53, NS
6 (25-30 min)	0.60, NS	5.06, $p \leq 0.06$	0.19, NS
7 (30-35 min)	0.97, NS	0.96, NS	1.39, NS
8 (35-40 min)	0.11, NS	4.20, NS	0.14, NS
9 (40-45 min)	0.45, NS	0.31, NS	3.01, NS
10 (45-50 min)	0.00, NS	0.44, NS	3.60, NS
11 (50-55 min)	0.49, NS	0.17, NS	0.23, NS
12 (55-60 min)	0.38, NS	0.48, NS	7.32, **$p \leq 0.05$**

Appendix 2.11 Bonferroni Post Hoc Tests for Main Effect of Rimonabant on Eat Duration in Timebins 1 - 4.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Main Effect of Rimonabant (1.5mg/kg)
	F Value df (1,9)
1 (0-5 min)	MD = 43.91, SE = 11.36, **$p \leq 0.01$**
2 (5-10 min)	MD = 77.13, SE = 14.75, **$p \leq 0.001$**
3 (10-15 min)	MD = 36.10, SE = 8.34, **$p \leq 0.01$**
4 (15-20 min)	MD = 34.47, SE = 12.42, **$p \leq 0.05$**

Appendix 3 CORRESPONDENCE WITH DRY MASH SUPPLIER REGARDING EXPERIMENT 2 FOOD CONTAMINATION.

From: Roxanne Newman [mailto:rn@dilsds.com]
Sent: 17 May 2012 15:32
To: Neil Lowley
Cc: Allula Warmington; Denise Myatt; Sue Dolan
Subject: CNCN 111124.08 BK001 (E) FG contaminated with insects

Dear Neil Lowley,

I would like to introduce myself as the Technical & Quality Assistant for SDS and I am currently investigating the report regarding CNCN 111124.08 BK001 (E) FG contaminated with insects.

Please accept my apologies for the delay in response regarding this CNCN, we have been reviewing our corrective actions over the last few months to ensure that they are working effectively.

Please see final report below:

Investigation
A sample of the insects was received and identified as Tribolium Confusum also known as a flour beetle.
We assessed and inspected all raw materials and areas of production and pest control logs. As part of this investigation we thoroughly inspected the grinder that this diet was manufactured on – this was found to be the source of the insects.

Corrective Action
Due to the presence of insects, the grinder has undergone a thorough cleaning and treatment program. As part of our ongoing improvement we have increased our vigorous pest control program for the grinding equipment that this diet was manufactured on.
As mentioned above SDS have been reviewing the grinder over the last few months and we have had no further issues.

3x bags of BK001 (E) FG have been replaced free of charge.

I hope that our report meets with your satisfaction and I would appreciate receiving your feedback and if you are happy for us to close out this non-conformance for use in our trend analysis.

Kind Regards,
Roxanne Newman
Technical & Quality Assistant

Special Diets Services
P.O. Box 705
Witham
Essex
CM8 3AD

Tel: +44 (0)1376 513651
Fax: +44 (0)1376 511247
Email: rn@dilsds.com

Appendix 4 Statistical details for Experiment 3 (Chapter 4) – The Effects with Acute Polytherapy of Rimonabant (1.5 mg/kg) and Nalxone (0.5 mg/kg) on Food Intake, The Microstructure of Feeding Behaviour and Bodyweight Gain in Male Rats (n=9).

Appendix 4.1 Bonferroni Post Hoc Tests for Habituation Week Food Intake.

Only significant differences are displayed. (MD = mean difference; SE = standard error)

Habituation Trial		Bonferroni Post Hoc Tests
1	3	MD = -4.33, SE = 1.10, **p ≤ 0.05**
	4	MD = -6.82, SE = 1.61, **p ≤ 0.01**

Appendix 4.2 3 x 2 way ANOVA results for Total (1-hour) Behavioural Measures.

Mauchly's values are not provided because both factors have only two levels

Behaviour	Main Effect of Rimonabant	Main effect of Naloxone	Rimonabant x Naloxone Interaction
	F value df (1,8)	**F value** df (1,8)	**F value** df (1,8)
Food Intake	115.63, **p ≤ 0.001**	4.46, NS	0.88, NS
Eat Frequency	7.50, **p ≤ 0.05**	12.94, **p ≤ 0.01**	2.03, NS
Eat Duration	39.31, **p ≤ 0.001**	2.12, NS	0.06, NS
Eat Bout Length	1.23, NS	0.52, NS	1.28, NS
Eat Rate	8.36, **p ≤ 0.05**	0.23, NS	0.01, NS
Eat Latency	0.60, NS	0.00, NS	0.28, NS
Food ID Latency	1.60, NS	0.17, NS	0.08, NS
Locomotion Frequency	19.54, **p ≤ 0.01**	0.26, NS	0.86, NS
Locomotion Duration	26.17, **p ≤ 0.001**	3.89, NS	2.56, NS
Rear Frequency	15.68, **p ≤ 0.01**	2.08, NS	0.27, NS
Rear Duration	26.05, **p ≤ 0.001**	0.25, NS	0.34, NS
Groom Frequency	45.97, **p ≤ 0.001**	7.12, **p ≤ 0.05**	4.40, NS
Groom Duration	87. 51, **p ≤ 0.001**	16.10, **p ≤ 0.01**	15.53, **p ≤ 0.01**
Scratch Frequency	155.21, **p ≤ 0.001**	2.77, NS	2.58, NS
Scratch Duration	66.85, **p ≤ 0.001**	11.15, **p ≤ 0.01**	13.26, **p ≤ 0.01**
Rest Frequency	0.36, NS	1.64, NS	2.65, NS
Rest Duration	1.09, NS	6.38, **p ≤ 0.05**	3.24, NS
Sniff Frequency	0.63, NS	4.04, NS	0.03, NS
Sniff Duration	10.35, **p ≤ 0.05**	3.44, NS	0.19, NS

Appendix 4.3 Bonferroni Post Hoc Tests for Significant Main Effects of Rimonabant.

Values represent significant differences between vehicle and rimonabant 1.5mg/kg. (MD = mean difference; SE = standard error)

Behaviour	Bonferroni Post Hoc Tests
Food Intake	MD = 7.08, SD = 0.66, **p ≤ 0.001**
Eat Frequency	MD = 14.61, SE = 5.34, **p ≤ 0.05**
Eat Duration	MD = 182.83, SE = 29.16, **p ≤ 0.001**
Eat Rate	MD = 0.34, SE = 0.12, **p ≤ 0.05**
Locomotion Frequency	MD = 45.42, SE = 10.28, **p ≤ 0.01**
Locomotion Duration	MD = 51.75, SE = 10.12, **p ≤ 0.001**
Rear Frequency	MD = 39.25, SE = 9.91, **p ≤ 0.01**
Rear Duration	MD = 189.72, SE = 37.17, **p ≤ 0.001**
Groom Frequency	MD = -22, 02, SE = 3.25, **p ≤ 0.001**

Groom Duration	MD = -298.51, SE = 31.91, **$p \leq 0.001$**
Scratch Frequency	MD = -71.82, SE = 5.77, **$p \leq 0.001$**
Scratch Duration	MD = -270.77, SE = 33.12, **$p \leq 0.001$**
Sniff Duration	MD = 320.37, SE = 99.60, **$p \leq 0.01$**

Appendix 4.4 Bonferroni Post Hoc Tests for Significant Main Effects of Naloxone.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour	Bonferroni Post Hoc Tests
Eat Frequency	MD = 10.68, SE = 2.97, **$p \leq 0.01$**
Groom Frequency	MD = -13.17, SE = 4.94, **$p \leq 0.05$**
Groom Duration	MD = 222.42, SE = 55.44, **$p \leq 0.01$**
Scratch Duration	MD = 138.59, SE = 41.50, **$p \leq 0.01$**
Rest Duration	MD = 356.48, SE = 141.11, **$p \leq 0.05$**

Appendix 4.5 Periodic (Timebin) Behavioural Analyses.

Behaviour	Main Effect of Time	Time x Rimonabant Interaction	Time x Naloxone Interaction	Time x Rimonabant x Naloxone Interaction
	F Value df (11,88)	**F Value** df (11,88)	**F Value** df (11,88)	**F Value** df (22,88)
Eat Frequency	72.36, **$p \leq 0.001$**	2.62, **$p \leq 0.01$**	0.60, NS	1.17, NS
Eat Duration	17.21, **$p \leq 0.001$**	4.18, **$p \leq 0.001$**	0.54, NS	0.76, NS
Locomotion Frequency	44.26, **$p \leq 0.001$**	1.52, NS	1.12, NS	0.63, NS
Locomotion Duration	35.78, **$p \leq 0.001$**	1.83, $p \leq 0.06$	0.87, NS	0.62, NS
Rear Frequency	37.76, **$p \leq 0.001$**	1.28, NS	0.44, NS	0.51, NS
Rear Duration	11.48, **$p \leq 0.001$**	2.28, **$p \leq 0.05$**	1.02, NS	0.81, NS
Groom Frequency	4.32, **$p \leq 0.001$**	2.41, **$p \leq 0.05$**	0.96, NS	0.51, NS
Groom Duration	2.04, **$p \leq 0.05$**	1.18, NS	1.56, NS	0.98, NS
Scratch Frequency	13.64, **$p \leq 0.001$**	14.52, **$p \leq 0.001$**	1.94, **$p \leq 0.05$**	1.76, NS
Scratch Duration	4.07, **$p \leq 0.001$**	3.71, **$p \leq 0.001$**	1.20, NS	1.25, NS
Rest Frequency	6.93, **$p \leq 0.001$**	1.33, NS	0.49, NS	0.94, NS
Rest Duration	9.64, **$p \leq 0.001$**	0.50, NS	2.63, **$p \leq 0.01$**	0.76, NS
Sniff Frequency	55.24, **$p \leq 0.001$**	0.94, NS	0.93, NS	0.55, NS
Sniff Duration	2.80, **$p \leq 0.01$**	2.19, **$p \leq 0.05$**	2.55, **$p \leq 0.01$**	0.79, NS

Appendix 4.6 Follow up ANOVAs for the Significant Time x Rimonabant Interactions for Eat Duration, Rear Duration, Scratch Duration, and Sniff Duration

The time x rimonabant interaction was followed up with 2 x 2 (rimonabant x naloxone) ANOVA's within each timebin to determine where there was a significant main effect of rimonabant.

Timebin	Main Effect of Rimonabant (1.5mg/kg) F Value df (1,8)			
	Eat Duration	**Rear Duration**	**Scratch Duration**	**Sniff Duration**
1 (0-5 min)	20.73, **$p \leq 0.01$**	0.59, NS	43.83, **$p \leq 0.001$**	6.06, **$p \leq 0.05$**
2 (5-10 min)	10.82, **$p \leq 0.05$**	3.68, NS	99.59, **$p \leq 0.001$**	1.44, NS
3 (10-15 min)	17.13, **$p \leq 0.01$**	4.01, NS	70.02, **$p \leq 0.001$**	0.61, NS
4 (15-20 min)	0.23, NS	43.39, **$p \leq 0.001$**	36.78, **$p \leq 0.001$**	8.85, **$p \leq 0.05$**
5 (20-25 min)	4.76, NS	5.35, **$p \leq 0.05$**	17.95, **$p \leq 0.01$**	3.56, NS
6 (25-30 min)	1.21, NS	15.62, **$p \leq 0.01$**	23.10, **$p \leq 0.001$**	2.78, NS
7 (30-35 min)	0.68, NS	3.15, NS	21.94, **$p \leq 0.01$**	9.78, **$p \leq 0.05$**
8 (35-40 min)	0.41, NS	18. 65, **$p \leq 0.01$**	10.59, **$p \leq 0.05$**	2.86, NS

9 (40-45 min)	0.06, NS	1.71, NS	15.46, **p ≤ 0.01**	1.34, NS
10 (45-50 min)	0.42, NS	5.01, p ≤ 0.06	16.63, **p ≤ 0.01**	5.87, **p ≤ 0.05**
11 (50-55 min)	3.60, NS	0.97, NS	1.48, NS	0.85, NS
12 (55-60 min)	2.45, NS	1.81, NS	11.67, **p ≤ 0.01**	4.89, p ≤ 0.06

Appendix 4.7 Follow up ANOVAs for the Significant Time x Rimonabant Interactions for Eat Frequency, Groom Frequency, and Scratch Frequency.

The time x rimonabant interaction was followed up with 2 x 2 (rimonabant x naloxone) ANOVA's within each timebin to determine where there was a significant main effect of rimonabant.

Timebin	**Main Effect of Rimonabant (1.5mg/kg) F Value** df (1,8)		
	Eat Frequency	**Groom Frequency**	**Scratch Frequency**
1 (0-5 min)	6.50, **p ≤ 0.05**	13.05, **p ≤ 0.01**	213.85, **p ≤ 0.001**
2 (5-10 min)	1.42, NS	34.23, **p ≤ 0.001**	167.19, **p ≤ 0.001**
3 (10-15 min)	6.70, **p ≤ 0.05**	17.33, **p ≤ 0.01**	204.47, **p ≤ 0.001**
4 (15-20 min)	1.10, NS	12.03, **p ≤ 0.01**	43.94, **p ≤ 0.001**
5 (20-25 min)	8.81, **p ≤ 0.05**	1.62, NS	39.41, **p ≤ 0.001**
6 (25-30 min)	5.91, **p ≤ 0.05**	11.59, **p ≤ 0.01**	40.84, **p ≤ 0.001**
7 (30-35 min)	0.02, NS	7.00, **p ≤ 0.05**	18.39, **p ≤ 0.01**
8 (35-40 min)	0.13, NS	1.94, NS	24.42, **p ≤ 0.001**
9 (40-45 min)	1.41, NS	6.09, **p ≤ 0.05**	24.00, **p ≤ 0.001**
10 (45-50 min)	0.26, NS	38.63, **p ≤ 0.001**	17.46, **p ≤ 0.01**
11 (50-55 min)	7.23, **p ≤ 0.05**	2.08, NS	3.65, NS
12 (55-60 min)	5.09, p ≤ 0.06	4.16, NS	13.17, **p ≤ 0.01**

Appendix 4.8 Bonferroni Post Hoc Tests for Main Effect of Rimonabant on Eat Duration in Timebins 1 – 3 and Rear Duration in Timebin 4 – 6 and 8.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	**Main Effect of Rimonabant (1.5mg/kg) F Value** df (1,8)	
	Eat Duration	**Rear Duration**
1 (0-5 min)	MD = 47.73, SE = 10.48, **p ≤ 0.01**	
2 (5-10 min)	MD = 59.77, SE = 18.17, **p ≤ 0.05**	
3 (10-15 min)	MD = 46.95, SE = 11.35, **p ≤ 0.01**	
4 (15-20 min)		MD = 38.50, SE = 5.85, **p ≤ 0.001**
5 (20-25 min)		MD = 19.68, SE = 8.51, **p ≤ 0.05**
6 (25-30 min)		MD = 25.99, SE = 6.58, **p ≤ 0.01**
8 (35-40 min)		MD = 19.86, SE = 4.60, **p ≤ 0.01**

Appendix 4.9 Bonferroni Post Hoc Tests for Main Effect of Rimonabant on Scratch Duration in Timebins 1 – 10 and 12 and Groom Frequency in Timebins 1 - 4, 6-7, and 9-10.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	**Main Effect of Rimonabant (1.5mg/kg) F Value** df (1,8)	
	Scratch Duration	**Groom Frequency**
1 (0-5 min)	MD = -10.36, SE = 1.56, **p ≤ 0.001**	MD = -1.76, SE = 0.49, **p ≤ 0.01**
2 (5-10 min)	MD = -25.75, SE = 2.58, **p ≤ 0.001**	MD = -3.84, SE = 0.66, **p ≤ 0.001**
3 (10-15 min)	MD = -22.25, SE = 2.66, **p ≤ 0.001**	MD = -2.17, SE – 0.52, **p ≤ 0.01**
4 (15-20 min)	MD = -29.36, SE = 4.84, **p ≤ 0.001**	MD = -3.45, SE = 1.00, **p ≤ 0.01**
5 (20-25 min)	MD = -33.28, SE = 7.86, **p ≤ 0.01**	
6 (25-30 min)	MD = -37.56, SE = 7.81, **p ≤ 0.001**	MD = -2.36, SE = 0.69, **p ≤ 0.01**

7 (30-35 min)	MD = -22.34, SE = 4.77, **p ≤ 0.01**	MD = -1.42, SE = 0.54, **p ≤ 0.05**
8 (35-40 min)	MD = -26.28, SE = 8.07, **p ≤ 0.05**	
9 (40-45 min)	MD = -22.70, SE = 5.77, **p ≤ 0.01**	MD = -1.32, SE = 0.54, **p ≤ 0.05**
10 (45-50 min)	MD = -20.91, SE = 5.13, **p ≤ 0.01**	MD = -2.52, SE = 0.41, **p ≤ 0.001**
12 (55-60 min)	MD = -15.50, SE = 4.54, **p ≤ 0.01**	

Appendix 4.10 Bonferroni Post Hoc Tests for Main Effect of Rimonabant on Eat Frequency in Timebins 1, 3, 5 and 6 and Sniff Duration in Timebins 1, 4, 7 and 10.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Main Effect of Rimonabant (1.5mg/kg) **F Value** df (1,8)	
	Eat Frequency	**Sniff Duration**
1 (0-5 min)	MD = 4.29, SE = 1.68, **p ≤ 0.05**	MD = 21.42, SE = 8.70, **p ≤ 0.05**
3 (10-15 min)	MD = 2.90, SE = 1.12, **p ≤ 0.05**	
4 (15-20 min)		MD = 42.09, SE = 14.15, **p ≤ 0.05**
5 (20-25 min)	MD = 2.08, SE = 0.70, **p ≤ 0.05**	
6 (25-30 min)	MD = 1.41, SE = 0.58, **p ≤ 0.05**	
7 (30-35 min)		MD = 61.48, SE = 19.66, **p ≤ 0.01**
10 (45-50 min)		MD = 58.84, SE = 24.29, **p ≤ 0.05**
10 (50-55 min)	MD = 1.44, SE = 0.54, **p ≤ 0.05**	

Appendix 4.11 Bonferroni Post Hoc Tests for Main Effect of Rimonabant on Scratch Frequency in Timebins 1-12.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Main Effect of Rimonabant (1.5mg/kg)
	F Value df (1,8)
1 (0-5 min)	MD = -9.88, SE = 0.68, **p ≤ 0.001**
2 (5-10 min)	MD = -12.10, SE = 0.94, **p ≤ 0.001**
3 (10-15 min)	MD = -7.58, SE = 0.53, **p ≤ 0.001**
4 (15-20 min)	MD = -8.43, SE = 1.27, **p ≤ 0.001**
5 (20-25 min)	MD = -7.38, SE = 1.18, **p ≤ 0.001**
6 (25-30 min)	MD = -6.18, SE = 0.97, **p ≤ 0.001**
7 (30-35 min)	MD = -5.31, SE = 1.24, **p ≤ 0.01**
8 (35-40 min)	MD = -4.25, SE = 0.86, **p ≤ 0.001**
9 (40-45 min)	MD = -3.57, SE = 0.73, **p ≤ 0.001**
10 (45-50 min)	MD = -4.25, SE = 1.02, **p ≤ 0.01**
12 (55-60 min)	MD = -2.42, SE = 0.67, **p ≤ 0.01**

Appendix 4.12 Follow up ANOVAs for the Significant Time x Naloxone Interactions for Eat Duration, Rear Duration, Scratch Duration, and Sniff Duration.

The time x rimonabant interaction was followed up with 2 x 2 (rimonabant x naloxone) ANOVA's within each timebin to determine where there was a significant main effect of naloxone.

Timebin	Main Effect of Naloxone (0.5mg/kg) **F Value** df (1,8)		
	Scratch Frequency	**Rest Duration**	**Sniff Duration**
1 (0-5 min)	0.66, NS	1.24, NS	2.41, NS
2 (5-10 min)	2.35, NS	1.64, NS	3.09, NS
3 (10-15 min)	0.85, NS	2.33, NS	8.55, **p ≤ 0.05**
4 (15-20 min)	7.21, **p ≤ 0.05**	0.04, NS	6.20, **p ≤ 0.05**
5 (20-25 min)	3.20, NS	0.95, NS	0.02, NS

6 (25-30 min)	0.64, NS	0.73, NS	4.89, $p \leq 0.06$
7 (30-35 min)	0.70, NS	0.47, NS	4.50, NS
8 (35-40 min)	0.30, NS	0.64, NS	0.01, NS
9 (40-45 min)	0.82, NS	0.55, NS	1.23, NS
10 (45-50 min)	2.87, NS	4.57, NS	0.04, NS
11 (50-55 min)	7.08, **$p \leq 0.05$**	13.23, **$p \leq 0.01$**	10.48, **$p \leq 0.05$**
12 (55-60 min)	1.34, NS	4.62, NS	1.54, NS

Appendix 4.13 Bonferroni Post Hoc Tests for Main Effect of Naloxone on Scratch Frequency in Timebins 4 and 11, and Rest Duration in Timebin 11.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	**Main Effect of Naloxone (0.5mg/kg)** **F Value** df (1,8)	
	Scratch Frequency	**Rest Duration**
4 (15-20 min)	MD = 3.99, SE = 1.48, **$p \leq 0.05$**	
11 (50-55 min)	MD = 2.26, SE = 0.85, **$p \leq 0.05$**	MD = 91.31, SE = 25.11, **$p \leq 0.01$**

Appendix 4.14 Bonferroni Post Hoc Tests for Main Effect of Naloxone on Sniff Duration in Timebins 3, 4 and 11.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	**Main Effect of Naloxone (0.5mg/kg)**
	F Value df (1,8)
3 (10-15 min)	MD = 17.45, SE = 5.96, **$p \leq 0.05$**
4 (15-20 min)	MD = 26.41, SE = 10.61, **$p \leq 0.05$**
11 (50-55 min)	MD = 43.24, SE = 13.35, **$p \leq 0.05$**

Appendix 5 STATISTICAL DETAILS FOR EXPERIMENT 4 (CHAPTER 5) – THE EFFECTS OF ACUTE BUPROPION (10, 20 AND 40MG/KG) TREATMENT ON FOOD INTAKE, THE MICROSTRUCTURE OF FEEDING BEHAVIOUR AND BODYWEIGHT GAIN IN MALE RATS.

Appendix 5.1 Bonferroni Post Hoc Tests for Habituation Week Food Intake.

Only significant differences are displayed. (MD = mean difference; SE = standard error)

Habituation Trial		Bonferroni Post Hoc Tests
1	3	MD = -7.29, SE = 1.05, **p ≤ 0.001**
	4	MD = -7.04, SE = 1.81, **p ≤ 0.05**
	5	MD = -10.00, SE = 1.24, **p ≤ 0.001**
2	3	MD = -4.73, SE = 0.47, **p ≤ 0.001**
	5	MD = -7.44, SE = 1.21, **p ≤ 0.01**

Appendix 5.2 One Way Repeated Measures ANOVA Results for Total (1-hour) Behavioural Measures.

Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Behaviour	Mauchly's W	F value df (3, 27)
Food Intake	0.41, NS	7.034, **p ≤ 0.001**
Eat Frequency	0.07, **p ≤ 0.05**	11.59, **p ≤ 0.001** (1.83, 16.44)
Eat Duration	0.44, NS	12.41, **p ≤ 0.001**
Eat Bout Length	0.06, **p ≤ 0.05**	7.19, **p ≤ 0.05** (1.27, 11.46)
Eat Rate	0.43, NS	1.40, NS
Eat Latency	0.65, NS	1.75, NS
Food ID Latency	0.37, NS	0.67, NS
Locomotion Frequency	0.22, **p ≤ 0.05**	33.81, **p ≤ 0.001** (1.57,14.15)
Locomotion Duration	0.07, **p ≤ 0.05**	13.71, **p ≤ 0.01** (1.30, 11.68)
Rear Frequency	0.24, NS	18.15, **p ≤ 0.001**
Rear Duration	0.45, NS	2.20, NS
Groom Frequency	0.79, NS	2.40, NS
Groom Duration	0.50, NS	10.46, **p ≤ 0.001**
Scratch Frequency	0.61, NS	2.25, NS
Scratch Duration	0.25, NS	1.49, NS
Rest Frequency	0.47, NS	4.76, **p ≤ 0.01**
Rest Duration	0.60, NS	4.58, **p ≤ 0.01**
Sniff Frequency	0.39, NS	24.96, **p ≤ 0.001**
Sniff Duration	0.48, NS	11.72, **p ≤ 0.001**

Appendix 5.3 Bonferroni Post Hoc Tests for Significant Treatment Effects of Bupropion on 1 hour behaviour.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour		Bonferroni Post Hoc Tests
Eat Frequency	40mg/kg	MD = -51.80, SE = 11.58, **p ≤ 0.01**
Eat Duration	40mg/kg	MD = 224.88, SE = 63.70, **p ≤ 0.05**
Eat Bout Length	40mg/kg	MD = 8.86, SE = 1.57, **p ≤ 0.01**
Locomotion Frequency	20mg/kg	MD = -58.100, SE = 14.84, **p ≤ 0.05**
	40mg/kg	MD = -233.40, SE = 34.14, **p ≤ 0.001**
Locomotion Duration	40mg/kg	MD = -309.09, SE = 74.71, **p ≤ 0.05**
Rear Frequency	40mg/kg	MD = -166.60, SE = 35.19, **p ≤ 0.01**

Groom Duration	40mg/kg	MD = 85.94, SE = 25.76, $p \leq 0.06$
Sniff Frequency	40mg/kg	MD = -203.30, SE = 34.26, **$p \leq 0.001$**
Sniff Duration	40mg/kg	MD = -587.86, SE = 157.90, **$p \leq 0.05$**

Appendix 5.4 Periodic (Timebin) Behavioural Analyses.

Behaviour	**Main Effect of Time**	**Time x Treatment Interaction**
	F Value df (11,99)	**F Value** df (33,297)
Eat Frequency	57.14, **$p \leq 0.001$**	0.71, NS
Eat Duration	25.35, **$p \leq 0.001$**	3.36, **$p \leq 0.001$**
Locomotion Frequency	29.82, **$p \leq 0.001$**	1.49, **$p \leq 0.05$**
Locomotion Duration	24.36, **$p \leq 0.001$**	1.45, $p \leq 0.06$
Rear Frequency	20.80, **$p \leq 0.001$**	1.14, NS
Rear Duration	3.22, **$p \leq 0.001$**	1.29, NS
Groom Frequency	1.27, NS	1.34, NS
Groom Duration	2.70, **$p \leq 0.01$**	1.30, NS
Scratch Frequency	1.33, NS	1.25, NS
Scratch Duration	1.49, NS	1.03, NS
Rest Frequency	7.18, **$p \leq 0.001$**	1.62, **$p \leq 0.01$**
Rest Duration	9.44, **$p \leq 0.001$**	1.84, **$p \leq 0.01$**
Sniff Frequency	35.35, **$p \leq 0.001$**	1.23, NS
Sniff Duration	10.07, **$p \leq 0.001$**	1.28, NS

Appendix 5.5 Follow up ANOVAs for the Significant Time x Treatment Interactions for Eat Duration and Locomotion Frequency

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Timebin	**Eat Duration**		**Locomotion Frequency**	
	Mauchly's W	**F Value df (3, 27)**	**Mauchly's W**	**F Value df (3, 27)**
1 (0-5 min)	0.50, NS	6.71, **$p \leq 0.01$**	0.20, **$p \leq 0.05$**	14.39, **$p \leq 0.01$** (1.90, 17.12)
2 (5-10 min)	0.46, NS	8.98, **$p \leq 0.001$**	0.25, NS	18.91, **$p \leq 0.001$**
3 (10-15 min)	0.70, NS	5.52, **$p \leq 0.01$**	0.49, NS	10.92, **$p \leq 0.001$**
4 (15-20 min)	0.63, NS	6.85, **$p \leq 0.001$**	0.45, NS	16.94, **$p \leq 0.001$**
5 (20-25 min)	0.68, NS	2.46, NS	0.26, NS	6.58, **$p \leq 0.01$**
6 (25-30 min)	0.78, NS	4.05, **$p \leq 0.01$**	0.57, NS	11.61, **$p \leq 0.001$**
7 (30-35 min)	0.71, NS	1.16, NS	0.46, NS	15.52, **$p \leq 0.001$**
8 (35-40 min)	0.35, NS	0.60, NS	0.29, NS	7.68, **$p \leq 0.001$**
9 (40-45 min)	0.21, **$p \leq 0.05$**	1.43, NS (1.93, 17.39)	0.61, NS	16.61, **$p \leq 0.001$**
10 (45-50 min)	0.42, NS	1.94, NS	0.48, NS	19.98, **$p \leq 0.001$**
11 (50-55 min)	0.30, NS	1.05, NS	0.41, NS	28.86, **$p \leq 0.001$**
12 (55-60 min)	0.23, **$p \leq 0.05$**	0.06, NS (1.97, 17.70)	0.41, NS	13.63, **$p \leq 0.001$**

Appendix 5.6 Bonferroni Post Hoc Tests for Significant Treatment Effects of Eat Duration for Timebin 4 and Locomotion Frequency for Timebins 1-4, and 6-12.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour	Timebin	Bonferroni Post Hoc Tests	
Eat Duration	4 (15-20 min)	40mg/kg	MD = 82.62, SE = 18.82, **$p \le 0.01$**
Locomotion Frequency	1 (0-5 min)	10mg/kg	MD = 5.60, SE = 1.56, **$p \le 0.05$**
		40mg/kg	MD = -12.50, SE = 3.78, **$p \le 0.05$**
	2 (5-10 min)	40mg/kg	MD = -26.60, SE = 5.12, **$p \le 0.01$**
	3 (10-15 min)	40mg/kg	MD = -21.30, SE = 5.25, **$p \le 0.05$**
	4 (15-20 min)	20mg/kg	MD = -8.40, SE = 2.20, **$p \le 0.05$**
		40mg/kg	MD = 22.20, SE = 3.80, **$p \le 0.001$**
	6 (24-30 min)	40mg/kg	MD = -15.40, SE = 3.69, **$p \le 0.01$**
	7 (30-35 min)	20mg/kg	MD = -8.40, SE = 2.59, **$p \le 0.05$**
		40mg/kg	MD = -21.20, SE = 2.59, **$p \le 0.001$**
	8 (35-40 min)	40mg/kg	MD = -15.10, SE = 4.25, **$p \le 0.05$**
	9 (40-45 min)	40mg/kg	MD = -19.40, SE = 4.01, **$p \le 0.01$**
	10 (45-50 min)	40mg/kg	MD = -22.90, SE = 3.38, **$p \le 0.001$**
	11 (50-55 min)	40mg/kg	MD = -25.40, SE = 3.12, **$p \le 0.001$**
	12 (55-60 min)	40mg/kg	MD = -21.20, SE = 4.46, **$p \le 0.01$**

Appendix 5.7 Follow up ANOVAs for the Significant Time x Treatment Interactions for Rest Duration and Rest Frequency

The time x treatment interaction was followed up with a one-way ANOVA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Timebin	Rest Duration		Rest Frequency	
	Mauchly's W	F value df (3, 27)	Mauchly's W	F value df (3, 27)
1 (0-5 min)	.	.	.	.
2 (5-10 min)	.	.	.	.
3 (10-15 min)	.	.	.	.
4 (15-20 min)	.	.	.	.
5 (20-25 min)	.	1.00, NS	.	1.00, NS
6 (25-30 min)	.	1.00, NS	.	1.00 NS
7 (30-35 min)	0.01, **$p \le 0.001$**	0.65, NS (1.43, 12.89)	0.50, NS	0.55, NS
8 (35-40 min)	0.03, **$p \le 0.001$**	1.29, NS (1.45, 13.01)	0.35, NS	0.98, NS
9 (40-45 min)	0.64, NS	1.18, NS	0.30, NS	2.74, $p \le 0.06$
10 (45-50 min)	0.31, NS	3.46, NS	0.27, NS	2.12, NS
11 (50-55 min)	0.26, NS	3.58, **$p \le 0.05$**	0.66, NS	4.40, **$p \le 0.01$**
12 (55-60 min)	0.66, NS	2.91, **$p \le 0.05$**	0.46, NS	1.95, NS

Appendix 6 STATISTICAL DETAILS FOR EXPERIMENT 5 (CHAPTER 5) – THE EFFECTS OF ACUTE NALTREXONE (0.1, 1.0 AND 3.0MG/KG) TREATMENT ON FOOD INTAKE, THE MICROSTRUCTURE OF FEEDING BEHAVIOUR AND BODYWEIGHT GAIN IN MALE RATS. (N = 9)

Appendix 6.1 Bonferroni Post Hoc Tests for Habituation Week Food Intake.
Only significant differences are displayed. (MD = mean difference; SE = standard error)

Habituation Trial		Bonferroni Post Hoc Tests
1	2	MD = -5.07, SE = 0.88 , **p ≤ 0.01**
	3	MD = -7.28, SE = 0.93, **p ≤ 0.001**
	4	MD = -7.54, SE = 0.90, **p ≤ 0.001**
	5	MD = -6.24, SE = 1.01, **p ≤ 0.01**

Appendix 6.2 One way repeated measures ANOVA results for Total (1-hour) Behavioural Measures.
Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Behaviour	Mauchly's W	**F value** df (3, 24)
Food Intake	0.32, NS	18.13, **p ≤ 0.001**
Eat Frequency	0.60, NS	14.93, **p ≤ 0.001**
Eat Duration	0.66, NS	10.00, **p ≤ 0.001**
Eat Bout Length	0.23, NS	1.76, NS
Eat Rate	0.55, NS	2.49, NS
Eat Latency	0.38, NS	1.49, NS
Food ID Latency	0.34, NS	0.84, NS
Locomotion Frequency	0.73, NS	3.16, **p ≤ 0.05**
Locomotion Duration	0.91, NS	3.20, **p ≤ 0.05**
Rear Frequency	0.27, NS	5.04, **p ≤ 0.01**
Rear Duration	0.34, NS	5.63, **p ≤ 0.01**
Groom Frequency	0.60, NS	0.50, NS
Groom Duration	0.35, NS	1.74, NS
Scratch Frequency	0.37, NS	1.96, NS
Scratch Duration	0.69, NS	1.23, NS
Rest Frequency	0.50, NS	2.46, NS
Rest Duration	0.12, **p ≤ 0.05**	6.63, **p ≤ 0.01** (1.71, 13.67)
Sniff Frequency	0.22, NS	6.53, **p ≤ 0.01**
Sniff Duration	0.54, NS	0.96, NS

Appendix 6.3 Bonferroni Post Hoc Tests for Significant Treatment Effects of Naltexone on 1 hour behaviour.
Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour		Bonferroni Post Hoc Tests
Food Intake	3.0mg/kg	MD = 8.35, SE = 1.32, **p ≤ 0.001**
Eat Frequency	1.0mg/kg	MD = 19.67, SE = 5.05, **p ≤ 0.05**
	3.0mg/kg	MD = 34.11, SE = 5.75, **p ≤ 0.01**
Eat Duration	3.0mg/kg	MD = 245.93, SE = 48.68, **p ≤ 0.01**
Locomotion Frequency	3.0mg/kg	MD = 68.92, SE = 19.85, **p ≤ 0.05**
Rest Duration	3.0mg/kg	MD = -942.27, SE = 205.05, **p ≤ 0.01**
Sniff Frequency	0.1mg/kg	MD = 30.22, SE = 7.80, **p ≤ 0.05**
	3.0mg/kg	MD = 96.56, SE = 25.99, **p ≤ 0.05**

Appendix 6.4 Periodic (Timebin) Behavioural Analyses.

Behaviour	Main Effect of Time	Time x Treatment Interaction
	F Value df (11,99)	**F Value** df (33,297)
Eat Frequency	103.79, **p ≤ 0.001**	2.03, **p ≤ 0.001**
Eat Duration	34.05, **p ≤ 0.001**	1.60, **p ≤ 0.05**
Locomotion Frequency	61.84, **p ≤ 0.001**	1.58, **p ≤ 0.05**
Locomotion Duration	55.06, **p ≤ 0.001**	1.20, NS
Rear Frequency	48.37, **p ≤ 0.001**	1.91, **p ≤ 0.01**
Rear Duration	7.41, **p ≤ 0.001**	2.14, **p ≤ 0.001**
Groom Frequency	1.61, NS	1.14, NS
Groom Duration	1.69, NS	1.32, NS
Scratch Frequency	1.81, p ≤ 0.06	0.88, NS
Scratch Duration	1.65, NS	1.06, NS
Rest Frequency	10.98, **p ≤ 0.001**	1.16, NS
Rest Duration	17.19, **p ≤ 0.001**	1.60, **p ≤ 0.05**
Sniff Frequency	56.52, **p ≤ 0.001**	1.54, **p ≤ 0.05**
Sniff Duration	8.91, **p ≤ 0.001**	1.79, **p ≤ 0.01**

Appendix 6.5 Follow up ANOVAs for the Significant Time x Treatment Interactions for Eat Frequency and Eat Duration

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Timebin	Eat Frequency		Eat Duration	
	Mauchly's W	**F value df (3, 27)**	**Mauchly's W**	**F value df (3, 27)**
1 (0-5 min)	0.83, NS	8.16, p ≤ 0.001	0.37, NS	4.79, p ≤ 0.01
2 (5-10 min)	0.44, NS	4.50, **p ≤ 0.01**	0.64, NS	3.85, **p ≤ 0.05**
3 (10-15 min)	0.65, NS	7.85, **p ≤ 0.001**	0.86, NS	4.15, **p ≤ 0.01**
4 (15-20 min)	0.22, NS	9.96, **p ≤ 0.001**	0.84, NS	2.72, p ≤ 0.06
5 (20-25 min)	0.33, NS	0.91, NS	0.29, NS	0.50, NS
6 (25-30 min)	0.37, NS	2.34, NS	0.07, **p ≤ 0.05**	1.37, NS (1.39, 11.11)
7 (30-35 min)	0.46, NS	1.53, NS	0.64, NS	0.26, NS
8 (35-40 min)	0.24, NS	1.52, NS	0.38, NS	1.54, NS
9 (40-45 min)	0.71, NS	1.03, NS	0.50, NS	0.12, NS
10 (45-50 min)	0.33, NS	1.93, NS	0.38, NS	1.51, NS
11 (50-55 min)	0.68, NS	2.68, NS	0.26, NS	1.85, NS
12 (55-60 min)	0.73, NS	1.53, NS	0.45, NS	1.14, NS

Appendix 6.6 Bonferroni Post Hoc Tests for Significant Treatment Effects of Eat Frequency for Timebins 1 and 4, and Eat Duration for Timebin 1

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour	Timebin	Bonferroni Post Hoc Tests	
Eat Frequency	1 (0-5 min)	3.0mg/kg	MD = 5.39, SE = 1.00, **p ≤ 0.01**
	4 (15-20 min)	1.0mg/kg	MD = 5.33, SE = 1.08, **p ≤ 0.01**
		3.0mg/kg	MD = 5.01, SE = 0.05, **p ≤ 0.05**
Eat Duration	1 (0-5 min)	0.1mg/kg	MD = -49.31, SE = 13.08, **p ≤ 0.05**

Appendix 6.7 Follow up ANOVAs for the Significant Time x Treatment Interactions for Rear Frequency and Rear Duration

The time x treatment interaction was followed up with a one-way ANOVA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported.

Timebin	Rear Frequency		Rear Duration	
	Mauchly's W	**F value df (3, 27)**	**Mauchly's W**	**F value df (3, 27)**
1 (0-5 min)	0.27, NS	2.16, NS	0.23, NS	3.25, **$p \leq 0.05$**
2 (5-10 min)	0.51, NS	1.45, NS	0.38, NS	2.50, NS
3 (10-15 min)	0.60, NS	4.44, **$p \leq 0.01$**	0.82, NS	2.40, NS
4 (15-20 min)	0.67, NS	3.99, **$p \leq 0.01$**	0.56, NS	2.46, NS
5 (20-25 min)	0.25, NS	3.77, **$p \leq 0.05$**	0.36, NS	8.13, **$p \leq 0.001$**
6 (25-30 min)	0.42, NS	6.84, **$p \leq 0.01$**	0.57, NS	6.10, **$p \leq 0.01$**
7 (30-35 min)	0.41, NS	3.49, **$p \leq 0.05$**	0.37, NS	4.66, **$p \leq 0.01$**
8 (35-40 min)	0.24, NS	5.87, **$p \leq 0.01$**	0.30, NS	4.62, **$p \leq 0.01$**
9 (40-45 min)	0.88, NS	5.62, **$p \leq 0.01$**	0.72, NS	5.15, **$p \leq 0.01$**
10 (45-50 min)	0.46, NS	2.22, NS	0.58, NS	1.42, NS
11 (50-55 min)	0.37, NS	1.23, NS	0.35, NS	1.70, NS
12 (55-60 min)	0.62, NS	0.63, NS	0.72, NS	0.61, NS

Appendix 6.8 Bonferroni Post Hoc Tests for Significant Treatment Effects of Rear Frequency for Timebins 5, 6 and 8, and Rear Duration for Timebin 1, 5, 8 and 9.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour	Timebin	Bonferroni Post Hoc Tests	
Rear Frequency	5 (20-25 min)	3.0mg/kg	MD = 9.68, SE = 2.72, **$p \leq 0.05$**
	6 (25-30 min)	1.0mg/kg	MD = 9.67, SE = 2.26, **$p \leq 0.01$**
	8 (35-40 min)	3.0mg/kg	MD = 9.75, SE = 2.31, **$p \leq 0.01$**
Rear Duration	1 (0-5 min)	0.1mg/kg	MD = 21.65, SE = 3.80, **$p \leq 0.01$**
	5 (20-25 min)	3.0mg/kg	MD = 53.89, SE = 9.04, **$p \leq 0.01$**
	8 (35-40 min)	3.0mg/kg	MD = 40.46, SE = 11.72, **$p \leq 0.05$**
	9 (40-45 min	3.0mg/kg	MD = 9.83, SE = 2.54, **$p \leq 0.05$**

Appendix 6.9 Follow up ANOVAs for the significant time x treatment interactions for Sniff Frequency and Sniff Duration

The time x treatment interaction was followed up with a one-way ANOVA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported.

Timebin	Sniff Frequency		Sniff Duration	
	Mauchly's W	**F value df (3, 27)**	**Mauchly's W**	**F value df (3, 27)**
1 (0-5 min)	0.28, NS	4.36, **$p \leq 0.01$**	0.38, NS	3.85, **$p \leq 0.05$**
2 (5-10 min)	0.51, NS	1.32, NS	0.50, NS	2.26, NS
3 (10-15 min)	0.81, NS	3.95, **$p \leq 0.05$**	0.91, NS	1.47, NS
4 (15-20 min)	0.19, NS	4.13, **$p \leq 0.05$**	0.81, NS	0.85, NS
5 (20-25 min)	0.53, NS	4.05, **$p \leq 0.01$**	0.19, NS	0.50, NS
6 (25-30 min)	0.34, NS	6.39, **$p \leq 0.01$**	0.50, NS	0.95, NS
7 (30-35 min)	0.34, NS	3.37, **$p \leq 0.05$**	0.74, NS	1.73, NS
8 (35-40 min)	0.17, NS	5.42, **$p \leq 0.01$**	0.64, NS	2,13, NS
9 (40-45 min)	0.73, NS	4.41, **$p \leq 0.01$**	0.93, NS	4.21, **$p \leq 0.01$**
10 (45-50 min)	0.39, NS	1.59, NS	0.44, NS	0.09, NS

11 (50-55 min)	0.55, NS	1.39, NS	0.94, NS	0.28, NS
12 (55-60 min)	0.74, NS	1.13, NS	0.37, NS	3.62, **$p \leq 0.05$**

Appendix 6.10 Bonferroni Post Hoc Tests for Significant Treatment Effects of Sniff Frequency for Timebins 1, 6, 8 and 9, and Sniff Duration for Timebin 9

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour	Timebin	Bonferroni Post Hoc Tests	
Sniff Frequency	1 (0-5 min)	0.1mg/kg	MD = 11.00, SE = 1.25, **$p \leq 0.001$**
	6 (25-30 min)	1.0mg/kg	MD = 10.11, SE = 2.12, **$p \leq 0.01$**
	8 (35-40 min)	3.0mg/kg	MD = 10.81, SE = 2.28, **$p \leq 0.01$**
	9 (40-45 min)	3.0mg/kg	MD = 11.60, SE = 2.73, **$p \leq 0.01$**
Sniff Duration	9 (40-45 min)	3.0mg/kg	MD = 105,01, SE = 28.36, **$p \leq 0.05$**

Appendix 6.11 Follow up ANOVAs for the significant time x treatment interactions for Locomotion Frequency and Rest Duration

The time x treatment interaction was followed up with a one-way ANOVA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Timebin	Locomotion Frequency		Rest Duration	
	Mauchly's W	F value df (3, 27)	Mauchly's W	F value df (3, 27)
1 (0-5 min)	0.53, NS	3.60, **$p \leq 0.05$**	.	.
2 (5-10 min)	0.42, NS	0.49, NS	.	.
3 (10-15 min)	0.24, NS	0.79, NS	.	1.81, NS
4 (15-20 min)	0.50, NS	1.47, NS	0.00, **$p \leq 0.05$**	1.52, NS (1.21, 9.71)
5 (20-25 min)	0.55, NS	1.64, NS	0.01, **$p \leq 0.05$**	1.80, NS (1.53, 12.26)
6 (25-30 min)	0.37, NS	1.73, NS	0.32, NS	2.79, $p \leq 0.06$
7 (30-35 min)	0.54, NS	2.47, NS	0.12, **$p \leq 0.05$**	1.46, NS (1.88, 15.02)
8 (35-40 min)	0.51, NS	3.53, **$p \leq 0.05$**	0.38, NS	5.00, **$p \leq 0.01$**
9 (40-45 min)	0.67, NS	3.44, **$p \leq 0.05$**	0.47, NS	5.22, **$p \leq 0.01$**
10 (45-50 min)	0.26, NS	0.72, NS	0.68, NS	1.89, NS
11 (50-55 min)	0.46, NS	1.75, NS	0.83, NS	1.91, NS
12 (55-60 min)	0.84, NS	2.26, NS	0.70, NS	2.65, NS

Appendix 6.12 Bonferroni Post Hoc Tests for Significant Treatment Effects of Rest Duration for Timebins 8 and 9, and Locomotion Frequency for Timebin 1, 8 and 9.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour	Timebin	Bonferroni Post Hoc Tests	
Rest Duration	8 (35-40 min)	3.0mg/kg	MD = -167.48, SE = 36.83, **$p \leq 0.01$**
	9 (40-45 min)	3.0mg/kg	MD = -172.28, SE = 33.97, **$p \leq 0.01$**
Locomotion Frequency	1 (0-5 min)	0.1mg/kg	MD = 11.00, SE = 2.70, **$p \leq 0.05$**
	8 (35-40 min)	3.0mg/kg	MD = 12.53, SE = 2.76, **$p \leq 0.01$**
	9 (40-45 min)	3.0mg/kg	MD = 11.92, SE – 2.99, **$p \leq 0.05$**

Appendix 7 STATISTICAL DETAILS FOR EXPERIMENT 6 (CHAPTER 5) – THE EFFECTS OF ACUTE POLYTHERAPY OF BUPROPION (20 MG/KG) AND NALTREXONE (0.1 AND 1.0 MG/KG) TREATMENT ON FOOD INTAKE, THE MICROSTRUCTURE OF FEEDING BEHAVIOUR AND BODYWEIGHT GAIN IN MALE RATS.

Appendix 7.1 Bonferroni Post Hoc Tests for Habituation Week Food Intake.
Only significant differences are displayed. (MD = mean difference; SE = standard error)

Habituation Trial		Bonferroni Post Hoc Tests
1	2	MD = -3.75, SE = 0.88, **p ≤ 0.05**
	3	MD = -5.17, SE = 1.21, **p ≤ 0.05**
	5	MD = -6.53, SE = 1.23, **p ≤ 0.01**

Appendix 7.2 3 x 2 way ANOVA results for Total (1-hour) Behavioural Measures.
A mauchly's value is not provided for the main effect of bupropion because this factor has only two levels. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Behaviour	Main Effect of Bupropion	Main effect of Naltrexone		Bupropion x Naltrexone Interaction	
	F value df (1,9)	Mauchly's	F value df (2,18)	Mauchly's	F value df (2,18)
Food Intake	33.74, **p ≤ 0.001**	0.44, **p ≤ 0.05**	10.71, **p ≤ 0.01** (1.28, 11.50)	0.73, NS	0.64, NS
Eat Frequency	12.44, **p ≤ 0.01**	0.59, NS	1.21, NS	0.76, NS	0.93, NS
Eat Duration	1.83, NS	0.81, NS	0.96, NS	0.89, NS	1.39, NS
Eat Bout Length	14.01, **p ≤ 0.01**	0.76, NS	0.43, NS	0.90. NS	1.48, NS
Eat Rate	13.64, **p ≤ 0.01**	0.84, NS	8.37, **p ≤ 0.01**	0.88, NS	1.87, NS
Eat Latency	0.59, NS	0.74, NS	0.07, NS	0.42, NS	1.26, NS
Food ID Latency	0.26, NS	0.51, NS	0.75, NS	0.76, NS	0.92, NS
Locomotion Frequency	29.61, **p ≤ 0.001**	0.64, NS	1.01, NS	0.52, NS	1.99, NS
Locomotion Duration	32.65, **p ≤ 0.001**	0.91, NS	0.67, NS	0.17, **p ≤ 0.05**	1.05, NS (1.09, 9.84)
Rear Frequency	10.42, **p ≤ 0.01**	0.81, NS	7.64, **p ≤ 0.01**	0.92, NS	4.51, **p ≤ 0.05**
Rear Duration	0.97, NS	0.76, NS	8.04, **p ≤ 0.01**	0.85, NS	0.58, NS
Groom Frequency	0.01, NS	0.66, NS	0.85, NS	0.86, NS	2.73, NS
Groom Duration	13.63, **p ≤ 0.01**	0.86, NS	5.19, **p ≤ 0.01**	0.88, NS	4.91, **p ≤ 0.05**
Scratch Frequency	10.85, **p ≤ 0.01**	0.90, NS	1.79, NS	0.43, **p ≤ 0.05**	3.04, NS (1.28, 11.50)
Scratch Duration	6.37, **p ≤ 0.05**	0.82, NS	1.26, NS	0.44, **p ≤ 0.05**	3.44, NS (1.28, 11.51)
Rest Frequency	2.25, NS	0.60, NS	4.49, NS	0.69, NS	1.45, NS
Rest Duration	13.19, **p ≤ 0.01**	0.43, NS	5.89, **p ≤ 0.01**	0.36, NS	2.50, NS
Sniff Frequency	26.19, **p ≤ 0.001**	0.54, NS	4.34, **p ≤ 0.05**	0.65, NS	4.60, **p ≤ 0.05**
Sniff Duration	50.57, **p ≤ 0.001**	0.42, **p ≤ 0.05**	0.61, NS (1.27, 11.40)	0.71, NS	0.84, NS

Appendix 7.3 Bonferroni Post Hoc Tests for Significant Main Effects of Bupropion on 1hour Behaviour.
Values represent significant differences between vehicle and rimonabant 1.5mg/kg. (MD = mean difference; SE = standard error)

Behaviour	Bonferroni Post Hoc Tests
Food Intake	MD = 4.03, SE = 0.69, **p ≤ 0.001**
Eat Frequency	MD = -13.67, SE = 3.93, **p ≤ 0.01**
Eat Bout Length	MD = 2.03, SE = 0.54, **p ≤ 0.01**
Eat Rate	MD = 0.27, SE = 0.07, **p ≤ 0.01**
Locomotion Frequency	MD = -52.80, SE = 9.70, **p ≤ 0.001**
Locomotion Duration	MD = -63.54, SE = 11.12, **p ≤ 0.001**

Rear Frequency	MD = -29.73, SE = 9.21, **$p \leq 0.01$**
Groom Duration	MD = 62.29, SE = 16.87, **$p \leq 0.01$**
Scratch Frequency	MD = 2.73, SE = 0.83, **$p \leq 0.01$**
Scratch Duration	MD = 13.98, SE = 5.53, **$p \leq 0.05$**
Rest Duration	MD = 152.19, SE = 41.91, **$p \leq 0.01$**
Sniff Frequency	MD = -42.93, SE = 8.39, **$p \leq 0.001$**
Sniff Duration	MD = -251.13, SE = 35.31, **$p \leq 0.001$**

Appendix 7.4 Bonferroni Post Hoc Tests for Significant Main Effects of Naltrexone on 1hour Behaviour.

Values represent significant differences between vehicle and rimonabant 1.5mg/kg. (MD = mean difference; SE = standard error)

Behaviour	Bonferroni Post Hoc Tests	
Food Intake	0.1mg/kg	MD = 2.77, SE = 0.58, **$p \leq 0.01$**
	1.0mg/kg	MD = 4.33, SE = 1.23, **$p \leq 0.01$**
Eat Rate	1.0mg/kg	MD = 0.29, SE = 0.06, **$p \leq 0.01$**
Rear Frequency	1.0mg/kg	MD = 33.95, SE = 10.48, **$p \leq 0.05$**
Rear Duration	1.0mg/kg	MD = 121.56, SE = 36.42, **$p \leq 0.05$**

Appendix 7.5 Periodic (Timebin) Behavioural Analyses.

Behaviour	Main Effect of Time	Time x Bupropion Interaction	Time x Naltrexone Interaction	Time x Bupropion x Naltrexone Interaction
	F Value df (11,99)	**F Value** df (11,99)	**F Value** df (22,198)	**F Value** df (22,198)
Eat Frequency	91.78, **$p \leq 0.001$**	1.01, NS	0.75, NS	1.45, NS
Eat Duration	22.24, **$p \leq 0.001$**	1.63, NS	0.71, NS	1.17, NS
Locomotion Frequency	69.13, **$p \leq 0.001$**	0.63, NS	0.70, NS	1.54, NS
Locomotion Duration	44.59, **$p \leq 0.001$**	0.92, NS	0.84, NS	0.90, NS
Rear Frequency	70.47, **$p \leq 0.001$**	1.39, NS	0.82, NS	158, **$p \leq 0.05$**
Rear Duration	8.15, **$p \leq 0.001$**	2.4, NS	1.41, NS	1.45, NS
Groom Frequency	1.13, NS	1.62, NS	0.81, NS	0.96, NS
Groom Duration	4.08, **$p \leq 0.001$**	1.13, NS	1.08, NS	1.50, NS
Scratch Frequency	0.75, NS	0.38, NS	0.88, NS	0.87, NS
Scratch Duration	1.71, NS	0.86, NS	0.61, NS	0.95, NS
Rest Frequency	8.03, **$p \leq 0.001$**	0.84, NS	1.57, **$p \leq 0.05$**	1.09, NS
Rest Duration	8.15, **$p \leq 0.001$**	2.4, **$p \leq 0.01$**	1.4, NS	1.45, NS
Sniff Frequency	91.48, **$p \leq 0.001$**	1.59, NS	0.97, NS	1.97, **$p \leq 0.01$**
Sniff Duration	9.45, **$p \leq 0.001$**	1.29, NS	1.33, NS	0.85, NS

Appendix 7.6 Follow up ANOVAs for the Significant Time x Bupropion Interactions for Rest Duration

The time x bupropion interaction was followed up with 3 x 2 (bupropion x naltrexone) ANOVA's within each timebin to determine where there was a significant main effect of bupropion. Therefore only the main effect of bupropion is reported; Mauchley's value is not provided for bupropion because this factor has only two levels.

Timebin	Main Effect of Bupropion
	F Value df (1,9)
1 (0-5 min)	.
2 (5-10 min)	0.46, NS
3 (10-15 min)	1.95, NS

4 (15-20 min)	1.91, NS
5 (20-25 min)	0.06, NS
6 (25-30 min)	0.77, NS
7 (30-35 min)	4.42, NS
8 (35-40 min)	10.74, **$p \leq 0.01$**
9 (40-45 min)	7.59, **$p \leq 0.05$**
10 (45-50 min)	12.70, **$p \leq 0.01$**
11 (50-55 min)	3.25, NS
12 (55-60 min)	0.00, NS

Appendix 7.7 Bonferroni Post Hoc Tests for Significant Main Effects of Bupropion for Rest Duration in Timebins 8-10.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Bonferoni Post Hoc Tests
8 (35-40 min)	MD = 26.64, SE = 8.13, **$p \leq 0.01$**
9 (40-45 min)	MD = 36.81, SE = 13.36, **$p \leq 0.05$**
10 (45-50 min)	MD = 42.11, SE = 11.82, **$p \leq 0.01$**

Appendix 7.8 Follow up ANOVAs for the Significant Time x Naltrexone Interaction for Rest Frequency

The time x naltrexone interaction was followed up with 3 x 2 (bupropion x naltrexone) ANOVA's within each timebin to determine where there was a significant main effect of naltrexone. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Timebin	Main Effect of Naltrexone	
	Mauchly's W	**F Value** df (1,9)
1 (0-5 min)	.	.
2 (5-10 min)	0.52, NS	1.47, NS
3 (10-15 min)	.	3.27, $p \leq 0.06$
4 (15-20 min)	0.56, NS	3.53, **$p \leq 0.05$**
5 (20-25 min)	0.90, NS	2.90, NS
6 (25-30 min)	0.40, **$p \leq 0.05$**	3.12, NS (1.25, 11.22)
7 (30-35 min)	0.45, **$p \leq 0.05$**	2.16, NS (1.29, 11.60)
8 (35-40 min)	0.62, NS	2.26, NS
9 (40-45 min)	0.93, NS	0.71, NS
10 (45-50 min)	0.95, NS	0.12, NS
11 (50-55 min)	0.97, NS	5.44, **$p \leq 0.01$**
12 (55-60 min)	0.91, NS	2.04, NS

Appendix 7.9 Bonferroni Post Hoc Tests for Significant Main Effects of Naltrexone for Rest Frequency in Timebin 11.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Bonferoni Post Hoc Tests
11 (50-55 min)	1.0mg/kg: MD = -1.05, SE = 0.34, **$p \leq 0.05$**

Appendix 7.10 Follow up ANOVAs for the significant time x bupropion x naltrexone interaction for Rear Frequency

The time x bupropion x naltrexone interaction was followed up with 3 x 2 (bupropion x naltrexone) ANOVA's within each timebin to determine where there was any significant dose effects. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Timebin	Main Effect of Bupropion	Main Effect of Naltrexone		Bupropion x Naltrexone Interaction	
	F Value df (1,9)	Mauchly's W	F Value df (11,99)	Mauchly's W	F Value df (11,99)
1 (0-5 min)	4.69, $p \leq 0.06$	0.70, NS	1.36, NS	0.58, NS	0.95, NS
2 (5-10 min)	4.81, $p \leq 0.06$	0.84, NS	0.69, NS	0.86, NS	4.69, **$p \leq 0.05$**
3 (10-15 min)	1.99, NS	0.81, NS	3.15, NS	0.91, NS	4.20, **$p \leq 0.05$**
4 (15-20 min)	4.11, NS	0.74, NS	4.27, **$p \leq 0.05$**	0.90, NS	2.95, NS
5 (20-25 min)	0.19, NS	0.77, NS	2.87, NS	0.72, NS	3.22, $p \leq 0.06$
6 (25-30 min)	1.17, NS	0.57, NS	6.24, **$p \leq 0.01$**	0.97, NS	0.69, NS
7 (30-35 min)	3.18, NS	0.93, NS	2.06, NS	0.79, NS	0.62, NS
8 (35-40 min)	14.55, **$p \leq 0.01$**	0.84, NS	0.62, NS	0.29, **$p \leq 0.05$**	0.98, NS (1.17, 10.53)
9 (40-45 min)	11.69, **$p \leq 0.01$**	0.93, NS	7.66, **$p \leq 0.01$**	0.95, NS	5.24, **$p \leq 0.01$**
10 (45-50 min)	0.57, NS	1.00, NS	1.85, NS	0.92, NS	1.66, NS
11 (50-55 min)	7.42, **$p \leq 0.05$**	0.84, NS	1.05, NS	0.84, NS	0.55, NS
12 (55-60 min)	0.08, NS	0.98, NS	0.64, NS	0.35, **$p \leq 0.05$**	0.57, NS

Appendix 7.11 Bonferroni Post Hoc Tests for Significant Main Effects of Bupropion for Rear Frequency in Timebins 8, 9 and 11.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Bonferroni Post Hoc Tests
8 (35-40 min)	MD = -4.10, SE = 1.08, **$p \leq 0.01$**
9 (40-45 min)	MD = -3.27, SE = 0.96, **$p \leq 0.01$**
11 (50-55 min)	MD = -3.13, SE = 1.15, **$p \leq 0.05$**

Appendix 7.12 Bonferroni Post Hoc Tests for Significant Main Effects of Naltrexone for Rear Frequency in Timebin 9.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Bonferroni Post Hoc Tests
9 (40-45 min)	1.0 mg/kg: MD = -3.80, SE = 1.19, **$p \leq 0.05$**

Appendix 7.13 Follow up ANOVAs for the significant time x bupropion x naltrexone interaction on Sniff Frequency

The time x bupropion x naltrexone interaction was followed up with 3 x 2 (bupropion x naltrexone) ANOVA's within each timebin to determine where there was any significant dose effects. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Timebin	Main Effect of Bupropion	Main Effect of Naltrexone		Bupropion x Naltrexone Interaction	
	F Value df (1,9)	Mauchly's W	F Value df (11,99)	Mauchly's W	F Value df (11,99)
1 (0-5 min)	11.25, **$p \leq 0.01$**	0.89, NS	1.53, NS	0.53, NS	3.66, **$p \leq 0.05$**
2 (5-10 min)	7.75, **$p \leq 0.05$**	0.94, NS	0.37, NS	0.73, NS	4.25, **$p \leq 0.05$**
3 (10-15 min)	6.89, **$p \leq 0.05$**	0.98, NS	3.47, **$p \leq 0.05$**	0.97, NS	2.40, NS
4 (15-20 min)	14.17, **$p \leq 0.01$**	0.80, NS	5.17, **$p \leq 0.01$**	0.83, NS	1.63, NS
5 (20-25 min)	0.58, NS	0.98, NS	1.29, NS	0.57, NS	2.89, NS
6 (25-30 min)	3.38, NS	0.79, NS	2.20, NS	0.99, NS	0.11, NS
7 (30-35 min)	3.92, NS	0.96, NS	1.01, NS	0.97, NS	0.62, NS
8 (35-40 min)	15.00, **$p \leq 0.01$**	0.44, **$p \leq 0.05$**	0.30, NS	0.41, **$p \leq 0.01$**	0.71, NS

			(1.29, 11.56)		(1.26, 11.31)
9 (40-45 min)	36.24, **$p \leq 0.001$**	0.81, NS	2.39, NS	0.96, NS	2.75, NS
10 (45-50 min)	3.14, NS	0.80, NS	1.98, NS	0.90, NS	2.72, NS
11 (50-55 min)	6.60, **$p \leq 0.05$**	0.97, NS	0.70, NS	0.94, NS	1.53, NS
12 (55-60 min)	0.35, NS	0.94, NS	1.21, NS	0.41, **$p \leq 0.05$**	0.40, NS (1.26, 11.34)

Appendix 7.14 Bonferroni Post Hoc Tests for Significant Main Effects of Bupropion for Sniff Frequency in Timebins 1-4, 8-9 and 11.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Bonferroni Post Hoc Tests
1 (0-5 min)	MD = -5.83, SE = 1.74, **$p \leq 0.01$**
2 (5-10 min)	MD = -6.90, SE = 2.48, **$p \leq 0.05$**
3 (10-15 min)	MD = -4.37, SE = 1.67, **$p \leq 0.05$**
4 (15-20 min)	MD = -5.13, SE = 1.36, **$p \leq 0.01$**
8 (35-40 min)	MD = -4.20, SE = 1.08, **$p \leq 0.01$**
9 (40-45 min)	MD = -4.07, SE = 0.68, **$p \leq 0.001$**
11 (50-55 min)	MD = -3.33, SE = 1.30, **$p \leq 0.05$**

Appendix 8 STATISTICAL DETAILS FOR EXPERIMENT 7 (CHAPTER 6) – THE EFFECTS OF ACUTE MCPP (0.1, 0.1 AND 3.0 MG/KG) TREATMENT ON FOOD INTAKE, THE MICROSTRUCTURE OF FEEDING BEHAVIOUR AND BODYWEIGHT GAIN IN MALE RATS.

Appendix 8.1 Bonferroni Post Hoc Tests for Habituation Week Food Intake.

Only significant differences are displayed. (MD = mean difference; SE = standard error)

Habituation Trial		Bonferroni Post Hoc Tests
1	3	MD = -4.48, SE = 0.66, **$p \leq 0.001$**
	4	MD = -5.61, SE = 0.78, **$p \leq 0.01$**
	5	MD = -5.87, SE = 1.09, **$p \leq 0.01$**

Appendix 8.2 One way repeated measures ANOVA results for Total (1-hour) Behavioural Measures.

Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Behaviour	Mauchly's W	F value df (3, 27)
Food Intake	0.42, NS	33.77, **$p \leq 0.001$**
Eat Frequency	0.48, NS	11.60, **$p \leq 0.001$**
Eat Duration	0.18, **$p \leq 0.05$**	0.41, NS (1.45, 13.09)
Eat Bout Length	0.09, **$p \leq 0.05$**	6.43, **$p \leq 0.05$** (1.29, 11.60)
Eat Rate	0.79, NS	40.15, **$p \leq 0.001$**
Eat Latency	0.18, **$p \leq 0.05$**	1.40, NS (1.64, 14.74)
Food ID Latency	0.04, **$p \leq 0.05$**	18.95, **$p \leq 0.001$** (1.22, 10.94)
Locomotion Frequency	0.31, NS	13.26, **$p \leq 0.001$**
Locomotion Duration	0.26, NS	7.22, **$p \leq 0.01$**
Rear Frequency	0.58, NS	2.34, NS
Rear Duration	0.48, NS	0.27, NS
Groom Frequency	0.64, NS	2.89, **$p \leq 0.05$**
Groom Duration	0.28, NS	9.82, **$p \leq 0.001$**
Scratch Frequency	0.56, NS	1.16, NS
Scratch Duration	0.51, NS	2.29, NS
Rest Frequency	0.80, NS	3.13, **$p \leq 0.05$**
Rest Duration	0.42, NS	1.74, NS
Sniff Frequency	0.35, NS	5.83, **$p \leq 0.01$**
Sniff Duration	0.56, NS	0.12, NS

Appendix 8.3 Bonferroni Post Hoc Tests for Significant Treatment Effects of mCPP on 1 hour behaviour.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour		Bonferroni Post Hoc Tests
Food Intake	1.0mg/kg	MD = 7.44, SE = 1.58, **$p \leq 0.01$**
	3.0mg/kg	MD = 11.06, SE = 0.70, **$p \leq 0.001$**
Eat Frequency	1.0mg/kg	MD = 27.60, SE = 8.43, $p \leq 0.06$
	3.0mg/kg	MD = 39.30, SE = 6.49, **$p \leq 0.001$**
Eat Bout Length	1.0mg/kg	MD = -5.08, SE = 1.54, $p \leq 0.06$
	3.0mg/kg	MD = -12.12, SE = 3.73, $p \leq 0.06$
Eat Rate	1.0mg/kg	MD = 0.71, SE = 0.10, **$p \leq 0.001$**
	3.0mg/kg	MD = 1.08, SE = 0.10, **$p \leq 0.001$**
Food ID Latency	3.0mg/kg	MD = -46.29, SE = 8.42, **$p \leq 0.01$**

Locomotion Frequency	3.0mg/kg	MD = 67.10, SE = 14.24, **p ≤ 0.01**
Locomotion Duration	3.0mg/kg	MD = 51.39, SE = 15.74, p ≤ 0.06
Groom Duration	3.0mg/kg	MD = -156.31, SE = 20.12, **p ≤ 0.001**
Sniff Frequency	3.0mg/kg	MD = 70.00, SE = 16.88, **p ≤ 0.01**

Appendix 8.4 Periodic (Timebin) Behavioural Analyses.

Behaviour	**Main Effect of Time**	**Time x Treatment Interaction**
	F Value df (11,99)	**F Value** df (33,297)
Eat Frequency	43.07, **p ≤ 0.001**	4.97, **p ≤ 0.001**
Eat Duration	8.00, NS	1.80, **p ≤ 0.01**
Locomotion Frequency	28.96, **p ≤ 0.001**	3.13, **p ≤ 0.001**
Locomotion Duration	23.35, **p ≤ 0.001**	1.82, **p ≤ 0.01**
Rear Frequency	21.50, **p ≤ 0.001**	3.29, **p ≤ 0.001**
Rear Duration	4.61, **p ≤ 0.001**	1.77, **p ≤ 0.01**
Groom Frequency	1.17, NS	1.41, NS
Groom Duration	0.74, NS	1.90, **p ≤ 0.01**
Scratch Frequency	1.02, NS	1.74, **p ≤ 0.01**
Scratch Duration	1.78, NS	1.46, **p ≤ 0.05**
Rest Frequency	11.29, **p ≤ 0.001**	1.02, NS
Rest Duration	8.20, **p ≤ 0.001**	1.03, NS
Sniff Frequency	32.64, **p ≤ 0.001**	4.80, **p ≤ 0.001**
Sniff Duration	3.13, **p ≤ 0.001**	1.01, NS

Appendix 8.5 Follow up ANOVAs for the Significant Time x Treatment Interactions for Eat Frequency and Eat Duration.

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Timebin	**Eat Frequency**		**Eat Duration**	
	Mauchly's W	**F value df (3, 27)**	**Mauchly's W**	**F value df (3, 27)**
1 (0-5 min)	0.42, NS	17.51, **p ≤ 0.001**	0.58, NS	1.78, NS
2 (5-10 min)	0.49, NS	23.69, **p ≤ 0.001**	0.51, NS	2.57, NS
3 (10-15 min)	0.52, NS	3.35, **p ≤ 0.05**	0.54, NS	1.92, NS
4 (15-20 min)	0.45, NS	2.28, NS	0.23, **p ≤ 0.05**	1.06, NS (1.79, 16.07)
5 (20-25 min)	0.42, NS	1.79, NS	0.35, NS	0.28, NS
6 (25-30 min)	0.61, NS	1.51, NS	0.26, NS	4.33, **p ≤ 0.01**
7 (30-35 min)	0.34, NS	3.50, **p ≤ 0.05**	0.43, NS	1.38, NS
8 (35-40 min)	0.61, NS	0.64, NS	0.35, NS	0.68, NS
9 (40-45 min)	0.67, NS	0.31, NS	0.17, **p ≤ 0.05**	1.35, NS (1.49, 13.41)
10 (45-50 min)	0.22, NS	1.13, NS	0.53, NS	1.11, NS
11 (50-55 min)	0.58, NS	0.87, NS	0.82, NS	1.35, NS
12 (55-60 min)	0.23, NS	0.92, NS	0.58, NS	0.31, NS

Appendix 8.6 Bonferroni Post Hoc Tests for Significant Treatment Effects of Eat Frequency for Timebin 1-3

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour	Timebin	Bonferroni Post Hoc Tests	
Eat Frequency	1 (0-5 min)	3.0mg/kg	MD = 12.70, SE = 2.29, **p ≤ 0.01**
	2 (5-10min)	1.0mg/kg	MD = 8.30, SE = 1.10, **p ≤ 0.001**
		3.0mg/kg	MD = 9.80, SE = 1.19, **p ≤ 0.001**
	3 (10-15min)	3.0mg/kg	MD = 6.10, SE = 1.25, **p ≤ 0.01**

Appendix 8.7 Follow up ANOVAs for the Significant Time x Treatment Interactions for Locomotion Frequency and Locomotion Duration.

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Timebin	Locomotion Frequency		Locomotion Duration	
	Mauchly's W	**F value df (3, 27)**	**Mauchly's W**	**F value df (3, 27)**
1 (0-5 min)	0.76, NS	19.47, **p ≤ 0.001**	0.21, **p ≤ 0.05**	9.41, **p ≤ 0.01**
2 (5-10 min)	0.71, NS	7.34, **p ≤ 0.001**	0.90, NS	6.10, **p ≤ 0.01**
3 (10-15 min)	0.74, NS	4.25, **p ≤ 0.01**	0.81, NS	1.27, NS
4 (15-20 min)	0.81, NS	6.18, **p ≤ 0.01**	0.61, NS	2.79, p ≤ 0.06
5 (20-25 min)	0.20, **p ≤ 0.05**	5.12, **p ≤ 0.01** (2.07, 18.64)	0.73, NS	3.21, **p ≤ 0.05**
6 (25-30 min)	0.37, NS	3.02, **p ≤ 0.05**	0.52, NS	1.92, NS
7 (30-35 min)	0.42, NS	0.62, NS	0.66, NS	0.25, NS
8 (35-40 min)	0.49, NS	2.02, NS	0.09, **p ≤ 0.05**	1.99, NS (1.38, 12.41)
9 (40-45 min)	0.37, NS	0.37, NS	0.67, NS	0.48, NS
10 (45-50 min)	0.93, NS	0.19, NS	0.96, NS	0.48, NS
11 (50-55 min)	0.67, NS	0.17, NS	0.61, NS	0.05, NS
12 (55-60 min)	0.29, NS	0.04, NS	0.43, NS	0.01, NS

Appendix 8.8 Bonferroni Post Hoc Tests for Significant Treatment Effects of Locomotion Frequency for Timebin 1-3, and Locomotion Duration for Timebin 1 and 2.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour	Timebin	Bonferroni Post Hoc Tests	
Locomotion Frequency	1 (0-5 min)	3.0mg/kg	MD = 22.90, SE = 2.67, **p ≤ 0.001**
	2 (5-10 min)	3.0mg/kg	MD = 8.40, SE = 1.65, **p ≤ 0.01**
	3 (10-15 min)	3.0mg/kg	MD = 7.30, SE = 2.03, **p ≤ 0.05**
Locomotion Duration	1 (0-5min)	3.0mg/kg	MD = 15.95, SE = 2.99, **p ≤ 0.01**
	2 (5-10 min)	3.0mg/kg	MD = 7.32, SE = 1.85, **p ≤ 0.05**

Appendix 8.9 Follow up ANOVAs for the significant time x treatment interactions for Rear Frequency and Rear Duration.

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Timebin	Rear Frequency		Rear Duration	
	Mauchly's W	**F value df (3, 27)**	**Mauchly's W**	**F value df (3, 27)**
1 (0-5 min)	0.86, NS	12.89, **p ≤ 0.001**	0.85, NS	3.35, **p ≤ 0.05**
2 (5-10 min)	0.39, NS	2.28, NS	0.70, NS	0.55, NS

3 (10-15 min)	0.76, NS	2.73, $p \leq 0.06$	0.67, NS	0.85, NS
4 (15-20 min)	0.37, NS	3.35, **$p \leq 0.05$**	0.29, NS	1.49, NS
5 (20-25 min)	0.60, NS	0.98, NS	0.66, NS	1.29, NS
6 (25-30 min)	0.64, NS	1.89, NS	0.31, NS	1.85, NS
7 (30-35 min)	0.53, NS	0.54, NS	0.40, NS	0.18, NS
8 (35-40 min)	0.51, NS	0.14, NS	0.75, NS	0.31, NS
9 (40-45 min)	0.90, NS	0.30, NS	0.69, NS	1.68, NS
10 (45-50 min)	0.60, NS	0.77, NS	0.75, NS	1.67, NS
11 (50-55 min)	0.21, **$p \leq 0.05$**	1.77, NS (1.80, 16.16)	0.61, NS	2.12, NS
12 (55-60 min)	0.55, NS	1.13, NS	0.17, **$p \leq 0.05$**	2.31, NS (1.79, 16.07)

Appendix 8.10 Bonferroni Post Hoc Tests for Significant Treatment Effects of Rear Frequency for Timebin 1

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour	Timebin	Bonferroni Post Hoc Tests	
Rear Frequency	1 (0-5 min)	3.0mg/kg	MD = 19.80, SE = 2.84, **$p \leq 0.001$**

Appendix 8.11 Follow up ANOVAs for the Significant Time x Treatment Interactions for Scratch Frequency, and Groom Duration.

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Timebin	Scratch Frequency		Groom Duration	
	Mauchly's W	F value df (3, 27)	Mauchly's W	F value df (3, 27)
1 (0-5 min)	0.26, NS	0.97, NS	0.20, **$p \leq 0.05$**	6.81, **$p \leq 0.01$** (1.49, 13.42)
2 (5-10 min)	0.75, NS	1.28, NS	0.18, **$p \leq 0.05$**	3.79, **$p \leq 0.05$** (1.93, 17.32)
3 (10-15 min)	0.15, NS	1.97, NS	0.53, NS	5.66, **$p \leq 0.01$**
4 (15-20 min)	0.38, NS	0.52, NS	0.41, NS	2.75, $p \leq 0.06$
5 (20-25 min)	0.19, **$p \leq 0.05$**	1.85, NS (1.60, 14.43)	0.52, NS	1.52, NS
6 (25-30 min)	0.22, **$p \leq 0.05$**	0.12, NS (1.64, 14.74)	0.27, NS	1.17, NS
7 (30-35 min)	0.19, **$p \leq 0.05$**	2.13, NS (1.62, 14.55)	0.62, NS	1.65, NS
8 (35-40 min)	0.42, NS	1.42, NS	0.23, **$p \leq 0.05$**	2.70, NS (1.74, 15.67)
9 (40-45 min)	0.57, NS	0.62, NS	0.28, NS	1.59, NS
10 (45-50 min)	0.12, NS	1.66, NS	0.35, NS	1.57, NS
11 (50-55 min)	0.21, NS	1.96, NS	0.71, NS	0.26, NS
12 (55-60 min)	0.30, NS	2.83, **$p \leq 0.05$**	0.21, **$p \leq 0.05$**	0.86, NS (1.75, 15.72)

Appendix 8.12 Follow up ANOVAs for the Significant Time x Treatment Interactions for Sniff Frequency.

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported.

Timebin	Sniff Frequency	
	Mauchly's W	F value df (3, 27)
1 (0-5 min)	0.52, NS	30.19, **$p \leq 0.001$**
2 (5-10 min)	0.26, NS	4.86, **$p \leq 0.01$**
3 (10-15 min)	0.67, NS	4.23, **$p \leq 0.05$**

4 (15-20 min)	0.71, NS	2.94, **p ≤ 0.05**
5 (20-25 min)	0.68, NS	3.67, **p ≤ 0.05**
6 (25-30 min)	0.29, NS	4.17, **p ≤ 0.01**
7 (30-35 min)	0.58, NS	0.33, NS
8 (35-40 min)	0.53, NS	1.15, NS
9 (40-45 min)	0.73, NS	0.45, NS
10 (45-50 min)	0.49, NS	0.75, NS
11 (50-55 min)	0.75, NS	1.95, NS
12 (55-60 min)	0.34, NS	0.53, NS

Appendix 8.13 Bonferroni Post Hoc Tests for Significant Treatment Effects of Groom Duration for Timebin 1-3

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour	Timebin	Bonferroni Post Hoc Tests	
Groom Duration	1 (0-5 min)	3.0mg/kg	MD = -36.38, SE = 10.06, **p ≤ 0.05**
	2 (5-10 min)	3.0mg/kg	MD = -32.46, SE = 7.76, **p ≤ 0.01**
	3 (10-15 min)	3.0mg/kg	MD = -44.47, SE = 11.88, **p ≤ 0.05**
Sniff Frequency	1 (0-5 min)	3.0mg/kg	MD = 26.90, SE = 1.98, **p ≤ 0.001**
	2 (5-10 min)	3.0mg/kg	MD = 13.40, SE = 2.51, **p ≤ 0.01**
	3 (10-15 min)	3.0mg/kg	MD = 10.10, SE = 2.60, **p ≤ 0.05**

Appendix 9 Statistical details for Experiment 8 (Chapter 6) – The Effects of Acute *m*CPP (0.1 mg/kg) and Naltrexone (0.1 and 1.0 mg/kg) Treatment, Alone and in Combination, on Food Intake, the Microstructure of Feeding Behaviour and Bodyweight Gain in Male Rats.

Appendix 9.1 Bonferroni Post Hoc Tests for Habituation Week Food Intake.

Only significant differences are displayed. (MD = mean difference; SE = standard error)

Habituation Trial		Bonferroni Post Hoc Tests
1	2	MD = -6.56, SE = 0.78, **$p \leq 0.001$**
	3	MD = -10.61, SE = 1.48, **$p \leq 0.001$**
	4	MD = -1.83, SE = 1.83, **$p \leq 0.001$**
	5	MD = -12.57, SE = 1.88, **$p \leq 0.001$**
2	3	MD = -4.05, SE = 0.97, **$p \leq 0.05$**
	4	MD = -5.77, SE = 1.41, **$p \leq 0.05$**
	5	MD = -6.01, SE = 1.57, **$p \leq 0.05$**

Appendix 9.2 2 x 3 ANOVA results for Total (1-hour) Behavioural Measures.

Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Behaviour	*m*CPP	Naltrexone		*m*CPP * Naltrexone	
	F value df (1, 9)	Mauchly's W	F value df (2, 18)	Mauchly's W	F value df (2, 18)
Food Intake	24.21, **$p \leq 0.001$**	0.93, NS	29.30, **$p \leq 0.001$**	0.51, NS	1.56, NS
Eat Frequency	3.07, NS	0.95, NS	5.81, **$p \leq 0.01$**	0.28, **$p \leq 0.05$**	1.48, NS (1.91, 17.20)
Eat Duration	3.10, NS	0.86, NS	11.63, **$p \leq 0.001$**	0.74, NS	0.77, NS
Eat Bout Length	3.35, NS	0.89, NS	0.26, NS	0.82, NS	2.67, NS
Eat Rate	6.70, **$p \leq 0.05$**	0.87, NS	5.59, **$p \leq 0.05$**	0.92, NS	0.85, NS
Eat Latency	0.30, NS	0.58, NS	0.59, NS	0.70, NS	1.64, NS
Food ID Latency	0.07, NS	0.91, NS	0.72, NS	0.71, NS	0.25, NS
Locomotion Frequency	1.66, NS	0.96, NS	3.74, **$p \leq 0.05$**	0.98, NS	3.93, **$p \leq 0.05$**
Locomotion Duration	8.23, **$p \leq 0.01$**	0.99, NS	2.38, NS	0.94, NS	4.15, NS
Rear Frequency	0.43, NS	0.81, NS	5.36, **$p \leq 0.01$**	0.90, NS	1.14, NS
Rear Duration	0.12, NS	0.49, NS	3.01, NS	0.75, NS	0.49, NS
Groom Frequency	0.43, NS	0.79, NS	4.73, **$p \leq 0.05$**	0.92, NS	0.17, NS
Groom Duration	3.16, NS	0.90, NS	14.30, **$p \leq 0.001$**	0.82, NS	0.92, NS
Scratch Frequency	0.33, NS	0.37, **$p \leq 0.05$**	7.27, **$p \leq 0.01$** (1.22, 11.01)	0.31, **$p \leq 0.05$**	0.16, NS (1.19, 10.67)
Scratch Duration	0.02, NS	0.10, **$p \leq 0.05$**	6.88, **$p \leq 0.05$** (1.05, 9.46)	0.26, **$p \leq 0.05$**	0.63, NS (1.15, 10.34)
Rest Frequency	0.10, NS	0.90, NS	2.20, NS	0.89, NS	0.00, NS
Rest Duration	0.03, NS	0.89, NS	6.46, **$p \leq 0.01$**	0.64, NS	0.91, NS
Sniff Frequency	0.80, NS	1.00, NS	7.18, **$p \leq 0.01$**	0.74, NS	1.66, NS
Sniff Duration	0.29, NS	0.62, NS	7.69, **$p \leq 0.01$**	0.93, NS	2.36, NS

Appendix 9.3 Bonferroni Post Hoc Tests for Significant Treatment Effects of mCPP on 1 hour Behaviour.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error).

Behaviour	Bonferroni Post Hoc Tests
Food Intake	MD = 2.71, SE = 0.55, **$p \leq 0.001$**
Eat Rate	MD = 0.16, SE = 0.06, **$p \leq 0.05$**
Locomotion Duration	MD = 20.41, SE = 7.12, **$p \leq 0.01$**

Appendix 9.4 Bonferroni Post Hoc Tests for Significant Treatment Effects of Naltrexone on 1 hour Behaviour.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error).

Behaviour	Bonferroni Post Hoc Tests	
Food Intake	0.1mg/kg	MD = 6.48, SE = 1.21, **p ≤ 0.001**
	1.0mg/kg	MD = 6.69, SE = 1.03, **p ≤ 0.001**
Eat Frequency	1.0mg/kg	MD = 17.85, SE = 6.01, **p ≤ 0.05**
Eat Duration	0.1mg/kg	MD = 181.29, SE = 54.12, **p ≤ 0.05**
	1.0mg/kg	MD = 204.57, SE = 40.07, **p ≤ 0.01**
Eat Rate	0.1mg/kg	MD = 0.16, SE = 0.05, **p ≤ 0.05**
Rear Frequency	0.1mg/kg	MD = 30.60, SE = 8.84, **p ≤ 0.05**
Groom Duration	0.1mg/kg	MD = 78.88, SE = 25.99, **p ≤ 0.05**
	1.0mg/kg	MD = 140.98, SE = 30.00, **p ≤ 0.01**
Scratch Frequency	0.1mg/kg	MD = 4.45, SE = 1.47, **p ≤ 0.05**
Rest Duration	1.0mg/kg	MD = -455.34, SE = 136.44, **p ≤ 0.05**
Sniff Frequency	0.1mg/kg	MD = 39.15, SE = 12.07, **p ≤ 0.05**
	1.0mg/kg	MD = 41.35, SE = 12.62, **p ≤ 0.05**
Sniff Duration	0.1mg/kg	MD = -250.91, SE = 45.25, **p ≤ 0.001**

Appendix 9.5 Periodic (Timebin) Behavioural Analyses.

Behaviour	Main Effect of Time	Time x mCPP Interaction	Time x Naltrexone Interation	mCPP x Naltrexone x Time Interaction
	F Value df (11,99)	**F Value** df (22, 198)	**F Value** df (22, 198)	**F Value** df (22, 198)
Eat Frequency	72.66, **p ≤ 0.001**	2.63, **p ≤ 0.01**	1.50, NS	2.13, **p ≤ 0.01**
Eat Duration	19.69, **p ≤ 0.001**	1.30, NS	2.34, **p ≤ 0.001**	1.32, NS
Locomotion Frequency	51.59, **p ≤ 0.001**	2.19, **p ≤ 0.05**	1.07, NS	1.52, NS
Locomotion Duration	31.98, **p ≤ 0.001**	2.08, **p ≤ 0.05**	1.20, NS	1.37, NS
Rear Frequency	33.40, **p ≤ 0.001**	1.34, NS	0.97, NS	0.95, NS
Rear Duration	6.16, **p ≤ 0.001**	1.57, NS	1.06, NS	0.84, NS
Groom Frequency	0.41, NS	1.59, NS	0.76, NS	0.84, NS
Groom Duration	1.04, NS	0.62, NS	0.81, NS	0.61, NS
Scratch Frequency	1.85, **p ≤ 0.05**	1.00, NS	1.25, NS	0.78, NS
Scratch Duration	1.22, NS	0.47, NS	1.34, NS	0.45, NS
Rest Frequency	7.30, **p ≤ 0.001**	1.66, NS	2.65, **p ≤ 0.001**	0.91, NS
Rest Duration	7.98, **p ≤ 0.001**	2.66, **p ≤ 0.01**	1.59, **p ≤ 0.05**	2.49, **p ≤ 0.001**
Sniff Frequency	57.99, **p ≤ 0.001**	2.34, **p ≤ 0.01**	1.02, NS	1.83, **p ≤ 0.01**
Sniff Duration	2.31, **p ≤ 0.01**	1.96, **p ≤ 0.05**	1.36, NS	1.95, **p ≤ 0.01**

Appendix 9.6 Follow up ANOVAs for the Significant Time x Treatment Interaction for Eat Frequency

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported.

TimeBin	Main Effect of *m*CPP	Main Effect of Naltrexone		*m*CPP x Naltrexone Interaction	
	F value df (1, 9)	**Mauchly's W**	**F value** df (2, 18)	**Mauchly's W**	**F value** df (2, 18)
1 (0-5 min)	5.15, **p ≤ 0.05**	0.75, NS	0.92, NS	0.98, NS	3.20, p ≤ 0.06
2 (5-10 min)	9.98, **p ≤ 0.01**	0.64, NS	3.90, **p ≤ 0.05**	0.61, NS	4.55, **p ≤ 0.05**
3 (10-15 min)	5.46, **p ≤ 0.05**	0.94, NS	4.50, **p ≤ 0.05**	0.88, NS	0.63, NS
4 (15-20 min)	1.47, NS	0.92, NS	2.40, NS	0.66, NS	0.30, NS
5 (20-25 min)	0.30, NS	0.98, NS	3.44, **p ≤ 0.05**	0.68, NS	0.97, NS
6 (25-30 min)	0.23, NS	0.83, NS	5.35, **p ≤ 0.01**	0.95, NS	1.46, NS
7 (30-35 min)	0.00, NS	0.84, NS	3.35, **p ≤ 0.05**	0.82, NS	2.06, NS
8 (35-40 min)	0.72, NS	0.66, NS	0.56, NS	0.74, NS	6.63, **p ≤ 0.01**
9 (40-45 min)	0.20, NS	0.87, NS	1.49, NS	0.60, NS	0.49, NS
10 (45-50 min)	1.07, NS	0.86, NS	4.22, **p ≤ 0.05**	0.40, NS	0.40, NS
11 (50-55 min)	0.43, NS	0.51, NS	0.51, NS	0.98, NS	0.38, NS
12 (55-60 min)	0.17, NS	0.85, NS	0.16, NS	0.98, NS	1.73, NS

Appendix 9.7 Follow up ANOVAs for the significant time x treatment interaction for Eat Duration

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

TimeBin	Main Effect of *m*CPP	Main Effect of Naltrexone		*m*CPP x Naltrexone Interaction	
	F value df (1, 9)	**Mauchly's W**	**F value** df (2, 18)	**Mauchly's W**	**F value** df (2, 18)
1 (0-5 min)	0.29, NS	0.52, NS	0.06, NS	0.89, NS	1.19, NS
2 (5-10 min)	5.47, **p ≤ 0.05**	0.99, NS	5.20, **p ≤ 0.01**	0.79, NS	7.18, **p ≤ 0.01**
3 (10-15 min)	5.53, **p ≤ 0.05**	0.56, NS	12.25, **p ≤ 0.001**	0.98, NS	0.07, NS
4 (15-20 min)	1.12, NS	0.61, NS	1.20, NS	0.83, NS	0.62, NS
5 (20-25 min)	0.24, NS	1.00, NS	4.16, **p ≤ 0.05**	0.85, NS	0.49, NS
6 (25-30 min)	0.38, NS	0.85, NS	16.80, **p ≤ 0.001**	0.79, NS	1.14, NS
7 (30-35 min)	0.85, NS	0.41, **p ≤ 0.05**	1.07, NS (1.26, 11.29)	0.74, NS	1.23, NS
8 (35-40 min)	0.64, NS	0.24, **p ≤ 0.05**	0.86, NS (1.13, 10.20)	0.79, NS	1.15, NS
9 (40-45 min)	0.08, NS	0.29, **p ≤ 0.05**	0.93, NS (1.17, 10.50)	0.49, NS	1.18, NS
10 (45-50 min)	1.34, NS	0.87, NS	5.17, **p ≤ 0.01**	0.63, NS	1.20, NS
11 (50-55 min)	0.02, NS	0.81, NS	0.16, NS	0.67, NS	1.55, NS
12 (55-60 min)	0.52, NS	0.91, NS	1.73, NS	0.84, NS	0.69, NS

Appendix 9.8 Bonferroni Post Hoc Tests for Significant Main Effects of *m*CPP for Eat Frequency and Eat Duration for Timebins 1-3.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Bonferroni Post Hoc Tests	
	Eat Frequency	Eat Duration
1 (0-5 min)	MD = 2.90, SE = 1.28, **$p \leq 0.05$**	
2 (5-10 min)	MD = 3.03, SE = 0.96, **$p \leq 0.05$**	MD = 31.56, SE = 13.50, **$p \leq 0.05$**
3 (10-15 min)	MD = 1.60, SE = 0.69, **$p \leq 0.05$**	MD = 19.14, SE = 8.14, **$p \leq 0.05$**

Appendix 9.9 Bonferroni Post Hoc Tests for Significant Main Effects of Naltrexone for Eat Frequency and Eat Duration for Timebins 2, 3 and 6.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Bonferroni Post Hoc Tests	
	Eat Frequency	Eat Duration
2 (5-10 min)		0.1mg/kg: MD = 34.39, SE = 10.60, **$p \leq 0.05$**
3 (10-15 min)		0.1mg/kg: MD = 52.98, SE = 13.57, **$p \leq 0.05$** 1.0mg/kg: MD = 62.35, SE = 17.04, **$p \leq 0.05$**
6 (25-30 min)	0.1mg/kg: MD = 2.70, SE = 0.90, **$p \leq 0.05$**	0.1mg/kg: MD = 41.66, SE = 9.02, **$p \leq 0.01$** 1.0mg/kg: MD = 44.09, SE = 6.91, **$p \leq 0.01$**

Appendix 9.10 Follow up ANOVAs for the Significant Time x Treatment Interaction for Locomotion Frequency

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

TimeBin	Main Effect of *m*CPP	Main Effect of Naltrexone		*m*CPP x Naltrexone Interaction	
	F value df (1, 9)	**Mauchly's W**	**F value** df (2, 18)	**Mauchly's W**	**F value** df (2, 18)
1 (0-5 min)	0.78, NS	0.99, NS	2.78, NS	0.97, NS	1.24, NS
2 (5-10 min)	2.09, NS	0.98, NS	0.45, NS	0.79, NS	2.78, NS
3 (10-15 min)	1.57, NS	0.72, NS	1.20, NS	0.98, NS	3.60, **$p \leq 0.05$**
4 (15-20 min)	3.86, NS	0.88, NS	1.62, NS	0.93, NS	2.96, NS
5 (20-25 min)	3.71, NS	0.87, NS	1.92, NS	0.63, NS	0.21, NS
6 (25-30 min)	5.19, **$p \leq 0.05$**	0.86, NS	1.98, NS	0.55, NS	0.67, NS
7 (30-35 min)	0.31, NS	0.55, NS	2.08, NS	0.48, **$p \leq 0.05$**	2.90, NS (1.32, 11.85)
8 (35-40 min)	0.04, NS	0.88, NS	2.79, NS	0.97, NS	0.76, NS
9 (40-45 min)	2.76, NS	0.99, NS	1.58, NS	0.44, **$p \leq 0.05$**	3.46, NS (1.28, 11.51)
10 (45-50 min)	4.01, NS	0.80, NS	0.68, NS	0.99, NS	3.41, **$p \leq 0.05$**
11 (50-55 min)	0.00, NS	0.84, NS	0.28, NS	0.80, NS	0.22, NS
12 (55-60 min)	3.36, NS	0.83, NS	1.05, NS	0.82, NS	7.77, **$p \leq 0.01$**

Appendix 9.11 Follow up ANOVAs for the Significant Time x Treatment Interaction for Locomotion Duration

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

TimeBin	Main Effect of *m*CPP	Main Effect of Naltrexone		*m*CPP x Naltrexone Interaction	
	F value df (1, 9)	**Mauchly's W**	**F value** df (2, 18)	**Mauchly's W**	**F value** df (2, 18)
1 (0-5 min)	4.67, p ≤ 0.06	0.97, NS	3.47, p ≤ 0.06	0.87, NS	1.14, NS
2 (5-10 min)	4.57, NS	0.95, NS	0.06, NS	0.88, NS	0.52, NS
3 (10-15 min)	5.48, **p ≤ 0.05**	0.49, NS	1.62, NS	0.94, NS	2.38, NS
4 (15-20 min)	2.70, NS	0.98, NS	2.14, NS	0.91, NS	2.23, NS
5 (20-25 min)	6.56, **p ≤ 0.05**	0.80, NS	1.56, NS	0.34, **p ≤ 0.05**	1.36, NS (1.21, 10.87)
6 (25-30 min)	3.25, NS	0.29, **p ≤ 0.05**	0.04, NS (1.17, 10.55)	0.85, NS	5.14, **p ≤ 0.01**
7 (30-35 min)	1.04, NS	0.65, NS	1.47, NS	0.40, **p ≤ 0.05**	1.44, NS (1.25, 11.23)
8 (35-40 min)	0.01, NS	0.96, NS	2.08, NS	0.86, NS	0.68, NS
9 (40-45 min)	2.43, NS	0.97, NS	0.41, NS	0.68, NS	2.39, NS
10 (45-50 min)	2.72, NS	0.44, **p ≤ 0.05**	0.45, NS (1.29, 11.57)	0.54, NS	3.74, **p ≤ 0.05**
11 (50-55 min)	0.25, NS	0.76, NS	0.15, NS	0.89, NS	0.20, NS
12 (55-60 min)	4.22, NS	0.63, NS	2.71, NS	0.63, NS	3.14, p ≤ 0.06

Appendix 9.12 Bonferroni Post Hoc Tests for Significant Main Effects of *m*CPP for Locomotion Frequency and Locomotion Duration for Timebins 3, 5 and 6.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Bonferroni Post Hoc Tests	
	Locomotion Frequency	**Locomotion Duration**
3 (10-15 min)		MD = 4.00, SE = 1.71, **p ≤ 0.05**
5 (20-25 min)		MD = 3.94, SE = 1.54, **p ≤ 0.05**
6 (25-30 min)	MD = 3.17, SE = 1.39, **p ≤ 0.05**	

Appendix 9.13 Follow up ANOVAs for the Significant Time x Treatment Interaction for Rest Frequency

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

TimeBin	Main Effect of *m*CPP	Main Effect of Naltrexone		*m*CPP x Naltrexone Interaction	
	F value df (1, 9)	**Mauchly's W**	**F value** df (2, 18)	**Mauchly's W**	**F value** df (2, 18)
1 (0-5 min)	2.14, NS	0.88, NS	1.36, NS	0.88, NS	1.36, NS
2 (5-10 min)	4.62, p ≤ 0.06	0.58, NS	1.49, NS	0.58, NS	1.49, NS
3 (10-15 min)	2.72, NS	0.58, NS	0.43, NS	0.95, NS	0.45, NS
4 (15-20 min)	1.35, NS	0.41, **p ≤ 0.05**	6.84, **p ≤ 0.01** (1.25, 11.28)	0.63, NS	0.44, NS
5 (20-25 min)	0.19, NS	0.99, NS	6.82, **p ≤ 0.01**	0.95, NS	0.46, NS
6 (25-30 min)	1.92, NS	0.79, NS	6.21, **p ≤ 0.01**	0.55, NS	0.53, NS
7 (30-35 min)	0.56, NS	0.85, NS	0.39, NS	0.75, NS	0.13, NS
8 (35-40 min)	2.95, NS	0.85, NS	0.40, NS	0.64, NS	2.30, NS
9 (40-45 min)	1.32, NS	0.94, NS	0.34, NS	0.96, NS	0.19, NS

10 (45-50 min)	0.07, NS	0.83, NS	2.98, NS	0.91, NS	1.87, NS
11 (50-55 min)	2.73, NS	0.85, NS	1.55, NS	0.51, NS	0.73, NS
12 (55-60 min)	0.64, NS	0.86, NS	0.17, NS	0.92, NS	0.98, NS

Appendix 9.14 Follow up ANOVAs for the Significant Time x Treatment Interaction for Rest Duration

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

TimeBin	**Main Effect of *m*CPP**	**Main Effect of Naltrexone**		***m*CPP x Naltrexone Interaction**	
	F value df (1, 9)	**Mauchly's W**	**F value** df (2, 18)	**Mauchly's W**	**F value** df (2, 18)
1 (0-5 min)	2.15, NS	0.50, NS	0.91, NS	0.50, NS	0.91, NS
2 (5-10 min)	2.43, NS	0.56, NS	1.19, NS	0.56, NS	1.19, NS
3 (10-15 min)	5.09, **$p \leq 0.05$**	0.73, NS	0.84, NS	0.63, NS	1.20, NS
4 (15-20 min)	4.27, $p \leq 0.06$	0.83, NS	3.14, $p \leq 0.06$	0.75, NS	0.21, NS
5 (20-25 min)	1.39, NS	0.95, NS	4.93, **$p \leq 0.05$**	0.57, NS	1.78, NS
6 (25-30 min)	0.87, NS	0.71, NS	5.88, **$p \leq 0.05$**	0.46, **$p \leq 0.05$**	1.16, NS (1.30, 11.65)
7 (30-35 min)	0.01, NS	0.81, NS	8.56, **$p \leq 0.01$**	0.89, NS	1.30, NS
8 (35-40 min)	0.48, NS	0.97, NS	1.89, NS	0.74, NS	1.45, NS
9 (40-45 min)	4.63, $p \leq 0.06$	0.89, NS	2.71, NS	0.85, NS	0.62, NS
10 (45-50 min)	4.35, $p \leq 0.06$	0.91, NS	1.09, NS	0.88, NS	2.19, NS
11 (50-55 min)	0.15, NS	0.51, NS	0.20, NS	0.48, NS	2.83, NS
12 (55-60 min)	1.80, NS	0.73, NS	1.40, NS	0.09, NS	5.08, **$p \leq 0.01$**

Appendix 9.15 Bonferroni Post Hoc Tests for Significant Main Effects of *m*CPP for Rest Duration in Timebin 3.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	**Bonferroni Post Hoc Tests**
3 (10-15 min)	MD = -21.81, SE = 9.67, **$p \leq 0.05$**

Appendix 9.16 Bonferroni Post Hoc Tests for Significant Main Effects of Naltrexone for Rest Frequency and Rest Duration.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	**Bonferroni Post Hoc Tests**	
	Rest Frequency	**Rest Duration**
4 (15-20 min)	1.0mg/kg: MD = -1.95, SE = 0.62, **$p \leq 0.05$**	
5 (20-25 min)	0.1mg/kg: MD = -1.50, SE = 0.49, **$p \leq 0.05$** 1.0mg/kg: MD = -1.55, SE = 0.46, **$p \leq 0.05$**	
6 (25-30 min)	1.0mg/kg: MD = -2.10, SE = 0.67, **$p \leq 0.05$**	1.0mg/kg: MD = -92.12, SE = 23.17, **$p \leq 0.01$**
7 (30-35 min)		1.0mg/kg: MD = -95.41, SE = 22.65, **$p \leq 0.01$**

Appendix 9.17 Follow up ANOVAs for the significant time x treatment interaction for Sniff Frequency

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported.

TimeBin	Main Effect of *m*CPP	Main Effect of Naltrexone		*m*CPP x Naltrexone Interaction	
	F value df (1, 9)	**Mauchly's W**	**F value** df (2, 18)	**Mauchly's W**	**F value** df (2, 18)
1 (0-5 min)	4.85, $p \leq 0.06$	0.56, NS	2.05, NS	0.96, NS	2.30, NS
2 (5-10 min)	2.56, NS	1.00, NS	3.83, **$p \leq 0.05$**	0.96, NS	3.65, **$p \leq 0.05$**
3 (10-15 min)	1.74, NS	0.54, NS	0.97, NS	0.98, NS	3.25, $p \leq 0.06$
4 (15-20 min)	2.43, NS	0.86, NS	2.94, NS	0.62, NS	0.25, NS
5 (20-25 min)	0.24, NS	0.72, NS	2.20, NS	0.94, NS	0.06, NS
6 (25-30 min)	0.91, NS	0.95, NS	3.93, **$p \leq 0.05$**	0.03, NS	0.31, NS
7 (30-35 min)	0.00, NS	0.97, NS	4.90, **$p \leq 0.05$**	0.61, NS	0.81, NS
8 (35-40 min)	0.01, NS	0.64, NS	2.20, NS	0.84, NS	1.78, NS
9 (40-45 min)	1.39, NS	0.98, NS	1.97, NS	0.65, NS	0.77, NS
10 (45-50 min)	2.68, NS	0.78, NS	2.20, NS	0.99, NS	0.63, NS
11 (50-55 min)	0.33, NS	0.83, NS	0.28, NS	0.94, NS	0.25, NS
12 (55-60 min)	1.20, NS	0.57, NS	1.51, NS	0.80, NS	4.44, **$p \leq 0.05$**

Appendix 9.18 Follow up ANOVAs for the significant time x treatment interaction for Sniff Duration

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

TimeBin	Main Effect of *m*CPP	Main Effect of Naltrexone		*m*CPP x Naltrexone Interaction	
	F value df (1, 9)	**Mauchly's W**	**F value** df (2, 18)	**Mauchly's W**	**F value** df (2, 18)
1 (0-5 min)	0.01, NS	0.22, **$p \leq 0.05$**	0.33, NS (1.13, 10.13)	0.71, NS	0.61, NS
2 (5-10 min)	1.76, NS	0.77, NS	4.63, **$p \leq 0.05$**	0.60, NS	1.24, NS
3 (10-15 min)	0.13, NS	0.78, NS	16.97, **$p \leq 0.001$**	0.99, NS	2.34, NS
4 (15-20 min)	0.13, NS	0.97, NS	0.12, NS	0.65, NS	1.26, NS
5 (20-25 min)	0.10, NS	0.71, NS	3.72, **$p \leq 0.05$**	0.83, NS	2.11, NS
6 (25-30 min)	4.56, $p \leq 0.06$	0.67, NS	0.91, NS	0.81, NS	0.71, NS
7 (30-35 min)	0.06, NS	0.89, NS	2.54, NS	0.74, NS	0.51, NS
8 (35-40 min)	0.23, NS	0.88, NS	1.59, NS	0.85, NS	0.55, NS
9 (40-45 min)	5.09, $p \leq 0.06$	0.86, NS	2.30, NS	0.97, NS	1.39, NS
10 (45-50 min)	4.08, NS	0.99, NS	1.21, NS	0.70, NS	1.06, NS
11 (50-55 min)	0.01, NS	0.59, NS	0.69, NS	0.32, **$p \leq 0.05$**	1.74, NS (1.19, 10.70)
12 (55-60 min)	1.76, NS	0.44, **$p \leq 0.05$**	0.94, NS (1.28,11.52)	0.86, NS	8.46, **$p \leq 0.01$**

Appendix 9.19 Bonferroni Post Hoc Tests for Significant Main Effects of Naltrexone for Sniff Frequency and Sniff Duration.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Bonferroni Post Hoc Tests	
	Sniff Frequency	**Sniff Duration**
2 (5-10 min)		0.1mg/kg: MD = -34.93, SE = 11.32, **$p \leq 0.05$**
3 (10-15 min)		0.1mg/kg: MD = -49.20, SE = 13.62, **$p \leq 0.05$** 1.0mg/kg: MD = -65.13, SE = 8.78, **$p \leq 0.001$**
7 (30-35 min)	1.0mg/kg: MD = 6.80, SE = 2.29, **$p \leq 0.05$**	

Appendix 10 STATISTICAL DETAILS FOR EXPERIMENT 9 (CHAPTER 7) – THE EFFECTS OF ACUTE EXENDIN-4 (0.025, 0.25 AND 2.5 µG/KG) TREATMENT ON FOOD INTAKE, THE MICROSTRUCTURE OF FEEDING BEHAVIOUR AND BODYWEIGHT GAIN IN MALE RATS.

Appendix 10.1 Bonferroni Post Hoc Tests for Habituation Week Food Intake.

Only significant differences are displayed. (MD = mean difference; SE = standard error)

Habituation Trial		Bonferroni Post Hoc Tests
1	2	MD = -2.42, SE = 0.50, **p ≤ 0.01**
	3	MD = -5.40, SE = 1.05, **p ≤ 0.01**
	5	MD = -8.23, SE = 1.00, **p ≤ 0.001**
2	5	MD = -5.81, SE = 0.82, **p ≤ 0.001**

Appendix 10.2 3 x 2 way ANOVA results for Total (1-hour) Behavioural Measures.

A mauchly's value is not provided for the main effect of Naltrexone because this factor has only two levels. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Behaviour	Main effect of Exendin-4	
	Mauchly's W	**F value** df (3, 27)
Food Intake	0.56, NS	48.89, **p ≤ 0.001**
Eat Frequency	0.50, NS	22.68, **p ≤ 0.001**
Eat Duration	0.43, NS	3.32, **p ≤ 0.05**
Eat Bout Length	0.39, NS	15.34, **p ≤ 0.001**
Eat Rate	0.05, **p ≤ 0.05**	15.18, **p ≤ 0.01** (1.21, 10.89)
Eat Latency	0.14, **p ≤ 0.05**	2.27, NS (1.92, 17.28)
Food ID Latency	0.10, **p ≤ 0.05**	4.68, **p ≤ 0.05** (1.73, 15.53)
Locomotion Frequency	0.47, NS	46.69, **p ≤ 0.001**
Locomotion Duration	0.67, NS	30.88, **p ≤ 0.001**
Rear Frequency	0.47, NS	45.89, **p ≤ 0.001**
Rear Duration	0.49, NS	32.85, **p ≤ 0.001**
Groom Frequency	0.66, NS	23.49, **p ≤ 0.001**
Groom Duration	0.54, NS	18.51, **p ≤ 0.001**
Scratch Frequency	0.15, **p ≤ 0.05**	12.72, **p ≤ 0.001** (1.59, 14.33)
Scratch Duration	0.09, **p ≤ 0.05**	5.45, **p ≤ 0.05** (1.37, 12.30)
Rest Frequency	0.65, NS	4.43, **p ≤ 0.01**
Rest Duration	0.42, NS	31.45, **p ≤ 0.001**
Sniff Frequency	0.55, NS	63.57, **p ≤ 0.001**
Sniff Duration	0.58, NS	9.42, **p ≤ 0.001**

Appendix 10.3 Bonferroni Post Hoc Tests for Significant Treatment Effects of Exendin-4 on 1 hour Behaviour.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour		Bonferroni Post Hoc Tests
Food Intake	0.25µg/kg	MD = 7.50, SE = 1.17, **p ≤ 0.001**
	2.5µg/kg	MD = 15.93, SE = 1.73, **p ≤ 0.001**
Eat Frequency	0.25µg/kg	MD = 34.10, SE = 7.02, **p ≤ 0.01**
	2.5µg/kg	MD = 54.50, SE = 9.26, **p ≤ 0.001**

Eat bout length	0.25µg/kg	MD = -3.10, SE = 0.74, **p ≤ 0.05**
	2.5µg/kg	MD = -7.92, SE = 1.14, **p ≤ 0.001**
Eat Rate	0.25µg/kg	MD = 0.50, SE – 0.13, **p ≤ 0.05**
	2.5µg/kg	MD = 1.36, SE = 0.15, **p ≤ 0.001**
Locomotion Frequency	0.25µg/kg	MD = 65.80, SE = 15.25, **p ≤ 0.05**
	2.5µg/kg	MD = 182.90, SE = 10.41, **p ≤ 0.001**
Locomotion Duration	2.5µg/kg	MD = 136.68, SE = 11.89, **p ≤ 0.001**
Rear Frequency	0.25µg/kg	MD = 105.00, SE = 18.87, **p ≤ 0.01**
	2.5µg/kg	MD = 191.00, SE = 14.49, **p ≤ 0.001**
Rear Duration	0.25µg/kg	MD = 386.17, SE = 70.14, **p ≤ 0.01**
	2.5µg/kg	MD = 722.60, SE = 85.92, **p ≤ 0.001**
Groom Frequency	0.25µg/kg	MD = 8.20, SE = 2.39, **p ≤ 0.05**
	2.5µg/kg	MD = 19.90, SE = 2.10, **p ≤ 0.001**
Groom Duration	2.5µg/kg	MD = 225.79, SE = 38.99, **p ≤ 0.01**
Scratch Frequency	2.5µg/kg	MD = 6.70, SE = 1.45, **p ≤ 0.01**
Rest Frequency	2.5µg/kg	MD = -10.10, SE = 2.57, **p ≤ 0.05**
Rest Duration	0.25µg/kg	MD = -588.72, SE = 116.64, **p ≤ 0.01**
	2.5µg/kg	MD = -1626.05, SE = 154.92, **p ≤ 0.001**
Sniff Frequency	0.25µg/kg	MD = 120.50, SE = 20.63, **p ≤ 0.001**
	2.5µg/kg	MD = 231, 10, SE = 17.02, **p ≤ 0.001**
Sniff Duration	2.5µg/kg	MD = 453.03, SE = 91.33, **p ≤ 0.01**

Appendix 10.4 Periodic (Timebin) Behavioural Analyses.

Behaviour	**Main Effect of Time**	**Time x Treatment Interaction**
	F Value df (11,99)	**F Value** df (33,297)
Eat Frequency	58.67, **p ≤ 0.001**	4.86, **p ≤ 0.001**
Eat Duration	35.87, **p ≤ 0.001**	3.28, **p ≤ 0.001**
Locomotion Frequency	33.24, **p ≤ 0.001**	6.79, **p ≤ 0.001**
Locomotion Duration	23.43, **p ≤ 0.001**	4.96, **p ≤ 0.001**
Rear Frequency	18.16, **p ≤ 0.001**	6.43, **p ≤ 0.001**
Rear Duration	3.23, **p ≤ 0.001**	1.87, **p ≤ 0.01**
Groom Frequency	0.85, NS	1.33, NS
Groom Duration	2.36, **p ≤ 0.01**	1.69, **p ≤ 0.01**
Scratch Frequency	0.28, NS	0.71, NS
Scratch Duration	0.86, NS	1.08, NS
Rest Frequency	6.31, **p ≤ 0.001**	1.56, **p ≤ 0.05**
Rest Duration	7.88, **p ≤ 0.001**	3.52, **p ≤ 0.001**
Sniff Frequency	36.69, **p ≤ 0.001**	7.09, **p ≤ 0.001**
Sniff Duration	1.57, NS	3.22, **p ≤ 0.001**

Appendix 10.5 Follow up ANOVAs for the Significant Time x Treatment Interactions for Eat Frequency and Eat Duration.

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Timebin	Eat Frequency		Eat Duration	
	Mauchly's W	F value df (3, 27)	Mauchly's W	F value df (3, 27)
1 (0-5 min)	0.38, NS	14.61, **p ≤ 0.001**	0.42, NS	2.66, NS
2 (5-10 min)	0.64, NS	14.33, **p ≤ 0.001**	0.35, NS	5.15, **p ≤ 0.01**
3 (10-15 min)	0.67, NS	13.57, **p ≤ 0.001**	0.48, NS	7.02, **p ≤ 0.001**
4 (15-20 min)	0.10, **p ≤ 0.05**	6.10, **p ≤ 0.05** (1.40, 12.55)	0.13, **p ≤ 0.05**	6.87, **p ≤ 0.01** (1.88, 16.95)
5 (20-25 min)	0.23, **p ≤ 0.05**	6.34, **p ≤ 0.05** (1.56, 14.00)	0.33, NS	2.80, p ≤ 0.06
6 (25-30 min)	0.47, NS	11.55, **p ≤ 0.001**	0.43, NS	4.91, **p ≤ 0.01**
7 (30-35 min)	0.35, NS	8.93, **p ≤ 0.001**	0.64, NS	1.15, NS
8 (35-40 min)	0.34, NS	0.81, NS	0.17, **p ≤ 0.05**	1.01, NS (1.45, 13.06)
9 (40-45 min)	0.45, NS	0.21, NS	0.20, **p ≤ 0.05**	0.38, NS (1.84, 16.54)
10 (45-50 min)	0.26, NS	2.48, NS	0.08, **p ≤ 0.05**	1.76, NS (1.35, 12.16)
11 (50-55 min)	0.62, NS	0.15, NS	0.42, NS	1.32, NS
12 (55-60 min)	0.30, NS	3.75, **p ≤ 0.05**	0.35, NS	1.22, NS

Appendix 10.6 Bonferroni Post Hoc Tests for Significant Exendin-4 Treatment Effects of Eat Frequency in Timebins 1-3, 6 and 7, and Eat Duration in Timebins 3 and 6

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour	Timebin	Bonferroni Post Hoc Tests	
Eat Frequency	1 (0-5 min)	2.5µg/kg	MD = 10.00, SE = 1.35, **p ≤ 0.001**
	2 (5-10 min)	2.5µg/kg	MD = 9.20, SE = 1.47, **p ≤ 0.001**
	3 (10-15 min)	0.25µg/kg	MD = 6.60, SE = 1.60, **p ≤ 0.05**
		2.5µg/kg	MD = 9.50, SE = 2.07, **p ≤ 0.01**
	6 (25-30 min)	0.25µg/kg	MD = 2.80, SE = 0.77, **p ≤ 0.05**
		2.5µg/kg	MD = 4.70, SE = 0.63, **p ≤ 0.001**
	7 (30-35 min)	2.5µg/kg	MD = 3.40, SE = 0.67, **p ≤ 0.01**
Eat Duration	3 (10-15 min)	0.25µg/kg	MD = 57.90, SE = 16.07, **p ≤ 0.05**
		2.5µg/kg	MD = 82.25, SE = 18.95, **p ≤ 0.05**
	6 (25-30 min)	2.5µg/kg	MD = 25.39, SE = 5.76, **p ≤ 0.01**

Appendix 10.7 Follow up ANOVAs for the Significant Time x Treatment Interactions for Locomotion Frequency and Locomotion Duration.

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported, following which the corrected degrees of freedom are stated in brackets.

Timebin	Locomotion Frequency		Locomotion Duration	
	Mauchly's W	F value df (3, 27)	Mauchly's W	F value df (3, 27)
1 (0-5 min)	0.30, NS	43.57, **p ≤ 0.001**	0.49, NS	27.46, **p ≤ 0.001**
2 (5-10 min)	0.21, **p ≤ 0.05**	20.62, **p ≤ 0.001** (1.99, 17.93)	0.35, NS	13.75, **p ≤ 0.001**

3 (10-15 min)	0.20, **p ≤ 0.05**	16.04, **p ≤ 0.001** (1.64, 14.74)	0.33, NS	19.71, **p ≤ 0.001**
4 (15-20 min)	0.77, NS	27.74, **p ≤ 0.001**	0.70, NS	20.80, **p ≤ 0.001**
5 (20-25 min)	0.29, NS	31.04, **p ≤ 0.001**	0.28, NS	22.66, **p ≤ 0.001**
6 (25-30 min)	0.55, NS	25.51, **p ≤ 0.001**	0.73, NS	20.62, **p ≤ 0.001**
7 (30-35 min)	0.84, NS	10.78, **p ≤ 0.001**	0.47, NS	8.84, **p ≤ 0.001**
8 (35-40 min)	0.27, NS	8.51, **p ≤ 0.001**	0.35, NS	5.56, **p ≤ 0.01**
9 (40-45 min)	0.45, NS	5.55, **p ≤ 0.01**	0.62, NS	3.93, **p ≤ 0.05**
10 (45-50 min)	0.62, NS	4.46, **p ≤ 0.05**	0.47, NS	2.89, p ≤ 0.06
11 (50-55 min)	0.39, NS	8.38, **p ≤ 0.001**	0.52, NS	4.13, **p ≤ 0.05**
12 (55-60 min)	0.48, NS	5.67, **p ≤ 0.01**	0.55, NS	5.03, **p ≤ 0.01**

Appendix 10.8 Bonferroni Post Hoc Tests for Significant Exendin-4 Treatment Effects of Locomotion Frequency and Locomotion Duration in Timebins 1-12

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour	Timebin	Bonferroni Post Hoc Tests	
Locomotion Frequency	1 (0-5 min)	2.5µg/kg	MD = 36.40, SE = 1.86, **p ≤ 0.001**
	2 (5-10 min)	0.25µg/kg	MD = 8.20, SE = 2.49, p ≤ 0.06
		2.5µg/kg	MD = 19.80, SE = 2.59, **p ≤ 0.001**
	3 (10-15 min)	2.5µg/kg	MD = 16.10, SE = 1.25, **p ≤ 0.001**
	4 (15-20 min)	2.5µg/kg	MD = 15.30, SE = 1.67, **p ≤ 0.001**
	5 (20-25 min)	0.25µg/kg	MD = 11.00, SE = 2.58, **p ≤ 0.05**
		2.5µg/kg	MD = 20.40, SE = 1.51, **p ≤ 0.001**
	6 (25-30 min)	0.25µg/kg	MD = 9.40, SE = 2.49, **p ≤ 0.05**
		2.5µg/kg	MD = 17.80, SE = 2.12, **p ≤ 0.001**
	7 (30-35 min)	2.5µg/kg	MD = 12.50, SE = 2.19, **p ≤ 0.01**
	8 (35-40 min)	2.5µg/kg	MD = 11.30, SE = 2.50, **p ≤ 0.01**
	9 (40-45 min)	2.5µg/kg	MD = 7.40, SE = 1.63, **p ≤ 0.01**
	11 (50-55 min)	2.5µg/kg	MD = 10.40, SE = 1.87, **p ≤ 0.01**
	12 (55-60 min)	2.5µg/kg	MD = 9.80, SE = 1.67, **p ≤ 0.001**
Locomotion Duration	1 (0-5 min)	2.5µg/kg	MD = 25.43, SE = 1.88, **p ≤ 0.001**
	2 (5-10 min)	2.5µg/kg	MD = 12.90, SE = 1.80, **p ≤ 0.001**
	3 (10-15 min)	2.5µg/kg	MD = 12.18, SE = 1.17, **p ≤ 0.001**
	4 (15-20 min)	2.5µg/kg	MD = 10.41, SE = 1.50, **p ≤ 0.001**
	5 (20-25 min)	0.25µg/kg	MD = 8.33, SE = 2.42, **p ≤ 0.05**
		2.5µg/kg	MD = 15.91, SE = 1.76, **p ≤ 0.001**
	6 (25-30 min)	0.25µg/kg	MD = 6.41, SE = 1.98, p ≤ 0.06
		2.5µg/kg	MD = 13.32, SE = 2.27, **p ≤ 0.001**
	7 (30-35 min)	2.5µg/kg	MD = 10.26, SE = 1.60, **p ≤ 0.001**
	9 (40-45 min)	2.5µg/kg	MD = 6.13, SE = 1.78, **p ≤ 0.05**
	11 (50-55 min)	2.5µg/kg	MD = 1.59, SE = 1.59, **p ≤ 0.05**
	12 (55-60 min)	2.5µg/kg	MD = 8.48, SE = 2.08, **p ≤ 0.05**

Appendix 10.9 Follow up ANOVAs for the significant time x treatment interactions for Rest Frequency and Rest Duration.

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported

Timebin	Rest Frequency		Rest Duration	
	Mauchly's W	F value df (3, 27)	Mauchly's W	F value df (3, 27)
1 (0-5 min)	0.00, **p ≤ 0.05**	1.82, NS (1.69, 2.90)	0.00, **p ≤ 0.05**	1.92, NS (1.22, 10.98)
2 (5-10 min)	0.00, **p ≤ 0.05**	3.96, **p ≤ 0.05** (1.63, 14.70)	0.00, **p ≤ 0.05**	5.80, **p ≤ 0.05** (1.10, 9.87)
3 (10-15 min)	0.00, **p ≤ 0.05**	14.81, **p ≤ 0.001** (1.57, 14.14)	0.00, **p ≤ 0.05**	22.63, **p ≤ 0.001** (1.49, 13.45)
4 (15-20 min)	0.23, **p ≤ 0.05**	8.36, **p ≤ 0.01** (2.15, 19.30)	0.03, **p ≤ 0.05**	22.94, **p ≤ 0.001** (1.94, 17.47)
5 (20-25 min)	0.47, NS	1.94, NS	0.22, **p ≤ 0.05**	31.58, **p ≤ 0.001** (2.04, 18.39)
6 (25-30 min)	0.32, NS	4.09, **p ≤ 0.05**	0.32, NS	33.87, **p ≤ 0.001**
7 (30-35 min)	0.61, NS	1.97, NS	0.37, NS	18.66, **p ≤ 0.001**
8 (35-40 min)	0.39, NS	1.01, NS	0.23, **p ≤ 0.05**	5.83, **p ≤ 0.05** (1.96, 17.63)
9 (40-45 min)	0.50, NS	1.71, NS	0.36, NS	1.40, NS
10 (45-50 min)	0.56, NS	1.79, NS	0.11, **p ≤ 0.05**	1.00, NS (1.74, 15.69)
11 (50-55 min)	0.39, NS	1.16, NS	0.68, NS	1.34, NS
12 (55-60 min)	0.32, NS	0.80, NS	0.46, NS	2.31, NS

Appendix 10.10 Bonferroni Post Hoc Tests for Significant Exendin-4 Treatment Effects of Rest Frequency in Timebins 3, 4 and 6 and Rest Duration in Timebins 3-8.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour	Timebin	Bonferroni Post Hoc Tests	
Rest Frequency	3 (10-15 min)	0.25µg/kg	MD = -2.00, SE = 0.52, **p ≤ 0.05**
		2.5µg/kg	MD = 1.70, SE = 0.34, **p ≤ 0.01**
	4 (15-20 min)	2.5µg/kg	MD = -2.30, SE = 0.70, p ≤ 0.06
	6 (25-30 min)	0.25µg/kg	MD = -2.40, SE = 0.73, p ≤ 0.06
		2.5µg/kg	MD = -2.30, SE = 0.34, **p ≤ 0.001**
Rest Duration	3 (10-15 min	2.5µg/kg	MD = -165.81, SE = 30.84, **p ≤ 0.01**
	4 (15-20 min)	2.5µg/kg	MD = -205.19, SE = 30.57, **p ≤ 0.001**
	5 (20-25 min)	2.5µg/kg	MD = -245.48, SE = 27.09, **p ≤ 0.001**
	6 (25-30 min)	2.5µg/kg	MD = -248.67, SE = 20.99, **p ≤ 0.001**
	7 (30-35 min)	2.5µg/kg	MD = -192.81, SE = 26.95, **p ≤ 0.001**
	8 (35-40 min)	0.25µg/kg	MD = -55.06, SE = 15.12, **p ≤ 0.05**
		2.5µg/kg	MD = -130.00, SE = 37.73, **p ≤ 0.05**

Appendix 10.11 Follow up ANOVAs for the Significant Time x Treatment Interactions for Sniff Frequency and Sniff Duration.

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported

Timebin	Sniff Frequency		Sniff Duration	
	Mauchly's W	F value df (3, 27)	Mauchly's W	F value df (3, 27)
1 (0-5 min)	0.69, NS	41.13, **p ≤ 0.001**	0.40, NS	0.01, NS
2 (5-10 min)	0.37, NS	21.96, **p ≤ 0.001**	0.12, **p ≤ 0.05**	2.66, NS (1.35, 12.18)

3 (10-15 min)	0.57, NS	25.51, **p ≤ 0.001**	0.57, NS	3.42, **p ≤ 0.05**
4 (15-20 min)	0.41, NS	35.02, **p ≤ 0.001**	0.60, NS	12.53, **p ≤ 0.001**
5 (20-25 min)	0.42, NS	59.73, **p ≤ 0.001**	0.23, **p ≤ 0.05**	14.22, **p ≤ 0.001** (2.13, 19.19)
6 (25-30 min)	0.88, NS	32.52, **p ≤ 0.001**	0.36, NS	14.02, **p ≤ 0.001**
7 (30-35 min)	0.87, NS	20.99, **p ≤ 0.001**	0.45, NS	4.72, **p ≤ 0.01**
8 (35-40 min)	0.86, NS	10.68, **p ≤ 0.001**	0.36, NS	3.66, **p ≤ 0.05**
9 (40-45 min)	0.71, NS	5.51, **p ≤ 0.01**	0.81, NS	1.26, NS
10 (45-50 min)	0.56, NS	4.95, **p ≤ 0.01**	0.46, NS	0.29, NS
11 (50-55 min)	0.70, NS	6.15, **p ≤ 0.01**	0.14, **p ≤ 0.05**	1.26, NS (1.91, 17.15)
12 (55-60 min)	0.17, **p ≤ 0.05**	8.99, **p ≤ 0.001** (1.74, 15.63)	0.16, **p ≤ 0.05**	0.41, NS (1.41, 12.69)

Appendix 10.12 Bonferroni Post Hoc Tests for Significant Exendin-4 Treatment Effects of Sniff Frequency in Timebins 1-12, and Sniff Duration in Timebins 3-6

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour	Timebin	Bonferroni Post Hoc Tests	
Sniff Frequency	1 (0-5 min)	0.25µg/kg	MD = 21.50, SE = 4.20, **p ≤ 0.01**
		2.5µg/kg	MD = 39.50, SE = 3.44, **p ≤ 0.001**
	2 (5-10 min)	0.25µg/kg	MD = 12.60, SE = 2.30, **p ≤ 0.01**
		2.5µg/kg	MD = 22.70, SE = 2.90, **p ≤ 0.001**
	3 (10-15 min)	0.25µg/kg	MD = 10.80, SE = 2.97, **p ≤ 0.05**
		2.5µg/kg	MD = 24.10, SE = 2.41, **p ≤ 0.001**
	4 (15-20 min)	0.25µg/kg	MD = 16.10, SE = 3.89, **p ≤ 0.05**
		2.5µg/kg	MD = 24.10, SE = 2.52, **p ≤ 0.001**
	5 (20-25 min)	0.25µg/kg	MD = 17.50, SE = 3.20, **p ≤ 0.01**
		2.5µg/kg	MD = 26.90, SE = 2.37, **p ≤ 0.001**
	6 (25-30 min)	0.25µg/kg	MD = 10.30, SE = 2.63, **p ≤ 0.05**
		2.5µg/kg	MD = 21.20, SE = 2.19, **p ≤ 0.001**
	7 (30-35 min)	2.5µg/kg	MD = 16.10, SE = 2.29, **p ≤ 0.001**
	8 (35-40 min)	2.5µg/kg	MD = 12.00, SE = 2.46, **p ≤ 0.01**
	9 (40-45 min)	2.5µg/kg	MD = 8.20, SE = 2.16, **p ≤ 0.05**
	11 (50-55 min)	2.5µg/kg	MD = 11.30, SE = 2.06, **p ≤ 0.01**
	12 (55-60 min)	2.5µg/kg	MD = 16.20, SE = 2.17, **p ≤ 0.001**
Sniff Duration	3 (10-15 min	0.25µg/kg	MD = -49.91, SE = 14.81, **p ≤ 0.05**
	4 (15-20 min)	2.5µg/kg	MD = 62.96, SE = 19.39, p ≤ 0.06
	5 (20-25 min)	2.5µg/kg	MD = 121.17, SE = 20.77, **p ≤ 0.001**
	6 (25-30 min)	2.5µg/kg	MD = 134.52, SE = 16.81, **p ≤ 0.001**

Appendix 10.13 Follow up ANOVAs for the significant time x treatment interactions for Rear Frequency and Rear Duration.

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported

Timebin	Rear Frequency		Rear Duration	
	Mauchly's W	**F value df (3, 27)**	**Mauchly's W**	**F value df (3, 27)**
1 (0-5 min)	0.54, NS	45.12, $\mathbf{p \le 0.001}$	0.37, NS	24.72, $\mathbf{p \le 0.001}$
2 (5-10 min)	0.51, NS	19.86, $\mathbf{p \le 0.001}$	0.42, NS	11.75, $\mathbf{p \le 0.001}$
3 (10-15 min)	0.47, NS	18.54, $\mathbf{p \le 0.001}$	0.55, NS	14.80, $\mathbf{p \le 0.001}$
4 (15-20 min)	0.37, NS	34.37, $\mathbf{p \le 0.001}$	0.87, NS	29.44, $\mathbf{p \le 0.001}$
5 (20-25 min)	0.41, NS	40.18, $\mathbf{p \le 0.001}$	0.27, NS	21.93, $\mathbf{p \le 0.001}$
6 (25-30 min)	0.43, NS	29.10, $\mathbf{p \le 0.001}$	0.46, NS	23.03, $\mathbf{p \le 0.001}$
7 (30-35 min)	0.73, NS	12.80, $\mathbf{p \le 0.001}$	0.68, NS	8.60, $\mathbf{p \le 0.001}$
8 (35-40 min)	0.65, NS	8.30, $\mathbf{p \le 0.001}$	0.63, NS	11.00, $\mathbf{p \le 0.001}$
9 (40-45 min)	0.58, NS	8.19, $\mathbf{p \le 0.001}$	0.24, NS	8.02, $\mathbf{p \le 0.001}$
10 (45-50 min)	0.74, NS	9.76, $\mathbf{p \le 0.001}$	0.38, NS	8.17, $\mathbf{p \le 0.001}$
11 (50-55 min)	0.51, NS	13.34, $\mathbf{p \le 0.001}$	0.51, NS	9.12, $\mathbf{p \le 0.001}$
12 (55-60 min)	0.14, $\mathbf{p \le 0.05}$	6.99, $\mathbf{p \le 0.05}$ (1.41, 12.71)	0.07, $\mathbf{p \le 0.05}$	3.95, NS (1.25, 11.25)

Appendix 10.14 Bonferroni Post Hoc Tests for Significant Exendin-4 Treatment Effects of Rear Frequency in Timebins 1-12. and Rear Duration in Timebins 1-10.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour	Timebin	Bonferroni Post Hoc Tests	
Rear Frequency	1 (0-5 min)	0.25µg/kg	MD = 20.20, SE = 3.88, $\mathbf{p \le 0.01}$
		2.5µg/kg	MD = 32.70, SE = 2.99, $\mathbf{p \le 0.001}$
	2 (5-10 min)	0.25µg/kg	MD = 8.30, SE = 1.80, $\mathbf{p \le 0.05}$
		2.5µg/kg	MD = 16.80, SE = 2.53, $\mathbf{p \le 0.001}$
	3 (10-15 min)	2.5µg/kg	MD = 17.00, SE = 1.95, $\mathbf{p \le 0.001}$
	4 (15-20 min)	0.25µg/kg	MD = 12.50, SE = 3.24, $\mathbf{p \le 0.05}$
		2.5µg/kg	MD = 19.00, SE = 2.17, $\mathbf{p \le 0.001}$
	5 (20-25 min)	0.25µg/kg	MD = 13.70, SE = 2.57, $\mathbf{p \le 0.01}$
		2.5µg/kg	MD = 20.20, SE = 2.12, $\mathbf{p \le 0.001}$
	6 (25-30 min)	0.25µg/kg	MD = 10.80, SE = 1.97, $\mathbf{p \le 0.01}$
		2.5µg/kg	MD = 18.30, SE = 1.78, $\mathbf{p \le 0.001}$
	7 (30-35 min)	2.5µg/kg	MD = 12.80, SE = 1.95, $\mathbf{p \le 0.001}$
	8 (35-40 min)	2.5µg/kg	MD = 11.50, SE = 2.44, $\mathbf{p \le 0.01}$
	9 (40-45 min)	2.5µg/kg	MD = 9.20, SE = 1.69, $\mathbf{p \le 0.01}$
	10 (45-50 min)	2.5µg/kg	MD = 10.50, SE = 2.33, $\mathbf{p \le 0.01}$
	11 (50-55 min)	0.25µg/kg	MD = 6.90, SE = 1.55, $\mathbf{p \le 0.01}$
		2.5µg/kg	MD = 12.40, SE = 1.40, $\mathbf{p \le 0.001}$
	12 (55-60 min)	0.025 µg/kg	MD = 6.00, SE = 1.69, $\mathbf{p \le 0.05}$
		2.5µg/kg	MD = 12.80, SE = 2.16, $\mathbf{p \le 0.001}$
Rear Duration	1 (0-5 min)	0.25µg/kg	MD = 41.35, SE = 10.74, $\mathbf{p \le 0.05}$
		2.5µg/kg	MD = 66.11, SE = 9.30, $\mathbf{p \le 0.001}$
	2 (5-10 min)	2.5µg/kg	MD = 51.56, SE = 11.07, $\mathbf{p \le 0.01}$
	3 (10-15 min)	2.5µg/kg	MD = 54.67, SE = 8.43, $\mathbf{p \le 0.001}$
	4 (15-20 min)	0.25µg/kg	MD = 41.95, SE = 10.02, $\mathbf{p \le 0.05}$

		2.5µg/kg	MD = 71.88, SE = 7.96, **$p \leq 0.001$**
	5 (20-25 min)	0.25µg/kg	MD = 44.45, SE = 10.39, **$p \leq 0.05$**
		2.5µg/kg	MD = 74.55, SE = 8.60, **$p \leq 0.001$**
	6 (25-30 min)	0.25µg/kg	MD = 50.89, SE = 10.83, **$p \leq 0.01$**
		2.5µg/kg	MD = 78.54, SE = 8.35, **$p \leq 0.001$**
	7 (30-35 min)	2.5µg/kg	MD = 54.51, SE = 10.04, **$p \leq 0.01$**
	8 (35-40 min)	2.5µg/kg	MD = 51.63, SE = 10.86, **$p \leq 0.01$**
	9 (40-45 min)	2.5µg/kg	MD = 58.88, SE = 16.39, **$p \leq 0.05$**
	10 (45-50 min)	2.5µg/kg	MD = 50.27, SE = 13.42, **$p \leq 0.05$**
	11 (50-55 min)	2.5µg/kg	MD = 54.61, SE = 8.47, **$p \leq 0.001$**

Appendix 10.15 Follow up ANOVAs for the Significant Time x Treatment Interactions for Groom Duration.

The time x treatment interaction was followed up with a one-way ANVOA within each timebin to determine where there was a significant main effect of dose. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported

Timebin	Groom Duration	
	Mauchly's W	**F value df (3, 27)**
1 (0-5 min)	0.67, NS	12.59, **$p \leq 0.001$**
2 (5-10 min)	0.27, NS	1.79, NS
3 (10-15 min)	0.22, **$p \leq 0.05$**	6.42, **$p \leq 0.01$** (1.92, 17.28)
4 (15-20 min)	0.24, NS	1.60, NS
5 (20-25 min)	0.32, NS	2.52, NS
6 (25-30 min)	0.42, NS	1.85, NS
7 (30-35 min)	0.06, **$p \leq 0.05$**	9.39, **$p \leq 0.01$** (1.76, 15.87)
8 (35-40 min)	0.20, **$p \leq 0.05$**	0.95, NS (1.49, 13.42)
9 (40-45 min)	0.32, NS	4.30, **$p \leq 0.05$**
10 (45-50 min)	0.37, NS	3.07, **$p \leq 0.05$**
11 (50-55 min)	0.24, **$p \leq 0.05$**	0.94, NS (1.71, 15.42)
12 (55-60 min)	0.08, **$p \leq 0.05$**	2.03, NS (1.76, 15.81)

Appendix 10.16 Bonferroni Post Hoc Tests for Significant Exendin-4 Treatment Effects of Sniff Frequency in Timebins 1, 3 and 7

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour	Timebin	Bonferroni Post Hoc Tests	
Groom Duration	1 (0-5 min)	2.5µg/kg	MD = 7.80, SE = 1.29, **$p \leq 0.001$**
	3 (10-15 min)	2.5µg/kg	MD 17.78, SE = 2.50, **$p \leq 0.001$**
	7 (30-35 min)	0.25µg/kg	MD = 45.76, SE = 12.02, **$p \leq 0.05$**
		2.5µg/kg	MD = 52.06, SE = 15.60, $p \leq 0.06$

Appendix 11 Statistical details for Experiment 10 (Chapter 7) – The Effects of Acute Polytherapy of Exendin-4 (0.025, and 0.25 µg/kg) and Naltrexone (0.1 mg/kg) Treatment on Food Intake, the Microstructure of Feeding Behaviour and Bodyweight Gain in Male Rats.

Appendix 11.1 Bonferroni Post Hoc Tests for Habituation Week Food Intake.
Only significant differences are displayed. (MD = mean difference; SE = standard error)

Habituation Trial		Bonferroni Post Hoc Tests
1	2	MD = -5.16, SE = 0.94, **p ≤ 0.01**
	3	MD = -8.50, SE = 1.49, **p ≤ 0.01**
	4	MD = -10.28,SE = 1.43, **p ≤ 0.001**
	5	MD = -12.49, SE = 1.55, **p ≤ 0.001**
	6	MD = -10.75, SE = 1.54, **p ≤ 0.001**
2	4	MD = -5.12, SE = 0.96, **p ≤ 0.01**
	5	MD = -7.33, SE = 1.16, **p ≤ 0.01**

Appendix 11.2 3 x 2 way ANOVA results for Total (1-hour) Behavioural Measures.
A mauchly's value is not provided for the main effect of Naltrexone because this factor has only two levels. Where data failed Mauchly's, corrected Greenhouse-Geisser F values are reported.

Behaviour	Main Effect of Naltrexone	Main effect of Exendin-4		Exendin-4 x Naltrexone Interaction	
	F value df (1,9)	**Mauchly's**	**F value** df (2,18)	**Mauchly's**	**F value** df (2,18)
Food Intake	24.63, **p ≤ 0.001**	0.54, NS	16.83, **p ≤ 0.001**	0.65, NS	21.38, **p ≤ 0.001**
Eat Frequency	10.72, **p ≤ 0.01**	0.80, NS	4.49, **p ≤ 0.05**	0.57, NS	20.97, **p ≤ 0.001**
Eat Duration	19.58, **p ≤ 0.01**	0.93, NS	1.77, NS	0.67, NS	26.45, **p ≤ 0.001**
Eat Bout Length	1.67, NS	0.71, NS	3.38, p ≤ 0.06	0.69, NS	0.32, NS
Eat Rate	0.03, NS	0.87, NS	2.81, NS	0.74, NS	0.33, NS
Eat Latency	0.10, NS	0.96, NS	1.73, NS	0.87, NS	0.25, NS
Food ID Latency	0.39, NS	0.25, **p ≤ 0.05**	2.26, NS (1.14, 10.29)	0.89, NS	0.47, NS
Locomotion Frequency	4.26, NS	0.73, NS	2.24, NS	0.79, NS	1.30, NS
Locomotion Duration	4.97, **p ≤ 0.05**	0.98, NS	1.59, NS	0.90, NS	1.02, NS
Rear Frequency	0.59, NS	0.82, NS	9.09, NS	0.87, NS	0.12, NS
Rear Duration	0.37, NS	0.82, NS	6.35, **p ≤ 0.01**	0.74, NS	0.42, NS
Groom Frequency	6.42, **p ≤ 0.05**	0.87, NS	1.98, NS	0.82, NS	0.69, NS
Groom Duration	36.28, **p ≤ 0.001**	0.32, **p ≤ 0.05**	0.18, NS (1.19, 10.70)	0.89, NS	0.39, NS
Scratch Frequency	3.33, NS	0.53, NS	0.29, NS	0.68, NS	1.68, NS
Scratch Duration	1.67, NS	0.86, NS	0.61, NS	0.64, NS	2.64, NS
Rest Frequency	1.55, NS	0.67, NS	9.87, **p ≤ 0.001**	0.69, NS	0.09, NS
Rest Duration	2.47, NS	0.81, NS	5.76, **p ≤ 0.01**	0.79, NS	1.72, NS
Sniff Frequency	2.58, NS	0.50, NS	9.80, **p ≤ 0.001**	0.96, NS	2.37, NS
Sniff Duration	0.65, NS	0.96, NS	0.36, NS	0.90, NS	0.97, NS

Appendix 11.3 Bonferroni Post Hoc Tests for Significant Main Effects of Naltrexone.
Values represent significant differences between vehicle and Naltrexone. (MD = mean difference; SE = standard error)

Behaviour	Bonferroni Post Hoc Tests
Eat Frequency	MD = 12.60, SE = 3.85, **p ≤ 0.01**
Eat Duration	MD = 107.71, SE = 24.34, **p ≤ 0.01**

Groom Frequency	MD = 4.57, SE = 1.80, **$p \leq 0.05$**
Groom Duration	MD = 87.79, SE = 14.58, **$p \leq 0.001$**
Locomotion Duration	MD = 16.89, SE = 7.58, **$p \leq 0.05$**

Appendix 11.4 Bonferroni Post Hoc Tests for Significant Main Effects of Exendin-4.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Behaviour	Bonferroni Post Hoc Tests	
Rear Duration	0.25µg/kg	MD = 167.52, SE = 56.60, **$p \leq 0.05$**
Sniff Frequency	0.25µg/kg	MD = 47.10, SE = 9.05, **$p \leq 0.01$**
Rest Frequency	0.25µg/kg	MD = -7.40, SE = 1.58, **$p \leq 0.01$**

Appendix 11.5 Periodic (Timebin) Behavioural Analyses.

Mauchley's values were not provided for the main effect of time, or for the time x exendin-4, time x naltrexone, or time x exendin-4 x naltrexone interactions, therefore corrected Greenhouse-Geisser F-values are reported.

Behaviour	Main Effect of Time	Time x Naltrexone Interaction	Time x Exendin-4 Interaction	Time x Exendin-4 x Naltrexone Interaction
	F Value df (11,99)	**F Value** df (11,99)	**F Value** df (22,198)	**F Value** df (22,198)
Eat Frequency	119.89, **$p \leq 0.001$**	0.92, NS	3.25, **$p \leq 0.001$**	0.72, NS
Eat Duration	31.14, **$p \leq 0.001$**	2.59, **$p \leq 0.01$**	1.16, NS	1.12, NS
Locomotion Frequency	52.17, **$p \leq 0.001$**	1.31, NS	1.03, NS	1.12, NS
Locomotion Duration	32.74, **$p \leq 0.001$**	1.18, NS	0.72, NS	1.02, NS
Rear Frequency	37.45, **$p \leq 0.001$**	1.65, NS	1.00, NS	0.12, NS
Rear Duration	8.30, **$p \leq 0.001$**	1.73, NS	1.00, NS	1.05, NS
Groom Frequency	0.33, NS	0.82, NS	1.11, NS	0.79, NS
Groom Duration	1.78, NS	0.82, NS	1.18, NS	0.54, NS
Scratch Frequency	0.73, NS	0.86, NS	1.01, NS	0.68, NS
Scratch Duration	1.80, NS	1.56, NS	0.90, NS	1.26, NS
Rest Frequency	11.99, **$p \leq 0.001$**	2.31, **$p \leq 0.01$**	1.42, NS	0.56, NS
Rest Duration	12.32, **$p \leq 0.001$**	1.31, NS	0.63, NS	1.14, NS
Sniff Frequency	59.12, **$p \leq 0.001$**	1.08, NS	1.39, NS	0.79, NS
Sniff Duration	3.45, **$p \leq 0.001$**	1.75, NS	1.15, NS	1.27, NS

Appendix 11.6 Follow up ANOVAs for the significant Time x Naltrexone Interactions for Eat Duration and Rest Frequency

The time x naltrexone interaction was followed up with 3 x 2 (Exendin-4 x Naltrexone) ANOVA's within each timebin to determine where there was a significant main effect of Naltrexone. (Therefore only the main effect of naltrexone is reported; Mauchley's value is not provided for naltrexone because this factor has only two levels)

Timebin	Main Effect of Naltrexone **F Value** df (1,9)	
	Eat Duration	**Rest Frequency**
1 (0-5 min)	2.62, NS	2.25, NS
2 (5-10 min)	16.15, **$p \leq 0.01$**	0.00, NS
3 (10-15 min)	4.63, $p \leq 0.06$	0.58, NS
4 (15-20 min)	3.14, NS	3.59, NS
5 (20-25 min)	0.73, NS	2.70, NS
6 (25-30 min)	18.80, **$p \leq 0.01$**	4.81, $p \leq 0.06$
7 (30-35 min)	7.57, **$p \leq 0.05$**	0.04, NS
8 (35-40 min)	4.38, NS	1.55, NS

9 (40-45 min)	8.21, **$p \leq 0.05$**	0.01, NS
10 (45-50 min)	1.14, NS	1.64, NS
11 (50-55 min)	0.21, NS	0.06, NS
12 (55-60 min)	0.23, NS	4.75, $p \leq 0.06$

Appendix 11.7 Bonferroni Post Hoc Tests for Significant Naltrexone Treatment Effects of Eat Duration in Timebins 2, 3, 7 and 9.

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Bonferroni
2 (5-10 min)	MD = 30.58, SE = 7.61, **$p \leq 0.01$**
6 (25-30 min)	MD = 16.60, SE = 3.83, **$p \leq 0.01$**
7 (30-35 min)	MD = 12.55, SE = 4.56, **$p \leq 0.05$**
9 (40-45 min)	MD = 8.13, SE = 2.84, **$p \leq 0.05$**

Appendix 11.8 Follow up ANOVAs for the significant time x Exendin-4 interactions for Eat Frequency, and Rear Frequency

The time x exendin-4 interaction was followed up with 3 x 2 (exendin-4 x naltrexone) ANOVA's within each timebin to determine where there was a significant main effect of exendin-4.

Timebin	Eat Frequency		Rear Frequency	
	Mauchly's W	**F Value** df (1,9)	**Mauchly's W**	**F Value** df (1,9)
1 (0-5 min)	0.90, NS	2.78, NS	1.00, NS	2.49, NS
2 (5-10 min)	0.98, NS	9.83, **$p \leq 0.001$**	0.55, NS	5.05, **$p \leq 0.01$**
3 (10-15 min)	0.69, NS	23.36, **$p \leq 0.001$**	0.89, NS	4.31, **$p \leq 0.05$**
4 (15-20 min)	0.77, NS	2.40, NS	0.75, NS	20.96, **$p \leq 0.001$**
5 (20-25 min)	0.73, NS	2.61, NS	0.84, NS	4.44, **$p \leq 0.05$**
6 (25-30 min)	0.41, NS	0.53, NS	0.57, NS	4.68, **$p \leq 0.05$**
7 (30-35 min)	0.95, NS	0.25, NS	0.85, NS	8.72, **$p \leq 0.01$**
8 (35-40 min)	0.96, NS	0.82, NS	0.90, NS	1.97, NS
9 (40-45 min)	0.99, NS	1.13, NS	0.93, NS	1.47, NS
10 (45-50 min)	0.77, NS	0.06, NS	0.74, NS	0.08, NS
11 (50-55 min)	0.79, NS	0.01, NS	0.52, NS	0.85, NS
12 (55-60 min)	0.76, NS	0.60, NS	0.87, NS	0.21, NS

Appendix 11.9 Bonferroni Post Hoc Tests for Significant Exendin-4 Treatment Effects of Eat Frequency in Timebin 3

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Bonferroni
3 (10-15 min)	0.25µg/kg: MD = 4.75, SE = 0.92, **$p \leq 0.01$**

Appendix 11.10 Bonferroni Post Hoc Tests for Significant Exendin-4 Treatment Effects of Rear Frequency in Timebins 4 and 7

Only differences from vehicle control are presented (MD = mean difference; SE = standard error)

Timebin	Bonferroni
4 (15-20 min)	0.25µg/kg: MD = 6.85, SE = 1.23, **$p \leq 0.001$**
7 (30-35 min)	0.25µg/kg: MD = 5.60, SE = 1.17, **$p \leq 0.01$**